WO2010107939A2

WO2010107939A2 - Human immunodeficiency virus (hiv) -neutralizing antibodies

Info

Publication number: WO2010107939A2
Application number: PCT/US2010/027695
Authority: WO
Inventors: Po-Ying Chan-Hui; Jennifer Mitcham; Ole Olsen; Steven Frey; Matthew Moyle; Sanjay K. Phogat; Dennis R. Burton; Laura Marjorie Walker; Pascal Raymond Georges Poignard
Original assignee: Theraclone Sciences, Inc.
Priority date: 2009-03-17
Filing date: 2010-03-17
Publication date: 2010-09-23
Also published as: PT3542817T; CA2980883A1; ES2848555T3; CY1121323T1; SI2408476T1; CA2980883C; PL3542817T3; US11584789B2; AU2010226668A1; AU2010226668B2; EP4085925A1; EP3260136A1; SI3260136T1; US10407493B2; CA2755821C; EP2408476A2; WO2010107939A3; EP3542817B1; AU2015234345C1; PT2408476T

Abstract

The invention provides a method for obtaining a broadly neutralizing antibody (bNab), including screening memory B cell cultures from a donor PBMC sample for neutralization activity against a plurality of HIV-I species, cloning a memory B cell that exhibits broad neutralization activity; and rescuing a monoclonal antibody from that memory B cell culture. The resultant monoclonal antibodies are characterized by their ability to selectively bind epitopes from the Env proteins in native or monomeric form, as well as to inhibit infection of HIV-I species from a plurality of clades. Compositions containing human monoclonal anti-HIV antibodies used for prophylaxis, diagnosis and treatment of HIV infection are provided. Methods for generating such antibodies by immunization using epitopes from conserved regions within the variable loops of gpl20 are provided. Immunogens for generating anti-HIV 1 bNAbs are also provided. Furthermore, methods for vaccination using suitable epitopes are provided.

Description

HUMAN IMMUNODEFICIENCY VIRUS (HIV)-NEUTRALIZING ANTIBODIES

RELATED APPLICATIONS

[01] This application claims the benefit of provisional applications USSN 61/161,010, filed March 17, 2009, USSN 61/165,829, filed April 1, 2009, USSN 61/224,739, filed July 10, 2009, and USSN 61/285,664, filed December 11, 2009, the contents of which are each herein incorporated by reference in their entirety.

FIELD OF THE INVENTION

[02] The present invention relates generally to therapy, diagnosis and monitoring of human immunodeficiency virus (HIV) infection. The invention is more specifically related to human neutralizing monoclonal antibodies specific for HIV-I, such as broad and potent neutralizing monoclonal antibodies specific for HIV-I and their manufacture and use. Broad neutralization suggests that the antibodies can neutralize HIV-I isolates from different individuals. Such antibodies are useful in pharmaceutical compositions for the prevention and treatment of HTV, and for the diagnosis and monitoring of HTV infection and for design of HIV vaccine immunogens.

BACKGROUND OF THE INVENTION

[03] AIDS was first reported in the United States in 1981 and has since become a major worldwide epidemic. AIDS is caused by the human immunodeficiency virus, or HIV. By killing or damaging cells of the body's immune system, HIV progressively destroys the body's ability to fight infections and certain cancers. People diagnosed with AIDS may get life-threatening diseases called opportunistic infections. These infections are caused by microbes such as viruses or bacteria that usually do not make healthy people sick. HTV is spread most often through unprotected sex with an infected partner. HIV also is spread through contact with infected blood.

The human immunodeficiency virus (HIV) is the cause of acquired immune deficiency syndrome (AIDS) (Barre-Sinoussi, F., et al., 1983, Science 220:868-870; Gallo, R., et al., 1984, Science 224:500-503). There are currently 1.25 million people in the US infected with HIV-induced acquired immunodeficiency syndrome according to a Center for Disease Control report. The epidemic is growing most rapidly among minority populations and is a leading killer of African- American males ages 25 to 44. According, AIDS affects nearly seven times more African Americans and three times more Hispanics than whites. In recent years, an increasing number of African- American women and children are being affected by HIV/ AIDS. With over 40 million people infected worldwide, the current global HIV pandemic ranks among the greatest infectious disease scourges in human history. [04] There is therefore a need for the efficient identification and production of neutralizing antibodies effective against multiple clades and strains of HIV as well as the elucidation of the target and antigenic determinants to which such antibodies bind.

SUMMARY OF THE INVENTION

[05] The present invention provides a novel method for isolating potent, broadly neutralizing monoclonal antibodies against HIV. Peripheral Blood Mononuclear Cells (PBMCs) are obtained from an HIV-infected donor selected for HIV-I neutralizing activity in the plasma, and memory B cells are isolated for culture in vitro. The B cell culture supernatants are then screened by a primary neutralization assay in a high throughput format, and B cell cultures exhibiting neutralizing activity are selected for rescue of monoclonal antibodies. It is surprisingly observed that neutralizing antibodies obtained by this method do not always exhibit gpl20 or gp41 binding at levels that correlate with neutralization activity. The method of the invention therefore allows identification of novel antibodies with cross- clade neutralization properties.

[06] The present invention provides human monoclonal antibodies specifically directed against HIV. In certain embodiments, the invention provides human anti-HTV monoclonal antibodies and sister clones thereof. For instance, an exemplary sister clone of the 1443 C16 (PG16) antibody is the 1503 H05 (PG16) antibody, the 1456 A12 (PG16) antibody, the 1469 M23 (PG 16) antibody, the 1489 113 (PG 16) antibody, or the 1480J08 (PG 16) antibody. [07] Specifically, the invention provides an isolated anti-HIV antibody, wherein said antibody has a heavy chain with three CDRs including an amino acid sequence selected from the group consisting of the amino acid sequences of SGFTFHKYGMH (SEQ ID NO: 88), LISDDGMRKYHSDSMW (SEQ ID NO: 89), and

EAGGPIWHDDVKYYDFNDGYYNYHYMDV (SEQ ID NO: 6), and a light chain with three CDRs that include an amino acid sequence selected from the group consisting of the amino acid sequences of NGTSSDVGGFDSVS (SEQ ID NO: 97), DVSHRPSG (SEQ ID NO: 95), and SSLTDRSHRI (SEQ ID NO: 41).

[08] The invention provides an isolated anti-HIV antibody, wherein said antibody has a heavy chain with three CDRs including an amino acid sequence selected from the group consisting of the amino acid sequences of SGFTFHKYGMH (SEQ ID NO: 88), LISDDGMRKYHSDSMW (SEQ ID NO: 89), and

EAGGPIWHDDVKYYDFNDGYYNYHYMDV (SEQ ID NO: 6), and a light chain with three CDRs that include an amino acid sequence selected from the group consisting of the amino acid sequences of NGTRSDVGGFDSVS (SEQ ID NO: 92), DVSHRPSG (SEQ ID NO: 95), and SSLTDRSHRI (SEQ ID NO: 41).

[09] The invention provides an isolated anti-HTV antibody, wherein said antibody has a heavy chain with three CDRs including an amino acid sequence selected from the group consisting of the amino acid sequences of SGFTFHKYGMH (SEQ ID NO: 88), LISDDGMRKYHSDSMW (SEQ ID NO: 89), and

EAGGPIWHDDVKYYDFNDGYYNYHYMDV (SEQ ID NO: 6), and a light chain with three CDRs that include an amino acid sequence selected from the group consisting of the amino acid sequences of NGTSRDVGGFDSVS (SEQ ID NO: 93), DVSHRPSG (SEQ ID NO: 95), and SSLTDRSHRI (SEQ ID NO: 41).

[10] The invention provides an isolated anti-HTV antibody, wherein said antibody has a heavy chain with three CDRs including an amino acid sequence selected from the group consisting of the amino acid sequences of SGFTFHKYGMH (SEQ ID NO: 88), LISDDGMRKYHSNSMW (SEQ ID NO: 98), and

[11] The invention provides an isolated anti-HTV antibody, wherein said antibody has a heavy chain with three CDRs including an amino acid sequence selected from the group consisting of the amino acid sequences of SGGTFSSYAFT (SEQ ID NO: 104), MVTPIFGEAKYSQRFE (SEQ ID NO: 105), and RAVPIATDNWLDP (SEQ ID NO: 102), and a light chain with three CDRs that include an amino acid sequence selected from the group consisting of the amino acid sequences of RASQTINNYLN (SEQ ID NO: 107), GASNLQNG (SEQ ID NO: 108), and QQSFSTPRT (SEQ ID NO: 42). [12] The invention provides an isolated anti-HIV antibody, wherein said antibody has a heavy chain with three CDRs including an amino acid sequence selected from the group consisting of the amino acid sequences of SGGTFSSYAFT (SEQ ID NO: 104), MVTPIFGEAKYSQRFE (SEQ ID NO: 105), and RRA VPI ATDN WLDP (SEQ ID NO: 103), and a light chain with three CDRs that include an amino acid sequence selected from the group consisting of the amino acid sequences of RASQTINNYLN (SEQ ID NO: 107), GASNLQNG (SEQ ID NO: 108), and QQSFSTPRT (SEQ ID NO: 42). [13] The invention provides an isolated anti-HIV antibody, wherein said antibody has a heavy chain with three CDRs including an amino acid sequence selected from the group consisting of the amino acid sequences of SGGAFSSYAFS (SEQ ID NO: 110), MITPVFGETKYAPRFQ (SEQ ID NO: 11 1), and RAVPIATDNWLDP (SEQ ID NO: 102), and a light chain with three CDRs that include an amino acid sequence selected from the group consisting of the amino acid sequences of RASQTIHTYL (SEQ ID NO: 113), GASTLQSG (SEQ ID NO: 1 14), and QQSYSTPRT (SEQ ID NO: 43). [14] The invention provides an isolated anti-HIV antibody, wherein said antibody has a heavy chain with three CDRs including an amino acid sequence selected from the group consisting of the amino acid sequences of SGGAFSSYAFS (SEQ ID NO: 110), MITPVFGETKYAPRFQ (SEQ ID NO: 11 1), and RRAVPIATDNWLDP (SEQ ID NO: 103), and a light chain with three CDRs that include an amino acid sequence selected from the group consisting of the amino acid sequences of RASQTTHTYL (SEQ ID NO: 113), GASTLQSG (SEQ ID NO: 1 14), and QQSYSTPRT (SEQ ID NO: 43). [15] The invention provides an isolated anti-HIV antibody, wherein said antibody has a heavy chain with three CDRs including an amino acid sequence selected from the group consisting of the amino acid sequences of SGYSFID YYLH (SEQ ID NO: 1 16), LIDPENGEARYAEKFQ (SEQ ID NO: 117), AVGADSGSWFDP (SEQ ID NO: 1 18), and a light chain with three CDRs that include an amino acid sequence selected from the group consisting of the amino acid sequences of SGSKLGDKYVS (SEQ ID NO: 120), ENDRRPSG (SEQ ID NO: 121), QAWETTTTTFVF (SEQ ID NO: 44). [16] The invention provides an isolated anti-HIV antibody, wherein said antibody has a heavy chain with three CDRs including an amino acid sequence selected from the group consisting of the amino acid sequences of SGFDFSRQGMH (SEQ ID NO: 123), FIKYDGSEKYHADSVW (SEQ ID NO: 124), and

EAGGPDYRNGYNYYDFYDGYYNYHYMDV (SEQ ID NO: 7), and a light chain with three CDRs that include an amino acid sequence selected from the group consisting of the amino acid sequences of NGTSND VGGYES VS (SEQ ID NO: 126), DVSKRPSG (SEQ ID NO: 127), and KSLTSTRRRV (SEQ ID NO: 45). [17] The invention provides an isolated anti-HIV antibody, wherein said antibody has a heavy chain with three CDRs including an amino acid sequence selected from the group consisting of the amino acid sequences of SGFTFHKYGMH (SEQ ID NO: 88), LISDDGMRKYHSDSMW (SEQ ID NO: 89),

EAGGPIWHDDVKYYDFNDGYYNYHYMDV (SEQ ID NO: 6), SGGTFSSYAFT (SEQ ID NO: 104), MVTPIFGEAKYSQRFE (SEQ ID NO: 105), RAVPIATDNWLDP (SEQ ID NO: 102), SGGAFSSYAFS (SEQ ID NO: 110), MITPVFGETKY APRFQ (SEQ ID NO: 111), SGYSFIDYYLH (SEQ ID NO: 116), LIDPENGEARY AEKFQ (SEQ ID NO: 117), AVGADSGSWFDP (SEQ ID NO: 118), SGFDFSRQGMH (SEQ ID NO: 123), FIKYDGSEKYHADSVW (SEQ ID NO: 124), EAGGPDYRNGYNYYDFYDGYYNYHYMDV (SEQ ID NO: 7),

LISDDGMRKYHSNSMW (SEQ ID NO: 98), wherein said antibody binds to and neutralizes HIV-I.

[18] The invention provides an isolated anti-HIV antibody, wherein said antibody has a light chain with three CDRs that include an amino acid sequence selected from the group consisting of the amino acid sequences of NGTSSDVGGFDSVS (SEQ ID NO: 97), DVSHRPSG (SEQ ID NO: 95), SSLTDRSHRI (SEQ ID NO: 41), RASQTTNNYLN (SEQ ID NO: 107), GASNLQNG (SEQ ID NO: 108), QQSFSTPRT (SEQ ID NO: 42), RASQΗHTYL (SEQ ID NO: 113), GASTLQSG (SEQ ID NO: 114), QQSYSTPRT (SEQ ID NO: 43), SGSKLGDKYVS (SEQ ID NO: 120), ENDRRPSG (SEQ ID NO: 121), QAWETTTTTFVF (SEQ ID NO: 44), NGTSNDVGGYESVS (SEQ ID NO: 126), DVSKRPSG (SEQ ID NO: 127), KSLTSTRRRV (SEQ ID NO: 45), NGTRSDVGGFDSVS (SEQ ID NO: 92), NGTSRDVGGFDSVS (SEQ ID NO: 93), wherein said antibody binds to and neutralizes HIV-I.

[19] The invention provides an isolated anti-HIV antibody, wherein said antibody has a heavy chain with three CDRs including an amino acid sequence selected from the group consisting of the amino acid sequences of SGFTFHKYGMH (SEQ ID NO: 88), LISDDGMRKYHSDSMW (SEQ ID NO: 89),

EAGGPIWHDDVKYYDFNDGYYNYHYMDV (SEQ ID NO: 6), SGGTFSSYAFT (SEQ ID NO: 104), MVTPIFGEAKYSQRFE (SEQ ID NO: 105), RRAVPIATDNWLDP (SEQ ID NO: 103), SGGAFSSYAFS (SEQ ID NO: 110), MITPVFGETKYAPRFQ (SEQ ID NO: 1 11), SGYSFIDYYLH (SEQ ID NO: 116), LIDPENGEARYAEKFQ (SEQ ID NO: 1 17), ' AVGADSGSWFDP (SEQ ID NO: 118), SGFDFSRQGMH (SEQ ID NO: 123), FIKYDGSEKYHADSVW (SEQ ID NO: 124), EAGGPDYRNGYNYYDFYDGYYNYHYMDV (SEQ ID NO: 7),

[20] The invention provides an isolated anti-HIV antibody, wherein said antibody has a light chain with three CDRs that include an amino acid sequence selected from the group consisting of the amino acid sequences of NGTSSDVGGFDSVS (SEQ ID NO: 97), DVSHRPSG (SEQ ID NO: 95), SSLTDRSHRI (SEQ ID NO: 41), RASQTINNYLN (SEQ ID NO: 107), GASNLQNG (SEQ ID NO: 108), QQSFSTPRT (SEQ ID NO: 42), RASQTIHTYL (SEQ ID NO: 113), GASTLQSG (SEQ ID NO: 114), QQSYSTPRT (SEQ ID NO: 43), SGSKLGDKYVS (SEQ ID NO: 120), ENDRRPSG (SEQ ID NO: 121), QAWETTTTTFVF (SEQ ID NO: 44), NGTSND VGGYESVS (SEQ ID NO: 126), DVSKRPSG (SEQ ID NO: 127), KSLTSTRRRV (SEQ ID NO: 45), NGTRSDVGGFDSVS (SEQ ID NO: 92), NGTSRDVGGFDSVS (SEQ ID NO: 93), wherein said antibody binds to and neutralizes HIV-I.

[21] The invention provides an isolated anti-HIV antibody or fragment thereof, wherein said antibody includes: (a) a V_H CDRl region comprising the amino acid sequence of SEQ ID NO: 88, 104, 110, 1 16, or 123; (b) a V_H CDR2 region comprising the amino acid sequence of SEQ ID NO: 98, 89, 91, 105, 1 11, 117, or 124; and (c) a V_H CDR3 region comprising the amino acid sequence of SEQ ID NO: 6, 102, 103, 118, or 7, wherein said antibody binds to and neutralizes HIV-I. In certain aspects, this antibody further includes: (a) a V_L CDRl region comprising the amino acid sequence of SEQ ID NO: 93, 92, 97, 94, 107, 113, 120, or 126; (b) a V_L CDR2 region comprising the amino acid sequence of SEQ ID NO: 95, 108, 114, 121, or 127; and (c) a V_L CDR3 region comprising the amino acid sequence of SEQ ID NO: 41, 42, 43, 44, or 45.

[22] The invention provides an isolated fully human monoclonal anti-HTV antibody including: a) a heavy chain sequence comprising the amino acid sequence of SEQ ID NO: 31 and a light chain sequence comprising amino acid sequence SEQ ID NO: 32, or b) a heavy chain sequence comprising the amino acid sequence of SEQ ID NO: 33 and a light chain sequence comprising amino acid sequence SEQ ID NO: 34, or c) a heavy chain sequence comprising the amino acid sequence of SEQ ID NO: 35 and a light chain sequence comprising amino acid sequence SEQ ID NO: 36, or d) a heavy chain sequence comprising the amino acid sequence of SEQ ID NO: 37 and a light chain sequence comprising amino acid sequence SEQ ID NO: 38, or e) a heavy chain sequence comprising the amino acid sequence of SEQ ID NO: 39 and a light chain sequence comprising amino acid sequence SEQ ID NO: 40, or f) a heavy chain sequence comprising the amino acid sequence of SEQ ID NO: 140 and a light chain sequence comprising amino acid sequence SEQ ID NO: 96, or g) a heavy chain sequence comprising the amino acid sequence of SEQ ID NO: 48 and a light chain sequence comprising amino acid sequence SEQ ID NO: 51, or h) a heavy chain sequence comprising the amino acid sequence of SEQ ID NO: 54 and a light chain sequence comprising amino acid sequence SEQ ID NO: 57, or i) a heavy chain sequence comprising the amino acid sequence of SEQ ID NO: 60 and a light chain sequence comprising amino acid sequence SEQ ID NO: 32.

[23] The invention provides a composition including any one of the isolated anti-HIV antibodies described herein.

[24] Optionally, an anti-HIV human monoclonal antibody of the invention is isolated from a B-cell from an HIV- 1 -infected human donor. In some embodiments, the antibody is effective in neutralizing a plurality of different clades of HIV. In some embodiments, the antibody is effective in neutralizing a plurality of different strain within the same clade of HTV- 1. In some embodiments, the neutralizing antibody binds to the HIV envelope proteins gpl20, or gp41 or envelope protein on HIV-I pseudovirions or expressed on transfected or infected cell surfaces. In some embodiments, the neutralizing antibody does not bind to recombinant or monomeric envelope proteins gpl20, or gp41 or envelope protein on HTV-I pseudovirions or expressed on transfected or infected cell surfaces but binds to natural trimeric forms of the HIV-I Env proteins.

[25] The present invention provides human monoclonal antibodies wherein the antibodies are potent, broadly neutralizing antibody (bNAb). In some embodiments, a broadly neutralizing antibody is defined as a bNAb that neutralizes HIV-I species belonging to two or more different clades. In some embodiments the different clades are selected from the group consisting of clades A, B, C, D, E, AE, AG, G or F. In some embodiments the HIV-I strains from two or more clades comprise virus from non-B clades.

[26] In some embodiments, a broadly neutralizing antibody is defined as a bNAb that neutralizes at least 60% of the HIV-I strains listed in Tables 18A-18F. In some embodiments, at least 70%, or at least 80%, or at least 90% of the HIV-I strains listed in Tables 18A-18F are neutralized. [27] In some embodiments, a potent, broadly neutralizing antibody is defined as a bNAb that displays a potency of neutralization of at least a plurality of HIV-I species with an IC50 value of less than 0.2 μg/mL. In some embodiments the potency of neutralization of the HIV- 1 species has an IC50 value of less than 0.15 μg/mL, or less than 0.10 μg/mL, or less than 0.05 μg/mL.

A potent, broadly neutralizing antibody is also defined as a bNAb that displays a potency of neutralization of at least a plurality of HIV-I species with an IC90 value of less than 2.0 μg/mL. In some embodiments the potency of neutralization of the HIV-I species has an IC90 value of less than 1.0 μg/mL, or less than 0.5 μg/mL.

[28] Exemplary monoclonal antibodies that neutralize HTV-I include 1496 C09 (PG9), 1443_C16 (PG16), 1456_P20 (PG20), 1460_G14 (PGG14), and 1495_C14 (PGC14) described herein. Alternatively, the monoclonal antibody is an antibody that binds to the same epitope as 1496_C09 (PG9), 1443_C16 (PG 16), 1456_P20 (PG20), 1460_G14 (PGG 14), and 1495_C14 (PGC 14). Specifically, monoclonal antibodies PG9 and PG 16 are broad and potent neutralizing antibodies. The antibodies are respectively referred to herein as HIV antibodies.

[29] The invention provides a number of isolated human monoclonal antibodies, wherein each said monoclonal antibody binds to HIV-I infected or transfected cells; and binds to HIV-I virus. A neutralizing antibody having potency in neutralizing HIV-I, or a fragment thereof is provided. In some embodiments a neutralizing antibody of the invention exhibits higher neutralization index and/or a higher affinity for binding to the envelope proteins gpl20, or gp41 than anti-HTV mAbs known in the art, such as the mAb bl2. (Burton DR et al., Science Vol. 266. no. 5187, pp. 1024 - 1027). Exemplary monoclonal antibodies 1496_C09 (PG9), 1443_C16 (PG16), 1456_P20 (PG20), 1460_G14 (PGG14), and 1495_C14 (PGC 14) exhibit binding to the envelope glycoprotein gpl20, but not gp41, in an ELISA assay, however gpl20 binding does not always correlate with neutralization activity against specific strains of HIV-I . In some embodiments, monoclonal antibodies, for example 1443_C16 (PG 16) and 1496_C09 (PG9), display none or weak gpl20 binding activity against a particular strain but bind to HIV-I trimer on transfected or infected cell surface and/or virion and exhibit broad and potent neutralization activity against that strain of HIV-I . [30] In one aspect the antibody is a monoclonal antibody comprising one or more polypeptides selected from the group consisting of 1496_C09 (PG9), 1443_C16 (PG 16), 1456_P20 (PG20), 1460_G14 (PGG14), and 1495_C14 (PGC14); comprising a heavy chain selected from the group consisting of the heavy chain of 1496_C09 (PG9), 1443_C16

(PG16), 1456_P20 (PG20), 1460_G14 (PGG14), and 1495_C14 (PGC14); comprising a heavy chain comprising a CDR selected from the group consisting of the CDRs of the heavy chain of 1496_C09 (PG9), 1443_C16 (PG16), 1456_P20 (PG20), 1460_G14 (PGG14), and

1495_C14 (PGC14); comprising a light chain selected from the group consisting of the light chain of 1496_C09 (PG9), 1443_C16 (PG16), 1456_P20 (PG20), 1460_G14 (PGG14), and

1495_C14 (PGC 14); comprising a light chain comprising a CDR selected from the group consisting of the CDRs of the light chain of 1496_C09 (PG9), 1443_C16 (PG16), 1456_P20

(PG20), 1460_G14 (PGG 14), and 1495_C14 (PGC 14).

[31] The invention relates to an antibody or a fragment thereof, such as Fab, Fab¹, F(ab')2 and Fv fragments that binds to an epitope or immunogenic polypeptide capable of binding to an antibody selected from 1496_C09 (PG9), 1443_C16 (PG 16), 1456_P20 (PG20),

1460_G14 (PGG14), and 1495_C14 (PGC14). The invention also relates to immunogenic polypeptides encoding such epitopes.

[32] Nucleic acid molecules encoding such antibodies, and vectors and cells carrying such nucleic acids are also provided.

[33] The invention relates to a pharmaceutical composition comprising at least one antibody or fragment as recited herein, together with a pharmaceutically acceptable carrier.

[34] The invention relates to a method of immunizing, preventing or inhibiting HIV infection or an HIV-related disease comprising the steps of identifying a patient in need of such treatment and administering to said patient a therapeutically effective amount of at least one monoclonal antibody as recited herein.

[35] In a further aspect the HIV antibodies according to the invention are linked to a therapeutic agent or a detectable label.

[36] Additionally, the invention provides methods for stimulating an immune response, treating, preventing or alleviating a symptom of an HIV viral infection by administering an

HIV antibody to a subject

[37] In another aspect, the invention provides methods of administering the HIV antibody of the invention to a subject prior to, and/or after exposure to an HIV virus. For example, the

HIV antibody of the invention is used to treat or prevent HIV infection. The HIV antibody is administered at a dose sufficient to promote viral clearance or eliminate HIV infected cells.

[38] Also included in the invention is a method for determining the presence of an HIV virus infection in a patient, by contacting a biological sample obtained from the patient with an HIV antibody; detecting an amount of the antibody that binds to the biological sample; and comparing the amount of antibody that binds to the biological sample to a control value.

[39] The invention further provides a diagnostic kit comprising an HTV monoclonal antibody.

[40] The invention relates to a broadly neutralizing antibody (bNAb) wherein the antibody neutralizes at least one member of each clade with a potency greater than that of the bNAbs bl2, 2G12, 2F5 and 4E10 respectively-

[41] The invention relates to a broadly neutralizing antibody (bNAb) wherein the antibody does not bind monomeric gpl20 or gp41 proteins of the HIV-I env gene. The antibody binds with higher affinity to trimeric forms of the HIV-I Env expressed on a cell surface than to the monomeric gpl20 or artificially trimerized gpl40. In some aspects, the antibody binds with high affinity to uncleaved HIV-I gpl60 trimers on a cell surface.

[42] The invention relates to a broadly neutralizing antibody (bNAb) wherein the antibody binds an epitope within the variable loop of gpl20, wherein the epitope comprises the conserved regions of V2 and V3 loops of gpl20, wherein the epitope comprises N- glycosylation site at residue Asn-160 within the V2 loop of gpl20, wherein the antibody binds an epitope presented by a trimeric spike of gpl20 on a cell surface, wherein the epitope is not presented when gpl20 is artificially trimerized. In some embodiments, the antibody does not neutralize the HIV-I in the absence of N-glycosylation site at residue Asn-160 within the V2 loop of gpl20.

[43] The invention relates to a broadly neutralizing antibody (bNAb) selected from the group consisting of PG 16 and PG9.

[44] The invention relates to an antigen or an immunogenic polypeptide, or a vaccine comprising such antigen or immunogenic polypeptide, for producing a broadly neutralizing antibody (bNAb) by an immune response, the antigen comprising an epitope within the variable loop of gpl20 according to the invention.

[45] The invention relates to method for passive or active immunization of an individual against a plurality of HIV-I species across one or more clades, the method comprising: providing a broadly neutralizing antibody (bNAb) wherein the bNAb neutralizes HIV-I species belonging to two or more clades, and further wherein the potency of neutralization of at least one member of each clade is determined by an IC50 value of less than 0.005 μg/mL.

In some embodiments, the antibody is selected from the group consisting of PG9 and PG 16. [46] In some embodiments, the antibody is produced by active immunization with an antigen comprising an epitope within the variable loop of gpl20, wherein the epitope comprises the conserved regions of V2 and V3 loops of gpl20 or, wherein the epitope comprises an N-glycosylation site at residue Asn-160 within the V2 loop of gpl20. In some aspects, the epitope is presented by a trimeric spike of gpl20 on a cell surface, and the epitope is not presented when gpl20 is monomeric or artficially trimerized. . [47] Other features and advantages of the invention will be apparent from and are encompassed by the following detailed description and claims.

BRIEF DESCRIPTION OF THE DRAWINGS

[48] Figure 1 A is a schematic tree diagram of Clustal W-aligned variable region sequences of heavy chains of the monoclonal antibodies.

[49] Figure IB is a schematic tree diagram of Clustal W-aligned variable region sequences of light chains of the monoclonal antibodies.

[50] Figure 2 is a flow chart of the process for isolation of monoclonal antibodies according to the invention.

[51] Figure 3A is a schematic diagram that summarizes the screening results for neutralization and HTV-env protein (gpl20 and gp41) binding assays from which B cell cultures were selected for antibody rescue and the monoclonal antibodies 1496 C09 (PG9),

1443_C16 (PG16), 1456_P20 (PG20), 1460_G14 (PGG14), and 1495_C14 (PGC14) were derived. A neutralization index value Of 1.5 was used as a cut-off.

[52] Figure 3B is a schematic diagram that summaries the neutralizing activity and HIV- env protein (gpl20 and gp41) binding activities of the monoclonal antibodies 1496_C09

(PG9), 1443_C16 (PG 16), 1456_P20 (PG20), 1460_G14 (PGG 14), and 1495_C14 (PGC 14) as determined by ELISA assays among the B cell supernatants using a neutralization index cut-off value of 2.0. The neutralization index was expressed as the ratio of normalized relative luminescence units (RLU) of SIVmac239 to that of test viral strain derived from the same test B cell culture supernatant. The cut-off values used to distinguish neutralizing hits were determined by the neutralization index of a large number of negative control wells containing B cell culture supernatants derived from healthy donors.

[53] Figure 4 is a series of graphs depicting the neutralization activity of monoclonal antibodies 1443_C16 (PG 16) and 1496_C09 (PG9) to additional pseudoviruses not included in Tables 17A and 17B. [54] Figure 5 is a graph depicting the dose response curves of 1456 P20 (PG20),

1495 C14 (PGC 14) and 1460_G14 (PGG 14) binding to recombinant gpl20 in ELISA as compared to control anti-gpl20 (bl2). Data is presented as average OD values of triplicate

ELISA wells obtained on the same plate.

[55] Figure 6 is a series of graphs depicting the results from ELISA binding assays of monoclonal antibodies 1443_C16 (PG 16) and 1496_C09 (PG9) to HIV-I YU2 gpl40, JR-

CSFgpl20, membrane-proximal external regions (MPER) peptide of gp41 and V3 polypeptide.

[56] Figure 7 is a graph depicting the results of a binding assay using monoclonal antibodies 1443_C16 (PG 16) and 1496_C09 (PG9) to HIV-I YU2 gpl60 expressed on the cell surface in the presence and absence of soluble CD4 (sCD4).

[57] Figure 8 is a graph depicting the results of a binding assay using monoclonal antibodies 1443_C16 (PG16) and 1496_C09 (PG9) to HIV-I gpl60 transfected cells.

[58] Figure 9 is a series of graphs depicting the results of a capture assay. The data describe capturing of entry-competent JRCSF pseudovirus by neutralizing monoclonal antibodies 1443_C16 (PG 16) and 1496_C09 (PG9) in a dose-dependent manner.

[59] Figure 1OA is a graph depicting the results of a competitive binding assay using monoclonal antibodies sCD4, PG 16 and PG9, wherein the claimed antibodies compete for the binding of monoclonal antibody 1443 C16 (PG16) to pseudovirus but control antibodies bl2,

2G12, 2F5 and 4E10 do not competitively bind to the pseudovirus.

[60] Figure 1OB is a graph depicting the results of a competitive binding assay using monoclonal antibodies sCD4, PG 16 and PG9, wherein the claimed antibodies compete for the binding of monoclonal antibody 1496 C09 (PG9) to pseudovirus but control antibodies bl2,

2G12, 2F5 and 4E10 do not competitively bind to the pseudovirus.

[61] Figure 1 IA is a series of graphs depicting the results of a binding assay using PG9 and PG16. The data show that PG9 and PG16 bind to monomeric gpl20 and artificially trimerized gpl40 constructs as determined by ELISA. IgG bl2 was used as a control for

ELISA assays.

[62] Figure 1 IB is a series of graphs depicting the results of a binding assay using PG9 and

PG 16. The data show that PG9 and PG 16 bind to Env expressed on the surface of 293T cells as determined by flow cytometry. The bNAb bl2 and the non-neutralizing antibody b6 are included in the cell surface binding assays to show the expected percentages of cleaved and unc leaved Env expressed on the cell surface. [63] Figure 12 is a series of graphs depicting the results of a binding assay using PG9 and

PG16 and cleavage-defective HIV-1YU2 trimers. PG9 and PG16 bind with high 'affinity to cleavage-defective HIV- 1YU2 trimers as determined by flow cytometry. Binding curves were generated by plotting the MFI of antigen binding as a function of antibody concentration.

[64] Figure 13A-E is a series of graphs depicting the mapping the PG9 and PG 16 epitopes.

Competitor antibody is indicated at the top of each graph. 2Gl 2 is included to control for cell surface Env expression. A: PG9 and PGl 6 compete with each other for cell surface Env binding and neither antibody competes with the CD4bs antibody bl2 for Env binding. B:

Ligation of cell surface Env with sCD4 diminishes binding of PG9 and PG 16. 2Gl 2 is included to control for CD4-induced shedding of gpl20. C: sCD4 inhibits binding of PG9 to artificially trimerized gpl40YU-2 as determined by ELISA. D: PG9 competes with 10/76b

(anti-V2), F425/b4e8 (anti-V3) and X5 (CD4i) for gpl20 binding in competition ELISA assays. E: PG9 and PG 16 fail to bind variable loop deleted HIV-IJR-CSF variants expressed on the surface of 293T cells.

[65] Figure 14 is a series of graphs depicting the results of competition ELISA assays using the monoclonal antibody PG9.

[66] Figure 15 is a graph depicting monoclonal antibody binding, PG9 or PG 16, to HTV-

1JR-FLΔCT E168K Env expressed on the surface of 293T cells as determined by flow cytometry.

[67] Figure 16 is a graph depicting monoclonal antibody PG9 binding to deglycosylated gpl20.

[68] Figure 17 is a series of graphs depicting the neutralization activity of PG9 and PG 16 against HTV- I SF 162 and HIV- ISF 162 K 160N, which was determined using a single-round replication luciferase reporter assay of pseudotyped virus.

[69] Figure 18 is a series of graphs depicting the binding of PG9 and PG 16 to mixed trimers. Alanine substitutions at positions 160 and 299 were introduced into HIV-I YU2 Env to abolish binding of PG9 and PG 16. An alanine substitution at position 295 was also introduced into the same construct to abrogate binding of 2G12. Co-transfection of 293T cells with WT and mutant plasmids in a 1 :2 ratio resulted in the expression of 29% mutant homotrimers, 44% heterotrimers with two mutant subunits, 23% heterotrimers with one mutant subunit, and 4% wild-type homotrimers. [70] Figure 19 is a series of graphical depictions of the number of nucleotide or amino acid differences in the heavy chain sequences of sister clones of 1443 Cl 6 (PGl 6) among each other. Note that the single nucleotide difference of 1408 108 translates into an identical protein sequence of 1443 C16. The nucleotide sequence of the 1408 108 light chain is identical to the nucleotide sequence of the light chain of 1443 C16.

[71] Figure 2OA is a tree diagram illustrating the correlation of the heavy chain of 1443

Cl 6 sister clones to the heavy chain of 1496 C09 at the nucleotide level.

[72] Figure 2OB is a tree diagram illustrating the correlation of the light chain of 1443 Cl 6 sister clones to the light chain of 1496 C09 at the nucleotide level.

[73] Figure 21 A is a tree diagram illustrating the correlation of the heavy chain of 1443

Cl 6 sister clones to the heavy chain of 1496 C09 at the protein level.

[74] Figure 21B is a tree diagram illustrating the correlation of the light chain of 1443 C16 sister clones to the light chain of 1496 C09 at the protein level.

DETAILED DESCRIPTION OF THE INVENTION

[75] In the sera of human immunodeficiency virus type 1 (HIV-I) infected patients, antivirus antibodies can be detected over a certain period after infection without any clinical manifestations of the acquired immunodeficiency syndrome (AIDS). At this state of active immune response, high numbers of antigen-specific B-cells are expected in the circulation. These B-cells are used as fusion partners for the generation of human monoclonal anti-HIV antibodies. One major drawback to finding a vaccine composition suitable for more reliable prevention of human individuals from HIV-I infection and/or for more successful therapeutic treatment of infected patients is the ability of the HIV-I virus to escape antibody capture by genetic variation, which very often renders the remarkable efforts of the researchers almost useless. Such escape mutants may be characterized by a change of only one or several of the amino acids within one of the targeted antigenic determinants and may occur, for example, as a result of spontaneous or induced mutation. In addition to genetic variation, certain other properties of the HIV-I envelope glycoprotein makes it difficult to elicit neutralizing antibodies making generation of undesirable non-neutralizing antibodies a major concern (see Phogat SK and Wyatt RT, Curr Pharm Design 2007; 13(2):213-227). [76] HIV-I is among the most genetically diverse viral pathogens. Of the three main branches of the HIV-I phylogenetic tree, the M (main), N (new), and O (outlier) groups, group M viruses are the most widespread, accounting for over 99% of global infections. This group is presently divided into nine distinct genetic subtypes, or clades (A through K), based on full-length sequences. Env is the most variable HIV-I gene, with up to 35% sequence diversity between clades, 20% sequence diversity within clades, and up to 10% sequence diversity in a single infected person (Shankarappa, R. et al. 1999. J. Virol. 73:10489-10502). Clade B is dominant in Europe, the Americas, and Australia. Clade C is common in southern Africa, China, and India and presently infects more people worldwide than any other clade (McCutchan, FE. 2000. Understanding the genetic diversity of HIV-I. AIDS 14(Suppl. 3):S31-S44). Clades A and D are prominent in central and eastern Africa. [77] Neutralizing antibodies (NAbs) against viral envelope proteins (Env) provide adaptive immune defense against human immunodeficiency virus type 1 (HIV-I) exposure by blocking the infection of susceptible cells (Kwong PD et al., 2002. Nature 420: 678-682). The efficacy of vaccines against several viruses has been attributed to their ability to elicit NAbs. However, despite enormous efforts, there has been limited progress toward an effective immunogen for HIV-I. (Burton, D. R. 2002. Nat. Rev. Immunol. 2:706-713). [78] HIV-I has evolved with an extensive array of strategies to evade antibody-mediated neutralization. (Barouch, D.H. Nature 455, 613-619 (2008); Kwong, P.D. & Wilson, LA. Nat Immunol 10, 573-578 (2009); Karlsson Hedestam, G.B., et al. Nat Rev Microbiol 6, 143-155 (2008)). However, broadly neutralizing antibodies (bNAbs) develop over time in a proportion of HIV-I infected individuals. (Leonidas Stamatatos, L.M., Dennis R Burton, and John Mascola. Nature Medicine (E-Pub: Jun. 14, 2009); PMID: 19525964.) A handful of broadly neutralizing monoclonal antibodies have been isolated from clade B infected donors. (Burton, D.R., et al. Science 266, 1024-1027 (1994); Trkola, A., et al. J Virol 69, 6609-6617 (1995); Stiegler, G., et al. AIDS Res Hum Retroviruses 17, 1757-1765 (2001)). These antibodies tend to display less breadth and potency against non-clade B viruses, and they recognize epitopes on the virus that have so far failed to elicit broadly neutralizing responses when incorporated into a diverse range of immunogens. (Phogat, S. & Wyatt, R. Curr Pharm Design 13, 213-227 (2007); Montero, M., van Houten, N.E., Wang, X. & Scott, J.K. Microbiol MoI Biol Rev 72, 54-84, table of contents (2008); Scanlan, C.N., Offer, J., Zitzmann, N. & Dwek, R. A. Nature 446, 1038-1045 (2007)).

Despite the enormous diversity of the human immunodeficiency virus (HIV), all HIV viruses known to date interact with the same cellular receptors (CD4 and/or a co-receptor, CCR5 or CXCR4). Most neutralizing antibodies bind to functional regions involved in receptor interactions and cell membrane fusion. However, the vast majority of neutralizing antibodies isolated to date do not recognize more than one clade, therefore exhibiting limited protective efficacy in vitro or in vivo. (See Binley JM et al., 2004. J. Virol. 78(23): 13232- 13252). The rare broadly neutralizing human monoclonal antibodies (mAbs) that have been isolated from HTV+ clade B-infected human donors bind to products of the env gene of HIV-I, gpl20 and the transmembrane protein gp41. (Parren, PW et al. 1999. AIDS 13:S137-S162). However, a well-known characteristic of the HIV-I envelope glycoprotein is its extreme variability. It has been recognized that even relatively conserved epitopes on HIV-I, such as the CD4 binding site, show some variability between different isolates (Poignard, P., et al., Ann. Rev. Immunol. (2001) 19:253-274). Even an antibody targeted to one of these conserved sites can be expected to suffer from a reduced breadth of reactivity across multiple different isolates. [79] The few cross-clade reactive monoclonal antibodies known to date have been isolated by processes involving generation of panels of specific viral antibodies from peripheral blood lymphocytes (PBLs) of HIV-infected individuals, either via phage display, or via conventional immortalization techniques such as hybridoma or Epstein Barr virus transformation, electrofusion and the like. These are selected based on reactivity in vitro to HIV-I proteins, followed by testing for HIV neutralization activity. [80] An antibody phage surface expression system was used to isolate the cross-clade neutralizing Fab (fragment, antigen binding) bl2 occurring in a combinatorial library. The Fab bl2 was screened by panning for envelope glycoprotein gpl20 binding activity and neutralizing activity against the HIV-I (HXBc2) isolate was observed. (Roben P et al., J. Virol. 68(8): 4821-4828(1994); Barbas CF et al., Proc. Natl. Acad. Sci. USA Vol. 89, pp. 9339-9343, (1992); Burton DP et al., Proc. Natl. Acad. Sci. USA Vol. 88, pp. 10134-10137 (1991)).

[81] Human B cell immortalization was used to isolate the cross-clade neutralizing monoclonal antibodies 2G12, 2F5, and 4E10 from HIV-infected individuals. The monoclonal antibody 2Gl 2 binds to a glycotope on the gpl20 surface glycoprotein of HIV-I and had been shown to display broad neutralizing patterns. (Trkola A., et al., J. Virol. 70(2):l 100-1108 (1996), Buchacher, A., et al., 1994. AIDS Res. Hum. Retroviruses 10:359- 369). The monoclonal antibody 2F5 which had been shown to bind a sequence within the external domain of the gp41 envelope glycoprotein of HTV-I was found to have broad neutralization properties. (Conley AJ Proc. Natl. Acad. Sci. USA Vol. 91, pp. 3348-3352 (1994); Muster T et al., J. Virol. 67(1 1):6642-6647 (1993); Buchacher A et al., 1992, Vaccines 92:191-195). The monoclonal antibody 4E10, which binds to a novel epitope C terminal of the ELDKWA sequence in gp41 recognized by 2F5, has also been found to have potent cross-clade neutralization activity. (Buchacher, A., et al., 1994. AIDS Res. Hum. Retroviruses 10:359-369; Stiegler, G., et al., 2001. AIDS Res. Hum. Retroviruses 17(18): 1757-1765)).

[82] Other studies on antibody neutralization of HIV-I (Nara, P. L., et al. (1991) FASEB J. 5:2437-2455.) focused on a single linear epitope in the third hypervariable region of the viral envelope glycoprotein gpl20 known as the V3 loop. Antibodies to this loop are suggested to neutralize by inhibiting fusion of viral and cell membranes. However there is sequence variability within the loop and neutralizing antibodies are sensitive to sequence variations outside the loop (Albert J. et al., (1990) AIDS 4, 107-112). Hence anti-V3 loop antibodies are often strain-specific and mutations in the loop in vivo may provide a mechanism for viral escape from antibody neutralization. There is some indication that not all neutralizing antibodies act by blocking the attachment of virus, since a number of mouse monoclonal antibodies inhibiting CD4 binding to gpl20 are either non-neutralizing (Lasky LA, et al., (1987) Cell 50:975-985.) or only weakly neutralizing (Sun N., et al., (1989) J. Virol. 63, 3579-3585).

[83] It is widely accepted that such a vaccine will require both T-cell mediated immunity as well as the elicitation of a broadly neutralizing antibody (bNAb) response. (Barouch, D.H. Nature 455, 613-619 (2008); Walker, B.D. & Burton, D.R. Science 320, 760-764 (2008); Johnston, M.I. & Fauci, A.S. N Engl J Med 356, 2073-2081 (2007)). All of the known bNAbs provide protection in the best available primate models (Veazey, R.S., et al. Nat Med 9, 343-346 (2003); Hessell, A.J., et al. PLoS Pathog 5, el000433 (2009); Parren, P. W., et al. J Virol 75, 8340-8347 (2001); Mascola, J.R. Vaccine 20, 1922-1925 (2002); Mascola, J.R., et al. Nat Med 6, 207-210 (2000); Mascola, J.R., et al. J Virol 73, 4009-4018 (1999)). Therefore, broadly neutralizing antibodies (bNAbs) are considered to be the types of antibodies that should be elicited by a vaccine. Unfortunately, existing immunogens, often designed based on these bNAbs, have failed to elicit NAb responses of the required breadth and potency. Therefore, it is of high priority to identify new bNAbs that bind to epitopes that may be more amenable to incorporation into immunogens for elicitation of NAb responses. [84] The present invention provides a novel method for isolating novel broad and potent neutralizing monoclonal antibodies against HIV. The method involves selection of a PBMC donor with high neutralization titer of antibodies in the plasma. B cells are screened for neutralization activity prior to rescue of antibodies. Novel broadly neutralizing antibodies are obtained by emphasizing neutralization as the initial screen.

[85] The invention relates to potent, broadly neutralizing antibody (bNAb) wherein the antibody neutralizes HIV-I species belonging to two or more clades, and further wherein the potency of neutralization of at least one member of each clade is determined by an IC50 value of less than 0.2 μg/mL. In some aspects, the clades are selected from Clade A, Clade B, Clade C, Clade D and Clade AE. In some aspects, the HIV-I belonging two or more clades are non-Clade B viruses. In some aspects, the broadly neutralizing antibody neutralizes at least 60% of the HIV-I strains listed in Tables 18A-18F. In some embodiments, at least 70%, or at least 80%, or at least 90% of the HIV-I strains listed in Tables 18A-18F are neutralized. [86] The invention relates to potent, broadly neutralizing antibody (bNAb) wherein the antibody neutralizes HTV-I species with a potency of neutralization of at least a plurality of HTV-I species with an IC50 value of less than 0.2 μg/mL. In some embodiments the potency of neutralization of the HIV-I species has an IC50 value of less than 0.15 μg/mL, or less than 0.10 μg/mL, or less than 0.05 μg/mL. In some aspects, a potent, broadly neutralizing antibody is defined as a bNAb that displays a potency of neutralization of at least a plurality of HIV-I species with an IC90 value of less than 2.0 μg/mL. In some embodiments the potency of neutralization of the HIV-I species has an IC90 value of less than 1.0 μg/mL, or less than 0.5 μg/mL.

[87] An exemplary method is illustrated in the schematic shown in Figure 4. Peripheral Blood Mononuclear Cells (PBMCs) were obtained from an HIV-infected donor selected for HTV-I neutralizing activity in the plasma. Memory B cells were isolated and B cell culture supernatants were subjected to a primary screen of neutralization assay in a high throughput format. Optionally, HIV antigen binding assays using ELISA or like methods were also used as a screen. B cell lysates corresponding to supernatants exhibiting neutralizing activity were selected for rescue of monoclonal antibodies by standard recombinant methods. [88] In one embodiment, the recombinant rescue of the monoclonal antibodies involves use of a B cell culture system as described in Weitcamp J-H et al., J. Immunol. 171 :4680- 4688 (2003). Any other method for rescue of single B cells clones known in the art also may be employed such as EBV immortalization of B cells (Traggiai E., et al., Nat. Med. 10(8):871-875 (2004)), electrofusion (Buchacher, A., et al., 1994. AIDS Res. Hum. Retroviruses 10:359-369), and B cell hybridoma (Karpas A. et al., Proc. Natl. Acad. Sci. USA 98:1799-1804 (2001). [89] In some embodiments, monoclonal antibodies were rescued from the B cell cultures using variable chain gene-specific RT-PCR, and transfectant with combinations of H and L chain clones were screened again for neutralization and HIV antigen binding activities. mAbs with neutralization properties were selected for further characterization. [90] A novel high-throughput strategy was used to screen IgG-containing culture screening supernatants from approximately 30,000 activated memory B cells from a clade A infected donor for recombinant, monomeric gpl20JR-CSF and gp41HxB2 (Env) binding as well as neutralization activity against HTV- IJR-CSF and HTV- ISF 162 (See Table 1).

[91] Table 1: Memory B cell Screening.

[92] Unexpectedly, a large proportion of the B cell supernatants that neutralized HTV-I JR- CSF did not bind monomeric gpl20JR-CSF or gp41HxB2, and there were only a limited number of cultures that neutralized both viruses (Fig. 3B). Antibody genes were rescued from five B cell cultures selected for differing functional profiles; one bound to gpl20 and only neutralized HTV-1SF162, two bound to gpl20 and weakly neutralized both viruses, and two potently neutralized HIV-IJR-CSF, failed to neutralize HIV-I SFl 62, and did not bind to monomeric gpl20 or gp41.

Five antibodies identified according to these methods are disclosed herein. The antibodies were isolated from a human sample obtained through International AIDS Vaccine Initiative's (IAVI's) Protocol G, and are produced by the B cell cultures referred to asl443_C16, 1456_P20, 1460_G14, 1495_C14 or 1496_C09. Antibodies referred to as 1443_C16 (PG 16), 1456_P20 (PG20), 1460_G14 (PGG 14), 1495_C14 (PGC 14) or 1496_C09 (PG9), were isolated from the corresponding B cell cultures. These antibodies have been shown to neutralize HIV in vitro.

Analysis of the antibody variable genes revealed that two antibody pairs were related by somatic hypermutation and that two of the somatic variants contained unusually long CDRH3 loops (Table 2). Long CDRH3 loops have previously been associated with polyreactivity. (Ichiyoshi, Y. & Casali, P. J Exp Med 180, 885-895 (1994)). The antibodies were tested against a panel of antigens and the antibodies were confirmed to be not polyreactive.

^* Germ line gene sequences were determined using the IMGT database, which is publicly available at imgt.cines.fr. "L" and "K" refer to lamda and kappa chains, respectively, b Bolded amino acids denote differences between somatic variants.

[96] The broadly neutralizing antibodies from 1443_C 16 (PG 16) and 1496_C09 (PG9) clones obtained by this method did not exhibit soluble gpl20 or gp41 binding at levels that correlate with neutralization activity. The method of the invention therefore allows identification of novel antibodies with broad cross-clade neutralization properties regardless of binding activities in an ELISA screen. Further characterization of PG 16 and PG9 is disclosed herein.

[97] All five antibodies were first tested for neutralization activity against a multi-clade 16-pseudovirus panel (Table 4). Two of the antibodies that bound to monomeric gpl20 in the initial screen (PGG 14 and PG20) did not show substantial neutralization breadth or potency against any of the viruses tested, and the third antibody that bound to gpl20 (PGC 14) neutralized 4/16 viruses with varying degrees of potency. In contrast, the two antibodies that failed to bind recombinant Env in the initial screen (PG9 and PG 16) neutralized a large proportion of the viruses at sub-microgram per ml concentrations. PG9 and PGl 6 neutralized non-clade B viruses with greater breadth than three out of the four existing bNAbs. This is significant considering that the majority of HTV-I infected individuals worldwide are infected with non-clade B viruses. [98] Table 4: Neutralization Profiles of Rescued mAbs

° Plateau observed in curve.

[99] Table 17A shows neutralization profiles (IC50 values) of monoclonal antibodies 1443_C16 (PG 16), 1456_P20 (PG20), 1460_G14 (PGG 14), 1495_C14 (PGC 14) and 1496_C09 (PG9) and the known cross-clade neutralizing antibodies bl2, 2G12, 2F5 and 4E10 on a diverse panel of 16 HIV pseudoviruses from different clades. 1443_C16 (PG16) and 1496_C09 (PG9) neutralize HIV-I species from Clades A, B, C, D and CRF01_AE with better potency for most viral strains tested than known and generally accepted broad and potent neutralizing antibodies. However, neutralization profiles of individual species of HIV- 1 belonging to these clades vary between 1443_C16 (PG 16) and 1496_C09 (PG9) and the known cross-clade neutralizing antibodies bl2, 2G12, 2F5 and 4E10. 1495_C14 (PGC 14) neutralizes fewer HIV-I species from Clades A, B and C comparable to other neutralizing antibodies. Table 17B shows IC90 values of the monoclonal antibodies 1443_C16 (PG 16) and 1496_C09 (PG9) and the known cross-clade neutralizing antibodies bl2, 2G12, 2F5 and 4E10 on the same panel of pseudoviruses. Figure 4 shows neutralization activities of monoclonal antibodies 1443_C16 (PG16) and 1496_C09 (PG9) to six other HIV pseudoviruses (YU2, BaI, ADA, DUl 72, DU422, and ZM 197) for clades B and C not included in Tables 17A and 17B.

[100] PG9, PG 16, and PGC 14 were next evaluated on a large multi-clade pseudovirus panel consisting of 162 viruses to further assess the neutralization breadth and potency of these three antibodies (Tables 5A-5B, Tables 18A-18F and Tables 19A- 19B). The bNAbs bl2, 2G12, 2F5, and 4E10, as well as the donor's serum, were also included in the panel for comparison. Overall, PG9 neutralized 127 out of 162 and PG 16 neutralized 1 19 out of 162 viruses with a potency that frequently considerably exceeded that noted for the four control bNAbs.

[101] The median IC50 and IC90 values for neutralized viruses across all clades were an order of magnitude lower for PG9 and PG16 than any of the four existing bNAbs (Table 5A, Tables 18A-18F and Tables 19A- 19B). Both mAbs showed overall greater neutralization breadth than bl2, 2G12, and 2F5 (Table 5B, Tables 18A-18F and Tables 19A- 19B). At low antibody concentrations, PG9 and PG 16 also demonstrated greater neutralization breadth than 4E10 (Table 5B). Furthermore, both mAbs potently neutralized one virus (IAVI-Cl 8) that exhibits resistance to all four existing bNAbs (Tables 18A- 18F). The mAb neutralization curves reveal that, whereas the PG9 neutralization curves usually exhibit sharp slopes, the neutralization curves for PG 16 sometimes exhibit gradual slopes or plateaus at less than 100% neutralization. Although neutralization curves with similar profiles have been reported previously ( W. J. Honnen et al., J Virol 81 , 1424 (Feb, 2007), A. Pinter et al., J Virol 79, 6909 (Jun, 2005)), the mechanism for this is not well understood.

[102] Comparison of the neutralization profile of the serum with the neutralization profile of PG9, PG 16 and PGC 14 revealed that these three antibodies could recapitulate the breadth of the serum neutralization in most cases (Tables 18A-18F). For example, almost all of the viruses that were neutralized by the serum with an IC50 > 1 :500 were neutralized by PG9 and/or PGl 6 at <0.05 μg/mL. The one case where this did not occur was against HIV- ISF 162, but this virus was potently neutralized by PGC 14. Despite the fact that PG9 and PG 16 are somatic variants, they exhibited different degrees of potency against a number of the viruses tested. For instance, PG9 neutralized HTV-16535.30 approximately 185 times more potently than PG 16, and PG 16 neutralized HIV- lMGRM-AG-001 approximately 440 times more potently than PG9. In some cases, the two antibodies also differed in neutralization breadth; PG9 neutralized nine viruses that were not affected by PG16, and PG 16 neutralized two viruses that were not affected by PG9.

Based on these results, it is postulated that broad serum neutralization might be mediated by somatic antibody variants that recognize slightly different epitopes and display varying degrees of neutralization breadth and potency against any given virus. In the face of an evolving viral response, it seems reasonable that the immune system might select for these types of antibodies.

[103] Comparison of the neutralization profile of the serum with the neutralization profile of PG9, PG 16 and PGC 14 revealed that these three antibodies could recapitulate the breadth of the serum neutralization in most cases. For example, almost all of the viruses that were neutralized by the serum with an IC50 > 1 :1000 were neutralized by PG9 and/or PGl 6 at <0.005 μg/mL. The one case where this did not occur was against HTV- I SF 162, but this virus was potently neutralized by PGC 14. Tables 5(a) and 5(b) show the neutralization activities — breadth and potency, respectively — of PG9, PG 16, and PGC 14 as well as four control bNAbs as measured by IC50 values. Tables 19A-19B show results of the same analysis using IC90 values.

[104] Table 5(A). Neutralization Potency of niAbs

Boxes are color coded as follows: white, median potency >50 μg/mL; light grey, median potency between 2 and 20 μg/mL; medium grey, median potency between 0.2 and 2 μg/mL; dark grey, median potency <0.2 μg/mL.

"CRF_07BC and CRF 08BC viruses are not included in the clade analysis because there was only one virus tested from each of these clades.

[105] Table 5(B). Neutralization Breadth of mAbs

Boxes are color coded as follows: white, no viruses neutralized; black, 1 to 30% of viruses neutralized; light grey, 30 to 60% of viruses neutralized; medium grey, 60 to 90% of viruses neutralized; dark grey, 90 to 100% of viruses neutralized.

"CRF 07BC and CRF 08BC viruses are not included in the clade analysis because there was only one virus tested from each of these clades.

[106] Despite the fact that PG9 and PGl 6 are somatic variants, they exhibited different degrees of potency against a number of the viruses tested. For instance, PG9 neutralized the virus 6535.30 about 100 times more potently than PG16, and PG16 neutralized the virus MGRM-AG-001 about 3000 times more potently than PG9. In some cases, the two antibodies also differed in neutralization breadth; PG9 neutralized seven viruses that were not neutralized by PG 16, and PG 16 neutralized three viruses that were not neutralized by PG9. Without being bound by theory, it appears that broad serum neutralization might be mediated by somatic variants that recognize slightly different epitopes and display varying degrees of neutralization breadth and potency against any given virus. In the face of an evolving viral response, the immune system likely selects for these types of antibodies. [107] The antibodies were also tested for ability to bind soluble recombinant HTV envelope proteins. Figure 5 shows dose response curves of 1456_P20 (PG20), 1495 C14 (PGC 14) and 1460_G14 (PGG14) binding to recombinant gpl20 in ELISA as compared to control anti- gpl20 (bl2). Figure 6 shows ELISA binding assays of monoclonal antibodies 1443_C16 (PG 16) and 1496_C09 (PG9) to HIV-I strain YU2 gp 140 and JR-CSF gpl20, the membrane proximal region (MPER) of HIV-I envelope glycoprotein gp41, and the V3 polypeptide. PG- 9 binds to YU2 gpl40 (IC₅₀ -20-40 nM), YU2 gpl20 and weakly binds to JR-CSF gpl20. However, PG16 weakly binds Yu2 gpl20, but not the soluble form of HIV-I envelope glycoprotein, gpl20 JR-CSF. Neither mAb binds to JR-FL gpl20, JR-FL gpl40, MPER peptide of gp41 or V3 peptide.

[108] Figure 7 shows binding of monoclonal antibodies 1443_C16 (PG16) and 1496_C09 (PG9) to HIV-I YU2 gplόO expressed on the cell surface in the presence and absence of sCD4.

Competitive inhibition of the binding by sCD4 indicates that the binding of monoclonal antibody 1496_C09 to HIV-I envelope protein gplόO expressed on the cell surface is presumably affected due to the conformational changes induced by sCD4. The data further suggest that 1443 C16 (PG 16) and 1496_C09 (PG9) exhibit relatively stronger binding to trimeric forms of the HIV-I Env (gpl60 and gpl40) than to the monomeric gpl20. [109] Figure 8 shows binding of monoclonal antibodies 1443_C16 (PG16) and 1496 C09 (PG9) to HIV-I transfected cells. PG9 and PG 16 do not bind untransfected cells. PG9 and PG 16 bind JR-CSF, ADA, and YU2 gplόO transfected cells. PG9 and PG 16 do not bind JR- FL gpl60 transfected cells (cleaved or uncleaved). PG9 and PG16 do not bind ADA ΔV1/ΔV2 transfected cells. PG9 and PG16 binding to JR-CSF gplόO transfected cells is inhibited by sCD4.

[110] Figure 9 shows the capturing of entry-competent JR-CSF pseudovirus by neutralizing monoclonal antibodies 1443_C16 (PG 16) and 1496_C09 (PG9) in a dose-dependent manner. The ability of both antibodies to capture JR-CSF pseudovirus is higher than IgG bl2 but comparable to IgG 2Gl 2. It is postulated that the capture may be mediated by the binding of the mAbs to the HIV-I Env on the virions.

[Ill] Figure 1OA shows that sCD4, PG16 and PG9 compete for the binding of monoclonal antibody 1443_C16 (PG16) to JR-CSF pseudovirus but bl2, 2G12, 2F5 and 4E10 do not. Figure 1OB shows sCD4, PG 16 and PG9 compete for the binding of monoclonal antibody 1496_C09 (PG9) to JR-CSF pseudovirus but bl2, 2G12, 2F5 and 4E10 do not. This suggests that the PG 16 and PG9 mAbs bind gp 120 at a site different from those bound by bl2 and 2Gl 2. PG9 and PGl 6 binding to HTV-I envelope protein is competitively inhibited by sCD4. Given that the MAbs are not inhibited by the CD4 binding site MAb bl2, this suggests that PG9 and PG 16 are binding to an epitope that is unavailable for sCD4 binding to gp 120 as a result of conformational changes.

The inability of PG9 and PG 16 to bind monomeric gpl20JR-CSF or gp41HxB2 in the initial screen while potently neutralizing HIV-IJR-CSF suggests that the epitope targeted by these antibodies is preferentially expressed on trimeric HIV envelope protein. The ability of PG9 and PG 16 to bind monomeric gpl20 from several different strains, artificially trimerized gpl40 constructs, and trimeric Env expressed on the surface of transfected cells respectively, was compared. Although both antibodies bound with high affinity to cell surface Env, PG 16 did not bind to any of the soluble gpl20 or gpl40 constructs and PG9 bound only weakly to monomeric gpl20 and trimerized gpl40 from certain strains (Fig. 1 1). It has been previously shown that a substantial fraction of cell surface Env is comprised of uncleaved gpl60 molecules. (Pancera, M. & Wyatt, R. Virology 332, 145-156 (2005)). That PG9 and PGl 6 do not exhibit exclusive specificity for native HIV-I trimers was confirmed by the fact that both antibodies bound with high affinity to cleavage-defective HIV- 1YU2 trimers expressed on the surface of transfected cells (Figure 12).

[112] The epitopes recognized by PG9 and PG16 were investigated. Since the PG9 and PG 16 antibodies are somatic variants, they recognize the same or overlapping epitopes. Both antibodies cross-competed for binding to HTV-IJR-CSF transfected cells (Fig. 13A). Ligation of monomeric gpl20 or cell surface Env with soluble CD4 diminished binding of both PG9 and PGl 6, although neither antibody competed with CD4-binding site antibodies for trimer binding (Fig. 13A- 13C). This result suggests that CD4-induced conformational changes cause a loss of the epitope targeted by the antibodies.

[113] Since PG9 bound well enough to gpl20 from certain isolates to generate ELISA binding curves, competition ELISAs were performed with PG9 using a panel of neutralizing and non-neutralizing antibodies. These data revealed that PG9 cross-competed with anti-V2, anti-V3, and to a lesser extent, CD4i antibodies for gpl20. (Figures 13D and 14). Neither PG9 nor PG16 bound to V1/V2 or V3 deleted HTV-IJR-CSF variants expressed on the surface of transfected cells, further suggesting contributions of variable loops in forming their epitopes (Fig. 13E). [114] To dissect the fine specificity of PG9 and PG 16, alanine scanning was performed using a large panel of HIV- IJR-CSF Env alanine mutants that have been described previously (Pantophlet, R., et al. J Virol 77, 642-658 (2003); Pantophlet, R., et al. J Virol 83, 1649-1659 (2009); Darbha, R., et al. Biochemistry 43, 1410-1417 (2004); Scanlan, C.N., et al. J Virol 76, 7306-7321 (2002)) as well as several new alanine mutants. Pseudoviruses incorporating single Env alanine mutations were generated, and PG9 and PG 16 were tested for neutralization activity against each mutant pseudovirus. Mutations that resulted in viral escape from PG9 and PG 16 neutralization were considered important for formation of the PG9 and PG 16 epitopes (Tables 12 and 13).

[115] Based on this criteria, and consistent with the competition experiments, residues that form the epitopes recognized by PG9 and PG 16 appear to be located in conserved regions of the V2 and V3 loops of gpl20. Certain co-receptor binding site mutations also had an effect on PG9 and PGl 6 neutralization, albeit to a lesser extent. Generally, PG9 and PG 16 were dependent on the same residues, although PG 16 was more sensitive to mutations located in the tip of the V3 loop than PG9. Interestingly, although neither antibody bound to wild-type HIV-IJR-FL transfected cells, a D to K mutation at position 168 in the V2 loop of HIV-IJR- FL generated high-affinity PG9 and PG 16 recognition (Tables 18A- 18F). N 156 and N 160, sites of V2 N-glycosylation, also appear to be critical in forming the epitope since substitutions at these positions resulted in escape from PG9 and PG 16 neutralization. Deglycosylation of gpl20 abolished binding of PG9 (Fig. 16), confirming that certain glycans may be important in forming the epitope.

[116] HIV-I SF 162 contains a rare N to K polymorphism at position 160, and mutation of this residue to an Asn renders this isolate sensitive to PG9 and PGl 6 (Fig. 17). [117] The preferential binding of PG9 and PG 16 to native trimers could either be a consequence of gpl20 subunit cross-linking or recognition of a preferred oligomeric gpl20 conformation. To address this question, the binding profiles of PG9 and PG 16 to mixed HIV- 1YU2 trimers were examined, in which two gpl20 subunits containing point mutations abolished binding of the two antibodies. A third substitution that abrogates binding of 2G12, which binds with high affinity to both monomeric gpl20 and trimeric Env, was also introduced into the same construct as an internal control. Cell surface binding analysis revealed that all three antibodies bound to the mixed trimers with similar apparent affinity as to wild-type trimers and all saturated at a similar lower level (Fig. 18). This result suggests that the preference of PG9 and PG 16 for trimeric Env is due to gpl20 subunit presentation in the context of the trimeric spike rather than gpl20 cross-linking.

[118] It has been shown that NAbs that bind to epitopes encompassing parts of the V2 or both the V2 and V3 domains can exhibit potency comparable to that of PG9 and PGl 6, although these antibodies have thus far displayed strong strain-specificity. (Honnen, W.J., et al. J Virol 81, 1424-1432 (2007); Gorny, M.K., et al. J Virol 79, 5232-5237 (2005)). Importantly, the epitopes recognized by these antibodies have been shown to differ from that of the clade B consensus sequence only by single amino acid substitutions, which suggested the existence of a relatively conserved structure within the V2 domain. (Honnen, W. J., et al. J Virol 81, 1424-1432 (2007)). The results observed with PG9 and PG 16 confirm that this region serves as a potent neutralization target and demonstrates that antibodies that recognize conserved parts of V2 and V3 can possess broad reactivity.

[119] The invention is based on novel monoclonal antibodies and antibody fragments that broadly and potently neutralize HIV infection. In some embodiments, these monoclonal antibodies and antibody fragments have a particularly high potency in neutralizing HIV infection in vitro across multiple clades or across a large number of different HIV species. Such antibodies are desirable, as only low concentrations are required to neutralize a given amount of virus. This facilitates higher levels of protection while administering lower amounts of antibody. Human monoclonal antibodies and the immortalized B cell clones that secrete such antibodies are included within the scope of the invention. [120] The invention provides methods for using high throughput functional screening to select neutralizing antibodies with unprecedented breadth and potency. The invention relates to other potent, and broadly neutralizing antibodies that can be developed using the same methods. In particular, the invention relates to potent, broadly neutralizing antibodies against different strains of HIV, wherein the bNAbs bind poorly to recombinant forms of Env. The invention provides two neutralizing antibodies, PG9 and PG 16, with broad neutralizing activities particularly against non-clade B isolates. The invention provides vaccine-induced antibodies of high specificity that provide protection against a diverse range of the most prevalent isolates of HTV circulating worldwide. The invention provides antibodies with very high and broad neutralization potency, such as that exhibited by PG9 and PG 16 in vitro, which provides protection at relatively modest serum concentrations, and are generated by vaccination unlike the broad NAbs known in the art. The invention provides immunogens that can be designed that focus the immune response on conserved regions of variable loops in the context of the trimeric spike of the gpl20 subunit of the Env protein.

[121] The invention also relates to the characterization of the epitope to which the antibodies bind and the use of that epitope in raising an immune response.

[122] The invention also relates to various methods and uses involving the antibodies of the invention and the epitopes to which they bind. For example, monoclonal antibodies according to the invention can be used as therapeutics. In some aspects, the monoclonal antibodies are used for adjuvant therapy. Adjuvant therapy refers to treatment with the therapeutic monoclonal antibodies, wherein the adjuvant therapy is administered after the primary treatment to increase the chances of a cure or reduce the statistical risk of relapse.

[123] The invention provides novel monoclonal or recombinant antibodies having particularly high potency in neutralizing HIV. The invention also provides fragments of these recombinant or monoclonal antibodies, particularly fragments that retain the antigen-binding activity of the antibodies, for example which retain at least one complementarity determining region (CDR) specific for HIV proteins. In this specification, by "high potency in neutralizing

HIV" is meant that an antibody molecule of the invention neutralizes HIV in a standard assay at a concentration lower than antibodies known in the art.

[124] Preferably, the antibody molecule of the present invention can neutralize at a concentration of 0.16 μg/ml or lower (i.e. 0.15, 0.125, 0.1, 0.075, 0.05, 0.025, 0.02, 0.016,

0.015, 0.0125, 0.01, 0.0075, 0.005, 0.004 or lower), preferably 0.016 μg/ml or lower (an antibody concentration of 10^"8 or lower, preferably 10^" M or lower, preferably 10^" M or lower, i.e. 10^"11 M, 10^"12 M, 10^"13 M or lower). This means that only very low concentrations of antibody are required for 50% neutralization of a clinical isolate of HIV in vitro. Potency can be measured using a standard neutralization assay as described in the art.

[125] The antibodies of the invention are able to neutralize HIV. Monoclonal antibodies can be produced by known procedures, e.g., as described by R. Kennet et al. in "Monoclonal

Antibodies and Functional Cell Lines; Progress and Applications". Plenum Press (New

York), 1984. Further materials and methods applied are based on known procedures, e.g., such as described in J. Virol. 67:6642-6647, 1993.

[126] These antibodies can be used as prophylactic or therapeutic agents upon appropriate formulation, or as a diagnostic tool.

[127] A "neutralizing antibody" is one that can neutralize the ability of that pathogen to initiate and/or perpetuate an infection in a host and/or in target cells in vitro. The invention provides a neutralizing monoclonal human antibody, wherein the antibody recognizes an antigen from HIV.

[128] Preferably an antibody according to the invention is a novel monoclonal antibody referred to herein as 1496_C09 (PG9), 1443_C16 (PG 16), 1456_P20 (PG20), 1460_G14 (PGG14), and 1495_C14 (PGC14). These antibodies were initially isolated from human samples and are produced by the B cell cultures referred to as 1443 C16, 1456_P20, 1460_G14, 1495_C14 or 1496_C09. These antibodies have been shown to neutralize fflV in vitro. PG9 and PG 16 have been shown to have broad, potent HIV neutralizing activity. [129] The CDRs of the antibody heavy chains are referred to as CDRHl , CDRH2 and CDRH3, respectively. Similarly, the CDRs of the antibody light chains are referred to as CDRLl, CDRL2 and CDRL3, respectively. The position of the CDR amino acids are defined according to the IMGT numbering system as: CDR1--IMGT positions 27 to 38, CDR2- IMGT positions 56 to 65 and CDR3--IMGT positions 105 to 117. (Lefranc, M P. et al. 2003 IMGT unique numbering for immunoglobulin and T cell receptor variable regions and Ig superfamily V-like domains. Dev Comp Immunol. 27(l):55-77; Lefranc, M P. 1997. Unique database numbering system for immunogenetic analysis. Immunology Today, 18:509; Lefranc, M P. 1999. The IMGT unique numbering for Immunoglobulins, T cell receptors and Ig-like domains. The Immunologist, 7:132-136.)

[130] The amino acid sequences of the CDR3 regions of the light and heavy chains of the antibodies are shown in Tables 3A and 3B.

[131] A phylogram is a branching diagram (tree) assumed to be an estimate of phylogeny, branch lengths are proportional to the amount of inferred evolutionary change. Tree diagrams of the five heavy chains and the five light chains were prepared using ClustalW (Larkin M.A., BIackshields G., Brown N.P., Chenna R., McGettigan P.A., Mc William H., Valentin F., Wallace I.M., WiIm A., Lopez R., Thompson J.D., Gibson T.J. and Higgins D.G. Bioinformatics 23(21): 2947-2948 (2007); Higgins DG et al. Nucleic Acids Research 22: 4673-4680. (1994)) and are shown in Figures IA and IB respectively. [132] The sequences of the antibodies were determined, including the sequences of the variable regions of the Gamma heavy and Kappa or Lambda light chains of the antibodies designated 1496_C09 (PG9), 1443_C16 (PG16), 1456_P20 (PG20), 1460_G14 (PGG14), and 1495_C14 (PGC 14). In addition, the sequence of each of the polynucleotides encoding the antibody sequences was determined. Shown below are the polypeptide and polynucleotide sequences of the gamma heavy chains and kappa light chains, with the signal peptides at the N-terminus (or 5' end) and the constant regions at the C-terminus (or 3' end) ofthe variable regions, which are shown in bolded text.

[133] 1443_C16 (PG16) gamma heavy chain nucleotide sequence: 1443 C16 γ3 coding sequence (variable region in bold)

ATGGAGTTTGGGCTGAGCTGGGTTTTCCTCGCAACTCTGTTAAGAGTTGTGAAGTGTCAGGAACAACT GGTGGAGTCTGGGGGAGGCGTGGTCCAGCCGGGGGGGTCCCTGAGACTCTCCTGTTTAGCGTCTGGAT TCACGTTTCACAAATATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGCCTGGAGTGGGTGGCA CTCATCTCAGATGACGGAATGAGGAAATATCATTCAGACTCCATGTGGGGCCGAGTCACCATCTCCAG AGACAATTCCAAGAACACTCTTTATCTGCAATTCAGCAGCCTGAAAGTCGAAGACACGGCTATGTTCT TCTGTGCGAGAGAGGCTGGTGGGCCAATCTGGCATGACGACGTCAAATATTACGATTTTAATGACGGC TACTACAACTACCACTACATGGACGTCTGGGGCAAGGGGACCACGGTCACCGTCTCGAGCGCCTCCAC CAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGG GCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGC GGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGT GCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGG TGGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAA CTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGAC CCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACG TGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGT GTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTC CAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCAC AGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTC AAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAA GACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTATAGCAAGCTCACCGTGGACAAGA

CAGAAGAGCCTCTCCCTGTCTCCGGGTAAATGA (SEQIDNO: 11)

[134] 1443_C16 (PG16) gamma heavy chain variable region nucleotide sequence:

CAGGAACAACTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCGGGGGGGTCCCTGAGACTCTCCTGTTT AGCGTCTGGATTCACGTTTCACAAATATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGCCTGG AGTGGGTGGCACTCATCTCAGATGACGGAATGAGGAAATATCATTCAGACTCCATGTGGGGCCGAGTC ACCATCTCCAGAGACAATTCCAAGAACACTCTTTATCTGCAATTCAGCAGCCTGAAAGTCGAAGACAC

TTAATGACGGCTACTACAACTACCACTACATGGACGTCTGGGGCAAGGGGACCACGGTCACCGTCTCG AGC (SEQ ID NO: 99)

[135] 1443_C16 (PG16) gamma heavy chain amino acid sequence: expressed protein with variable region in bold.

QEQLVESGGGWQPGGSLRLSCLASGFTFHKYGMHWVRQAPGKGLEWVALISDDGMRKYHSDS MWGRVTISRDNSKNTLYLQFSSLKVEDTAMFFCAREAGGPIWHDDVKYYDFNDGYYNYHYMDV

WGKGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYPPEPVTVSWNSGALTSGVHTFPAVL QSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFP PKPKDTLMISRTPEVTCVVVDVSHEDPEVKFN WYVDGVEVHNAKTKPREEQYNSTYRWSVLTVLHQ DWLNGKEYKCKVSNKALP APIEKTISKAKGQPREPQ VYTLPPSREEMTKNQVSLTCLVKGFYPSDIA VE WESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 12)

[136] 1443 C16 (PG 16) gamma heavy chain variable region amino acid sequence: (Kabat CDRs underlined, Chothia CDRs in bold italics) QEQLVESGGGWQPGGSLRLSCLA^GFrFWyyGMWWVROAPGKGLEWVAZ./yflflCMR^ytfyD^A/^ GR VTISRDNSKNTL YLQFSSLKVEDTAMFFCAREΛ GGPlWHDD VKYYDFNDGYYNYHYMD FWGKGTT VTVSS (SEQ ID NO: 31)

[137] 1443_C 16 (PG 16) gamma heavy chain Kabat CDRs:

CDR 1 : SGFTFHKYGMH (SEQ ID NO: 88)

CDR 2: LISDDGMRKYHSDSMW (SEQ ID NO: 89)

CDR 3: EAGGPIWHDDVKYYDFNDGYYNYHYMDV (SEQ ID NO: 6)

[138] 1443 C16 (PG 16) gamma heavy chain Chothia CDRs:

CDR 1 : SGFTFHKYGMH (SEQ ID NO: 88)

CDR 2: LISDDGMRKYHSDSMW (SEQ ID NO: 89)

CDR 3: EAGGPIWHDDVKYYDFNDGYYNYHYMDV (SEQ ID NO: 6)

[139] 1443_C16 (PG 16) lambda light chain nucleotide sequence: 1443_C16 λ2 coding sequence (variable region in bold)

CTGAGCCTGACGCC TGAGCAGTGGAAGTC CCCTACAGAATGTTCATAG (SEQ ID NO: 13)

[140] 1443 C16 (PG16) lambda light chain variable region nucleotide sequence:

TTCGGCGGCGGGACCAAGGTGACCGTTCTA (SEQIDNO: 100)

[141] 1443_C16 (PG16) lambda light chain amino acid sequence: expressed protein with variable region in bold.

QSALTQPASVSGSPGQTITISCNGTSSDVGGFDSVSWYQQSPGKAPKVMVFDVSHRPSGISNRFSGS KSGNTASLTISGLHIEDEGDYFCSSLTDRSHRIFGGGTKVTVLGQPKAAPSVTLFPPSSEELQANKAT

LVCLISDFYPGA VTVA WKADSSPVKAGVETTTPSKQSNNKY AASSYLSLTPEQWKSHKSYSCQVTHEG STVEKTVAPTECS (SEQ ID NO: 14)

[142] 1443_C16 (PG16) lambda light chain variable region amino acid sequence: (Kabat CDRs underlined, Chothia CDRs in bold italics)

OSALTOPASVSGSPGOTITISC^Gr^flKGGFgSKyWYOOSPGKAPKVMVFflKyWt^GISNRFSGSKSG NTASLTISGLHIEDEGDYFCS-?l,TO/?SJ/K/FGGGTKVTVL (SEQ ID NO: 32)

[143] 1443_C16 (PG 16) lambda light chain Kabat CDRs: CDR 1 : NGTSSDVGGFDSVS (SEQ ID NO: 97) CDR 2: DVSHRPSG (SEQ ID NO: 95) CDR 3: SSLTDRSHRI (SEQ ID NO: 41) [144] 1443_C16 (PG16) lambda light chain Chothia CDRs: CDR 1 : NGTSSDVGGFDSVS (SEQ ID NO: 97) CDR 2: DVSHRPSG (SEQ ID NO: 95) CDR 3: SSLTDRSHRI (SEQ ID NO: 41)

[145] 1456_P20 (PG20) gamma heavy chain nucleotide sequence: 1456_P20 γl coding sequence (variable region in bold)

ATGGACTGGATTTGGAGGTTCCTCTTTGTGGTGGCAGCAGCTACAGGTGTCCAGTCCCAGGTCCGCCT GGTACAGTCTGGGCCTGAGGTGAAGAAGCCTGGGTCCTCGGTGACGGTCTCCTGCCAGGCTTCTGGAG GCACCTTCAGCAGTTATGCTTTCACCTGGGTGCGCCAGGCCCCCGGACAAGGTCTTGAGTGGTTGGGC ATGGTCACCCCAATCTTTGGTGAGGCCAAGTACTCACAAAGATTCGAGGGCAGAGTCACCATCACCGC GGACGAATCCACGAGCACAACCTCCATAGAATTGAGAGGCCTGACATCCGAAGACACGGCCATTTATT ACTGTGCGCGAGATCGGCGCGCGGTTCCAATTGCCACGGACAACTGGTTAGACCCCTGGGGCCAGGGG ACCCTGGTCACCGTCTCGAGCGCCTCCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAA GAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGG TGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGA CTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAA CGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTC ACACATGCCCACCGTGCCCAGCACCTGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAA CCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGA AGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGC GGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTG AATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTC CAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCA AGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAG AGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTT CCTCTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGA TGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAATGA(SEQID NO: 15)

[146] 1456 P20 (PG20) gamma heavy chain variable region nucleotide sequence:

CAGGTCCGCCTGGTACAGTCTGGGCCTGAGGTGAAGAAGCCTGGGTCCTCGGTGACGGTCTCCTGCCA GGCTTCTGGAGGCACCTTCAGCAGTTATGCTTTCACCTGGGTGCGCCAGGCCCCCGGACAAGGTCTTG AGTGGTTGGGCATGGTCACCCCAATCTTTGGTGAGGCCAAGTACTCACAAAGATTCGAGGGCAGAGTC ACCATCACCGCGGACGAATCCACGAGCACAACCTCCATAGAATTGAGAGGCCTGACATCCGAAGACAC GGCCATTTATTACTGTGCGCGAGATCGGCGCGCGGTTCCAATTGCCACGGACAACTGGTTAGACCCCT GGGGCCAGGGGACCCTGGTCACCGTCTCGAGC (SEQIDNO: 101)

[147] 1456_P20 (PG20) gamma heavy chain amino acid sequence: expressed protein with variable region in bold.

QVRLVQSGPEVKKPGSSVTVSCQASGGTFSSYAFTWVRQAPGQGLEWLGMVTPIFGEAKYSQRF EGRVTIT ADESTSTTSIELRGLTSEDTAIYYCARDRRAVPIATDNWLDPWGQGTLVTVSSASTKGPS

VFPLAPSSKSTSGGTAALGCL VKDYFPEPVTVSWNSGALTSGVHTFPA VLQSSGLYSLSSVVTVPSSSLG TQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVV DVSHEDPEVKFNWYVDGVEVHN AKTKPREEQYNSTYRWSVLTVLHQDWLNGKEYKCKVSNKALP APIEKTISKAKGQPREPQ VYTLPPSREEMTKNQVSLTCL VKGFYPSDIA VEWESNGQPENNYKTTPPVL DSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 16)

[148] 1456 P20 (PG20) gamma heavy chain variable region amino acid sequence: (Kabat CDRs underlined, Chothia CDRs in bold italics) 0VRLVQSGPEVKKPGSSVTVSC0A5GGrFraFΛFmW0APGOGLEWLGMKr/7FG£Λ/rreo;?F,EGR VTITADESTSTTSIELRGLTSEDTAI YYCARDRRA VPIA TDNWLDPΨGOGTLVτVSS (SEQ ID NO: 33)

[149] 1456_P20 (PG20) gamma heavy chain Kabat CDRs: CDR 1 : SGGTFSSYAFT (SEQ ID NO: 104) CDR 2: MVTPIFGEAKYSQRFE (SEQ ID NO: 105) CDR 3: RAVPIATDNWLDP (SEQ ID NO: 102)

[150] 1456_P20 (PG20) gamma heavy chain Chothia CDRs: CDR 1 : SGGTFSSYAFT (SEQ ID NO: 104) CDR 2: MVTPIFGEAKYSQRFE (SEQ ID NO: 105) CDR 3: RRAVPIATDNWLDP (SEQ ID NO: 103)

[151] 1456_P20 (PG20) kappa light chain nucleotide sequence: 1456_P20 κl coding sequence (variable region in bold)

CATCCAGTTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTTGGCGACAGAGTCTCCATCACTTGCC GGGCGAGTCAGACCATTAACAACTACTTAAATTGGTATCAACAGACACCCGGGAAAGCCCCTAAACTC CTGATCTATGGTGCCTCCAATTTGCAAAATGGGGTCCCATCAAGGTTCAGCGGCAGTGGCTCTGGGAC

TCAGTACTCCGAGGACCTTCGGCCAAGGGACACGACTGGATATTAAACGTACGGTGGCTGCACCATCT GTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAA TAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCC AGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGC AAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGT CACAAAGAGCTTCAACAGGGGAGAGTGTTAG (SEQ ID NO: 17)

[152] 1456 P20 (PG20) kappa light chain variable region nucleotide sequence:

GACATCCAGTTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTTGGCGACAGAGTCTCCATCACTTG CCGGGCGAGTCAGACCATTAACAACTACTTAAATTGGTATCAACAGACACCCGGGAAAGCCCCTAAAC TCCTGATCTATGGTGCCTCCAATTTGCAAAATGGGGTCCCATCAAGGTTCAGCGGCAGTGGCTCTGGG ACAGACTTCACTCTCACCATCAGCAGTCTGCAACCTGAGGATTTTGCAACTTACTACTGTCAACAGAG TTTCAGTACTCCGAGGACCTTCGGCCAAGGGACACGACTGGATATTAAA (SEQIDNO: 106)

[153] 1456 P20 (PG20) kappa light chain amino acid sequence: expressed protein with variable region in bold.

DIQLTQSPSSLSASVGDRVSITCRASQTINNYLNWYQQTPGKAPKLLIYGASNLQNGVPSRFSGSGS GTDFTLTISSLQPEDFATYYCQQSFSTPRTFGQGTRLDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLL

NNFYPRE AKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKAD YEKHK VYACEVTHQGLSS PVTKSFNRGEC (SEQ ID NO: 18)

[154] 1456 P20 (PG20) kappa light chain variable region amino acid sequence: (Kabat CDRs underlined, Chothia CDRs in bold italics)

DIOLTOSPSSLSASVGDRVSITCV^5C>77ΛWyi,Λ^fWYOOTPGKAPKLLIYG/<-?M.θyVCVPSRFSGSGSGTD FTLTISSLQPEDFATΥYCfifiSFSTP/LΪFGQGTRLDIK (SEQ ID NO: 34)

[155] 1456_P20 (PG20) kappa light chain Kabat CDRs: CDR 1 : RASQTINNYLN (SEQ ID NO: 107) CDR 2: GASNLQNG (SEQ ID NO: 108) CDR 3: QQSFSTPRT (SEQ ID NO: 42)

[156] 1456_P20 (PG20) kappa light chain Chothia CDRs: CDR 1 : RASQTINNYLN (SEQ ID NO: 107) CDR 2: GASNLQNG (SEQ ID NO: 108) CDR 3: QQSFSTPRT (SEQ ID NO: 42)

[157] 1460_G14 (PGG14) gamma heavy chain nucleotide sequence: 1460 G14 γl coding sequence (variable region in bold)

GCGCCTTCAGTAGTTATGCTTTCAGCTGGGTGCGACAGGCCCCTGGACAGGGGCTTGAATGGATGGGC ATGATCACCCCTGTCTTTGGTGAGACTAAATATGCACCGAGGTTCCAGGGCAGACTCACACTTACCGC GGAAGAATCCTTGAGCACCACCTACATGGAATTGAGAAGCCTGACATCTGATGACACGGCCTTTTATT ATTGTACGAGAGATCGGCGCGTAGTTCCAATGGCCACAGACAACTGGTTAGACCCCTGGGGCCAGGGG

GAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGG TGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGA CTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAA CGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTC ACACATGCCCACCGTGCCCAGCACCTGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAA CCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGA AGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGC GGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTG AATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTC CAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCA AGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAG AGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTT CCTCTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGA TGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAATGA(SEQID NO: 19)

[158] 1460 G14 (PGG14) gamma heavy chain variable region nucleotide sequence:

CAGGTCCTGCTGGTGCAGTCTGGGACTGAGGTGAAGAAGCCTGGGTCCTCGGTGAAGGTCTCCTGTCA GGCTTCTGGAGGCGCCTTCAGTAGTTATGCTTTCAGCTGGGTGCGACAGGCCCCTGGACAGGGGCTTG AATGGATGGGCATGATCACCCCTGTCTTTGGTGAGACTAAATATGCACCGAGGTTCCAGGGCAGACTC ACACTTACCGCGGAAGAATCCTTGAGCACCACCTACATGGAATTGAGAAGCCTGACATCTGATGACAC GGCCTTTTATTATTGTACGAGAGATCGGCGCGTAGTTCCAATGGCCACAGACAACTGGTTAGACCCCT GGGGCCAGGGGACGCTGGTCACCGTCTCGAGC (SEQ ID NO: 109)

[159] 1460 G 14 gamma heavy chain amino acid sequence: expressed protein with variable region in bold.

QVLLVQSGTEVKKPGSSVKVSCQASGGAFSSYAFSWVRQAPGQGLEWMGMITPVFGETKYAPRF QGRLTLTAEESLSTTYMELRSLTSDDTAFYYCTRDRR WPMATDNWLDPWGQGTLVTVSSASTK

GPSVFPLAPSSKSTSGGTAALGCL VKDYFPEPVTVSWNSGALTSGVHTFPA VLQSSGLYSLSSVVTVPSS SLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTC VVVDVSHEDPEVKFN WY VDGVE VHN AKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNK ALPAPIEKTISKAKGQPREPQ VYTLPPSREEMTKNQVSLTCLVKGFYPSDIA VEWESNGQPENNYKTTPP VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 20) [160] 1460_G14 gamma heavy chain variable region amino acid sequence: (Kabat CDRs underlined, Chothia CDRs in bold italics)

QVLLVQSGTEVKKPGSSVKVSCOA^GG^F^^F/lKywVROAPGQGLEWMGM/rFKFGErA-y^f/tFQGR LTLTAEESLSTTYMELRSLTSDDTAFY YCTKDRJt VVPMA 7T⁾MrZ-Z⁾PWGOGTLVTVSS (SEQ ID NO: 35)

[161] 1460_G14 gamma heavy chain Kabat CDRs: CDR 1 : SGGAFSSYAFS (SEQ ID NO: 110) CDR 2: MITPVFGETKYAPRFQ (SEQ ID NO: 1 11) CDR 3: RVVPMATDNWLDP (SEQ ID NO: 102)

[162] 1460_G14 gamma heavy chain Chothia CDRs: CDR 1 : SGGAFSSYAFS (SEQ ID NO: 110) CDR 2: MITPVFGETKYAPRFQ (SEQ ID NO: 111) CDR 3: RRVVPMATDNWLDP (SEQ ID NO: 103)

[163] 1460 G14 (PGG14) kappa light chain nucleotide sequence: 1460_G14 κl coding sequence (variable region in bold)

CATCCAGTTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGGGTCACCGTCACTTGCC GGGCGAGTCAGACCATACACACCTATTTAAATTGGTATCAGCAAATTCCAGGAAAAGCCCCTAAGCTC CTGATCTATGGTGCCTCCACCTTGCAAAGTGGGGTCCCGTCAAGGTTCAGTGGCAGTGGATCTGGGAC AGATTTCACTCTCACCATCAACAGTCTCCAACCTGAGGACTTTGCAACTTACTACTGTCAACAGAGTT

GTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAA TAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCC AGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGC AAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGT CACAAAGAGCTTCAACAGGGGAGAGTGTTAG (SEQ ID NO: 21)

[164] 1460 G 14 (PGG 14) kappa light chain variable region nucleotide sequence:

GACATCCAGTTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGGGTCACCGTCACTTG

TCCTGATCTATGGTGCCTCCACCTTGCAAAGTGGGGTCCCGTCAAGGTTCAGTGGCAGTGGATCTGGG ACAGATTTCACTCTCACCATCAACAGTCTCCAACCTGAGGACTTTGCAACTTACTACTGTCAACAGAG TTACAGTACCCCAAGGACCTTCGGCCAAGGGACACGACTGGATATTAAA (SEQIDNO: 112)

[165] 1460_G14 kappa light chain amino acid sequence: expressed protein with variable region in bold.

DIQLTQSPSSLSASVGDRVTVTCRASQTIHTYLNWYQQIPGKAPKLLIYGASTLQSGVPSRFSGSGS GTDFTLTINSLQPEDFATYYCQQSYSTPRTFGQGTRLDIKRTVAAPSVFIFPPSDEQLKSGTASVVCL

LNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKAD YEKHKVYACEVTHQGLS SPVTKSFNRGEC (SEQ ID NO: 22)

[166] 1460_G14 kappa light chain variable region amino acid sequence: (Kabat CDRs underlined, Chothia CDRs in bold italics) DIQLTQSPSSLSASVGDRVTVTC/M.ϊρT'WT'KLΛWYQQIPGKAPKLLIYC/l-ϊrZ.ρ^CVPSRFSGSGSGTD FTLTINSLQPEDFATYYCPOSKSTy/t 7T¹GOGTRLDIK (SEQ ID NO: 36)

[167] 1460 G 14 kappa light chain Kabat CDRs: CDR 1 : RASQTTHTYL (SEQ ID NO: 1 13) CDR 2: GASTLQSG (SEQ ID NO: 114) CDR 3: QQSYSTPRT (SEQ ID NO: 43)

[168] 1460_G14 kappa light chain Chothia CDRs: CDR 1 : RASQTIHTYL (SEQ ID NO: 1 13) CDR 2: GASTLQSG (SEQ ID NO: 114) CDR 3: QQSYSTPRT (SEQ ID NO: 43)

[169] 1495_C14 (PGC 14) gamma heavy chain nucleotide sequence: 1495_C14 γl coding sequence (variable region in bold)

ATGGACTGGATTTGGAGGATCCTCCTCTTGGTGGCAGCAGCTACAGGCACCCTCGCCGACGGCCACCT GGTTCAGTCTGGGGTTGAGGTGAAGAAGACTGGGGCTACAGTCAAAATCTCCTGCAAGGTTTCTGGAT

GTCACCGTCTCGAGCGCCTCCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCAC CTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGT GGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTAC TCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAA

GCCCACCGTGCCCAGCACCTGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAG GACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCC TGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGG AGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGC

CAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACC AGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAAT GGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTA TAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATG AGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAATGA (SEQ ID NO: 23)

[170] 1495 C14 (PGC14) gamma heavy chain variable region nucleotide sequence:

GACGGCCACCTGGTTCAGTCTGGGGTTGAGGTGAAGAAGACTGGGGCTACAGTCAAAATCTCCTGCAA GGTTTCTGGATACAGCTTCATCGACTACTACCTTCATTGGGTGCAACGGGCCCCTGGAAAAGGCCTTG

ACCATAATCGCGGACACGTCTATAGATACAGGCTACATGGAAATGAGGAGCCTGAAATCTGAGGACAC GGCCGTGTATTTCTGTGCAGCAGGTGCCGTGGGGGCTGATTCCGGGAGCTGGTTCGACCCCTGGGGCC AGGGAACTCTGGTCACCGTCTCGAGC (SEQIDNO: 115)

[171] 1495 C14 (PGC14) gamma heavy chain amino acid sequence: expressed protein with variable region in bold.

DGHLVQSGVEVKKTGATVKISCKVSGYSFIDYYLHWVQRAPGKGLEWVGLIDPENGEARYAEKF QGRVTIUDTSIDTGYMEMRSLKSEDTAVYFCAAGAVGADSGSWFDPWGQGTL VTVSSASTKGPS VFPLAPSSKSTSGGTAALGCL VKD YFPEPVTVSWNSGALTSGVHTFPA VLQSSGLYSLSSVVTVPSSSLG TQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVV DVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALP APIEKTISKAKGQPREPQ VYTLPPSREEMTKNQVSLTCLVKGFYPSDIA VEWESNGQPENNYKTTPPVL DSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 24)

[172] 1495_C14 (PGC14) gamma heavy chain variable region amino acid sequence: (Kabat CDRs underlined, Chothia CDRs in bold italics)

OGHLVQSGVEVKKTGATVKISCKVSGYSFIDYYLHWVQRAPGKGLEWVGLIDPEIVGEARYAEKFOGR VTIIADTSIDTGYMEMRSLKSEDTA VYFCAAGΛ VGA DSGS WFDPW GOGTL VTVSS (SEQ ID NO: 37)

[173] 1495_C 14 gamma heavy chain Kabat CDRs: CDR 1 : SGYSFIDYYLH (SEQ ID NO: 116) CDR 2: LIDPENGEARYAEKFQ (SEQ ID NO: 117) CDR 3: AVGADSGSWFDP (SEQ ID NO: 118)

[174] 1495_C14 gamma heavy chain Chothia CDRs: CDR 1 : SGYSFIDYYLH (SEQ ID NO: 116) CDR 2: LIDPENGEARYAEKFQ (SEQ ID NO: 117) CDR 3: AVGADSGSWFDP (SEQ ID NO: 118)

[175] 1495_C14 (PGC 14) lambda light chain nucleotide sequence: 1495_C14 λ3 coding sequence (variable region in bold)

ATGGCCTGGATCCCTCTCTTCCTCGGCGTCCTTGCTTACTGCACAGATTCCGTAGTCTCCTATGAACT

TGGGGGATAAATATGTTTCCTGGTATCAACTGAGGCCAGGCCAGTCCCCCATACTGGTCATGTATGAA AATGACAGGCGGCCCTCCGGGATCCCTGAGCGATTCTCCGGTTCCAATTCTGGCGACACTGCCACTCT GACCATCAGCGGGACCCAGGCTTTGGATGAGGCTGACTTCTACTGTCAGGCGTGGGAGACCACCACCA CCACTTTTGTTTTCTTCGGCGGAGGGACCCAGCTGACCGTTCTAGGTCAGCCCAAGGCTGCCCCCTCG

GTCACTCTGTTCCCGCCCTCCTCTGAGGAGCTTCAAGCCAACAAGGCCACACTGGTGTGTCTCATAAG TGACTTCTACCCGGGAGCCGTGACAGTGGCCTGGAAGGCAGATAGCAGCCCCGTCAAGGCGGGAGTGG AGACCACCACACCCTCCAAACAAAGCAACAACAAGTACGCGGCCAGCAGCTACCTGAGCCTGACGCCT GAGCAGTGGAAGTCCCACAAAAGCTACAGCTGCCAGGTCACGCATGAAGGGAGCACCGTGGAGAAGAC AGTGGCCCCTACAGAATGTTCATAG (SEQ ID NO: 25)

[176] 1495_C14 (PGC14) lambda light chain variable region nucleotide sequence:

TCCTATGAACTGACTCAGCCACCCTCAGTGTCCGTGTCCCCAGGACAGACAGCCAGCATCACCTGTTC TGGATCTAAATTGGGGGATAAATATGTTTCCTGGTATCAACTGAGGCCAGGCCAGTCCCCCATACTGG TCATGTATGAAAATGACAGGCGGCCCTCCGGGATCCCTGAGCGATTCTCCGGTTCCAATTCTGGCGAC ACTGCCACTCTGACCATCAGCGGGACCCAGGCTTTGGATGAGGCTGACTTCTACTGTCAGGCGTGGGA GACCACCACCACCACTTTTGTTTTCTTCGGCGGAGGGACCCAGCTGACCGTTCTA (SEQ ID NO: 119)

[177] 1495_C14 (PGC 14) lambda light chain amino acid sequence: expressed protein with variable region in bold.

SYELTQPPSVSVSPGQTASITCSGSKLGDKYVSWYQLRPGQSPILVMYENDRRPSGIPERFSGSNSG DTATLTISGTQALDEADFYCQAWETTTTTFVFFGGGTQLTVLGQPKAAPSVTLFPPSSEELQANKA

TL VCLISDFYPGA VTVA WKADSSPVKAGVETTTPSKQSNNKY AASSYLSLTPEQWKSHKSYSCQVTHE GSTVEKTVAPTECS (SEQ ID NO: 26) [178] 1495 C14 (PGC 14) lambda light chain variable region amino acid sequence: (Kabat CDRs underlined, Chothia CDRs in bold italics)

SYELTQPPSVSVSPGQTASITCSGSKLGDKYVSV/YQLRPGQSPILVMYENDRRPSGIPERFSGSNSGDTA TLTISGTQALDEADFYCβ4ffΕ7777TfrFFGGGTQLTVL (SEQ ID NO: 38)

[179] 1495_C14 (PGC 14) lambda light chain Kabat CDRs: CDR 1 : SGSKLGDKYVS (SEQ ID NO: 120) CDR 2: ENDRRPSG (SEQ ID NO: 121) CDR 3: QAWETTTTTFVF (SEQ ID NO: 44)

[180] 1495lci4 (PGC14) lambda light chain Chothia CDRs: CDR 1 : SGSKLGDKYVS (SEQ ID NO: 120) CDR 2: ENDRRPSG (SEQ ID NO: 121) CDR 3: QAWETTTTTFVF (SEQ ID NO: 44)

[181] 1496_C09 (PG9) gamma heavy chain nucleotide sequence: 1496 C09 γ3 coding sequence (variable region in bold)

ATGGAGTTTGGGCTGAGCTGGGTTTTCCTCGTTGCTTTCTTAAGAGGTGTCCAGTGTCAGCGATTAGT GGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGTCGTCCCTGAGACTCTCCTGTGCAGCGTCCGGATTCG ACTTCAGTAGACAAGGCATGCACTGGGTCCGCCAGGCTCCAGGCCAGGGGCTGGAGTGGGTGGCATTT ATTAAATATGATGGAAGTGAGAAATATCATGCTGACTCCGTATGGGGCCGACTCAGCATCTCCAGAGA CAATTCCAAGGATACGCTTTATCTCCAAATGAATAGCCTGAGAGTCGAGGACACGGCTACATATTTTT GTGTGAGAGAGGCTGGTGGGCCCGACTACCGTAATGGGTACAACTATTACGATTTCTATGATGGTTAT TATAACTACCACTATATGGACGTCTGGGGCAAAGGGACCACGGTCACCGTCTCGAGCGCCTCCACCAA GGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCT GCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGC GTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCC CTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGG ACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAACTC CTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCC TGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGG ACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTG GTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAA CAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGG TGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAA GGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGAC CACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTATAGCAAGCTCACCGTGGACAAGAGCA GGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAG AAGAGCCTCTCCCTGTCTCCGGGTAAATGA (SEQ ID NO: 27)

[182] 1496 C09 (PG9) gamma heavy chain variable region nucleotide sequence:

CAGCGATTAGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGTCGTCCCTGAGACTCTCCTGTGCAGCGTCCGGA

GATACGCTTTATCTCCAAATGAATAGCCTGAGAGTCGAGGACACGGCTACATATTTTTGTGTGAGAGAGGCTGGT GGGCCCGACTACCGTAATGGGTACAACTATTACGATTTCTATGATGGTTATTATAACTACCACTATATGGACGTC TGGGGCAAAGGGACCACGGTCACCGTCTCGAGC (SEQ ID NO: 122)

[183] 1496 C09 (PG9) gamma heavy chain amino acid sequence: expressed protein with variable region in bold. QRLVESGGGWQPGSSLRLSCAASGFDFSRQGMHWVRQAPGQGLEWVAFIKYDGSEKYHADSV WGRLSISRDNSKDTLYLQMNSLRVEDTATYFCVREAGGPDYRNGYNYYDFYDG YYNYHYMD VλV

GKGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKD YFPEPVTVSWNSGALTSGVHTFPA VLQ SSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPP KPKDTLMISRTPEVTCVWDVSHEDPEVKFN WYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQ VYTLPPSREEMTKNQVSLTCLVKGFYPSDIA VE WESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 28)

[184] 1496_C09 (PG9) gamma heavy chain variable region amino acid sequence: (Kabat CDRs underlined, Chothia CDRs in bold italics)

ORLVESGGGVVOPGSSLRLSCAASGFDFSROGMHΨVROAFGOGLEΨVAFIKYDGSEKYHADSVWGR LSISRONSKOTLYLOMNSLRVEOTATYFCVREAGGPDYRNGYNYYDFYDGYYNYHYMDVWGKGTTVJ VSS (SEQ ID NO: 39)

[185] 1496 C09 (PG9) gamma heavy chain Kabat CDRs:

CDR 1 : SGFDFSRQGMH (SEQ ID NO: 123)

CDR 2: FIKYDGSEKYHADSVW (SEQ ID NO: 124)

CDR 3: EAGGPDYRNGYNYYDFYDGYYNYHYMDV (SEQ ID NO: 7)

[186] 1496_C09 (PG9) gamma heavy chain Chothia CDRs:

CDR 1 : SGFDFSRQGMH (SEQ ID NO: 123)

CDR 2: FIKYDGSEKYHADSVW (SEQ ID NO: 124)

CDR 3: EAGGPDYRNGYNYYDFYDGYYNYHYMDV (SEQ ID NO: 7)

[187] 1496_C09 (PG9) lambda light chain nucleotide sequence: 1496_C09 λ2 coding sequence (variable region in bold)

ATGGCCTGGGCTCTGCTTTTCCTCACCCTCCTCACTCAGGGCACAGGGTCCTGGGCCCAGTCTGCCCT GACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGACAGTCGATCACCATCTCCTGCAATGGAACCAGCA

ATTTATGATGTCAGTAAACGGCCCTCAGGGGTTTCTAATCGCTTCTCTGGCTCCAAGTCCGGCAACAC GGCCTCCCTGACCATCTCTGGGCTCCAGGCTGAGGACGAGGGTGACTATTACTGCAAGTCTCTGACAA

TCGGTCACTCTGTTCCCGCCCTCCTCTGAGGAGCTTCAAGCCAACAAGGCCACACTGGTGTGTCTCAT AAGTGACTTCTACCCGGGAGCCGTGACAGTGGCCTGGAAGGCAGATAGCAGCCCCGTCAAGGCGGGAG TGGAGACCACCACACCCTCCAAACAAAGCAACAACAAGTACGCGGCCAGCAGCTACCTGAGCCTGACG CCTGAGCAGTGGAAGTCCCACAAAAGCTACAGCTGCCAGGTCACGCATGAAGGGAGCACCGTGGAGAA GACAGTGGCCCCTACAGAATGTTCATAG (SEQ ID NO: 29)

[188] 1496_C09 (PG9) lambda light chain variable region nucleotide sequence:

CAGTCTGCCCTGACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGACAGTCGATCACCATCTCCTGCAA TGGAACCAGCAATGATGTTGGTGGCTATGAATCTGTCTCCTGGTACCAACAACATCCCGGCAAAGCCC CCAAAGTCGTGATTTATGATGTCAGTAAACGGCCCTCAGGGGTTTCTAATCGCTTCTCTGGCTCCAAG TCCGGCAACACGGCCTCCCTGACCATCTCTGGGCTCCAGGCTGAGGACGAGGGTGACTATTACTGCAA GTCTCTGACAAGCACGAGACGTCGGGTTTTCGGCACTGGGACCAAGCTGACCGTTCTA (SEQ ID NO: 125)

[189] 1496_C09 (PG9) lambda light chain amino acid sequence: expressed protein with variable region in bold. QSALTQPASVSGSPGQSITISCNGTSNDVGGYESVSWYQQHPGKAPKWIYDVSKRPSGVSNRFSG SKSGNTASLTISGLQ AEDEGDYYCKSLTSTRRRVFGTGTKLTVLGQPKAAPSVTLFPPSSEELQANK

ATL VCLISDFYPGA VTVA WKADSSPVKAGVETTTPSKQSNNKY AASSYLSLTPEQWKSHKSYSCQVTH EGSTVEKTVAPTECS (SEQ ID NO: 30)

[190] 1496 C09 (PG9) lambda light chain variable region amino acid sequence: (Kabat CDRs underlined, Chothia CDRs in bold italics)

QSALTQPASVSGSPGQSITISC^VCTΪVWf^Cra^røWYQQHPGKAPKVVIYDra^ΛSσVSNRFSGSKS GNTASLTISGLOAEDEGDYYCΛSZrerft/t/t ETGTGTKLTVL (SEQ ID NO: 40)

[191] 1496_C09 (PG9) lambda light chain Kabat CDRs: CDR 1 : NGTSNDVGGYESVS (SEQ ID NO: 126) CDR 2: DVSKRPSG (SEQ ID NO: 127) CDR 3: KSLTSTRRRV (SEQ ID NO: 45)

[192] 1496_C09 (PG9) lambda light chain Chothia CDRs: CDR 1 : NGTSNDVGGYESVS (SEQ ID NO: 126) CDR 2: DVSKRPSG (SEQ ID NO: 127) CDR 3: KSLTSTRRRV (SEQ ID NO: 45)

[193] The PGl 6 antibody includes a heavy chain variable region (SEQ ID NO: 31), encoded by the nucleic acid sequence shown in SEQ ID NO: 99, and a light chain variable region

(SEQ ID NO: 32) encoded by the nucleic acid sequence shown in SEQ ID NO: 100.

[194] The heavy chain CDRs of the PG 16 antibody have the following sequences per Kabat and Chothia definitions: SGFTFHKYGMH (SEQ ID NO: 88), LISDDGMRKYHSDSMW

(SEQ ID NO: 89), and EAGGPIWHDDVKYYDFNDGYYNYHYMDV (SEQ ID NO: 6).

The light chain CDRs of the PG 16 antibody have the following sequences per Kabat and

Chothia definitions: NGTSSDVGGFDSVS (SEQ ID NO: 97), DVSHRPSG (SEQ ID NO:

95), and SSLTDRSHRI (SEQ ID NO: 41).

[195] The PG20 antibody includes a heavy chain variable region (SEQ ID NO: 33), encoded by the nucleic acid sequence shown in SEQ ID NO: 101, and a light chain variable region

(SEQ ID NO: 34) encoded by the nucleic acid sequence shown in SEQ ID NO: 106.

[196] The heavy chain CDRs of the PG20 antibody have the following sequences per Kabat definition: SGGTFSSYAFT (SEQ ID NO: 104), MVTPIFGEAKYSQRFE (SEQ ID NO:

105), and RAVPIATDNWLDP (SEQ ID NO: 102). The light chain CDRs of the PG20 antibody have the following sequences per Kabat definition: RASQTTNNYLN (SEQ ID NO:

107), GASNLQNG (SEQ ID NO: 108), and QQSFSTPRT (SEQ ID NO: 42).

[197] The heavy chain CDRs of the PG20 antibody have the following sequences per

Chothia definition: SGGTFSSYAFT (SEQ ID NO: 104), MVTPIFGEAKYSQRFE (SEQ ID

NO: 105), and RRAVPIATDNWLDP (SEQ ID NO: 103). The light chain CDRs of the PG20 antibody have the following sequences per Chothia definition: RASQTINNYLN (SEQ ID NO: 107), GASNLQNG (SEQ ID NO: 108), and QQSFSTPRT (SEQ ID NO: 42). [198J The PGG14 antibody includes a heavy chain variable region (SEQ ID NO: 35), encoded by the nucleic acid sequence shown in SEQ ID NO: 109, and a light chain variable region (SEQ ID NO: 36) encoded by the nucleic acid sequence shown in SEQ ID NO: 1 12. [199] The heavy chain CDRs of the PGG14 antibody have the following sequences per Kabat definition: SGGAFSSYAFS (SEQ ID NO: 110), MITPVFGETKY APRFQ (SEQ ID NO: 111), and RWPMATDNWLDP (SEQ ID NO: 102). The light chain CDRs of the PGG 14 antibody have the following sequences per Kabat definition: RASQTIHTYL (SEQ ID NO: 113), GASTLQSG (SEQ ID NO: 114), and QQSYSTPRT (SEQ ID NO: 43). [200] The heavy chain CDRs of the PGG 14 antibody have the following sequences per Chothia definition: SGGAFSSYAFS (SEQ ID NO: 110), MITPVFGETKY APRFQ (SEQ ID NO: 11 1), RRVVPMATDNWLDP (SEQ ID NO: 103). The light chain CDRs of the PGG 14 antibody have the following sequences per Chothia definition: RASQTIHTYL (SEQ ID NO: 113), GASTLQSG (SEQ ID NO: 114), and QQSYSTPRT (SEQ ID NO: 43). [201] The PGC 14 antibody includes a heavy chain variable region (SEQ ID NO: 37), encoded by the nucleic acid sequence shown in SEQ ID NO: 115, and a light chain variable region (SEQ ID NO: 38) encoded by the nucleic acid sequence shown in SEQ ID NO: 1 19. [202] The heavy chain CDRs of the PGC 14 antibody have the following sequences per Kabat and Chothia definitions: SGYSFIDYYLH (SEQ ID NO: 1 16), LIDPENGEARYAEKFQ (SEQ ID NO: 1 17), and AVGADSGS WFDP (SEQ ID NO: 1 18). The light chain CDRs of the PGC 14 antibody have the following sequences per Kabat and Chothia definitions: SGSKLGDKYVS (SEQ ID NO: 120), ENDRRPSG (SEQ ID NO: 121), and QAWETTTTTFVF (SEQ ID NO: 44).

[203] The PG9 antibody includes a heavy chain variable region (SEQ ID NO: 39), encoded by the nucleic acid sequence shown in SEQ ID NO: 122, and a light chain variable region (SEQ ID NO: 40) encoded by the nucleic acid sequence shown in SEQ ID NO: 125. [204] The heavy chain CDRs of the PG9 antibody have the following sequences per Kabat and Chothia definitions: SGFDFSRQGMH (SEQ ID NO: 123), FIKYDGSEKYHADSVW (SEQ ID NO: 124), and EAGGPD YRNGYNYYDFYDGYYNYHYMDV (SEQ ID NO: 7). The light chain CDRs of the PG9 antibody have the following sequences per Kabat and Chothia definitions: NGTSNDVGGYESVS (SEQ ID NO: 126), DVSKRPSG (SEQ ID NO: 127), and KSLTSTRRRV (SEQ ID NO: 45). [205] Table 6A. Heavy Chain Variable Region Protein Alignment

[207] The sequences of sister clones to human monoclonal antibody 1443 C16 (PG 16) were determined, including the sequences of the variable regions of the Gamma heavy and Kappa or Lambda light chains. In addition, the sequence of each of the polynucleotides encoding the antibody sequences was determined. Shown below are the polypeptide and polynucleotide sequences of the gamma heavy chains and kappa light chains, with the signal peptides at the N- terminus (or 5' end) and the constant regions at the C-terminus (or 3' end) of the variable regions, which are shown in bolded text.

[208] 1469 M23 gamma heavy chain nucleotide sequence: 1469 M23 γ3 coding sequence (variable region in bold)

ATGGAGTTTGGGCTGAGCTGGGTTTTCCTCGCAACTCTGTTAAGAGTTGTGAAGTGTCAGGAAAAACT GGTGGAGTCTGGGGGAGGCGTGGTCCAGCCGGGGGGGTCCCTGAGACTCTCCTGTTTAGCGTCTGGAT TCACCTTTCACAAATATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGCCTGGAGTGGGTGGCA CTCATCTCAGATGACGGAATGAGGAAATATCATTCAGACTCCATGTGGGGCCGAGTCACCATCTCCAG AGACAATTCCAAGAACACTCTATATCTGCAATTCaGCAGCCTGAAAGTCGAAGACACGGCTATGTTCT TCTGTGCGAGAGAGGCTGGTGGGCCAATCTGGCATGACGACGTCAAATATTACGATTTTAATGACGGC TACTACAACTACCACTACATGGACGTCTGGGGCAAGGGGACCACGGTCACCGtCTCCTCAGCGTCGAC CAAGGGCCCATCGGTCTTCCCTCTGGCACCATCATCCAAGTCGACCTCTGGGGGCACAGCGGCCCTGG GCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGC GGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGT GCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGG TGGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAA CTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGAC CCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACG TGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGT GTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTC CAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCAC AGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTC AAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAA GACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTATAGCAAGCTCACCGTGGACAAGA GCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACG CAGAAGAGCCTCTCCCTGTCTCCGGGTAAATGA (SEQ ID NO: 138)

[209] 1469 M23 gamma heavy chain variable region nucleotide sequence:

CAGGAAAAACTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCGGGGGGGTCCCTGAGACTCTCCTGTTT AGCGTCTGGATTCACCTTTCACAAATATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGCCTGG AGTGGGTGGCACTCATCTCAGATGACGGAATGAGGAAATATCATTCAGACTCCATGTGGGGCCGAGTC ACCATCTCCAGAGACAATTCCAAGAACACTCTATATCTGCAATTCaGCAGCCTGAAAGTCGAAGACAC GGCTATGTTCTTCTGTGCGAGAGAGGCTGGTGGGCCAATCTGGCATGACGACGTCAAATATTACGATT TTAATGACGGCTACTACAACTACCACTACATGGACGTCTGGGGCAAGGGGACCACGGTCACCGtCTCC TCA(SEQIDNO: 128)

[210] 1469 M23 gamma heavy chain amino acid sequence: expressed protein with variable region in bold.

QEKLVESGGGWQPGGSLRLSCLASGFTFHKYGMHWVRQAPGKGLEWVALISDDGMR KYHSDSMWGRVTISRDNSKNTLYLQFSSLKVEDTAMFFCAREAGGPIWHDDVKYYDFN

DGYYNYHYMDVWGKGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVT VSWNSGALTSGVHTFPA VLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEP KSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD GVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKG QPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIA VEWESNGQPENNYKTTPPVLDSDGSF FLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 139)

[211] 1469_M23 gamma heavy chain variable region amino acid sequence: (Kabat CDRs underlined, Chothia CDRs in bold italics)

OEKLVESGGGVVOPGGSLRLSCLA^GFr/^AryCΛ/^WVROAPGKGLEWVAZ./S'PPgΛffl/ry^ SDSMWGRVTISRDNSKKTLYLQFSSLKVEDTAMFFCAREAGGPfWHDDVKYYDFNDGYYNY HYMD ^WGKGTTVTVSS (SEQ ID NO: 140)

[212] ^' 1469 M23 gamma heavy chain Kabat CDRs:

CDR 1 : SGFTFHKYGMH (SEQ ID NO: 88)

CDR 2: LISDDGMRKYHSDSMW (SEQ ID NO: 89)

CDR 3: EAGGPIWHDDVKYYDFNDGYYNYΉYMDV (SEQ ID NO: 6)

[213] 1469_M23 gamma heavy chain Chothia CDRs:

CDR 1 : SGFTFHKYGMH (SEQ ID NO: 88)

CDR 2: LISDDGMRKYHSDSMW (SEQ ID NO: 89)

CDR 3: EAGGPIWHDDVKYYDFNDGYYNYHYMDV (SEQ ID NO: 6)

[214] 1469_M23 lambda light chain nucleotide sequence: 1469_M23 λ2 coding sequence (variable region in bold)

ATGGCCTGGGCTCTGCTATTCCTCACCCTCTTCACTCAGGGCACAGGGTCCTGGGGCCAGTCTGCCCT GACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGACAGACGATCACCATCTCCTGCAATGGAACCAGAA GTGACGTTGGTGGATTTGACTCTGTCTCCTGGTACCAACAATCCCCAGGGAGAGCCCCCAAAGTCATG GTTTTTGATGTCAGTCATCGGCCCTCAGGTATCTCTAATCGCTTCTCTGGCTCCAAGTCCGGCAACAC GGCCTCCCTGACCATCTCTGGGCTCCACATTGAGGACGAGGGCGATTATTTCTGCTCTTCACTGACAG ACAGAAGCCATCGCATATTCGGCGGCGGGACCAAGCTGACCGTTCTAGGTCAGCCCAAGGCTGCCCCC

TCGGTCACTCTGTTCCCGCCCTCCTCTGAGGAGCTTCAAGCCAACAAGGCCACACTGGTGTGTCTCAT AAGTGACTTCTACCCGGGAGCCGTGACAGTGGCCTGGAAGGCAGATAGCAGCCCCGTCAAGGCGGGAG TGGAGACCACCACACCCTCCAAACAAAGCAACAACAAGTACGCGGCCAGCAGCTACCTGAGCCTGACG CCTGAGCAGTGGAAGTCCCACAAAAGCTACAGCTGCCAGGTCACGCATGAAGGGAGCACCGTGGAGAA GACAGTGGCCCCTACAGAATGTTCATAG (SEQIDNO: 141)

[215] 1469_M23 lambda light chain variable region nucleotide sequence:

CAGTCTGCCCTGACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGACAGACGATCACCATCTCCTGCAA

TGGAACCAGAAGTGACGTTGGTGGATTTGACTCTGTCTCCTGGTACCAACAATCCCCAGGGAGAGCCC

CCAAAGTCATGGTTTTTGATGTCAGTCATCGGCCCTCAGGTATCTCTAATCGCTTCTCTGGCTCCAAG

TCCGGCAACACGGCCTCCCTGACCATCTCTGGGCTCCACATTGAGGACGAGGGCGATTATTTCTGCTC

TTCACTGACAGACAGAAGCCATCGCATATTCGGCGGCGGGACCAAGCTGACCGTTCTA (SEQ ID NO:

129)

[216] 1469_M23 lambda light chain amino acid sequence: expressed protein with variable region in bold.

QSALTQPASVSGSPGQTITISCNGTRSDVGGFDSVSWYQQSPGRAPKVMVFDVSHRPSGI SNRFSGSKSGNT ASLTISGLHIEDEGDYFCSSLTDRSHRIFGGGTKLTVLGQPKAAPSVTLF

PPSSEELQANKATLVCLISDFYPGAVTVA WKADSSPVKAGVETTTPSKQSNNKY AASSYLSL TPEQWKSHKSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 142)

[217] 1469 M23 lambda light chain variable region amino acid sequence: (Kabat CDRs underlined, Chothia CDRs in bold italics)

OS ALTOPAS VSGSPG0TITISCM7mSD raGFZXSF.SWYOOSPGRAPKVMVFZ) VSHRPSG1SNR FSGSKSGNTASLTISGLHIEDEGDYFGSSl, TDRSHRIFGGGTKLTVL (SEQ ID NO: 96)

[218] 1469_M23 lambda light chain Kabat CDRs: CDR 1 : NGTRSDVGGFDSVS (SEQ ID NO: 92) CDR 2: DVSHRPSG (SEQ ID NO: 95) CDR 3: SSLTDRSHRI (SEQ ID NO: 41)

[219] 1469_M23 lambda light chain Chothia CDRs: CDR 1 : NGTRSDVGGFDSVS (SEQ ID NO: 92) CDR 2: DVSHRPSG (SEQ ID NO: 95) CDR 3: SSLTDRSHRI (SEQ ID NO: 41)

[220] 1456_A12 gamma heavy chain nucleotide sequence: 1456 A12 γ3 coding sequence (variable region in bold)

ATGGAGTTTGGGCTGAGCTGGGTTTTCCTCGCAACTCTGTTAAGAGTTGTGAAGTGTCACGAACAACT GGTGGAGGCCGGGGGAGGCGTGGTCCAGCCGGGGGGGTCCCTGAGACTCTCCTGTTTAGCGTCTGGAT TCACGTTTCACAAATATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGCCTGGAGTGGGTGGCA CTCATCTCAGATGACGGAATGAGGAAATATCATTCAGACTCCATGTGGGGCCGAGTCACCATCTCCAG AGACAATTCCAAGAACACTCTTTATCTGCAATTCAGCAGCCTGAGAGTCGAAGACACGGCTATGTTCT TCTGTGCGAGAGAGGCCGGTGGGCCAATCTGGCATGACGACGTCAAATATTACGATTTTAATGACGGC TACTACAACTATCACTACATGGACGTCTGGGGCAAGGGGACCAAGGTCACCGTCTCCTCAGCGTCGAC CAAGGGCCCATCGGTCTTCCCTCTGGCACCATCATCCAAGTCGACCTCTGGGGGCACAGCGGCCCTGG GCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGC GGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGT GCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGG TGGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAA CTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGAC CCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACG TGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGT GTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTC CAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCAC AGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTC AAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAA GACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTATAGCAAGCTCACCGTGGACAAGA GCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACG CAGAAGAGCCTCTCCCTGTCTCCGGGTAAATGA (SEQ ID NO: 46)

[221] 1456_A12 gamma heavy chain variable region nucleotide sequence:

CACGAACAACTGGTGGAGGCCGGGGGAGGCGTGGTCCAGCCGGGGGGGTCCCTGAGACTCTCCTGTTT AGCGTCTGGATTCACGTTTCACAAATATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGCCTGG AGTGGGTGGCACTCATCTCAGATGACGGAATGAGGAAATATCATTCAGACTCCATGTGGGGCCGAGTC

GGCTATGTTCTTCTGTGCGAGAGAGGCCGGTGGGCCAATCTGGCATGACGACGTCAAATATTACGATT TCA (SEQIDNO: 130)

[222] 1456_A12 gamma heavy chain amino acid sequence: expressed protein with variable region in bold.

HEQLVEAGGGWQPGGSLRLSCLASGFTFHKYGMHWVRQAPGKGLEWVALISDDGM RKYHSDSMWGRVTISRDNSKNTLYLQFSSLRVEDTAMFFCAREAGGPIWHDDVKYYDF

NDG YYNYHYMD VΛVGKGTKVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCL VKD YFPEPV TVSWNSGALTSGVHTFPA VLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEP KSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD GVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKE YKCKVSNKALPAPIEKTISKAKG QPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIA VEWESNGQPENNYKTTPPVLDSDGSF FLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 47)

[223] 1456_A12 gamma heavy chain variable region amino acid sequence: (Kabat CDRs underlined, Chothia CDRs in bold italics)

HEOLVEAGGGVVOPGGSLRLSCLAS'GFrFfl^yCΛfflWVROAPGKGLEWVAZ.ΛyggGΛfflΛry amSMFTGRVTISRDNSKNTL YLOFSSLRVEDTAMFFCAREΛ GGPIWHDD VKYYDFNDGYYN YHYMD FWGKGTKVTVSS (SEQ ID NO: 48)

[224] 1456_A 12 gamma heavy chain Kabat CDRs:

CDR 1 : SGFTFHKYGMH (SEQ ID NO: 88)

CDR 2: LISDDGMRKYHSDSMW (SEQ ID NO: 89)

CDR 3: EAGGPIWHDDVKYYDFNDGYΎNYHYMDV (SEQ ID NO: 6)

[225] 1456 A12 gamma heavy chain Chothia CDRs:

CDR 1 : SGFTFHKYGMH (SEQ ID NO: 88)

CDR 2: LISDDGMRKYHSDSMW (SEQ ID NO: 89)

CDR 3 : EAGGPIWHDDVKYYDFNDGYYNYHYMDV (SEQ ID NO: 6) [226] 1456_A12 lambda light chain nucleotide sequence: 1456_A12 λ2 coding sequence (variable region in bold)

ATGGCCTGGGCTTGCTATTCCTCACCCTCTTCACTCAGGGCACAGGGTCCTGGGGCCAGTCTGCCCTG ACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGACAGACGATCACCATCTCCTGCAATGGAACCAGCCG TGACGTTGGTGGATTTGACTCTGTCTCCTGGTATCAACAATCCCCAGGGAAAGCCCCCAAAGTCATGG TTTTTGATGTCAGTCATCGGCCCTCAGGTATGTCTAATCGCTTCTCTGGCTCCAAGTCCGGCAACACG GCCTCCCTGACCATTTCTGGGCTCCACATTGAGGACGAGGGCGATTATTTCTGCTCTTCATTGACAGA CAGAAGCCATCGCATATTCGGCGGCGGGACCAAGCTGACCGTTCTAGGTCAGCCCAAGGCTGCCCCCT CGGTCACTCTGTTCCCGCCCTCCTCTGAGGAGCTTCAAGCCAACAAGGCCACACTGGTGTGTCTCATA AGTGACTTCTACCCGGGAGCCGTGACAGTGGCCTGGAAGGCAGATAGCAGCCCCGTCAAGGCGGGAGT GGAGACCACCACACCCTCCAAACAAAGCAACAACAAGTACGCGGCCAGCAGCTACCTGAGCCTGACGC CTGAGCAGTGGAAGTCCCACAAAAGCTACAGCTGCCAGGTCACGCATGAAGGGAGCACCGTGGAGAAG ACAGTGGCCCCTACAGAATGTTCATAG (SEQ ID NO: 49)

[227] 1456 A12 lambda light chain variable region nucleotide sequence:

TGGAACCAGCCGTGACGTTGGTGGATTTGACTCTGTCTCCTGGTATCAACAATCCCCAGGGAAAGCCC CCAAAGTCATGGTTTTTGATGTCAGTCATCGGCCCTCAGGTATGTCTAATCGCTTCTCTGGCTCCAAG TCCGGCAACACGGCCTCCCTGACCATTTCTGGGCTCCACATTGAGGACGAGGGCGATTATTTCTGCTC TTCATTGACAGACAGAAGCCATCGCATATTCGGCGGCGGGACCAAGCTGACCGTTCTA (SEQ ID NO: 131)

[228] 1456 A12 lambda light chain amino acid sequence: expressed protein with variable region in bold.

QSALTQPASVSGSPGQTITISCNGTSRDVGGFDSVSWYQQSPGKAPKVMVFDVSHRPSG MSNRFSGSKSGNTASLTISGLHIEDEGDYFCSSLTDRSHRIFGGGTKLTVLGQPKAAPSVT

LFPPSSEELQANKATLVCLISDFYPGA VTVA WKADSSPVKAGVETTTPSKQSNNKY AASSYLS LTPEQWKSHKSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 50)

[229] 1456_A12 lambda light chain variable region amino acid sequence: (Kabat CDRs underlined, Chothia CDRs in bold italics)

OSALTOPASVSGSPGOTlTlSCNGTSRDVGGFDSVSWYQOSPGYJiPKVMVFDVSHRPSGMSK RFSGSKSGNTASLTISGLHIEDEGDYFGSSZ, TDRSHRIFGGGTKLTVL (SEQ ID NO: 51)

[230] 1456_A12 lambda light chain Kabat CDRs: CDR 1 : NGTSRDVGGFDSVS (SEQ ID NO: 93) CDR 2: DVSHRPSG (SEQ ID NO: 95) CDR 3: SSLTDRSHRI (SEQ ID NO: 41)

[231] 1456_A12 lambda light chain Chothia CDRs: CDR 1 : NGTSRDVGGFDSVS (SEQ ID NO: 93) CDR 2: DVSHRPSG (SEQ ID NO: 95) CDR 3: SSLTDRSHRI (SEQ ID NO: 41)

[232] 1503 H05 gamma heavy chain nucleotide sequence: 1503 H05 γ3 coding sequence (variable region in bold) ATGGAGTTTGGCTGAGCTGGGTTTTCCTCGCAACTCTGTTAAGAGTTGTGAAGTGTCAGGAAAAACTG GTGGAGTCTGGGGGAGGCGTGGTCCAGCCGGGGGGGTCCCTGAGACTCTCCTGTTTAGCGTCTGGATT CACCTTTCACAAATATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGCCTGGAGTGGGTGGCAC TCATCTCAGATGACGGAATGAGGAAATATCATTCAGACTCCATGTGGGGCCGAGTCACCATCTCCAGA GACAATTCCAAGAACACTTTATATCTGCAATTCAGCAGCCTGAAAGTCGAAGACACGGCTATGTTCTT CTGTGCGAGAGAGGCTGGTGGGCCAATCTGGCATGACGACGTCAAATATTACGATTTTAATGACGGCT ACTACAATTACCACTACATGGACGTCTGGGGCAAGGGGACCATTGTCACCGTCTCCTCAGCGTCGACC AAGGGCCCATCGGTCTTCCCTCTGGCACCATCATCCAAGTCGACCTCTGGGGGCACAGCGGCCCTGGG CTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCG GCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTG CCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGT GGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAAC TCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACC CCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGT GGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTG TGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCC AACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACA GGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCA AAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAG ACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTATAGCAAGCTCACCGTGGACAAGAG CAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGC AGAAGAGCCTCTCCCTGTCTCCGGGTAAATGA (SEQ ID NO: 52)

[233] 1503 H05 gamma heavy chain variable region nucleotide sequence:

CAGGAAAAACTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCGGGGGGGTCCCTGAGACTCTCCTGTTT AGCGTCTGGATTCACCTTTCACAAATATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGCCTGG AGTGGGTGGCACTCATCTCAGATGACGGAATGAGGAAATATCATTCAGACTCCATGTGGGGCCGAGTC ACCATCTCCAGAGACAATTCCAAGAACACTTTATATCTGCAATTCAGCAGCCTGAAAGTCGAAGACAC GGCTATGTTCTTCTGTGCGAGAGAGGCTGGTGGGCCAATCTGGCATGACGACGTCAAATATTACGATT TTAATGACGGCTACTACAATTACCACTACATGGACGTCTGGGGCAAGGGGACCATTGTCACCGTCTCC TCA(SEQ IDNO: 132)

[234] 1503 H05 gamma heavy chain amino acid sequence: expressed protein with variable region in bold.

QEKL VESGGGVVQPGGSLRLSCLASGFTFHKYGMHWVRQAPGKGLEWVALISDDGMR KYHSDSMWGRVTISRDNSKNTLYLQFSSLKVEDT AMFFCAREAGGPIWHDDVKYYDFN

DGYYNYHYMDVWGKGTIVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTV SWNSGALTSGVHTFPA VLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKS CDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDG VEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQ PREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFF LYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 53).

[235] 1503 H05 gamma heavy chain variable region amino acid sequence: (Kabat CDRs underlined, Chothia CDRs in bold italics)

OEKLVESGGGVVOPGGSLRLSCLA5C7FrF#ΛΥGM/7WVROAPGKGLEWVA£/S/)/>CM/Mfr/7 SZλSMFFGRVTISRDNSKNTL YLOFSSLKVEDTAMFFCAREAGGPItVHDDVKYYDFNDGYYNY HYMD nVGKGTIVTVSS (SEQ ID NO: 54)

[236] 1503_H05 gamma heavy chain Kabat CDRs: CDR 1 : SGFTFHKYGMH (SEQ ID NO: 88)

CDR 2: LISDDGMRKYHSDSMW (SEQ ID NO: 89)

CDR 3: EAGGPIWHDDVKYYDFNDGYYNYHYMDV (SEQ ID NO: 6)

[237] 1503 H05 gamma heavy chain Chothia CDRs:

CDR 1 : SGFTFHKYGMH (SEQ ID NO: 88)

CDR 2: LISDDGMRKYHSDSMW (SEQ ID NO: 89)

CDR 3: EAGGPIWHDDVKYYDFNDGYYNYHYMDV (SEQ ID NO: 6)

[238] 1503 H05 lambda light chain nucleotide sequence: 1503 H05 λ2 coding sequence (variable region in bold)

ATGGCCTGGGCTTGCTATTCCTCACCCTCTTCACTCAGGGCACAGGGTCCTGGGGCCAGTCTGCCCTG ACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGACAGACGATCACCATCTCCTGCAATGGAACCAGAAG TGACGTTGGTGGATTTGACTCTGTCTCCTGGTACCAACAATCCCCAGGGAAAGCCCCCAAAGTCATGG TTTTTGATGTCAGTCATCGGCCCTCAGGTATCTCTAATCGCTTCTCTGGCTCCAAGTCCGGCAACACG GCCTCCCTGACCATCTCTGGGCTCCACATTGAGGACGAGGGCGATTATTTCTGCTCTTCACTGACAGA CAGAAGCCATCGCATATTCGGCGGCGGGACCAAGGTGACCGTTCTAGGTCAGCCCAAGGCTGCCCCCT CGGTCACTCTGTTCCCGCCCTCCTCTGAGGAGCTTCAAGCCAACAAGGCCACACTGGTGTGTCTCATA AGTGACTTCTACCCGGGAGCCGTGACAGTGGCCTGGAAGGCAGATAGCAGCCCCGTCAAGGCGGGAGT GGAGACCACCACACCCTCCAAACAAAGCAACAACAAGTACGCGGCCAGCAGCTACCTGAGCCTGACGC CTGAGCAGTGGAAGTCCCACAAAAGCTACAGCTGCCAGGTCACGCATGAAGGGAGCACCGTGGAGAAG ACAGTGGCCCCTACAGAATGTTCATAG (SEQ ID NO: 55)

[239] 1503 H05 lambda light chain variable region nucleotide sequence:

CAGTCTGCCCTGACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGACAGACGATCACCATCTCCTGCAA

TGGAACCAGAAGTGACGTTGGTGGATTTGACTCTGTCTCCTGGTACCAACAATCCCCAGGGAAAGCCC

CCAAAGTCATGGTTTTTGATGTCAGTCATCGGCCCTCAGGTATCTCTAATCGCTTCTCTGGCTCCAAG

TCCGGCAACACGGCCTCCCTGACCATCTCTGGGCTCCACATTGAGGACGAGGGCGATTATTTCTGCTC

TTCACTGACAGACAGAAGCCATCGCATATTCGGCGGCGGGACCAAGGTGACCGTTCTA (SEQ ID NO:

133)

[240] 1503 H05 lambda light chain amino acid sequence: expressed protein with variable region in bold.

QSALTQPASVSGSPGQTITISCNGTRSDVGGFDSVSWYQQSPGKAPKVMVFDVSHRPSGI SNRFSGSKSGNT ASLTISGLHIEDEGDYFCSSLTDRSHRIFGGGTKVT VLGQPKAAPSVTL FPPSSEELQANKATLVCLISDFYPGA VTVA WKADSSPVKAGVETTTPSKQSNNKY AASSYLSL TPEQWKSHKSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 56)

[241] 1503 H05 lambda light chain variable region amino acid sequence: (Kabat CDRs underlined, Chothia CDRs in bold italics)

QSALTQPASVSGSPGQTITISCNGTRSDVGGFDSVSWYQOSPGKAPKVMVFDVSHRPSGISNR FSGSKSGNTASLTISGLHIEDEGDYFCSffl.røfl.Stfft/FGGGTKVTVL (SEQ ID NO: 57)

[242] 1503_H05 lambda light chain Kabat CDRs: CDR 1 : NGTRSDVGGFDSVS (SEQ ID NO: 92) CDR 2: DVSHRPSG (SEQ ID NO: 95) CDR 3: SSLTDRSHRI (SEQ ID NO: 41) [243] 15O3_HO5 lambda light chain Chothia CDRs: CDR 1 : NGTRSDVGGFDSVS (SEQ ID NO: 92) CDR 2: DVSHRPSG (SEQ ID NO: 95) CDR 3: SSLTDRSHRI (SEQ ID NO: 41)

[244] 1489_I13 gamma heavy chain nucleotide sequence: 1489_I13 γ3 coding sequence (variable region in bold)

ATGGAGTTTGGGCTGAGCTGGGTTTTCCTCGCAACTCTGTTAAGAGTTGTGAAGTGTCAGGAACAACT GTTGGAGTCTGGGGGAGGCGTGGTCCAGCCGGGGGGGTCCCTGAGACTCTCCTGTTTAGCGTCTGGAT TCACGTTTCACAAATATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGCCTGGAGTGGGTGGCA CTCATCTCAGATGACGGAATGAGGAAATATCATTCAAACTCCATGTGGGGCCGAGTCACCATCTCCAG AGACAATTCCAAGAACACTCTTTATCTGCAATTCAGCAGCCTGAAAGTCGAAGACACGGCTATGTTCT TCTGTGCGAGAGAGGCTGGTGGGCCAATCTGGCATGACGACGTCAAATATTACGATTTTAATGACGGC TACTACAACTACCACTACATGGACGTCTGGGGCAAGGGGACCACGGTCACCGTCTCCTCAGCGTCGAC CAAGGGCCCATCGGTCTTCCCTCTGGCACCATCATCCAAGTCGACCTCTGGGGGCACAGCGGCCCTGG GCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGC GGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGT GCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGG TGGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAA CTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGAC CCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACG TGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGT GTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTC CAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCAC AGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTC

GACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTATAGCAAGCTCACCGTGGACAAGA GCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACG CAGAAGAGCCTCTCCCTGTCTCCGGGTAAATGA (SEQIDNO: 58)

[245] 1489 113 gamma heavy chain variable region nucleotide sequence:

CAGGAACAACTGTTGGAGTCTGGGGGAGGCGTGGTCCAGCCGGGGGGGTCCCTGAGACTCTCCTGTTT AGCGTCTGGATTCACGTTTCACAAATATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGCCTGG AGTGGGTGGCACTCATCTCAGATGACGGAATGAGGAAATATCATTCAAACTCCATGTGGGGCCGAGTC ACCATCTCCAGAGACAATTCCAAGAACACTCTTTATCTGCAATTCAGCAGCCTGAAAGTCGAAGACAC GGCTATGTTCTTCTGTGCGAGAGAGGCTGGTGGGCCAATCTGGCATGACGACGTCAAATATTACGATT TTAATGACGGCTACTACAACTACCACTACATGGACGTCTGGGGCAAGGGGACCACGGTCACCGTCTCC TCA (SEQIDNO: 134)

[246] 1489 113 gamma heavy chain amino acid sequence: expressed protein with variable region in bold.

QEQLLESGGGVVQPGGSLRLSCLASGFTFHKYGMHWVRQAPGKGLEWVALISDDGMR KYHSNSMWGRVTISRDNSKNTLYLQFSSLKVEDTAMFFCAREAGGPIWHDDVKYYDFN

DGYYNYHYMDVWGKGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVT VSWNSGALTSGVHTFPA VLQSSGL YSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEP KSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD GVEVHNAKTKPREEQYNSTYRVVSVL WLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKG QPREPQVYTLPPSREEMTKNQVSLTCL VKGFYPSDIA VEWESNGQPENNYKTTPPVLDSDGSF FLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 59) [247] 1489 113 gamma heavy chain variable region amino acid sequence: (Kabat CDRs underlined, Chothia CDRs in bold italics)

QEQLLESGGGVVQVGGSLRLSCLASGFTFHKYGMHΨVROAPGKGLEΨV ALISDDGMRKYH SΛffMFFGRVTISRDNSKNTLYLOFSSLKVEDTAMFFCAREΛ GGPIWHDD VKYYDFNDGYYNY HYMD FWGKGTTVTVSS (SEQ ID NO: 60)

[248] 1489_113 gamma heavy chain Kabat CDRs:

CDR 1 : SGFTFHKYGMH (SEQ ID NO: 88)

CDR 2: LISDDGMRKYHSNSMW (SEQ ID NO: 98)

CDR 3: EAGGPIWHDDVKYYDFNDGYYNYHYMDV (SEQ ID NO: 6)

[249] 1489 113 gamma heavy chain Chothia CDRs:

CDR 1 : SGFTFHKYGMH (SEQ ID NO: 88)

CDR 2: LISDDGMRKYHSNSMW (SEQ ID NO: 98)

CDR 3: EAGGPIWHDDVKYYDFNDGYYNYHYMDV (SEQ ID NO: 6)

[250] 1489 113 lambda light chain nucleotide sequence: 1489 113 λ2 coding sequence (variable region in bold)

GACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGACAGACGATCACCATCTCCTGCAATGGAACCAGCA GTGACGTTGGTGGATTTGACTCTGTCTCCTGGTATCAACAATCCCCAGGGAAAGCCCCCAAAGTCATG GTTTTTGATGTCAGTCATCGGCCCTCAGGTATCTCTAATCGCTTCTCTGGCTCCAAGTCCGGCAACAC

ACAGAAGCCATCGCATATTCGGCGGCGGGACCAAGGTGACCGTTCTAGGTCAGCCCAAGGCTGCCCCC

TCGGTCACTCTGTTCCCGCCCTCCTCTGAGGAGCTTCAAGCCAACAAGGCCACACTGGTGTGTCTCAT AAGTGACTTCTACCCGGGAGCCGTGACAGTGGCCTGGAAGGCAGATAGCAGCCCCGTCAAGGCGGGAG TGGAGACCACCACACCCTCCAAACAAAGCAACAACAAGTACGCGGCCAGCAGCTACCTGAGCCTGACG CCTGAGCAGTGGAAGTCCCACAAAAGCTACAGCTGCCAGGTCACGCATGAAGGGAGCACCGTGGAGAA GACAGTGGCCCCTACAGAATGTTCATAG (SEQ ID NO: 61)

[251] 1489_I13 lambda light chain variable region nucleotide sequence:

CAGTCTGCCCTGACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGACAGACGATCACCATCTCCTGCAA

TGGAACCAGCAGTGACGTTGGTGGATTTGACTCTGTCTCCTGGTATCAACAATCCCCAGGGAAAGCCC

CCAAAGTCATGGTTTTTGATGTCAGTCATCGGCCCTCAGGTATCTCTAATCGCTTCTCTGGCTCCAAG

TCCGGCAACACGGCCTCCCTGACCATCTCTGGGCTCCACATTGAGGACGAGGGCGATTATTTCTGCTC

TTCACTGACAGACAGAAGCCATCGCATATTCGGCGGCGGGACCAAGGTGACCGTTCTA (SEQ ID NO:

135)

[252] 1489 113 lambda light chain amino acid sequence: expressed protein with variable region in bold.

QSALTQPASVSGSPGQTITISCNGTSSDVGGFDSVSWYQQSPGKAPKVMVFDVSHRPSGI SNRFSGSKSGNT ASLTISGLHIEDEGDYFCSSLTDRSHRIFGGGTKVTVLGQPKAAPSVTL

FPPSSEELQANKATLVCLISDFYPGA VTVA WKADSSPVKAGVETTTPSKQSNNKY AASSYLSL TPEQWKSHKSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 14)

[253] 1489_I13 lambda light chain variable region amino acid sequence: (Kabat CDRs underlined, Chothia CDRs in bold italics). QSALTQPAS VSGSPGOTITISCyVGraSO VGGFDS EffWYQQSPGKAPK VMVFZ) VSHRPSG1SNR FSGSKSGNTASLTISGLHIEDEGDYFC^XJOΛ^rø/FGGGTKVTVL (SEQ ID NO: 32)

[254] 1489_113 lambda light chain Kabat CDRs: CDR 1 : NGTSSDVGGFDSVS (SEQ ID NO: 97) CDR 2: DVSHRPSG (SEQ ID NO: 95) CDR 3: SSLTDRSHRI (SEQ ID NO: 41)

[255] 1489J13 lambda light chain Chothia CDRs: CDR 1 : NGTSSDVGGFDSVS (SEQ ID NO: 97) CDR 2: DVSHRPSG (SEQ ID NO: 95) CDR 3: SSLTDRSHRI (SEQ ID NO: 41)

[256] 1480_I08 gamma heavy chain nucleotide sequence: 1480 108 γ3 coding sequence (variable region in bold)

ATGGAGTTTGGCTGAGCTGGGTTTTCCTCGCAACTCTGTTAAGAGTTGTGAAGTGTCAGGAACAACTG GTGGAGTCTGGGGGAGGCGTGGTCCAGCCGGGGGGGTCCCTGAGACTCTCCTGTTTAGCGTCTGGATT CACGTTTCACAAATATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGCCTGGAGTGGGTGGCAC TCATCTCAGATGACGGAATGAGGAAATATCATTCAGACTCCATGTGGGGCCGAGTCACCATCTCCAGA GACAATTCCAAGAACACTCTTTATCTGCAATTCAGCAGCCTGAAAGTCGAAGACACGGCTATGTTCTT CTGTGCGAGAGAGGCTGGTGGGCCAATCTGGCATGACGACGTCAAATATTACGATTTTAATGACGGCT ACTACAACTACCACTACATGGACGTCTGGGGCAAGGGGACCACGGTCACCGTCTCCTCAGCGTCGACC AAGGGCCCATCGGTCTTCCCTCTGGCACCATCATCCAAGTCGACCTCTGGGGGCACAGCGGCCCTGGG

GCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTG

GGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAAC TCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACC CCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGT GGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTG TGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCC AACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACA GGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCA AAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAG ACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTATAGCAAGCTCACCGTGGACAAGAG CAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGC AGAAGAGCCTCTCCCTGTCTCCGGGTAAATGA (SEQ ID NO: 64)

[257] 1480_I08 gamma heavy chain variable region nucleotide sequence:

CAGGAACAACTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCGGGGGGGTCCCTGAGACTCTCCTGTTT AGCGTCTGGATTCACGTTTCACAAATATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGCCTGG AGTGGGTGGCACTCATCTCAGATGACGGAATGAGGAAATATCATTCAGACTCCATGTGGGGCCGAGTC ACCATCTCCAGAGACAATTCCAAGAACACTCTTTATCTGCAATTCAGCAGCCTGAAAGTCGAAGACAC GGCTATGTTCTTCTGTGCGAGAGAGGCTGGTGGGCCAATCTGGCATGACGACGTCAAATATTACGATT TTAATGACGGCTACTACAACTACCACTACATGGACGTCTGGGGCAAGGGGACCACGGTCACCGTCTCC TCA(SEQIDNO: 136)

[258] 1480_I08 gamma heavy chain amino acid sequence: expressed protein with variable region in bold. QEQLVESGGGVVQPGGSLRLSCLASGFTFHKYGMHWVRQAPGKGLEWVALISDDGMR KYHSDSMWGRVTISRDNSKNTLYLQFSSLKVEDTAMFFCAREAGGPIWHDDVKYYDFN

DGYYNYHYMDVWGKGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVT VSWNSGALTSGVHTFPA VLQSSGL YSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEP KSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD GVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKE YKCKVSNKALPAPIEKTISKAKG QPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIA VEWESNGQPENNYKTTPPVLDSDGSF FLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 65)

[259] 1480_I08 gamma heavy chain variable region amino acid sequence: (Kabat CDRs underlined, Chothia CDRs in bold italics)

OEOLVESGGGVVOPGGSLRLSCLASGFTFHKYGMHWVROAPGKGLEWVALISDDGMRKYH SZλSΛ/EFGRVTISRDNSKNTLYLOFSSLKVEDTAMFFCARE/l GGPIWHDD VKYYDFNDGYYNY HYMD FWGKGTTVTVSS (SEQ ID NO: 31)

[260] 1480J08 gamma heavy chain Kabat CDRs:

CDR 1 : SGFTFHKYGMH (SEQ ID NO: 88)

CDR 2: LISDDGMRKYHSDSMW (SEQ ID NO: 89)

CDR 3: EAGGPI WHDDVKYYDFNDGYYNYHYMDV (SEQ ID NO: 6)

[261] 1480 108 gamma heavy chain Chothia CDRs:

CDR 1 : SGFTFHKYGMH (SEQ ID NO: 88)

CDR 2: LISDDGMRKYHSDSMW (SEQ ID NO: 89)

CDR 3: EAGGPIWHDDVKYYDFNDGYYNYHYMDV (SEQ ID NO: 6)

[262] 1480 108 lambda light chain nucleotide sequence: 1480_I08λ2 coding sequence (variable region in bold)

ATGGCCTGGGCTCTGCTATTCGTCACCCTCCTCACTCAGGGCACAGGGTCCTGGGGCCAGTCTGCCCT GACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGACAGACGATCACCATCTCCTGCAATGGAACCAGCA GTGACGTTGGTGGATTTGACTCTGTCTCCTGGTATCAACAATCCCCAGGGAAAGCCCCCAAAGTCATG

GGCCTCCCTGACCATCTCTGGGCTCCACATTGAGGACGAGGGCGATTATTTCTGCTCTTCACTGACAG ACAGAAGCCATCGCATATTCGGCGGCGGGACCAAGGTGACCGTTCTAGGTCAGCCCAAGGCTGCCCCC TCGGTCACTCTGTTCCCGCCCTCCTCTGAGGAGCTTCAAGCCAACAAGGCCACACTGGTGTGTCTCAT

TGGAGACCACCACACCCTCCAAACAAAGCAACAACAAGTACGCGGCCAGCAGCTACCTGAGCCTGACG CCTGAGCAGTGGAAGTCCCACAAAAGCTACAGCTGCCAGGTCACGCATGAAGGGAGCACCGTGGAGAA GACAGTGGCCCCTACAGAATGTTCATAG (SEQ ID NO: 67)

[263] 1480_I08 lambda light chain variable region nucleotide sequence:

CAGTCTGCCCTGACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGACAGACGATCACCATCTCCTGCAA

TGGAACCAGCAGTGACGTTGGTGGATTTGACTCTGTCTCCTGGTATCAACAATCCCCAGGGAAAGCCC

CCAAAGTCATGGTTTTTGATGTCAGTCATCGGCCCTCAGGTATCTCTAATCGCTTCTCTGGCTCCAAG

TCCGGCAACACGGCCTCCCTGACCATCTCTGGGCTCCACATTGAGGACGAGGGCGATTATTTCTGCTC

TTCACTGACAGACAGAAGCCATCGCATATTCGGCGGCGGGACCAAGGTGACCGTTCTA (SEQ ID NO:

137)

[264] 1480 108 lambda light chain amino acid sequence: expressed protein with variable region in bold. QSALTQPASVSGSPGQTITISCNGTSSDVGGFDSVSWYQQSPGKAPKVMVFDVSHRPSGI SNRFSGSKSGNTASLTISGLHIEDEGDYFCSSLTDRSHRIFGGGTKVTVLGQPKAAPSVTL

FPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSL TPEQWKSHKSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 14)

[265] 1480 108 lambda light chain variable region amino acid sequence: (Kabat CDRs underlined, Chothia CDRs in bold italics)

OSALTOPASVSGSPGOTmSCNGTSSDVGGFDSVSWYOOSPGKAPKVMVTDVSHRPSGlSNR FSGSKSGNTASLTISGLHIEDEGDYFraSLTO/re/y/ΪTFGGGTKVTVL (SEQ ID NO: 32)

[266] 1480J08 lambda light chain Kabat CDRs: CDR 1 : NGTSSDVGGFDSVS (SEQ ID NO: 97) CDR 2: DVSHRPSG (SEQ ID NO: 95) CDR 3: SSLTDRSHRI (SEQ ID NO: 41)

[267] 1480 108 lambda light chain Chothia CDRs:

CDR 1 : NGTSSDVGGFDSVS (SEQ ID NO: 97)

CDR 2: DVSHRPSG (SEQ ID NO: 95)

CDR 3: SSLTDRSHRI (SEQ ID NO: 41)

[268] The 1469_M23 (PG 16) antibody includes a heavy chain variable region (SEQ ID NO:

139), encoded by the nucleic acid sequence shown in SEQ ID NO: 128, and a light chain variable region (SEQ ID NO: 142) encoded by the nucleic acid sequence shown in SEQ ID NO: 129.

[269] The heavy chain CDRs of the 1469_M23 (PG 16) antibody have the following sequences per Kabat and Chothia definitions: SGFTFHKYGMH (SEQ ID NO: 88), LISDDGMRKYHSDSMW (SEQ ID NO: 89), and

EAGGPIWHDDVKYYDFNDGYYNYHYMDV (SEQ ID NO: 6). The light chain CDRs of the 1469_M23 (PG16) antibody have the following sequences per Kabat and Chothia definitions: NGTRSDVGGFDSVS (SEQ ID NO: 92), DVSHRPSG (SEQ ID NO: 95), and SSLTDRSHRI (SEQ ID NO: 41).

[270] The 1456_A12 (PG 16) antibody includes a heavy chain variable region (SEQ ID NO: 47), encoded by the nucleic acid sequence shown in SEQ ID NO: 130, and a light chain variable region (SEQ ID NO: 50) encoded by the nucleic acid sequence shown in SEQ ID NO: 131.

[271] The heavy chain CDRs of the 1456_A12 (PG16) antibody have the following sequences per Kabat and Chothia definitions: SGFTFHKYGMH (SEQ ID NO: 88), LISDDGMRKYHSDSMW (SEQ ID NO: 89), and

EAGGPIWHDDVKYYDFNDGYYNYHYMDV (SEQ ID NO: 6). The light chain CDRs of the 1456_A12 (PG 16) antibody have the following sequences per Kabat and Chothia definitions: NGTSRDVGGFDSVS (SEQ ID NO: 93), DVSHRPSG (SEQ ID NO: 95), and

SSLTDRSHRI (SEQ ID NO: 41).

[272] The 1503_H05 (PG 16) antibody includes a heavy chain variable region (SEQ ID NO:

53), encoded by the nucleic acid sequence shown in SEQ ID NO: 132, and a light chain variable region (SEQ ID NO: 56) encoded by the nucleic acid sequence shown in SEQ ID

NO: 133.

[273] The heavy chain CDRs of the 1503 H05 (PG 16) antibody have the following sequences per Kabat and Chothia definitions: SGFTFHKYGMH (SEQ ID NO: 88),

LISDDGMRKYHSDSMW (SEQ ID NO: 89), and

EAGGPIWHDDVKYYDFNDGYYNYHYMDV (SEQ ID NO: 6). The light chain CDRs of the 1503 H05 (PGl 6) antibody have the following sequences per Kabat and Chothia definitions: NGTRSDVGGFDSVS (SEQ ID NO: 92), DVSHRPSG (SEQ ID NO: 95), and

SSLTDRSHRI (SEQ ID NO: 41).

[274] The 1489 113 (PG16) antibody includes a heavy chain variable region (SEQ ID NO:

59), encoded by the nucleic acid sequence shown in SEQ ID NO: 134, and a light chain variable region (SEQ ID NO: 14) encoded by the nucleic acid sequence shown in SEQ ID

NO: 135.

[275] The heavy chain CDRs of the 1489J13 (PG16) antibody have the following sequences per Kabat and Chothia definitions: SGFTFHKYGMH (SEQ ID NO: 88),

LISDDGMRKYHSNSMW (SEQ ID NO: 98), and

EAGGPIWHDDVKYYDFNDGYYNYHYMDV (SEQ ID NO: 6). The light chain CDRs of the 1489 113 (PG16) antibody have the following sequences per Kabat and Chothia definitions: NGTSSDVGGFDSVS (SEQ ID NO: 97), DVSHRPSG (SEQ ID NO: 95), and

SSLTDRSHRI (SEQ ID NO: 41).

[276] The 1480J08 (PG 16) antibody includes a heavy chain variable region (SEQ ID NO:

65), encoded by the nucleic acid sequence shown in SEQ ID NO: 136, and a light chain variable region (SEQ ID NO: 14) encoded by the nucleic acid sequence shown in SEQ ID

NO: 137.

[277] The heavy chain CDRs of the 1480J08 (PG 16) antibody have the following sequences per Kabat and Chothia definitions: SGFTFHKYGMH (SEQ ID NO: 88),

LISDDGMRKYHSDSMW (SEQ ID NO: 89), and

EAGGPIWHDDVKYYDFNDGYYNYHYMDV (SEQ ID NO: 6). The light chain CDRs of the 1480_I08 (PG 16) antibody have the following sequences per Kabat and Chothia definitions: NGTSSDVGGFDSVS (SEQ ID NO: 97), DVSHRPSG (SEQ ID NO: 95), and SSLTDRSHRI (SEQ ID NO: 41).

[278] In one aspect, an antibody according to the invention contains a heavy chain having the amino acid sequence of SEQ ID NOs: 12, 16, 20, 24, 28, 139, 47, 53, 59, or 65 and a light chain having the amino acid sequence of SEQ ID NOs: 14, 18, 22, 26, 30, 142, 50, or 56. Alternatively, an antibody according to the invention contains a heavy chain variable region having the amino acid sequence of SEQ ID NOs: 31, 33, 35, 37, 39, 140, 48, 54, or 60 and a light chain variable region having the amino acid sequence of SEQ ID NOs: 32, 34, 36, 38, 40, 96, 51, or 57.

[279] In another aspect, an antibody according to the invention contains a heavy chain having the amino acid sequence encoded by the nucleic acid sequence of SEQ ID NOs: 11, 15, 19, 23, 27, 138, 46, 52, 58, or 64 and a light chain having the amino acid sequence encoded by the nucleic acid sequence of SEQ ID NOs: 13, 17, 21, 25, 29, 141, 49, 55, 61, or 67. Alternatively, an antibody according to the invention contains a heavy chain variable region having the amino acid sequence encoded by the nucleic acid sequence of SEQ ID NOs: 99, 101, 109, 115, 122, 128, 130, 132, 134, or 136 and a light chain variable region having the amino acid sequence encoded by the nucleic acid sequence of SEQ ID NOs: 100, 106, 112, 119, 125, 129, 131, 133, 135, or 137. Furthermore, an antibody according to the invention contains a heavy chain having the amino acid sequence encoded by a nucleic acid sequence of SEQ ID NOs: 11, 15, 19, 23, 27, 138, 46, 52, 58, or 64, which contains a silent or degenerate mutation, and a light chain having the amino acid sequence encoded by the nucleic acid sequence of SEQ ID NOs: 13, 17, 21, 25, 29, 141, 49, 55, 61, or 67, which contains a silent or degenerate mutation. Silent and degenerate mutations alter the nucleic acid sequence, but do not alter the resultant amino acid sequence.

[280] Preferably the three heavy chain CDRs include an amino acid sequence of at least 90%, 92%, 95%, 97%, 98%, 99%, or more identical to the amino acid sequence of SGFTFHKYGMH (SEQ ID NO: 88), LISDDGMRKYHSDSMW (SEQ ID NO: 89), EAGGPIWHDDVKYYDFNDGYYNYHYMDV (SEQ ID NO: 6), SGGTFSSYAFT (SEQ ID NO: 104), MVTPIFGEAKYSQRFE (SEQ ID NO: 105), RA VPI ATDNWLDP (SEQ ID NO: 102), SGGAFSSYAFS (SEQ ID NO: 110), MITPVFGETKY APRFQ (SEQ ID NO: 111), SGYSFIDYYLH (SEQ ID NO: 1 16), LIDPENGEARY AEKFQ (SEQ ID NO: 1 17), AVGADSGSWFDP (SEQ ID NO: 1 18), SGFDFSRQGMH (SEQ ID NO: 123), FIKYDGSEKYHADSVW (SEQ ID NO: 124), EAGGPDYRNGYNYYDFYDGYYNYHYMDV (SEQ ID NO: 7), LISDDGMRKYHSNSMW (SEQ ID NO: 98) (as determined by the Kabat method) or SGFTFHKYGMH (SEQ ID NO: 88), LISDDGMRKYHSDSMW (SEQ ID NO: 89), EAGGPIWHDDVKYYDFNDGYYNYHYMDV (SEQ ID NO: 6), SGGTFSSYAFT (SEQ ID NO: 104), MVTPIFGEAKYSQRFE (SEQ ID NO: 105), RRAVPIATDNWLDP (SEQ ID NO: 103), SGGAFSSYAFS (SEQ ID NO: 110), MITPVFGETKY APRFQ (SEQ ID NO: 111), SGYSFIDYYLH (SEQ ID NO: 116), LIDPENGEARYAEKFQ (SEQ ID NO: 117), AVGADSGSWFDP (SEQ ID NO: 118), SGFDFSRQGMH (SEQ ID NO: 123), FIKYDGSEKYHADSVW (SEQ ID NO: 124), EAGGPDYRNGYNYYDFYDGYYNYHYMDV (SEQ ID NO: 7),

LISDDGMRKYHSNSMW (SEQ ID NO: 98) (as determined by the Chothia method) and a light chain with three CDRs that include an amino acid sequence of at least 90%, 92%, 95%, 97%, 98%, 99%, or more identical to the amino acid sequence of NGTSSDVGGFDSVS (SEQ ID NO: 97), DVSHRPSG (SEQ ID NO: 95), SSLTDRSHRI (SEQ ID NO: 41), RASQTINNYLN (SEQ ID NO: 107), GASNLQNG (SEQ ID NO: 108), QQSFSTPRT (SEQ ID NO: 42), RASQTIHTYL (SEQ ID NO: 113), GASTLQSG (SEQ ID NO: 1 14), QQSYSTPRT (SEQ ID NO: 43), SGSKLGDKYVS (SEQ ID NO: 120), ENDRRPSG (SEQ ID NO: 121), QAWETTTTTFVF (SEQ ID NO: 44), NGTSND VGGYESVS (SEQ ID NO: 126), DVSKRPSG (SEQ ID NO: 127), KSLTSTRRRV (SEQ ID NO: 45), NGTRSDVGGFDSVS (SEQ ID NO: 92), NGTSRD VGGFDS V S (SEQ ID NO: 93) (as determined by the Kabat method) or NGTSSDVGGFDSVS (SEQ ID NO: 97), DVSHRPSG (SEQ ID NO: 95), SSLTDRSHRI (SEQ ID NO: 41), RASQTINNYLN (SEQ ID NO: 107), GASNLQNG (SEQ ID NO: 108), QQSFSTPRT (SEQ ID NO: 42), RASQTIHTYL (SEQ ID NO: 113), GASTLQSG (SEQ ID NO: 114), QQSYSTPRT (SEQ ID NO: 43), SGSKLGDKYVS (SEQ ID NO: 120), ENDRRPSG (SEQ ID NO: 121), QAWETTTTTFVF (SEQ ID NO: 44), NGTSNDVGGYESVS (SEQ ID NO: 126), DVSKRPSG (SEQ ID NO: 127), KSLTSTRRRV (SEQ ID NO: 45), NGTRSDVGGFDSVS (SEQ ID NO: 92), NGTSRDVGGFDSVS (SEQ ID NO: 93) (as determined by the Chothia method). [281] The heavy chain of the anti-HIV monoclonal antibody is derived from a germ line variable (V) gene such as, for example, the IGHVl or IGHV3 germline gene. [282] The anti-HIV antibodies of the invention include a variable heavy chain (V_H) region encoded by a human IGHVl or IGHV3 germline gene sequence. IGHVl germline gene sequences are shown, e.g., in Accession numbers L22582, X27506, X92340, M83132, X67905, L22583, Z29978, Z14309, Z14307, Z14300, Z14296, and Z14301. IGHV3 germline gene sequences are shown, e.g., in Accession numbers ABOl 9439, M99665, M77305, M77335, and M77334. The anti-HTV antibodies of the invention include a VH region that is encoded by a nucleic acid sequence that is at least 80% homologous to the IGHVl or IGHV3 germline gene sequence. Preferably, the nucleic acid sequence is at least 90%, 95%, 96%, 97% homologous to the IGHVl or IGHV3 germline gene sequence, and more preferably, at least 98%, 99% homologous to the IGHVl or IGHV3 germline gene sequence. The V_H region of the anti-HIV antibody is at least 80% homologous to the amino acid sequence of the V_H region encoded by the IGHVl or IGHV3 V_H germline gene sequence. Preferably, the amino acid sequence of V_H region of the anti-HIV antibody is at least 90%, 95%, 96%, 97% homologous to the amino acid sequence encoded by the IGHVl or IGHV3 germline gene sequence, and more preferably, at least 98%, 99% homologous to the sequence encoded by the IGHVl or IGHV3 germline gene sequence.

[283] The light chain of the anti-HIV monoclonal antibody is derived from a germ line variable (V) gene such as, for example, the IGLV2, IGLV3 or IGKVl germline gene. [284] The anti-HIV antibodies of the invention also include a variable light chain (V_L) region encoded by a human IGLV2, IGLV3 or IGKVl germline gene sequence. A human IGL V2 V_L germline gene sequence is shown, e.g., Accession numbers Z73664, L27822, Y12412, and Y12413. A human IGL V3 V_L germline gene sequence is shown, e.g., Accession number X57826.

[285] A human IGKVl V_L germline gene sequence is shown, e.g., Accession numbers AF306358, AF490911, L12062, L12064, L12065, L12066, L12068, L12072, L12075, L12076, L12079, L12080, L12081, L12082, L12083, L12084, L12085, L12086, :12088, L12091, L12093, L12101, L12106, L12108, L121 10, L12112, M95721 , M95722, M95723, X73855, X73860, X98972, X98973, Z15073, Z15074, Z15075, Z15077, Z15079, Z15081. Alternatively, the anti-HIV antibodies include a V_L region that is encoded by a nucleic acid sequence that is at least 80% homologous to the IGLV2, IGLV3 or IGKVl germline gene sequence. Preferably, the nucleic acid sequence is at least 90%, 95%, 96%, 97% homologous to the IGL V2, IGLV3 or IGKVl germline gene sequence, and more preferably, at least 98%, 99% homologous to the IGLV2, IGLV3 or IGKVl germline gene sequence. The V_L region of the anti-CMV antibody is at least 80% homologous to the amino acid sequence of the V_L region encoded the IGL V2, IGLV3 or IGKVl germline gene sequence. Preferably, the amino acid sequence of VL region of the anti-HIV antibody is at least 90%, 95%, 96%, 97% homologous to the amino acid sequence encoded by the IGLV2, IGLV3 or IGKVl germline gene sequence, and more preferably, at least 98%, 99% homologous to the sequence encoded by the IGL V2, IGLV3 or IGKVl germline gene sequence.

[286] Table 7. Alignment of heavy chain coding sequences of the variable domain of 1443 C16 sister clones to 1443 C16 and 1496 C09. Kabat CDR sequences for the PG16 sister clones are highlighted in boxes.

[287] Table 8. Alignment of light chain coding sequences of the variable domain of 1443 Cl 6 sister clones to 1443 Cl 6 and 1496 C09. Kabat CDR sequences for the PGl 6 sister clones are highlighted in boxes.

[288] Table 9. Alignment of heavy chain protein sequences of the variable domain of 1443 Cl 6 sister clones to 1443 C16 and 1496 C09. Kabat CDR sequences for the PG 16 sister clones are highlighted in boxes.

CXiHl v,

[289] Table 10. Alignment of light chain protein sequences of the variable domain of 1443 Cl 6 sister clones to 1443 Cl 6 and 1496 C09. Kabat CDR sequences for the PG 16 sister clones are highlighted in black boxes.

[290] Table 11. Consensus nucleotide sequences of Kabat CDRs of heavy chains of 1443 PG 16 sister clones.

CDRl :

1443 C16 TCTGGATTCACGTTTCACAAATATGGCATGCAC (SEQ ID NO : 68 ) 1469 M23 TCTGGATTCACCTTTCACAAATATGGCATGCAC (SEQ ID NO : 69 ) 1456 A12 TCTGGATTCACGTTTCACAAATATGGCATGCAC (SEQ ID NO : 68 ) 1503 H05 TCTGGATTCACCTTTCACAAATATGGCATGCAC (SEQ ID NO : 70 ) 1489 113 TCTGGATTCACGTTTCACAAATATGGCATGCAC (SEQ ID NO : 68 ) 1480 108 TCTGGATTCACGTTTCACAAATATGGCATGCAC (SEQ ID NO : 68 ) Consensus* TCTGGATTCACXTTTCACAAATATGGCATGCAC (SEQ ID NO : 71 ) Variationl TCTGGATTCACGTTTCACAAATATGGCATGCAC (SEQ ID NO : 68 ) Variation2 TCTGGATTCACCTTTCACAAATATGGCATGCAC (SEQ ID NO : 70 )

* Wherein X is C or G, or wherein X is an amino acid with similar physical properties to either C or G.

CDR2:

1443 C16 CTCATCTCAGATGACGGAATGAGGAAATATCATTCAGACTCCATGTGG (SEQ ID NO : 72 ) 1469 M23 CTCATCTCAGATGACGGAATGAGGAAATATCATTCAGACTCCATGTGG (SEQ ID NO : 72 ) 1456 A12 CTCATCTCAGATGACGGAATGAGGAAATATCATTCAGACTCCATGTGG (SEQ ID NO : 72 ) 1503 H05 CTCATCTCAGATGACGGAATGAGGAAATATCATTCAGACTCCATGTGG (SEQ ID NO : 72 ) 1489 113 CTCATCTCAGATGACGGAATGAGGAAATATCATTCAAACTCCATGTGG (SEQ ID NO : 73 ) 1480 108 CTCATCTCAGATGACGGAATGAGGAAATATCATTCAGACTCCATGTGG (SEQ ID NO : 72 ) Consensus* CTCATCTCAGATGACGGAATGAGGAAATATCATTCAXACTCCATGTGG (SEQ ID NO : 74 ) Variationl CTCATCTCAGATGACGGAATGAGGAAATATCATTCAGACTCCATGTGG (SEQ ID NO : 72 ) Variation2 CTCATCTCAGATGACGGAATGAGGAAATATCATTCAAACTCCATGTGG (SEQ ID NO : 73 )

* Wherein X is A or G, or wherein X is an amino acid with similar physical properties to either A or G.

CDR3:

1443 ClO (SEQ ID NO: 75)

1469 M23 (SEQ ID NO: 75)

GAGGCTGGTGGGCCAATCTGGCATGACGACGTCAAATATTACGATTTTAATGACGGCTACTACAACTACCACTACATGGACGT C

1456 A12 (SEQ ID NO: 77)

1503 H05 (SEQ ID NO:79)

1489 113 (SEQ ID NO: 75)

GAGGCTGGTGGGCCAATCTGGCATGACGACGTCAAATATTACGATTTTAATGACGGCTACTACAACTACCACTACATGGACGT C 1480 108 (SEQ ID NO: 75)

Consensus (SEQ ID NO: 76)

C

Variationl (SEQ ID NO: 78)

GAGGCGGGTGGGCCAATCTGGCATGACGACGTCAAATATTACGATTTTAATGACGGCTACTACAACTATCACTACATGGACGT C

Variation2 (SEQ ID NO: 77)

C

* Wherein X is T, C or G, or wherein X is an amino acid with similar physical properties to either T, C or G.

[291] Table 12. Consensus nucleotide sequences of Kabat CDRs of light chains of 1443 PG 16 sister clones.

CDRl:

1443 Cl6 AATGGAACCAGCAGTGACGTTGGTGGATTTGACTCTGTCTCC (SEQ ID NO: 80)

1469 M23 AATGGAACCAGAAGTGACGTTGGTGGATTTGACTCTGTCTCC (SEQ ID NO: 82)

1456 Al2 AATGGAACCAGCCGTGACGTTGGTGGATTTGACTCTGTCTCC (SEQ ID NO: 83)

1503 HO5 AATGGAACCAGAAGTGACGTTGGTGGATTTGACTCTGTCTCC (SEQ ID NO: 82)

1489 113 AATGGAACCAGCAGTGACGTTGGTGGATTTGACTCTGTCTCC (SEQ ID NO: 80)

1480 108 AATGGAACCAGCAGTGACGTTGGTGGATTTGACTCTGTCTCC (SEQ ID NO: 80)

Consensus* AATGGAACCAGX₁X₂GTGACGTTGGTGGATTTGACTCTGTCTCC (SEQ ID NO: 81)

Variationl AATGGAACCAGCAGTGACGTTGGTGGATTTGACTCTGTCTCC (SEQ ID NO: 80)

Variation2 AATGGAACCAGAAGTGACGTTGGTGGATTTGACTCTGTCTCC (SEQ ID NO: 82)

Variation2 AATGGAACCAGCCGTGACGTTGGTGGATTTGACTCTGTCTCC (SEQ ID NO: 83)

* Wherein Xi is C or A, or wherein Xi is an amino acid with similar physical properties to either C or A. Wherein X₂ is C or A, or wherein X₂ is an amino acid with similar physical properties to either C or A.

CDR2 :

1443 C16 GATGTCAGTCATCGGCCCTCAGGT (SEQ ID NO: 84)

1469 M23 GATGTCAGTCATCGGCCCTCAGGT (SEQ ID NO: 84)

1456 A12 GATGTCAGTCATCGGCCCTCAGGT (SEQ ID NO: 84)

1503 HO5 GATGTCAGTCATCGGCCCTCAGGT (SEQ ID NO: 84)

1489 113 GATGTCAGTCATCGGCCCTCAGGT (SEQ ID NO: 84)

1480 108 GATGTCAGTCATCGGCCCTCAGGT (SEQ ID NO: 84)

Consensus GATGTCAGTCATCGGCCCTCAGGT (SEQ ID NO: 84)

CDR3:

1443 Cl6 TCTTCACTGACAGACAGAAGCCATCGCATA (SEQ ID NO: 85)

1469 M23 TCTTCACTGACAGACAGAAGCCATCGCATA (SEQ ID NO: 85)

1456 A12 TCTTCATTGACAGACAGAAGCCATCGCATA (SEQ ID NO: 86)

1503 H05 TCTTCACTGACAGACAGAAGCCATCGCATA (SEQ ID NO: 85)

1489 113 TCTTCACTGACAGACAGAAGCCATCGCATA (SEQ ID NO: 85)

1480 108 TCTTCACTGACAGACAGAAGCCATCGCATA (SEQ ID NO: 85)

Consensus* TCTTCAXTGACAGACAGAAGCCATCGCATA (SEQ ID NO: 87)

Variationl TCTTCACTGACAGACAGAAGCCATCGCATA (SEQ ID NO: 85)

Variation2 TCTTCATTGACAGACAGAAGCCATCGCATA (SEQ ID NO: 86)

* Wherein X is C or T, or wherein X is an amino acid with similar physical properties to either C or T. [292] Table 13. Consensus protein sequences of Kabat CDRs of Heavy chains of 1443 PG 16 sister clones.

CDRl: 1443 C16 SGFTFHKYGMH (SEQ ID NO: 88) 1469 M23 SGFTFHKYGMH (SEQ ID NO: 88) 1456 A12 SGFTFHKYGMH (SEQ ID NO: 88) 1503 H05 SGFTFHKYGMH (SEQ ID NO: 88) 1489 113 SGFTFHKYGMH (SEQ ID NO: 88) 1480 108 SGFTFHKYGMH (SEQ ID NO: 88) Consensus SGFTFHKYGMH (SEQ ID NO: 88)

CDR2 : 1443 C16 LISDDGMRKYHSDSMW (SEQ ID NO: 89) 1469 M23 LISDDGMRKYHSDSMW (SEQ ID NO: 89) 1456 A12 LISDDGMRKYHSDSMW (SEQ ID NO: 89) 1503 H05 LISDDGMRKYHSDSMW (SEQ ID NO: 89) 1489 113 LISDDGMRKYHSNSMW (SEQ ID NO: 98) 1480 108 LISDDGMRKYHSDSMW (SEQ ID NO: 89 ) Consensus* LISDDGMRKYHSXSMW (SEQ ID NO: 91 ) Variationl LISDDGMRKYHSDSMW (SEQ ID NO: 89 ) Variation2 LISDDGMRKYHSNSMW (SEQ ID NO: 98 )

^♦Wherein X is D or N, or wherein X is an amino acid with similar physical properties to either D or N.

CDR3: 1443 C16 EAGGPIWHDDVKYYDFNDGYYNYHYMDV (SEQ ID NO: 6) 1469 M23 EAGGPIWHDDVKYYDFNDGYYNYHYMDV (SEQ ID NO: 6) 1456 A12 EAGGPIWHDDVKYYDFNDGYYNYHYMDV (SEQ ID NO: 6) 1503 H05 EAGGPIWHDDVKYYDFNDGYYNYHYMDV (SEQ ID NO: 6) 1489 113 EAGGPIWHDDVKYYDFNDGYYNYHYMDV (SEQ ID NO: 6) 1480 108 EAGGPIWHDDVKYYDFNDGYYNYHYMDV (SEQ ID NO: 6)

Consensus EAGGPIWHDDVKYYDFNDGYYNYHYMDV (SEQ ID NO: 6)

[293] Table 14. Consensus protein sequences of Kabat CDRs of light chains of 1443 PG 16 sister clones.

CDRl: 1443 C16 NGTSSDVGGFDSVS (SEQ ID NO: 97) 1469 M23 NGTRSDVGGFDSVS (SEQ ID NO: 92) 1456 A12 NGTSRDVGGFDSVS (SEQ ID NO: 93) 1503 H05 NGTRSDVGGFDSVS (SEQ ID NO: 92) 1489 113 NGTSSDVGGFDSVS (SEQ ID NO: 97) 1480 108 NGTSSDVGGFDSVS (SEQ ID NO: 97) Consensus* NGTX₁X₂DVGGFDSVS (SEQ ID NO: 94) Variationl NGTSSDVGGFDSVS (SEQ ID NO: 97) Variation2 NGTRSDVGGFDSVS (SEQ ID NO: 92) Variation3 NGTSRDVGGFDSVS (SEQ ID NO: 93) * Wherein X₁ is S or R, or wherein Xi is an amino acid with similar physical properties to either S or R. Wherein X₂ is S or R, or wherein X₂ is an amino acid with similar physical properties to either S or R.

CDR2: 1443 C16 DVSHRPSG (SEQ ID NO: 95) 1469 M23 DVSHRPSG (SEQ ID NO: 95) 1456 A12 DVSHRPSG (SEQ ID NO: 95) 1503 H05 DVSHRPSG (SEQ ID NO: 95) 1489 113 DVSHRPSG (SEQ ID NO: 95) 1408 108 DVSHRPSG (SEQ ID NO: 95) Consensus DVSHRPSG (SEQ ID NO: 95) CDR3:

1443 C16 SSLTDRSHRI (SEQ ID NO: 41)

1469 M23 SSLTDRSHRI (SEQ ID NO: 41)

1456 A12 SSLTDRSHRI (SEQ ID NO: 41)

1503 HO5 SSLTDRSHRI (SEQ ID NO: 41)

1489 113 SSLTDRSHRI (SEQ ID NO: 41)

1480 108 SSLTDRSHRI (SEQ ID NO: 41)

Consensus SSLTDRSHRI (SEQ ID NO: 41)

[294] Monoclonal and recombinant antibodies are particularly useful in identification and purification of the individual polypeptides or other antigens against which they are directed. The antibodies of the invention have additional utility in that they may be employed as reagents in immunoassays, radioimmunoassays (RIA) or enzyme-linked immunosorbent assays (ELISA). In these applications, the antibodies can be labeled with an analytically- detectable reagent such as a radioisotope, a fluorescent molecule or an enzyme. The antibodies may also be used for the molecular identification and characterization (epitope mapping) of antigens.

[295] As mentioned above, the antibodies of the invention can be used to map the epitopes to which they bind. Applicants have discovered that the antibodies 1496_C09 (PG9), 1443_C16 (PG16), 1456_P20 (PG20), 1460_G14 (PGG14), 1495_C14 (PGC14), 1469_M23 (PG16), 1456_A12 (PG16), 1503_H05 (PG16), 1489J13 (PG16), and 1080J08 (PG16) neutralize HIV. Although the Applicant does not wish to be bound by this theory, it is postulated that the antibodies 1496_C09 (PG9), 1443_C16 (PG 16), 1456_P20 (PG20), 1460_G14 (PGG14), 1495_C14 (PGC14), 1469_M23 (PG16), 1456_A12 (PG16), 1503JH05 (PG 16), 1489J13 (PG 16), and/or 1080J08 (PG 16) bind to one or more conformational epitopes formed by HIVl -encoded proteins.

[296] Neutralization activity of human monoclonal antibodies was tested against HIV-I strains SF 162 and JR-CSF. HIV-I strains SF 162 and JR-CSF both belong to HIV clade B. Each clonal monoclonal antibody was screened for neutralization activity and for anti-gpl20, anti-gp41 and total IgG in quantitative ELISA. For the monoclonal antibodies 1456 P20, 1495_C14, and 1460 G 14 anti-gpl20 antigen-specific binding was detected. Neutralizing activity against SF 162, but not JR-CSF was detected for 1456_P20 (PG20), 1495_C14 (PGC 14), and 1460 G 14 (PGG 14). For the two monoclonal antibody preparations that did not show binding to gpl20 in the ELISA assay, 1443 C16 (PG 16) and 1496_C09 (PG9), high quantities of human IgG were determined to be present in the assay. However, 1443 C16 (PG16) and 1496_C09 (PG9) both were found to exhibit neutralizing activity against HTV-I strain JR-CSF, but not against strain SF 162. 1443_C16 (PG 16) and 1496_C09

(PG9) also were found to lack gp41 binding activity in the ELISA assay.

[297] The epitopes recognized by these antibodies may have a number of uses. The epitopes and mimotopes in purified or synthetic form can be used to raise immune responses (i.e. as a vaccine, or for the production of antibodies for other uses) or for screening patient serum for antibodies that immunoreact with the epitopes or mimotopes. Preferably, such an epitope or mimotope, or antigen comprising such an epitope or mimotope is used as a vaccine for raising an immune response. The antibodies of the invention can also be used in a method to monitor the quality of vaccines in particular to check that the antigen in a vaccine contains the correct immunogenic epitope in the correct conformation.

[298] The epitopes may also be useful in screening for ligands that bind to said epitopes.

Such ligands preferably block the epitopes and thus prevent infection. Such ligands are encompassed within the scope of the invention.

[299] Standard techniques of molecular biology may be used to prepare DNA sequences coding for the antibodies or fragments of the antibodies of the present invention. Desired

DNA sequences may be synthesized completely or in part using oligonucleotide synthesis techniques. Site-directed mutagenesis and polymerase chain reaction (PCR) techniques may be used as appropriate.

[300] Any suitable host cell/vector system may be used for expression of the DNA sequences encoding the antibody molecules of the present invention or fragments thereof.

Bacterial, for example E. coli, and other microbial systems may be used, in part, for expression of antibody fragments such as Fab and F(ab')₂ fragments, and especially Fv fragments and single chain antibody fragments, for example, single chain Fvs. Eukaryotic, e.g. mammalian, host cell expression systems may be used for production of larger antibody molecules, including complete antibody molecules. Suitable mammalian host cells include

CHO, HEK293T, PER.C6, myeloma or hybridoma cells.

[301] The present invention also provides a process for the production of an antibody molecule according to the present invention comprising culturing a host cell comprising a vector of the present invention under conditions suitable for leading to expression of protein from DNA encoding the antibody molecule of the present invention, and isolating the antibody molecule.

The antibody molecule may comprise only a heavy or light chain polypeptide, in which case only a heavy chain or light chain polypeptide coding sequence needs to be used to transfect the host cells. For production of products comprising both heavy and light chains, the cell line may be transfected with two vectors, a first vector encoding a light chain polypeptide and a second vector encoding a heavy chain polypeptide. Alternatively, a single vector may be used, the vector including sequences encoding light chain and heavy chain polypeptides. [302] Alternatively, antibodies according to the invention may be produced by i) expressing a nucleic acid sequence according to the invention in a cell, and ii) isolating the expressed antibody product. Additionally, the method may include iii) purifying the antibody. Transformed B cells are screened for those producing antibodies of the desired antigen specificity, and individual B cell clones can then be produced from the positive cells. The screening step may be carried out by ELISA, by staining of tissues or cells (including transfected cells), a neutralization assay or one of a number of other methods known in the art for identifying desired antigen specificity. The assay may select on the basis of simple antigen recognition, or may select on the additional basis of a desired function e.g. to select neutralizing antibodies rather than just antigen-binding antibodies, to select antibodies that can change characteristics of targeted cells, such as their signaling cascades, their shape, their growth rate, their capability of influencing other cells, their response to the influence by other cells or by other reagents or by a change in conditions, their differentiation status, etc. [303] The cloning step for separating individual clones from the mixture of positive cells may be carried out using limiting dilution, micromanipulation, single cell deposition by cell sorting or another method known in the art. Preferably the cloning is carried out using limiting dilution.

[304] The immortalized B cell clones of the invention can be used in various ways e.g. as a source of monoclonal antibodies, as a source of nucleic acid (DNA or mRNA) encoding a monoclonal antibody of interest, for research, etc.

[305] Unless otherwise defined, scientific and technical terms used in connection with the present invention shall have the meanings that are commonly understood by those of ordinary skill in the art. Further, unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular. Generally, nomenclatures utilized in connection with, and techniques of, cell and tissue culture, molecular biology, and protein and oligo- or polynucleotide chemistry and hybridization described herein are those well known and commonly used in the art. Standard techniques are used for recombinant DNA, oligonucleotide synthesis, and tissue culture and transformation (e.g., electroporation, lipofection). Enzymatic reactions and purification techniques are performed according to manufacturer's specifications or as commonly accomplished in the art or as described herein. The practice of the present invention will employ, unless indicated specifically to the contrary, conventional methods of virology, immunology, microbiology, molecular biology and recombinant DNA techniques within the skill of the art, many of which are described below for the purpose of illustration. Such techniques are explained fully in the literature. See, e.g., Sambrook, et al. Molecular Cloning: A Laboratory Manual (2nd Edition, 1989); Maniatis et al. Molecular Cloning: A Laboratory Manual (1982); DNA Cloning: A Practical Approach, vol. I & II (D. Glover, ed.); Oligonucleotide Synthesis (N. Gait, ed., 1984); Nucleic Acid Hybridization (B. Hames & S. Higgins, eds., 1985); Transcription and Translation (B. Hames & S. Higgins, eds., 1984); Animal Cell Culture (R. Freshney, ed., 1986); Perbal, A Practical Guide to Molecular Cloning (1984).

The nomenclatures utilized in connection with, and the laboratory procedures and techniques of, analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described herein are those well known and commonly used in the art. Standard techniques are used for chemical syntheses, chemical analyses, pharmaceutical preparation, formulation, and delivery, and treatment of patients.

[306] The following definitions are useful in understanding the present invention: The term "antibody" (Ab) as used herein includes monoclonal antibodies, polyclonal antibodies, multispecific antibodies {e.g., bispecific antibodies), and antibody fragments, as long as they exhibit the desired biological activity. The term "immunoglobulin" (Ig) is used interchangeably with "antibody" herein.

[307] A "neutralizing antibody" may inhibit the entry of HTV-I virus for example SF 162 and/or JR-CSF with a neutralization index > 1.5 or >2.0. (Kostrikis LG et al. J Virol. 1996; 70(1): 445—458.) By "broad and potent neutralizing antibodies" are meant antibodies that neutralize more than one HIV-I virus species (from diverse clades and different strains within a clade) in a neutralization assay. A broad neutralizing antibody may neutralize at least 2, 3, 4, 5, 6, 7, 8, 9 or more different strains of HIV-I, the strains belonging to the same or different clades. A broad neutralizing antibody may neutralize multiple HIV-I species belonging to at least 2, 3, 4, 5, or 6 different clades. The inhibitory concentration of the monoclonal antibody may be less than about 25 mg/ml to neutralize about 50% of the input virus in the neutralization assay.

[308] An "isolated antibody" is one that has been separated and/or recovered from a component of its natural environment. Contaminant components of its natural environment are materials that would interfere with diagnostic or therapeutic uses for the antibody, and may include enzymes, hormones, and other proteinaceous or nonproteinaceous solutes. In preferred embodiments, the antibody is purified: (1) to greater than 95% by weight of antibody as determined by the Lowry method, and most preferably more than 99% by weight; (2) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by use of a spinning cup sequenator; or (3) to homogeneity by SDS-PAGE under reducing or non-reducing conditions using Coomassie blue or, preferably, silver stain. Isolated antibody includes the antibody in situ within recombinant cells since at least one component of the antibody's natural environment will not be present. Ordinarily, however, isolated antibody will be prepared by at least one purification step. [309] The basic four-chain antibody unit is a heterotetrameric glycoprotein composed of two identical light (L) chains and two identical heavy (H) chains. An IgM antibody consists of 5 basic heterotetramer units along with an additional polypeptide called J chain, and therefore contain 10 antigen binding sites, while secreted IgA antibodies can polymerize to form polyvalent assemblages comprising 2-5 of the basic 4-chain units along with J chain. In the case of IgGs, the 4-chain unit is generally about 150,000 daltons. Each L chain is linked to an H chain by one covalent disulfide bond, while the two H chains are linked to each other by one or more disulfide bonds depending on the H chain isotype. Each H and L chain also has regularly spaced intrachain disulfide bridges. Each H chain has at the N-terminus, a variable region (V_H) followed by three constant domains (C_H) for each of the α and γ chains and four C_H domains for μ and ε isotypes. Each L chain has at the N-terminus, a variable region (V_L) followed by a constant domain (C_L) at its other end. The V_L is aligned with the V_H and the C_L is aligned with the first constant domain of the heavy chain (C_HI )- Particular amino acid residues are believed to form an interface between the light chain and heavy chain variable regions. The pairing of a V_H and V_L together forms a single antigen-binding site. For the structure and properties of the different classes of antibodies, see, e.g., Basic and Clinical Immunology, 8th edition, Daniel P. Stites, Abba I. Terr and Tristram G. Parslow (eds.), Appleton & Lange, Norwalk, Conn., 1994, page 71, and Chapter 6.

[310] The L chain from any vertebrate species can be assigned to one of two clearly distinct types, called kappa (K) and lambda (λ), based on the amino acid sequences of their constant domains (C_L). Depending on the amino acid sequence of the constant domain of their heavy chains (C_H), immunoglobulins can be assigned to different classes or isotypes. There are five classes of immunoglobulins: IgA, IgD, IgE, IgG, and IgM, having heavy chains designated alpha (α), delta (δ), epsilon (ε), gamma (γ) and mu (μ), respectively. The γ and α classes are further divided into subclasses on the basis of relatively minor differences in CH sequence and function, e.g., humans express the following subclasses: IgGl, IgG2, IgG3, IgG4, IgAl, and IgA2.

[311] The term "variable" refers to the fact that certain segments of the V domains differ extensively in sequence among antibodies. The V domain mediates antigen binding and defines specificity of a particular antibody for its particular antigen. However, the variability is not evenly distributed across the 110-amino acid span of the variable regions. Instead, the V regions consist of relatively invariant stretches called framework regions (FRs) of 15-30 amino acids separated by shorter regions of extreme variability called "hypervariable regions" that are each 9-12 amino acids long. The variable regions of native heavy and light chains each comprise four FRs, largely adopting a β-sheet configuration, connected by three hypervariable regions, which form loops connecting, and in some cases forming part of, the β-sheet structure. The hypervariable regions in each chain are held together in close proximity by the FRs and, with the hypervariable regions from the other chain, contribute to the formation of the antigen-binding site of antibodies (see Kabat et al, Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (1991)). The constant domains are not involved directly in binding an antibody to an antigen, but exhibit various effector functions, such as participation of the antibody in antibody dependent cellular cytotoxicity (ADCC).

[312] The term "hypervariable region" when used herein refers to the amino acid residues of an antibody that are responsible for antigen binding. The hypervariable region generally comprises amino acid residues from a "complementarity determining region" or "CDR" {e.g., around about residues 24-34 (Ll), 50-56 (L2) and 89-97 (L3) in the V_L, and around about 31- 35 (Hl), 50-65 (H2) and 95-102 (H3) in the V_H when numbered in accordance with the Kabat numbering system; Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (1991)); and/or those residues from a "hypervariable loop" {e.g., residues 24-34 (Ll), 50-56 (L2) and 89-97 (L3) in the V_L, and 26-32 (Hl), 52-56 (H2) and 95-101 (H3) in the V_H when numbered in accordance with the Chothia numbering system; Chothia and Lesk, J. MoI. Biol. 196:901-917 (1987)); and/or those residues from a "hypervariable loop'VCDR {e.g., residues 27-38 (Ll), 56-65 (L2) and 105-120 (L3) in the V_L, and 27-38 (Hl), 56-65 (H2) and 105-120 (H3) in the V_H when numbered in accordance with the IMGT numbering system; Lefranc, M.P. et al. Nucl. Acids Res. 27:209-212 (1999), Ruiz, M. e al. Nucl. Acids Res. 28:219-221 (2000)). Optionally the antibody has symmetrical insertions at one or more of the following points 28, 36 (Ll), 63, 74-75 (L2) and 123 (L3) in the V_L, and 28, 36 (Hl), 63, 74-75 (H2) and 123 (H3) in the V_H when numbered in accordance with AHo; Honneger, A. and Plunkthun, A. J. MoI. Biol. 309:657-670 (2001)).

[313] By "germline nucleic acid residue" is meant the nucleic acid residue that naturally occurs in a germline gene encoding a constant or variable region. "Germline gene" is the DNA found in a germ cell (i.e., a cell destined to become an egg or in the sperm). A "germline mutation" refers to a heritable change in a particular DNA that has occurred in a germ cell or the zygote at the single-cell stage, and when transmitted to offspring, such a mutation is incorporated in every cell of the body. A germline mutation is in contrast to a somatic mutation which is acquired in a single body cell. In some cases, nucleotides in a germline DNA sequence encoding for a variable region are mutated (i.e., a somatic mutation) and replaced with a different nucleotide.

[314] The term "monoclonal antibody" as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site. Furthermore, in contrast to polyclonal antibody preparations that include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen. In addition to their specificity, the monoclonal antibodies are advantageous in that they may be synthesized uncontaminated by other antibodies. The modifier "monoclonal" is not to be construed as requiring production of the antibody by any particular method. For example, the monoclonal antibodies useful in the present invention may be prepared by the hybridoma methodology first described by Kohler et al., Nature, 256:495 (1975), or may be made using recombinant DNA methods in bacterial, eukaryotic animal or plant cells (see, e.g., U.S. Pat. No. 4,816,567). The "monoclonal antibodies" may also be isolated from phage antibody libraries using the techniques described in Clackson et al., Nature, 352:624-628 (1991) and Marks et al., J. MoI. Biol., 222:581-597 (1991), for example.

[315] In some aspects, the alternative EBV immortalization method described in WO2004/076677 is used. Using this method, B-cells producing the antibody of the invention can be transformed with EBV in the presence of a polyclonal B cell activator. Transformation with EBV is a Standard technique and can easily be adapted to include polyclonal B cell activators. Additional stimulants of cellular growth and differentiation may be added during the transformation step to further enhance the efficiency. These stimulants may be cytokines such as IL-2 and IL-15. In a particularly preferred aspect, IL-2 is added during the immortalization step to further improve the efficiency of immortalization, but its use is not essential.

[316] The monoclonal antibodies herein include "chimeric" antibodies in which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity (see U.S. Pat. No. 4,816,567; and Morrison et al, Proc. Natl. Acad. Sci. USA, 81 :6851-6855 (1984)). The present invention provides variable region antigen-binding sequences derived from human antibodies. Accordingly, chimeric antibodies of primary interest herein include antibodies having one or more human antigen binding sequences {e.g., CDRs) and containing one or more sequences derived from a non-human antibody, e.g., an FR or C region sequence. In addition, chimeric antibodies of primary interest herein include those comprising a human variable region antigen binding sequence of one antibody class or subclass and another sequence, e.g., FR or C region sequence, derived from another antibody class or subclass. Chimeric antibodies of interest herein also include those containing variable region antigen-binding sequences related to those described herein or derived from a different species, such as a non-human primate {e.g., Old World Monkey, Ape, etc). Chimeric antibodies also include primatized and humanized antibodies. [317] Furthermore, chimeric antibodies may comprise residues that are not found in the recipient antibody or in the donor antibody. These modifications are made to further refine antibody performance. For further details, see Jones et al, Nature 321 :522-525 (1986); Riechmann et al, Nature 332:323-329 (1988); and Presta, Curr. Op. Struct. Biol. 2:593-596 (1992).

[318] A "humanized antibody" is generally considered to be a human antibody that has one or more amino acid residues introduced into it from a source that is non-human. These non- human amino acid residues are often referred to as "import" residues, which are typically taken from an "import" variable region. Humanization is traditionally performed following the method of Winter and co-workers (Jones et al., Nature, 321 :522-525 (1986); Reichmann et al, Nature, 332:323-327 (1988); Verhoeyen et al., Science, 239:1534-1536 (1988)), by substituting import hypervariable region sequences for the corresponding sequences of a human antibody.

Accordingly, such "humanized" antibodies are chimeric antibodies (U.S. Pat. No. 4,816,567) wherein substantially less than an intact human variable region has been substituted by the corresponding sequence from a non-human species.

[319] A "human antibody" is an antibody containing only sequences present in an antibody naturally produced by a human. However, as used herein, human antibodies may comprise residues or modifications not found in a naturally occurring human antibody, including those modifications and variant sequences described herein. These are typically made to further refine or enhance antibody performance.

[320] An "intact" antibody is one that comprises an antigen-binding site as well as a C_L and at least heavy chain constant domains, C_H 1, C_H 2 and C_H 3. The constant domains may be native sequence constant domains (e.g., human native sequence constant domains) or amino acid sequence variant thereof. Preferably, the intact antibody has one or more effector functions.

[321] An "antibody fragment" comprises a portion of an intact antibody, preferably the antigen binding or variable region of the intact antibody. Examples of antibody fragments include Fab, Fab', F(ab')₂, and Fv fragments; diabodies; linear antibodies (see U.S. Pat. No. 5,641,870; Zapata et al., Protein Eng. 8(10): 1057-1062 [1995]); single-chain antibody molecules; and multispecific antibodies formed from antibody fragments. [322] The phrase "functional fragment or analog" of an antibody is a compound having qualitative biological activity in common with a full-length antibody. For example, a functional fragment or analog of an anti-IgE antibody is one that can bind to an IgE immunoglobulin in such a manner so as to prevent or substantially reduce the ability of such molecule from having the ability to bind to the high affinity receptor, Fc_εRI. [323] Papain digestion of antibodies produces two identical antigen-binding fragments, called "Fab" fragments, and a residual "Fc" fragment, a designation reflecting the ability to crystallize readily. The Fab fragment consists of an entire L chain along with the variable region domain of the H chain (V_H), and the first constant domain of one heavy chain (C_H 1). Each Fab fragment is monovalent with respect to antigen binding, i.e., it has a single antigen- binding site. Pepsin treatment of an antibody yields a single large F(ab')₂ fragment that roughly corresponds to two disulfide linked Fab fragments having divalent antigen-binding activity and is still capable of cross-linking antigen. Fab' fragments differ from Fab fragments by having additional few residues at the carboxy terminus of the CHI domain including one or more cysteines from the antibody hinge region. Fab'-SH is the designation herein for Fab' in which the cysteine residue(s) of the constant domains bear a free thiol group. F(ab')₂ antibody fragments originally were produced as pairs of Fab' fragments that have hinge cysteines between them. Other chemical couplings of antibody fragments are also known. [324] The "Fc" fragment comprises the carboxy-terminal portions of both H chains held together by disulfides. The effector functions of antibodies are determined by sequences in the Fc region, which region is also the part recognized by Fc receptors (FcR) found on certain types of cells.

[325] "Fv" is the minimum antibody fragment that contains a complete antigen-recognition and -binding site. This fragment consists of a dimer of one heavy- and one light-chain variable region domain in tight, non-covalent association. From the folding of these two domains emanate six hypervariable loops (three loops each from the H and L chain) that contribute the amino acid residues for antigen binding and confer antigen binding specificity to the antibody. However, even a single variable region (or half of an Fv comprising only three CDRs specific for an antigen) has the ability to recognize and bind antigen, although at a lower affinity than the entire binding site.

[326] "Single-chain Fv" also abbreviated as "sFv" or "scFv" are antibody fragments that comprise the V_H and V_L antibody domains connected into a single polypeptide chain. Preferably, the sFv polypeptide further comprises a polypeptide linker between the V_H and V_L domains that enables the sFv to form the desired structure for antigen binding. For a review of sFv, see Pluckthun in The Pharmacology of Monoclonal Antibodies, vol. 113, Rosenburg and Moore eds., Springer-Verlag, New York, pp. 269-315 (1994); Borrebaeck 1995, infra.

[327] The term "diabodies" refers to small antibody fragments prepared by constructing sFv fragments (see preceding paragraph) with short linkers (about 5-10 residues) between the V_H and V_L domains such that inter-chain but not intra-chain pairing of the V domains is achieved, resulting in a bivalent fragment, i.e., fragment having two antigen-binding sites. Bispecific diabodies are heterodimers of two "crossover" sFv fragments in which the V_H and V_L domains of the two antibodies are present on different polypeptide chains. Diabodies are described more fully in, for example, EP 404,097; WO 93/11161; and Hollinger et al, Proc. Natl. Acad. Sci. USA, 90:6444-6448 (1993).

[328] Domain antibodies (dAbs), which can be produced in fully human form, are the smallest known antigen-binding fragments of antibodies, ranging from 1 1 kDa to 15 kDa. dAbs are the robust variable regions of the heavy and light chains of immunoglobulins (VH and VL respectively). They are highly expressed in microbial cell culture, show favourable biophysical properties including solubility and temperature stability, and are well suited to selection and affinity maturation by in vitro selection systems such as phage display. dAbs are bioactive as monomers and, owing to their small size and inherent stability, can be formatted into larger molecules to create drugs with prolonged serum half-lives or other pharmacological activities. Examples of this technology have been described in WO9425591 for antibodies derived from Camelidae heavy chain Ig, as well in US20030130496 describing the isolation of single domain fully human antibodies from phage libraries. [329] As used herein, an antibody that "internalizes" is one that is taken up by {i.e., enters) the cell upon binding to an antigen on a mammalian cell (e.g., a cell surface polypeptide or receptor). The internalizing antibody will of course include antibody fragments, human or chimeric antibody, and antibody conjugates. For certain therapeutic applications, internalization in vivo is contemplated. The number of antibody molecules internalized will be sufficient or adequate to kill a cell or inhibit its growth, especially an infected cell. Depending on the potency of the antibody or antibody conjugate, in some instances, the uptake of a single antibody molecule into the cell is sufficient to kill the target cell to which the antibody binds. For example, certain toxins are highly potent in killing such that internalization of one molecule of the toxin conjugated to the antibody is sufficient to kill the infected cell.

[330] As used herein, an antibody is said to be "immunospecific," "specific for" or to "specifically bind" an antigen if it reacts at a detectable level with the antigen, preferably with an affinity constant, K_a, of greater than or equal to about 1 O^ M" 1 , or greater than or equal to about 10^ M" 1, greater than or equal to about 10^ M"l, greater than or equal to about

10^ M^~l, or greater than or equal to 10^ M^"1. Affinity of an antibody for its cognate antigen is also commonly expressed as a dissociation constant K_D, and in certain embodiments, HIVl antibody specifically binds to an HIVl polypeptide if it binds with a K_D of less than or equal to 10^"4 M, less than or equal to about 10^'^ M, less than or equal to about 10^"6 M, less than or equal to 10^"? M, or less than or equal to 10^' 8 M. Affinities of antibodies can be readily determined using conventional techniques, for example, those described by Scatchard et al. {Ann. N. Y. Acad. ScL USA 51 :660 (1949)).

[331] Binding properties of an antibody to antigens, cells or tissues thereof may generally be determined and assessed using immunodetection methods including, for example, immunofluorescence-based assays, such as immuno-histochemistry (IHC) and/or fluorescence-activated cell sorting (FACS).

[332] An antibody having a "biological characteristic" of a designated antibody is one that possesses one or more of the biological characteristics of that antibody which distinguish it from other antibodies. For example, in certain embodiments, an antibody with a biological characteristic of a designated antibody will bind the same epitope as that bound by the designated antibody and/or have a common effector function as the designated antibody. [333] The term "antagonist" antibody is used in the broadest sense, and includes an antibody that partially or fully blocks, inhibits, or neutralizes a biological activity of an epitope, polypeptide, or cell that it specifically binds. Methods for identifying antagonist antibodies may comprise contacting a polypeptide or cell specifically bound by a candidate antagonist antibody with the candidate antagonist antibody and measuring a detectable change in one or more biological activities normally associated with the polypeptide or cell. [334] An "antibody that inhibits the growth of infected cells" or a "growth inhibitory" antibody is one that binds to and results in measurable growth inhibition of infected cells expressing or capable of expressing an HIVl epitope bound by an antibody. Preferred growth inhibitory antibodies inhibit growth of infected cells by greater than 20%, preferably from about 20% to about 50%, and even more preferably, by greater than 50% (e.g., from about 50% to about 100%) as compared to the appropriate control, the control typically being infected cells not treated with the antibody being tested. Growth inhibition can be measured at an antibody concentration of about 0.1 to 30 μg/ml or about 0.5 nM to 200 nM in cell culture, where the growth inhibition is determined 1-10 days after exposure of the infected cells to the antibody. Growth inhibition of infected cells in vivo can be determined in various ways known in the art.

[335] The antibody is growth inhibitory in vivo if administration of the antibody at about 1 μg/kg to about 100 mg/kg body weight results in reduction the percent of infected cells or total number of infected cells within about 5 days to 3 months from the first administration of the antibody, preferably within about 5 to 30 days. [336] An antibody that "induces apoptosis" is one which induces programmed cell death as determined by binding of annexin V, fragmentation of DNA, cell shrinkage, dilation of endoplasmic reticulum, cell fragmentation, and/or formation of membrane vesicles (called apoptotic bodies). Preferably the cell is an infected cell. Various methods are available for evaluating the cellular events associated with apoptosis. For example, phosphatidyl serine (PS) translocation can be measured by annexin binding; DNA fragmentation can be evaluated through DNA laddering; and nuclear/chromatin condensation along with DNA fragmentation can be evaluated by any increase in hypodiploid cells. Preferably, the antibody that induces apoptosis is one that results in about 2 to 50 fold, preferably about 5 to 50 fold, and most preferably about 10 to 50 fold, induction of annexin binding relative to untreated cell in an annexin binding assay.

[337] Antibody "effector functions" refer to those biological activities attributable to the Fc region (a native sequence Fc region or amino acid sequence variant Fc region) of an antibody, and vary with the antibody isotype. Examples of antibody effector functions include: CIq binding and complement dependent cytotoxicity; Fc receptor binding; antibody-dependent cell-mediated cytotoxicity (ADCC); phagocytosis; down regulation of cell surface receptors (e.g. , B cell receptor); and B cell activation.

[338] "Antibody-dependent cell-mediated cytotoxicity" or "ADCC" refers to a form of cytotoxicity in which secreted Ig bound to Fc receptors (FcRs) present on certain cytotoxic cells (e.g., Natural Killer (NK) cells, neutrophils, and macrophages) enable these cytotoxic effector cells to bind specifically to an antigen-bearing target cell and subsequently kill the target cell with cytotoxins. The antibodies "arm" the cytotoxic cells and are required for such killing. The primary cells for mediating ADCC, NK cells, express FcγRIII only, whereas monocytes express FcγRI, FcγRII and FcγRIII. FcR expression on hematopoietic cells is summarized in Table 4 on page 464 of Ravetch and Kinet, Annu. Rev. Immunol 9:457-92 (1991). To assess ADCC activity of a molecule of interest, an in vitro ADCC assay, such as that described in U.S. Pat. No. 5,500,362 or U.S. Pat. No. 5,821,337 may be performed. Useful effector cells for such assays include peripheral blood mononuclear cells (PBMC) and Natural Killer (NK) cells.

[339] Alternatively, or additionally, ADCC activity of the molecule of interest may be assessed in vivo, e.g., in a animal model such as that disclosed in Clynes et al, Proc. Natl. Acad. Sci. (USA) 95:652-656 (1998). [340J "Fc receptor" or "FcR" describes a receptor that binds to the Fc region of an antibody. In certain embodiments, the FcR is a native sequence human FcR. Moreover, a preferred FcR is one that binds an IgG antibody (a gamma receptor) and includes receptors of the Fc-)RI, FcγRII, and FcγRIII subclasses, including allelic variants and alternatively spliced forms of these receptors. FCγRII receptors include FcγRIIA (an "activating receptor") and FcγRIIB (an "inhibiting receptor"), which have similar amino acid sequences that differ primarily in the cytoplasmic domains thereof. Activating receptor FcγRIIA contains an immunoreceptor tyros ine-based activation motif (ITAM) in its cytoplasmic domain. Inhibiting receptor FcγRIIB contains an immunoreceptor tyros ine-based inhibition motif (ITIM) in its cytoplasmic domain, {see review M. in Daeron, Annu. Rev. Immunol. 15:203-234 (1997)). FcRs are reviewed in Ravetch and Kinet, Annu. Rev. Immunol 9:457-92 (1991); Capel et al, Immunomethods 4:25-34 (1994); and de Haas et al, J. Lab. Clin. Med. 126:330-41 (1995). Other FcRs, including those to be identified in the future, are encompassed by the term "FcR" herein. The term also includes the neonatal receptor, FcRn, which is responsible for the transfer of maternal IgGs to the fetus (Guyer et al, J. Immunol. 117:587 (1976) and Kim et al, J. Immunol. 24:249 (1994)).

[341] "Human effector cells" are leukocytes that express one or more FcRs and perform effector functions. Preferably, the cells express at least FcγRIII and perform ADCC effector function. Examples of human leukocytes that mediate ADCC include PBMC, NK cells, monocytes, cytotoxic T cells and neutrophils; with PBMCs and NK cells being preferred. The effector cells may be isolated from a native source, e.g., from blood.

[342] "Complement dependent cytotoxicity" or "CDC" refers to the lysis of a target cell in the presence of complement. Activation of the classical complement pathway is initiated by the binding of the first component of the complement system (CIq) to antibodies (of the appropriate subclass) that are bound to their cognate antigen. To assess complement activation, a CDC assay, e.g., as described in Gazzano-Santoro et al, J. Immunol. Methods 202:163 (1996), may be performed.

[343] A "mammal" for purposes of treating an infection, refers to any mammal, including humans, domestic and farm animals, and zoo, sports, or pet animals, such as dogs, cats, cattle, horses, sheep, pigs, goats, rabbits, etc. Preferably, the mammal is human. [344] "Treating" or "treatment" or "alleviation" refers to both therapeutic treatment and prophylactic or preventative measures; wherein the object is to prevent or slow down (lessen) the targeted pathologic condition or disorder. Those in need of treatment include those already with the disorder as well as those prone to have the disorder or those in whom the disorder is to be prevented. A subject or mammal is successfully "treated" for an infection if, after receiving a therapeutic amount of an antibody according to the methods of the present invention, the patient shows observable and/or measurable reduction in or absence of one or more of the following: reduction in the number of infected cells or absence of the infected cells; reduction in the percent of total cells that are infected; and/or relief to some extent, one or more of the symptoms associated with the specific infection; reduced morbidity and mortality, and improvement in quality of life issues. The above parameters for assessing successful treatment and improvement in the disease are readily measurable by routine procedures familiar to a physician.

[345] The term "therapeutically effective amount" refers to an amount of an antibody or a drug effective to "treat" a disease or disorder in a subject or mammal. See preceding definition of "treating."

[346] "Chronic" administration refers to administration of the agent(s) in a continuous mode as opposed to an acute mode, so as to maintain the initial therapeutic effect (activity) for an extended period of time. "Intermittent" administration is treatment that is not consecutively done without interruption, but rather is cyclic in nature.

[347] Administration "in combination with" one or more further therapeutic agents includes simultaneous (concurrent) and consecutive administration in any order. [348] "Carriers" as used herein include pharmaceutically acceptable carriers, excipients, or stabilizers that are nontoxic to the cell or mammal being exposed thereto at the dosages and concentrations employed. Often the physiologically acceptable carrier is an aqueous pH buffered solution. Examples of physiologically acceptable carriers include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid; low molecular weight (less than about 10 residues) polypeptide; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, arginine or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming counterions such as sodium; and/or nonionic surfactants such as TWEEN™ polyethylene glycol (PEG), and PLURONICS™.

[349] The term "cytotoxic agent" as used herein refers to a substance that inhibits or prevents the function of cells and/or causes destruction of cells. The term is intended to include radioactive isotopes (e.g., At²¹¹, 1¹³¹, 1¹²⁵, Y⁹⁰, Re¹⁸⁶, Re¹⁸⁸, Sm¹⁵³, Bi²¹², P³² and radioactive isotopes of Lu), chemotherapeutic agents e.g., methotrexate, adriamicin, vinca alkaloids (vincristine, vinblastine, etoposide), doxorubicin, melphalan, mitomycin C, chlorambucil, daunorubicin or other intercalating agents, enzymes and fragments thereof such as nucleolytic enzymes, antibiotics, and toxins such as small molecule toxins or enzymatically active toxins of bacterial, fungal, plant or animal origin, including fragments and/or variants thereof, and the various antitumor or anticancer agents disclosed below. Other cytotoxic agents are described below.

[350] A "growth inhibitory agent" when used herein refers to a compound or composition which inhibits growth of a cell, either in vitro or in vivo. Examples of growth inhibitory agents include agents that block cell cycle progression, such as agents that induce Gl arrest and M-phase arrest. Classical M-phase blockers include the vinca alkaloids (vincristine, vinorelbine and vinblastine), taxanes, and topoisomerase II inhibitors such as doxorubicin, epirubicin, daunorubicin, etoposide, and bleomycin. Those agents that arrest Gl also spill over into S-phase arrest, for example, DNA alkylating agents such as tamoxifen, prednisone, dacarbazine, mechlorethamine, cisplatin, methotrexate, 5-fluorouracil, and ara-C. Further information can be found in The Molecular Basis of Cancer, Mendelsohn and Israel, eds., Chapter 1 , entitled "Cell cycle regulation, oncogenes, and antineoplastic drugs" by Murakami et al. (W B Saunders: Philadelphia, 1995), especially p. 13. The taxanes (paclitaxel and docetaxel) are anticancer drugs both derived from the yew tree. Docetaxel (TAXOTERE™, Rhone-Poulenc Rorer), derived from the European yew, is a semisynthetic analogue of paclitaxel (TAXOL®, Bristol-Myers Squibb). Paclitaxel and docetaxel promote the assembly of microtubules from tubulin dimers and stabilize microtubules by preventing depolymerization, which results in the inhibition of mitosis in cells. [351] "Label" as used herein refers to a detectable compound or composition that is conjugated directly or indirectly to the antibody so as to generate a "labeled" antibody. The label may be detectable by itself (e.g., radioisotope labels or fluorescent labels) or, in the case of an enzymatic label, may catalyze chemical alteration of a substrate compound or composition that is detectable.

[352] The term "epitope tagged" as used herein refers to a chimeric polypeptide comprising a polypeptide fused to a "tag polypeptide." The tag polypeptide has enough residues to provide an epitope against which an antibody can be made, yet is short enough such that it does not interfere with activity of the polypeptide to which it is fused. The tag polypeptide is also preferably fairly unique so that the antibody does not substantially cross-react with other epitopes. Suitable tag polypeptides generally have at least six amino acid residues and usually between about 8 and 50 amino acid residues (preferably, between about 10 and 20 amino acid residues).

[353] A "small molecule" is defined herein to have a molecular weight below about 500 Daltons.

[354] The terms "nucleic acid" and "polynucleotide" are used interchangeably herein to refer to single- or double-stranded RNA, DNA, or mixed polymers. Polynucleotides may include genomic sequences, extra-genomic and plasmid sequences, and smaller engineered gene segments that express, or may be adapted to express polypeptides. [355] An "isolated nucleic acid" is a nucleic acid that is substantially separated from other genome DNA sequences as well as proteins or complexes such as ribosomes and polymerases, which naturally accompany a native sequence. The term embraces a nucleic acid sequence that has been removed from its naturally occurring environment, and includes recombinant or cloned DNA isolates and chemically synthesized analogues or analogues biologically synthesized by heterologous systems. A substantially pure nucleic acid includes isolated forms of the nucleic acid. Of course, this refers to the nucleic acid as originally isolated and does not exclude genes or sequences later added to the isolated nucleic acid by the hand of man.

[356] The term "polypeptide" is used in its conventional meaning, i.e., as a sequence of amino acids. The polypeptides are not limited to a specific length of the product. Peptides, oligopeptides, and proteins are included within the definition of polypeptide, and such terms may be used interchangeably herein unless specifically indicated otherwise. This term also does not refer to or exclude post-expression modifications of the polypeptide, for example, glycosylations, acetylations, phosphorylations and the like, as well as other modifications known in the art, both naturally occurring and non-naturally occurring. A polypeptide may be an entire protein, or a subsequence thereof. Particular polypeptides of interest in the context of this invention are amino acid subsequences comprising CDRs and being capable of binding an antigen or HIV-infected cell.

[357] An "isolated polypeptide" is one that has been identified and separated and/or recovered from a component of its natural environment. In preferred embodiments, the isolated polypeptide will be purified (1) to greater than 95% by weight of polypeptide as determined by the Lo wry method, and most preferably more than 99% by weight, (2) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by use of a spinning cup sequenator, or (3) to homogeneity by SDS-PAGE under reducing or non-reducing conditions using Coomassie blue or, preferably, silver stain. Isolated polypeptide includes the polypeptide in situ within recombinant cells since at least one component of the polypeptide's natural environment will not be present. Ordinarily, however, isolated polypeptide will be prepared by at least one purification step. [358] A "native sequence" polynucleotide is one that has the same nucleotide sequence as a polynucleotide derived from nature. A "native sequence" polypeptide is one that has the same amino acid sequence as a polypeptide (e.g., antibody) derived from nature (e.g., from any species). Such native sequence polynucleotides and polypeptides can be isolated from nature or can be produced by recombinant or synthetic means.

[359] A polynucleotide "variant," as the term is used herein, is a polynucleotide that typically differs from a polynucleotide specifically disclosed herein in one or more substitutions, deletions, additions and/or insertions. Such variants may be naturally occurring or may be synthetically generated, for example, by modifying one or more of the polynucleotide sequences of the invention and evaluating one or more biological activities of the encoded polypeptide as described herein and/or using any of a number of techniques well known in the art.

[360] A polypeptide "variant," as the term is used herein, is a polypeptide that typically differs from a polypeptide specifically disclosed herein in one or more substitutions, deletions, additions and/or insertions. Such variants may be naturally occurring or may be synthetically generated, for example, by modifying one or more of the above polypeptide sequences of the invention and evaluating one or more biological activities of the polypeptide as described herein and/or using any of a number of techniques well known in the art. [361] Modifications may be made in the structure of the polynucleotides and polypeptides of the present invention and still obtain a functional molecule that encodes a variant or derivative polypeptide with desirable characteristics. When it is desired to alter the amino acid sequence of a polypeptide to create an equivalent, or even an improved, variant or portion of a polypeptide of the invention, one skilled in the art will typically change one or more of the codons of the encoding DNA sequence.

[362] For example, certain amino acids may be substituted for other amino acids in a protein structure without appreciable loss of its ability to bind other polypeptides (e.g., antigens) or cells. Since it is the binding capacity and nature of a protein that defines that protein's biological functional activity, certain amino acid sequence substitutions can be made in a protein sequence, and, of course, it's underlying DNA coding sequence, and nevertheless obtain a protein with like properties. It is thus contemplated that various changes may be made in the peptide sequences of the disclosed compositions, or corresponding DNA sequences that encode said peptides without appreciable loss of their biological utility or activity.

[363] In many instances, a polypeptide variant will contain one or more conservative substitutions. A "conservative substitution" is one in which an amino acid is substituted for another amino acid that has similar properties, such that one skilled in the art of peptide chemistry would expect the secondary structure and hydropathic nature of the polypeptide to be substantially unchanged.

[364] In making such changes, the hydropathic index of amino acids may be considered. The importance of the hydropathic amino acid index in conferring interactive biologic function on a protein is generally understood in the art (Kyte and Doolittle, 1982). It is accepted that the relative hydropathic character of the amino acid contributes to the secondary structure of the resultant protein, which in turn defines the interaction of the protein with other molecules, for example, enzymes, substrates, receptors, DNA, antibodies, antigens, and the like. Each amino acid has been assigned a hydropathic index on the basis of its hydrophobicity and charge characteristics (Kyte and Doolittle, 1982). These values are: isoleucine (+4.5); valine (+4.2); leucine (+3.8); phenylalanine (+2.8); cysteine/cystine (+2.5); methionine (+1.9); alanine (+1.8); glycine (-0.4); threonine (-0.7); serine (-0.8); tryptophan (-0.9); tyrosine (-1.3); proline (-1.6); histidine (-3.2); glutamate (-3.5); glutamine (-3.5); aspartate (-3.5); asparagine (-3.5); lysine (-3.9); and arginine (-4.5).

[365] It is known in the art that certain amino acids may be substituted by other amino acids having a similar hydropathic index or score and still result in a protein with similar biological activity, i.e. still obtain a biological functionally equivalent protein. In making such changes, the substitution of amino acids whose hydropathic indices are within ±2 is preferred, those within ±1 are particularly preferred, and those within ±0.5 are even more particularly preferred. It is also understood in the art that the substitution of like amino acids can be made effectively on the basis of hydrophilicity. U. S. Patent 4,554,101 states that the greatest local average hydrophilicity of a protein, as governed by the hydrophilicity of its adjacent amino acids, correlates with a biological property of the protein. . [366] As detailed in U. S. Patent 4,554,101, the following hydrophilicity values have been assigned to amino acid residues: arginine (+3.0); lysine (+3.0); aspartate (+3.0 ± 1); glutamate (+3.0 + 1); serine (+0.3); asparagine (+0.2); glutamine (+0.2); glycine (0); threonine (-0.4); proline (-0.5 + 1); alanine (-0.5); histidine (-0.5); cysteine (-1.0); methionine (-1.3); valine (-1.5); leucine (-1.8); isoleucine (-1.8); tyrosine (-2.3); phenylalanine (-2.5); tryptophan (-3.4). It is understood that an amino acid can be substituted for another having a similar hydrophilicity value and still obtain a biologically equivalent, and in particular, an immunologically equivalent protein. In such changes, the substitution of amino acids whose hydrophilicity values are within ±2 is preferred, those within ±1 are particularly preferred, and those within ±0.5 are even more particularly preferred. [367] As outlined above, amino acid substitutions are generally therefore based on the relative similarity of the amino acid side-chain substituents, for example, their hydrophobicity, hydrophilicity, charge, size, and the like. Exemplary substitutions that take various of the foregoing characteristics into consideration are well known to those of skill in the art and include: arginine and lysine; glutamate and aspartate; serine and threonine; glutamine and asparagine; and valine, leucine and isoleucine.

[368] Amino acid substitutions may further be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity and/or the amphipathic nature of the residues. For example, negatively charged amino acids include aspartic acid and glutamic acid; positively charged amino acids include lysine and arginine; and amino acids with uncharged polar head groups having similar hydrophilicity values include leucine, isoleucine and valine; glycine and alanine; asparagine and glutamine; and serine, threonine, phenylalanine and tyrosine. Other groups of amino acids that may represent conservative changes include: (1) ala, pro, gly, glu, asp, gin, asn, ser, thr; (2) cys, ser, tyr, thr; (3) val, ile, leu, met, ala, phe; (4) lys, arg, his; and (5) phe, tyr, trp, his. A variant may also, or alternatively, contain nonconservative changes. In a preferred embodiment, variant polypeptides differ from a native sequence by substitution, deletion or addition of five amino acids or fewer. Variants may also (or alternatively) be modified by, for example, the deletion or addition of amino acids that have minimal influence on the immunogenicity, secondary structure and hydropathic nature of the polypeptide.

[369] Polypeptides may comprise a signal (or leader) sequence at the N-terminal end of the protein, which co-translationally or post-translationally directs transfer of the protein. The polypeptide may also be conjugated to a linker or other sequence for ease of synthesis, purification or identification of the polypeptide (e.g., poly-His), or to enhance binding of the polypeptide to a solid support. For example, a polypeptide may be conjugated to an immunoglobulin Fc region.

[370] When comparing polynucleotide and polypeptide sequences, two sequences are said to be "identical" if the sequence of nucleotides or amino acids in the two sequences is the same when aligned for maximum correspondence, as described below. Comparisons between two sequences are typically performed by comparing the sequences over a comparison window to identify and compare local regions of sequence similarity. A "comparison window" as used herein, refers to a segment of at least about 20 contiguous positions, usually 30 to about 75, 40 to about 50, in which a sequence may be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned. [371] Optimal alignment of sequences for comparison may be conducted using the Megalign program in the Lasergene suite of bioinformatics software (DNASTAR, Inc., Madison, WI), using default parameters. This program embodies several alignment schemes described in the following references: Dayhoff, M.O. (1978) A model of evolutionary change in proteins - Matrices for detecting distant relationships. In Dayhoff, M.O. (ed.) Atlas of Protein Sequence and Structure, National Biomedical Research Foundation, Washington DC Vol. 5, Suppl. 3, pp. 345-358; Hein J. (1990) Unified Approach to Alignment and Phylogenes pp. 626-645 Methods in Enzymology vol. 183, Academic Press, Inc., San Diego, CA; Higgins, D.G. and Sharp, P.M. (1989) CABIOS 5:151-153; Myers, E. W. and Muller W. (1988) CABIOS 4:11-17; Robinson, E.D. (1971) Comb. Theor 77:105; Santou, N. Nes, M. (1987) MoI. Biol. Evol. 4:406-425; Sneath, P.H.A. and Sokal, R.R. (1973) Numerical Taxonomy - the Principles and Practice of Numerical Taxonomy, Freeman Press, San Francisco, CA; Wilbur, WJ. and Lipman, D.J. (1983) Proc. Natl. Acad., Sci. USA 80:126- 730.

[372] Alternatively, optimal alignment of sequences for comparison may be conducted by the local identity algorithm of Smith and Waterman (1981) Λdtf. APL. Math 2:482, by the identity alignment algorithm of Needleman and Wunsch (1970) J. MoI. Biol. 48:443, by the search for similarity methods of Pearson and Lipman (1988) Proc. Natl. Acad. Sci. USA 85: 2444, by computerized implementations of these algorithms (GAP, BESTFIT, BLAST, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group (GCG), 575 Science Dr., Madison, WI), or by inspection. [373] One preferred example of algorithms that are suitable for determining percent sequence identity and sequence similarity are the BLAST and BLAST 2.0 algorithms, which are described in Altschul et al. (1977) Nucl. Acids Res. 25:3389-3402 and Altschul et al. (1990) J. MoI. Biol. 215:403-410, respectively. BLAST and BLAST 2.0 can be used, for example with the parameters described herein, to determine percent sequence identity for the polynucleotides and polypeptides of the invention. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information. [374] In one illustrative example, cumulative scores can be calculated using, for nucleotide sequences, the parameters M (reward score for a pair of matching residues; always >0) and N (penalty score for mismatching residues; always <0). Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses as defaults a wordlength (W) of 11, and expectation (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff and Henikoff (1989) Proc. Natl. Acad. Sci. USA 89:10915) alignments, (B) of 50, expectation (E) of 10, M=5, N=-4 and a comparison of both strands. [375] For amino acid sequences, a scoring matrix can be used to calculate the cumulative score. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T and X determine the sensitivity and speed of the alignment.

[376] In one approach, the "percentage of sequence identity" is determined by comparing two optimally aligned sequences over a window of comparison of at least 20 positions, wherein the portion of the polynucleotide or polypeptide sequence in the comparison window may comprise additions or deletions {i.e., gaps) of 20 percent or less, usually 5 to 15 percent, or 10 to 12 percent, as compared to the reference sequences (which does not comprise additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which the identical nucleic acid bases or amino acid residues occur in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the reference sequence (i.e., the window size) and multiplying the results by 100 to yield the percentage of sequence identity.

[377] "Homology" refers to the percentage of residues in the polynucleotide or polypeptide sequence variant that are identical to the non-variant sequence after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent homology. In particular embodiments, polynucleotide and polypeptide variants have at least 70%, at least 75%, at least 80%, at least 90%, at least 95%, at least 98%, or at least 99% polynucleotide or polypeptide homology with a polynucleotide or polypeptide described herein.

[378] "Vector" includes shuttle and expression vectors. Typically, the plasmid construct will also include an origin of replication (e.g., the CoIEl origin of replication) and a selectable marker (e.g., ampicillin or tetracycline resistance), for replication and selection, respectively, of the plasmids in bacteria. An "expression vector" refers to a vector that contains the necessary control sequences or regulatory elements for expression of the antibodies including antibody fragment of the invention, in bacterial or eukaryotic cells.

Suitable vectors are disclosed below.

As used in this specification and the appended claims, the singular forms "a," "an" and "the" include plural references unless the content clearly dictates otherwise.

[379] The invention also includes nucleic acid sequences encoding part or all of the light and heavy chains and CDRs of the present invention. Due to redundancy of the genetic code, variants of these sequences will exist that encode the same amino acid sequences.

[380] Variant antibodies are also included within the scope of the invention. Thus, variants of the sequences recited in the application are also included within the scope of the invention.

Further variants of the antibody sequences having improved affinity may be obtained using methods known in the art and are included within the scope of the invention. For example, amino acid substitutions may be used to obtain antibodies with further improved affinity.

Alternatively, codon optimization of the nucleotide sequence may be used to improve the efficiency of translation in expression systems for the production of the antibody.

[381] Preferably, such variant antibody sequences will share 70% or more (i.e. 80, 85, 90,

95, 97, 98, 99% or more) sequence identity with the sequences recited in the application.

Preferably such sequence identity is calculated with regard to the full length of the reference sequence (i.e. the sequence recited in the application). Preferably, percentage identity, as . referred to herein, is as determined using BLAST version 2.1.3 using the default parameters specified by the NCBI (the National Center for Biotechnology Information; http://www.ncbi.nlm.nih.gov/) [Blosum 62 matrix; gap open penalty=l 1 and gap extension penalty=l].

[382] Further included within the scope of the invention are vectors such as expression vectors, comprising a nucleic acid sequence according to the invention. Cells transformed with such vectors are also included within the scope of the invention. [383] As will be understood by the skilled artisan, general description of antibodies herein and methods of preparing and using the same also apply to individual antibody polypeptide constituents and antibody fragments.

[384] The antibodies of the present invention may be polyclonal or monoclonal antibodies. However, in preferred embodiments, they are monoclonal. In particular embodiments, antibodies of the present invention are human antibodies. Methods of producing polyclonal and monoclonal antibodies are known in the art and described generally, e.g., in U.S. Patent No. 6,824,780.

[385] Typically, the antibodies of the present invention are produced recombinantly, using vectors and methods available in the art, as described further below. Human antibodies may also be generated by in vitro activated B cells (see U.S. Pat. Nos. 5,567,610 and 5,229,275). [386] Human antibodies may also be produced in transgenic animals (e.g., mice) that are capable of producing a full repertoire of human antibodies in the absence of endogenous immunoglobulin production. For example, it has been described that the homozygous deletion of the antibody heavy-chain joining region (J_H) gene in chimeric and germ-line mutant mice results in complete inhibition of endogenous antibody production. Transfer of the human germ-line immunoglobulin gene array into such germ-line mutant mice results in the production of human antibodies upon antigen challenge. See, e.g., Jakobovits et al, Proc. Natl. Acad. Sci. USA, 90:2551 (1993); Jakobovits et al, Nature, 362:255-258 (1993); Bruggemann et al., Year in Immune, 7:33 (1993); U.S. Pat. Nos. 5,545,806, 5,569,825, 5,591,669 (all of GenPharm); U.S. Pat. No. 5,545,807; and WO 97/17852. Such animals may be genetically engineered to produce human antibodies comprising a polypeptide of the present invention.

[387] In certain embodiments, antibodies of the present invention are chimeric antibodies that comprise sequences derived from both human and non-human sources. In particular embodiments, these chimeric antibodies are humanized or primatized™. In practice, humanized antibodies are typically human antibodies in which some hypervariable region residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies.

[388] In the context of the present invention, chimeric antibodies also include human antibodies wherein the human hypervariable region or one or more CDRs are retained, but one or more other regions of sequence have been replaced by corresponding sequences from a non-human animal.

[389] The choice of non-human sequences, both light and heavy, to be used in making the chimeric antibodies is important to reduce antigenicity and human anti-non-human antibody responses when the antibody is intended for human therapeutic use. It is further important that chimeric antibodies retain high binding affinity for the antigen and other favorable biological properties. To achieve this goal, according to a preferred method, chimeric antibodies are prepared by a process of analysis of the parental sequences and various conceptual chimeric products using three-dimensional models of the parental human and non- human sequences. Three-dimensional immunoglobulin models are commonly available and are familiar to those skilled in the art. Computer programs are available which illustrate and display probable three-dimensional conformational structures of selected candidate immunoglobulin sequences.

[390] Inspection of these displays permits analysis of the likely role of the residues in the functioning of the candidate immunoglobulin sequence, i.e., the analysis of residues that influence the ability of the candidate immunoglobulin to bind its antigen. In this way, FR residues can be selected and combined from the recipient and import sequences so that the desired antibody characteristic, such as increased affinity for the target antigen(s), is achieved. In general, the hypervariable region residues are directly and most substantially involved in influencing antigen binding.

[391] As noted above, antibodies (or immunoglobulins) can be divided into five different classes, based on differences in the amino acid sequences in the constant region of the heavy chains. All immunoglobulins within a given class have very similar heavy chain constant regions. These differences can be detected by sequence studies or more commonly by serological means (i.e. by the use of antibodies directed to these differences). Antibodies, or fragments thereof, of the present invention may be any class, and may, therefore, have a gamma, mu, alpha, delta, or epsilon heavy chain. A gamma chain may be gamma 1, gamma 2, gamma 3, or gamma 4; and an alpha chain may be alpha 1 or alpha 2. [392] In a preferred embodiment, an antibody of the present invention, or fragment thereof, is an IgG. IgG is considered the most versatile immunoglobulin, because it is capable of carrying out all of the functions of immunoglobulin molecules. IgG is the major Ig in serum, and the only class of Ig that crosses the placenta. IgG also fixes complement, although the IgG4 subclass does not. Macrophages, monocytes, PMN's and some lymphocytes have Fc receptors for the Fc region of IgG. Not all subclasses bind equally well; IgG2 and IgG4 do not bind to Fc receptors. A consequence of binding to the Fc receptors on PMN's, monocytes and macrophages is that the cell can now internalize the antigen better. IgG is an opsonin that enhances phagocytosis. Binding of IgG to Fc receptors on other types of cells results in the activation of other functions. Antibodies of the present invention may be of any IgG subclass. [393] In another preferred embodiment, an antibody, or fragment thereof, of the present invention is an IgE. IgE is the least common serum Ig since it binds very tightly to Fc receptors on basophils and mast cells even before interacting with antigen. As a consequence of its binding to basophils and mast cells, IgE is involved in allergic reactions. Binding of the allergen to the IgE on the cells results in the release of various pharmacological mediators that result in allergic symptoms. IgE also plays a role in parasitic helminth diseases. Eosinophils have Fc receptors for IgE and binding of eosinophils to IgE-coated helminths results in killing of the parasite. IgE does not fix complement.

[394] In various embodiments, antibodies of the present invention, and fragments thereof, comprise a variable light chain that is either kappa or lambda. The lamba chain may be any of subtype, including, e.g., lambda 1, lambda 2, lambda 3, and lambda 4. [395] As noted above, the present invention further provides antibody fragments comprising a polypeptide of the present invention. In certain circumstances there are advantages of using antibody fragments, rather than whole antibodies. For example, the smaller size of the fragments allows for rapid clearance, and may lead to improved access to certain tissues, such as solid tumors. Examples of antibody fragments include: Fab, Fab', F(ab')₂ and Fv fragments; diabodies; linear antibodies; single-chain antibodies; and multispecifϊc antibodies formed from antibody fragments.

[396] Various techniques have been developed for the production of antibody fragments. Traditionally, these fragments were derived via proteolytic digestion of intact antibodies (see, e.g., Morimoto et al., Journal of Biochemical and Biophysical Methods 24:107-1 17 (1992); and Brennan et al., Science, 229:81 (1985)). However, these fragments can now be produced directly by recombinant host cells. Fab, Fv and ScFv antibody fragments can all be expressed in and secreted from E. coli, thus allowing the facile production of large amounts of these fragments. Fab'-SH fragments can be directly recovered from E. coli and chemically coupled to form F(ab')₂ fragments (Carter et al, Bio/Technology 10:163-167 (1992)). According to another approach, F(ab')₂ fragments can be isolated directly from recombinant host cell culture. Fab and F(ab')₂ fragment with increased in vivo half-life comprising a salvage receptor binding epitope residues are described in U.S. Pat. No. 5,869,046. Other techniques for the production of antibody fragments will be apparent to the skilled practitioner. [397] In other embodiments, the antibody of choice is a single chain Fv fragment (scFv). See WO 93/16185; U.S. Pat. Nos. 5,571,894; and 5,587,458. Fv and sFv are the only species with intact combining sites that are devoid of constant regions. Thus, they are suitable for reduced nonspecific binding during in vivo use. sFv fusion proteins may be constructed to yield fusion of an effector protein at either the amino or the carboxy terminus of an sFv. See Antibody Engineering, ed. Borrebaeck, supra. The antibody fragment may also be a "linear antibody", e.g., as described in U.S. Pat. No. 5,641,870 for example. Such linear antibody fragments may be monospecific or bispecific.

[398] In certain embodiments, antibodies of the present invention are bispecific or multi- specific. Bispecific antibodies are antibodies that have binding specificities for at least two different epitopes. Exemplary bispecific antibodies may bind to two different epitopes of a single antigen. Other such antibodies may combine a first antigen binding site with a binding site for a second antigen. Alternatively, an anti- HIVl arm may be combined with an arm that binds to a triggering molecule on a leukocyte, such as a T-cell receptor molecule (e.g., CD3), or Fc receptors for IgG (FcγR), such as FcγRI (CD64), FcγRII (CD32) and FcγRIII (CDl 6), so as to focus and localize cellular defense mechanisms to the infected cell. Bispecific antibodies may also be used to localize cytotoxic agents to infected cells. These antibodies possess an HIVl -binding arm and an arm that binds the cytotoxic agent (e.g., saporin, anti- interferon-α, vinca alkaloid, ricin A chain, methotrexate or radioactive isotope hapten). Bispecific antibodies can be prepared as full length antibodies or antibody fragments (e.g., F(ab')₂ bispecific antibodies). WO 96/16673 describes a bispecific anti-ErbB2/anti-FcγRJII antibody and U.S. Pat. No. 5,837,234 discloses a bispecific anti-ErbB2/anti-FcγRI antibody. A bispecific anti-ErbB2/Fcα antibody is shown in WO98/02463. U.S. Pat. No. 5,821 ,337 teaches a bispecific anti-ErbB2/anti-CD3 antibody.

[399] Methods for making bispecific antibodies are known in the art. Traditional production of full length bispecific antibodies is based on the co-expression of two immunoglobulin heavy chain-light chain pairs, where the two chains have different specificities (Millstein et α/., Nature, 305:537-539 (1983)). Because of the random assortment of immunoglobulin heavy and light chains, these hybridomas (quadromas) produce a potential mixture of ten different antibody molecules, of which only one has the correct bispecific structure. Purification of the correct molecule, which is usually done by affinity chromatography steps, is rather cumbersome, and the product yields are low. Similar procedures are disclosed in WO 93/08829, and in Traunecker et al, EMBO J., 10:3655-3659 (1991). [400J According to a different approach, antibody variable regions with the desired binding specificities (antibody-antigen combining sites) are fused to immunoglobulin constant domain sequences. Preferably, the fusion is with an Ig heavy chain constant domain, comprising at least part of the hinge, C_H2, and C_H3 regions. It is preferred to have the first heavy-chain constant region (C_HI) containing the site necessary for light chain bonding, present in at least one of the fusions. DNAs encoding the immunoglobulin heavy chain fusions and, if desired, the immunoglobulin light chain, are inserted into separate expression vectors, and are co-transfected into a suitable host cell. This provides for greater flexibility in adjusting the mutual proportions of the three polypeptide fragments in embodiments when unequal ratios of the three polypeptide chains used in the construction provide the optimum yield of the desired bispecific antibody. It is, however, possible to insert the coding sequences for two or all three polypeptide chains into a single expression vector when the expression of at least two polypeptide chains in equal ratios results in high yields or when the ratios have no significant affect on the yield of the desired chain combination.

[401] In a preferred embodiment of this approach, the bispecific antibodies are composed of a hybrid immunoglobulin heavy chain with a first binding specificity in one arm, and a hybrid immunoglobulin heavy chain-light chain pair (providing a second binding specificity) in the other arm. It was found that this asymmetric structure facilitates the separation of the desired bispecific compound from unwanted immunoglobulin chain combinations, as the presence of an immunoglobulin light chain in only one half of the bispecific molecule provides for a facile way of separation. This approach is disclosed in WO 94/04690. For further details of generating bispecific antibodies see, for example, Suresh et al., Methods in Enzymology, 121 :210 (1986).

[402] According to another approach described in U.S. Pat. No. 5,731 ,168, the interface between a pair of antibody molecules can be engineered to maximize the percentage of heterodimers that are recovered from recombinant cell culture. The preferred interface comprises at least a part of the C_H 3 domain. In this method, one or more small amino acid side chains from the interface of the first antibody molecule are replaced with larger side chains (e.g., tyrosine or tryptophan). Compensatory "cavities" of identical or similar size to the large side chain(s) are created on the interface of the second antibody molecule by replacing large amino acid side chains with smaller ones (e.g., alanine or threonine). This provides a mechanism for increasing the yield of the heterodimer over other unwanted end- products such as homodimers.

[403] Bispecific antibodies include cross-linked or "heteroconjugate" antibodies. For example, one of the antibodies in the heteroconjugate can be coupled to avidin, the other to biotin. Such antibodies have, for example, been proposed to target immune system cells to unwanted cells (U.S. Pat. No. 4,676,980), and for treatment of fflV infection (WO 91/00360, WO 92/200373, and EP 03089). Heteroconjugate antibodies may be made using any convenient cross-linking methods. Suitable cross-linking agents are well known in the art, and are disclosed in U.S. Pat. No. 4,676,980, along with a number of cross-linking techniques.

[404] Techniques for generating bispecific antibodies from antibody fragments have also been described in the literature. For example, bispecific antibodies can be prepared using chemical linkage. Brennan et al, Science, 229: 81 (1985) describe a procedure wherein intact antibodies are proteolytically cleaved to generate F(ab')₂ fragments. These fragments are reduced in the presence of the dithiol complexing agent, sodium arsenite, to stabilize vicinal dithiols and prevent intermolecular disulfide formation. The Fab' fragments generated are then converted to thionitrobenzoate (TNB) derivatives. One of the Fab'-TNB derivatives is then reconverted to the Fab'-thiol by reduction with mercaptoethylamine and is mixed with an equimolar amount of the other Fab'-TNB derivative to form the bispecific antibody. The bispecific antibodies produced can be used as agents for the selective immobilization of enzymes.

[405] Recent progress has facilitated the direct recovery of Fab'-SH fragments from E. coli, which can be chemically coupled to form bispecific antibodies. Shalaby et al., J. Exp. Med., 175: 217-225 (1992) describe the production of a humanized bispecific antibody F(ab')₂ molecule. Each Fab' fragment was separately secreted from E. coli and subjected to directed chemical coupling in vitro to form the bispecific antibody. The bispecific antibody thus formed was able to bind to cells overexpressing the ErbB2 receptor and normal human T cells, as well as trigger the lytic activity of human cytotoxic lymphocytes against human breast tumor targets.

[406] Various techniques for making and isolating bispecific antibody fragments directly from recombinant cell culture have also been described. For example, bispecific antibodies have been produced using leucine zippers. Kostelny et al, J. Immunol., 148(5): 1547-1553 (1992). The leucine zipper peptides from the Fos and Jun proteins were linked to the Fab' portions of two different antibodies by gene fusion. The antibody homodimers were reduced at the hinge region to form monomers and then re-oxidized to form the antibody heterodimers. This method can also be utilized for the production of antibody homodimers. The "diabody" technology described by Hollinger et al, Proc. Natl. Acad. Sci. USA, 90:6444-6448 (1993) has provided an alternative mechanism for making bispecific antibody fragments. The fragments comprise a V_H connected to a V_L by a linker that is too short to allow pairing between the two domains on the same chain. Accordingly, the V_H and V_L domains of one fragment are forced to pair with the complementary V_L and V_H domains of another fragment, thereby forming two antigen-binding sites. Another strategy for making bispecific antibody fragments by the use of single-chain Fv (sFv) dimers has also been reported. See Gruber et al, J. Immunol., 152:5368 (1994).

[407] Antibodies with more than two valencies are contemplated. For example, trispecific antibodies can be prepared. Tutt et al, J. Immunol. 147: 60 (1991). A multivalent antibody may be internalized (and/or catabolized) faster than a bivalent antibody by a cell expressing an antigen to which the antibodies bind. The antibodies of the present invention can be multivalent antibodies with three or more antigen binding sites (e.g., tetravalent antibodies), which can be readily produced by recombinant expression of nucleic acid encoding the polypeptide chains of the antibody. The multivalent antibody can comprise a dimerization domain and three or more antigen binding sites. The preferred dimerization domain comprises (or consists of) an Fc region or a hinge region. In this scenario, the antibody will comprise an Fc region and three or more antigen binding sites amino-terminal to the Fc region. The preferred multivalent antibody herein comprises (or consists of) three to about eight, but preferably four, antigen binding sites. The multivalent antibody comprises at least one polypeptide chain (and preferably two polypeptide chains), wherein the polypeptide chain(s) comprise two or more variable regions. For instance, the polypeptide chain(s) may comprise VDl-(Xl)_n -VD2-(X2)_n -Fc, wherein VDl is a first variable region, VD2 is a second variable region, Fc is one polypeptide chain of an Fc region, Xl and X2 represent an amino acid or polypeptide, and n is 0 or 1. For instance, the polypeptide chain(s) may comprise: VH-CHl -flexible linker-VH-CHl-Fc region chain; or VH-CHl -VH-CHl -Fc region chain. The multivalent antibody herein preferably further comprises at least two (and preferably four) light chain variable region polypeptides. The multivalent antibody herein may, for instance, comprise from about two to about eight light chain variable region polypeptides. The light chain variable region polypeptides contemplated here comprise a light chain variable region and, optionally, further comprise a C_L domain. [408] Antibodies of the invention further include single chain antibodies. In particular embodiments, antibodies of the invention are internalizing antibodies. [409] Amino acid sequence modification(s) of the antibodies described herein are contemplated. For example, it may be desirable to improve the binding affinity and/or other biological properties of the antibody. Amino acid sequence variants of the antibody may be prepared by introducing appropriate nucleotide changes into a polynucleotide that encodes the antibody, or a chain thereof, or by peptide synthesis. Such modifications include, for example, deletions from, and/or insertions into and/or substitutions of, residues within the amino acid sequences of the antibody. Any combination of deletion, insertion, and substitution may be made to arrive at the final antibody, provided that the final construct possesses the desired characteristics. The amino acid changes also may alter post- translational processes of the antibody, such as changing the number or position of glycosylation sites. Any of the variations and modifications described above for polypeptides of the present invention may be included in antibodies of the present invention. [410] A useful method for identification of certain residues or regions of an antibody that are preferred locations for mutagenesis is called "alanine scanning mutagenesis" as described by Cunningham and Wells in Science, 244: 1081-1085 (1989). Here, a residue or group of target residues are identified (e.g., charged residues such as arg, asp, his, lys, and glu) and replaced by a neutral or negatively charged amino acid (most preferably alanine or polyalanine) to affect the interaction of the amino acids with PSCA antigen. Those amino acid locations demonstrating functional sensitivity to the substitutions then are refined by introducing further or other variants at, or for, the sites of substitution. Thus, while the site for introducing an amino acid sequence variation is predetermined, the nature of the mutation per se need not be predetermined. For example, to analyze the performance of a mutation at a given site, ala scanning or random mutagenesis is conducted at the target codon or region and the expressed anti- antibody variants are screened for the desired activity. [411] Amino acid sequence insertions include amino- and/or carboxyl-terminal fusions ranging in length from one residue to polypeptides containing a hundred or more residues, as well as intrasequence insertions of single or multiple amino acid residues. Examples of terminal insertions include an antibody with an N-terminal methionyl residue or the antibody fused to a cytotoxic polypeptide. Other insertional variants of an antibody include the fusion to the N- or C-terminus of the antibody to an enzyme (e.g., for ADEPT) or a polypeptide that increases the serum half-life of the antibody.

[412] Another type of variant is an amino acid substitution variant. These variants have at least one amino acid residue in the antibody molecule replaced by a different residue. The sites of greatest interest for substitutional mutagenesis include the hypervariable regions, but FR alterations are also contemplated. Conservative and non-conservative substitutions are contemplated.

[413] Substantial modifications in the biological properties of the antibody are accomplished by selecting substitutions that differ significantly in their effect on maintaining (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain.

[414] Any cysteine residue not involved in maintaining the proper conformation of the antibody also may be substituted, generally with serine, to improve the oxidative stability of the molecule and prevent aberrant crosslinking. Conversely, cysteine bond(s) may be added to the antibody to improve its stability (particularly where the antibody is an antibody fragment such as an Fv fragment).

[415] One type of substitutional variant involves substituting one or more hypervariable region residues of a parent antibody. Generally, the resulting variant(s) selected for further development will have improved biological properties relative to the parent antibody from which they are generated. A convenient way for generating such substitutional variants involves affinity maturation using phage display. Briefly, several hypervariable region sites (e.g., 6-7 sites) are mutated to generate all possible amino substitutions at each site. The antibody variants thus generated are displayed in a monovalent fashion from filamentous phage particles as fusions to the gene III product of Ml 3 packaged within each particle. The phage-displayed variants are then screened for their biological activity (e.g., binding affinity) as herein disclosed. In order to identify candidate hypervariable region sites for modification, alanine scanning mutagenesis can be performed to identify hypervariable region residues contributing significantly to antigen binding. Alternatively, or additionally, it may be beneficial to analyze a crystal structure of the antigen-antibody complex to identify contact points between the antibody and an antigen or infected cell. Such contact residues and neighboring residues are candidates for substitution according to the techniques elaborated herein. Once such variants are generated, the panel of variants is subjected to screening as described herein and antibodies with superior properties in one or more relevant assays may be selected for further development.

[416] Another type of amino acid variant of the antibody alters the original glycosylation pattern of the antibody. By altering is meant deleting one or more carbohydrate moieties found in the antibody, and/or adding one or more glycosylation sites that are not present in the antibody.

Glycosylation of antibodies is typically either N-linked or O-linked. N-linked refers to the attachment of the carbohydrate moiety to the side chain of an asparagine residue. The tripeptide sequences asparagine-X-serine and asparagine-X-threonine, where X is any amino acid except proline, are the recognition sequences for enzymatic attachment of the carbohydrate moiety to the asparagine side chain. Thus, the presence of either of these tripeptide sequences in a polypeptide creates a potential glycosylation site. O-linked glycosylation refers to the attachment of one of the sugars N-aceylgalactosamine, galactose, or xylose to a hydroxyamino acid, most commonly serine or threonine, although 5- hydroxyproline or 5-hydroxylysine may also be used.

Addition of glycosylation sites to the antibody is conveniently accomplished by altering the amino acid sequence such that it contains one or more of the above-described tripeptide sequences (for N-linked glycosylation sites). The alteration may also be made by the addition of, or substitution by, one or more serine or threonine residues to the sequence of the original antibody (for O-linked glycosylation sites).

[417] The antibody of the invention is modified with respect to effector function, e.g., so as to enhance antigen-dependent cell-mediated cyotoxicity (ADCC) and/or complement dependent cytotoxicity (CDC) of the antibody. This may be achieved by introducing one or more amino acid substitutions in an Fc region of the antibody. Alternatively or additionally, cysteine residue(s) may be introduced in the Fc region, thereby allowing interchain disulfide bond formation in this region. The homodimeric antibody thus generated may have improved internalization capability and/or increased complement-mediated cell killing and antibody- dependent cellular cytotoxicity (ADCC). See Caron et al., J. Exp Med. 176: 1 191-1195 (1992) and Shopes, B. J. Immunol. 148:2918-2922 (1992). Homodimeric antibodies with enhanced anti-infection activity may also be prepared using heterobifunctional cross-linkers as described in Wolff et al, Cancer Research 53:2560-2565 (1993). Alternatively, an antibody can be engineered which has dual Fc regions and may thereby have enhanced complement lysis and ADCC capabilities. See Stevenson et al, Anti-Cancer Drug Design 3:219-230 (1989).

To increase the serum half-life of the antibody, one may incorporate a salvage receptor binding epitope into the antibody (especially an antibody fragment) as described in U.S. Pat. No. 5,739,277, for example. As used herein, the term "salvage receptor binding epitope" refers to an epitope of the Fc region of an IgG molecule {e.g., IgGi, IgG₂, IgG3, or IgG₄) that is responsible for increasing the in vivo serum half-life of the IgG molecule. [418] Antibodies of the present invention may also be modified to include an epitope tag or label, e.g., for use in purification or diagnostic applications. The invention also pertains to therapy with immunoconjugates comprising an antibody conjugated to an anti-cancer agent such as a cytotoxic agent or a growth inhibitory agent. Chemotherapeutic agents useful in the generation of such immunoconjugates have been described above. [419] Conjugates of an antibody and one or more small molecule toxins, such as a calicheamicin, maytansinoids, a trichothene, and CC 1065, and the derivatives of these toxins that have toxin activity, are also contemplated herein.

[420] In one preferred embodiment, an antibody (full length or fragments) of the invention is conjugated to one or more maytansinoid molecules. Maytansinoids are mitototic inhibitors that act by inhibiting tubulin polymerization. Maytansine was first isolated from the east African shrub Maytenus serrata (U.S. Pat. No. 3,896,1 11). Subsequently, it was discovered that certain microbes also produce maytansinoids, such as maytansinol and C-3 maytansinol esters (U.S. Pat. No. 4,151,042). Synthetic maytansinol and derivatives and analogues thereof are disclosed, for example, in U.S. Pat. Nos. 4,137,230; 4,248,870; 4,256,746; 4,260,608; 4,265,814; 4,294,757; 4,307,016; 4,308,268; 4,308,269; 4,309,428; 4,313,946; 4,315,929; 4,317,821 ; 4,322,348; 4,331,598; 4,361,650; 4,364,866; 4,424,219; 4,450,254; 4,362,663; and 4,371,533.

[421] In an attempt to improve their therapeutic index, maytansine and maytansinoids have been conjugated to antibodies specifically binding to tumor cell antigens. Immunoconjugates containing maytansinoids and their therapeutic use are disclosed, for example, in U.S. Pat. Nos. 5,208,020, 5,416,064 and European Patent EP 0 425 235 Bl . Liu et al., Proc. Natl. Acad. Sci. USA 93:8618-8623 (1996) described immunoconjugates comprising a maytansinoid designated DMl linked to the monoclonal antibody C242 directed against human colorectal cancer. The conjugate was found to be highly cytotoxic towards cultured colon cancer cells, and showed antitumor activity in an in vivo tumor growth assay. [422] Antibody-maytansinoid conjugates are prepared by chemically linking an antibody to a maytansinoid molecule without significantly diminishing the biological activity of either the antibody or the maytansinoid molecule. An average of 3-4 maytansinoid molecules conjugated per antibody molecule has shown efficacy in enhancing cytotoxicity of target cells without negatively affecting the function or solubility of the antibody, although even one molecule of toxin/antibody would be expected to enhance cytotoxicity over the use of naked antibody. Maytansinoids are well known in the art and can be synthesized by known techniques or isolated from natural sources. Suitable maytansinoids are disclosed, for example, in U.S. Pat. No. 5,208,020 and in the other patents and nonpatent publications referred to hereinabove. Preferred maytansinoids are maytansinol and maytansinol analogues modified in the aromatic ring or at other positions of the maytansinol molecule, such as various maytansinol esters.

[423] There are many linking groups known in the art for making antibody conjugates, including, for example, those disclosed in U.S. Pat. No. 5,208,020 or EP Patent 0 425 235 Bl, and Chari et al, Cancer Research 52: 127-131 (1992). The linking groups include disufide groups, thioether groups, acid labile groups, photolabile groups, peptidase labile groups, or esterase labile groups, as disclosed in the above-identified patents, disulfide and thioether groups being preferred.

[424] Immunoconjugates may be made using a variety of bifunctional protein coupling agents such as N-succinimidyl-3-(2-pyridyldithio)propionate (SPDP), succinimidyl-4-(N- maleimidomethyl)cyclohexane-l-carboxylate, iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCL), active esters (such as disuccinimidyl suberate), aldehydes (such as glutareldehyde), bis-azido compounds (such as bis (p- azidobenzoyl)hexanediamine), bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyl)- ethylenediamine), diisocyanates (such as toluene 2,6-diisocyanate), and bis-active fluorine compounds (such as l,5-difluoro-2,4-dinitrobenzene). Particularly preferred coupling agents include N-succinimidyl-3-(2-pyridyldithio)propionate (SPDP) (Carlsson et al, Biochem. J. 173:723-737 [1978]) and N-succinimidyl-4-(2-pyridylthio)pentanoate (SPP) to provide for a disulfide linkage. For example, a ricin immunotoxin can be prepared as described in Vitetta et al, Science 238: 1098 (1987). Carbon- 14-labeled l-isothiocyanatobenzyl-3-methyldiethylene triaminepentaacetic acid (MX-DTPA) is an exemplary chelating agent for conjugation of radionucleotide to the antibody. See WO94/11026. The linker may be a "cleavable linker" facilitating release of the cytotoxic drug in the cell. For example, an acid-labile linker, Cancer Research 52: 127-131 (1992); U.S. Pat. No. 5,208,020) may be used. [425] Another immunoconjugate of interest comprises an antibody conjugated to one or more calicheamicin molecules. The calicheamicin family of antibiotics are capable of producing double-stranded DNA breaks at sub-picomolar concentrations. For the preparation of conjugates of the calicheamicin family, see U.S. Pat. Nos. 5,712,374, 5,714,586, 5,739,1 16, 5,767,285, 5,770,701, 5,770,710, 5,773,001, 5,877,296 (all to American Cyanamid Company). Another drug that the antibody can be conjugated is QFA which is an antifolate. Both calicheamicin and QFA have intracellular sites of action and do not readily cross the plasma membrane. Therefore, cellular uptake of these agents through antibody mediated internalization greatly enhances their cytotoxic effects.

[426] Examples of other agents that can be conjugated to the antibodies of the invention include BCNU, streptozoicin, vincristine and 5-fIuorouracil, the family of agents known collectively LL-E33288 complex described in U.S. Pat. Nos. 5,053,394, 5,770,710, as well as esperamicins (U.S. Pat. No. 5,877,296).

[427] Enzymatically active toxins and fragments thereof that can be used include, e.g., diphtheria A chain, nonbinding active fragments of diphtheria toxin, exotoxin A chain (from Pseudomonas aeruginosa), ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordii proteins, dianthin proteins, Phytolaca americana proteins (PAPI, PAPII, and PAP-S), momordica charantia inhibitor, curcin, crotin, sapaonaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin and the tricothecenes. See, for example, WO 93/21232.

[428] The present invention further includes an immunoconjugate formed between an antibody and a compound with nucleolytic activity {e.g., a ribonuclease or a DNA endonuclease such as a deoxyribonuclease; DNase).

[429] For selective destruction of infected cells, the antibody includes a highly radioactive atom. A variety of radioactive isotopes are available for the production of radioconjugated anti-PSCA antibodies. Examples include At²¹¹, 1¹³¹, 1¹²⁵, Y⁹⁰, Re¹⁸⁶, Rc¹⁸⁸, Sm¹⁵³, Bi²¹², P³², Pb²¹² and radioactive isotopes of Lu. When the conjugate is used for diagnosis, it may comprise a radioactive atom for scintigraphic studies, for example tc^99m or I¹²³, or a spin label for nuclear magnetic resonance (NMR) imaging (also known as magnetic resonance imaging, mri), such as iodine- 123, iodine-131, indium-I l l, fluorine- 19, carbon- 13, nitrogen- 15, oxygen- 17, gadolinium, manganese or iron.

[430] The radio- or other label is incorporated in the conjugate in known ways. For example, the peptide may be biosynthesized or may be synthesized by chemical amino acid synthesis using suitable amino acid precursors involving, for example, fluorine- 19 in place of hydrogen. Labels such as tc"^m or I¹²³, Re¹⁸⁶, Re¹⁸⁸ and In¹¹¹ can be attached via a cysteine residue in the peptide. Yttrium-90 can be attached via a lysine residue. The IODOGEN method (Fraker et al. (1978) Biochem. Biophys. Res. Commun. 80: 49-57 can be used to incorporate iodine- 123. "Monoclonal Antibodies in Immunoscintigraphy" (Chatal,CRC Press 1989) describes other methods in detail.

[431] Alternatively, a fusion protein comprising the antibody and cytotoxic agent is made, e.g., by recombinant techniques or peptide synthesis. The length of DNA may comprise respective regions encoding the two portions of the conjugate either adjacent one another or separated by a region encoding a linker peptide which does not destroy the desired properties of the conjugate.

The antibodies of the present invention are also used in antibody dependent enzyme mediated prodrug therapy (ADET) by conjugating the antibody to a prodrug-activating enzyme which converts a prodrug (e.g., a peptidyl chemotherapeutic agent, see WO81/01145) to an active anti-cancer drug (see, e.g., WO 88/07378 and U.S. Pat. No. 4,975,278). [432] The enzyme component of the immunoconjugate useful for ADEPT includes any enzyme capable of acting on a prodrug in such a way so as to covert it into its more active, cytotoxic form. Enzymes that are useful in the method of this invention include, but are not limited to, alkaline phosphatase useful for converting phosphate-containing prodrugs into free drugs; arylsulfatase useful for converting sulfate-containing prodrugs into free drugs; cytosine deaminase useful for converting non-toxic 5-fluorocytosine into the anti-cancer drug, 5-fluorouracil; proteases, such as serratia protease, thermolysin, subtilisin, carboxypeptidases and cathepsins (such as cathepsins B and L), that are useful for converting peptide-containing prodrugs into free drugs; D-alanylcarboxypeptidases, useful for converting prodrugs that contain D-amino acid substituents; carbohydrate-cleaving enzymes such as β-galactosidase and neuraminidase useful for converting glycosylated prodrugs into free drugs; β-lactamase useful for converting drugs derivatized with β-lactams into free drugs; and penicillin amidases, such as penicillin V amidase or penicillin G amidase, useful for converting drugs derivatized at their amine nitrogens with phenoxyacetyl or phenylacetyl groups, respectively, into free drugs. Alternatively, antibodies with enzymatic activity, also known in the art as "abzymes", can be used to convert the prodrugs of the invention into free active drugs (see, e.g., Massey, Nature 328: 457-458 (1987)). Antibody-abzyme conjugates can be prepared as described herein for delivery of the abzyme to a infected cell population. [433] The enzymes of this invention can be covalently bound to the antibodies by techniques well known in the art such as the use of the heterobifunctional crosslinking reagents discussed above. Alternatively, fusion proteins comprising at least the antigen binding region of an antibody of the invention linked to at least a functionally active portion of an enzyme of the invention can be constructed using recombinant DNA techniques well known in the art (see, e.g., Neuberger et al, Nature, 312: 604-608 (1984). [434] Other modifications of the antibody are contemplated herein. For example, the antibody may be linked to one of a variety of nonproteinaceous polymers, e.g., polyethylene glycol, polypropylene glycol, polyoxyalkylenes, or copolymers of polyethylene glycol and polypropylene glycol. The antibody also may be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization (for example, hydroxymethylcellulose or gelatin-microcapsules and poly-

(methylmethacylate)microcapsules, respectively), in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules), or in macroemulsions. Such techniques are disclosed in Remington's Pharmaceutical Sciences, 16th edition, Oslo, A., Ed., (1980). [435] The antibodies disclosed herein are also formulated as immunoliposomes. A "liposome" is a small vesicle composed of various types of lipids, phospholipids and/or surfactant that is useful for delivery of a drug to a mammal. The components of the liposome are commonly arranged in a bilayer formation, similar to the lipid arrangement of biological membranes. Liposomes containing the antibody are prepared by methods known in the art, such as described in Epstein et al, Proc. Natl. Acad. Sci. USA, 82:3688 (1985); Hwang et al, Proc. Natl Acad. Sci. USA, 77:4030 (1980); U.S. Pat. Nos. 4,485,045 and 4,544,545; and WO97/38731 published Oct. 23, 1997. Liposomes with enhanced circulation time are disclosed in U.S. Pat. No. 5,013,556.

[436] Particularly useful liposomes can be generated by the reverse phase evaporation method with a lipid composition comprising phosphatidylcholine, cholesterol and PEG- derivatized phosphatidylethanolamine (PEG-PE). Liposomes are extruded through filters of defined pore size to yield liposomes with the desired a diameter. Fab' fragments of the antibody of the present invention can be conjugated to the liposomes as described in Martin et al, J. Biol. Chem. 257: 286-288 (1982) via a disulfide interchange reaction. A chemotherapeutic agent is optionally contained within the liposome. See Gabizon et al, J. National Cancer Inst. 81(19)1484 (1989).

Antibodies of the present invention, or fragments thereof, may possess any of a variety of biological or functional characteristics. In certain embodiments, these antibodies are HIVl protein specific antibodies, indicating that they specifically bind to or preferentially bind to HIVl as compared to a normal control cell.

[437] In particular embodiments, an antibody of the present invention is an antagonist antibody, which partially or fully blocks or inhibits a biological activity of a polypeptide or cell to which it specifically or preferentially binds. In other embodiments, an antibody of the present invention is a growth inhibitory antibody, which partially or fully blocks or inhibits the growth of an infected cell to which it binds. In another embodiment, an antibody of the present invention induces apoptosis. In yet another embodiment, an antibody of the present invention induces or promotes antibody-dependent cell-mediated cytotoxicity or complement dependent cytotoxicity.

[438] HTVl -expressing cells or virus described above are used to screen the biological sample obtained from a patient infected with HTVl for the presence of antibodies that preferentially bind to the cell expressing HIVl polypeptides using standard biological techniques. For example, in certain embodiments, the antibodies may be labeled, and the presence of label associated with the cell detected, e.g., using FMAT or FACs analysis. In particular embodiments, the biological sample is blood, serum, plasma, bronchial lavage, or saliva. Methods of the present invention may be practiced using high throughput techniques. [439] Identified human antibodies may then be characterized further. For example the particular conformational epitopes with in the HTVl polypeptides that are necessary or sufficient for binding of the antibody may be determined, e.g., using site-directed mutagenesis of expressed HIVl polypeptides. These methods may be readily adapted to identify human antibodies that bind any protein expressed on a cell surface. Furthermore, these methods may be adapted to determine binding of the antibody to the virus itself, as opposed to a cell expressing recombinant HIVl or infected with the virus. [440] Polynucleotide sequences encoding the antibodies, variable regions thereof, or antigen-binding fragments thereof may be subcloned into expression vectors for the recombinant production of human anti-HIVl antibodies. In one embodiment, this is accomplished by obtaining mononuclear cells from the patient from the serum containing the identified HIVl antibody was obtained; producing B cell clones from the mononuclear cells; inducing the B cells to become antibody-producing plasma cells; and screening the supernatants produced by the plasma cells to determine if it contains the HIVl antibody. Once a B cell clone that produces an HIVl antibody is identified, reverse-transcription polymerase chain reaction (RT-PCR) is performed to clone the DNAs encoding the variable regions or portions thereof of the HIVl antibody. These sequences are then subcloned into expression vectors suitable for the recombinant production of human HIVl antibodies. The binding specificity may be confirmed by determining the recombinant antibody's ability to bind cells expressing HIVl polypeptide.

[441] In particular embodiments of the methods described herein, B cells isolated from peripheral blood or lymph nodes are sorted, e.g., based on their being CD 19 positive, and plated, e.g., as low as a single cell specificity per well, e.g., in 96, 384, or 1536 well configurations. The cells are induced to differentiate into antibody-producing cells, e.g., plasma cells, and the culture supernatants are harvested and tested for binding to cells expressing the infectious agent polypeptide on their surface using, e.g., FMAT or FACS analysis. Positive wells are then subjected to whole well RT-PCR to amplify heavy and light chain variable regions of the IgG molecule expressed by the clonal daughter plasma cells. The resulting PCR products encoding the heavy and light chain variable regions, or portions thereof, are subcloned into human antibody expression vectors for recombinant expression. The resulting recombinant antibodies are then tested to confirm their original binding specificity and may be further tested for pan-specificity across various strains of isolates of the infectious agent.

[442] Thus, in one embodiment, a method of identifying HTVl antibodies is practiced as follows. First, full length or approximately full length HIVl cDNAs are transfected into a cell line for expression of HIVl polypeptides. Secondly, individual human plasma or sera samples are tested for antibodies that bind the cell-expressed HIVl polypeptides. And lastly, MAbs derived from plasma- or serum-positive individuals are characterized for binding to the same cell-expressed HIVl polypeptides. Further definition of the fine specificities of the MAbs can be performed at this point.

[443] Polynucleotides that encode the HTVl antibodies or portions thereof of the present invention may be isolated from cells expressing HTVl antibodies, according to methods available in the art and described herein, including amplification by polymerase chain reaction using primers specific for conserved regions of human antibody polypeptides. For example, light chain and heavy chain variable regions may be cloned from the B cell according to molecular biology techniques described in WO 92/02551; U.S. Patent No. 5,627,052; or Babcook et al., Proc. Natl. Acad. Sci. USA 93:7843-48 (1996). In certain embodiments, polynucleotides encoding all or a region of both the heavy and light chain variable regions of the IgG molecule expressed by the clonal daughter plasma cells expressing the HTVl antibody are subcloned and sequenced. The sequence of the encoded polypeptide may be readily determined from the polynucleotide sequence. [444] Isolated polynucleotides encoding a polypeptide of the present invention may be subcloned into an expression vector to recombinantly produce antibodies and polypeptides of the present invention, using procedures known in the art and described herein. [445] Binding properties of an antibody (or fragment thereof) to HIVl polypeptides or HIvI infected cells or tissues may generally be determined and assessed using immunodetection methods including, for example, immunofluorescence-based assays, such as immuno-histochemistry (IHC) and/or fluorescence-activated cell sorting (FACS). Immunoassay methods may include controls and procedures to determine whether antibodies bind specifically to HIVl polypeptides from one or more specific clades or strains of HIV, and do not recognize or cross-react with normal control cells.

[446] Following pre-screening of serum to identify patients that produce antibodies to an infectious agent or polypeptide thereof, e.g., HIVl, the methods of the present invention typically include the isolation or purification of B cells from a biological sample previously obtained from a patient or subject. The patient or subject may be currently or previously diagnosed with or suspect or having a particular disease or infection, or the patient or subject may be considered free or a particular disease or infection. Typically, the patient or subject is a mammal and, in particular embodiments, a human. The biological sample may be any sample that contains B cells, including but not limited to, lymph node or lymph node tissue, pleural effusions, peripheral blood, ascites, tumor tissue, or cerebrospinal fluid (CSF). In various embodiments, B cells are isolated from different types of biological samples, such as a biological sample affected by a particular disease or infection. However, it is understood that any biological sample comprising B cells may be used for any of the embodiments of the present invention. _t [447] Once isolated, the B cells are induced to produce antibodies, e.g., by culturing the B cells under conditions that support B cell proliferation or development into a plasmacyte, plasmablast, or plasma cell. The antibodies are then screened, typically using high throughput techniques, to identify an antibody that specifically binds to a target antigen, e.g., a particular tissue, cell, infectious agent, or polypeptide. In certain embodiments, the specific antigen, e.g., cell surface polypeptide bound by the antibody is not known, while in other embodiments, the antigen specifically bound by the antibody is known. [448] According to the present invention, B cells may be isolated from a biological sample, e.g., a tumor, tissue, peripheral blood or lymph node sample, by any means known and available in the art. B cells are typically sorted by FACS based on the presence on their surface of a B cell-specific marker, e.g., CD 19, CD 138, and/or surface IgG. However, other methods known in the art may be employed, such as, e.g., column purification using CD19 magnetic beads or IgG-specific magnetic beads, followed by elution from the column. However, magnetic isolation of B cells utilizing any marker may result in loss of certain B cells. Therefore, in certain embodiments, the isolated cells are not sorted but, instead, phicol- purified mononuclear cells isolated from tumor are directly plated to the appropriate or desired number of specificities per well.

[449] In order to identify B cells that produce an infectious agent-specific antibody, the B cells are typically plated at low density (e.g., a single cell specificity per well, 1-10 cells per well, 10-100 cells per well, 1-100 cells per well, less than 10 cells per well, or less than 100 cells per well) in multi-well or microliter plates, e.g., in 96, 384, or 1536 well configurations. When the B cells are initially plated at a density greater than one cell per well, then the methods of the present invention may include the step of subsequently diluting cells in a well identified as producing an antigen-specific antibody, until a single cell specificity per well is achieved, thereby facilitating the identification of the B cell that produces the antigen-specific antibody. Cell supernatants or a portion thereof and/or cells may be frozen and stored for future testing and later recovery of antibody polynucleotides.

[450] In certain embodiments, the B cells are cultured under conditions that favor the production of antibodies by the B cells. For example, the B cells may be cultured under conditions favorable for B cell proliferation and differentiation to yield antibody-producing plasmablast, plasmacytes, or plasma cells. In particular embodiments, the B cells are cultured in the presence of a B cell mitogen, such as lipopolysaccharide (LPS) or CD40 ligand. In one specific embodiment, B cells are differentiated to antibody-producing cells by culturing them with feed cells and/or other B cell activators, such as CD40 ligand. [451] Cell culture supernatants or antibodies obtained therefrom may be tested for their ability to bind to a target antigen, using routine methods available in the art, including those described herein. In particular embodiments, culture supernatants are tested for the presence of antibodies that bind to a target antigen using high- throughput methods. For example, B cells may be cultured in multi-well microtiter dishes, such that robotic plate handlers may be used to simultaneously sample multiple cell supernatants and test for the presence of antibodies that bind to a target antigen. In particular embodiments, antigens are bound to beads, e.g., paramagnetic or latex beads) to facilitate the capture of antibody /antigen complexes. In other embodiments, antigens and antibodies are fluorescently labeled (with different labels) and FACS analysis is performed to identify the presence of antibodies that bind to target antigen. In one embodiment, antibody binding is determined using FMAT™ analysis and instrumentation (Applied Biosystems, Foster City, CA). FMAT™ is a fluorescence macro-confocal platform for high-throughput screening, which mix-and-read, non-radioactive assays using live cells or beads.

[452] In the context of comparing the binding of an antibody to a particular target antigen (e.g., a biological sample such as infected tissue or cells, or infectious agents) as compared to a control sample (e.g., a biological sample such as uninfected cells, or a different infectious agent), in various embodiments, the antibody is considered to preferentially bind a particular target antigen if at least two-fold, at least three-fold, at least five-fold, or at least ten-fold more antibody binds to the particular target antigen as compared to the amount that binds a control sample.

[453] Polynucleotides encoding antibody chains, variable regions thereof, or fragments thereof, may be isolated from cells utilizing any means available in the art. In one embodiment, polynucleotides are isolated using polymerase chain reaction (PCR), e.g. , reverse transcription-PCR (RT-PCR) using oligonucleotide primers that specifically bind to heavy or light chain encoding polynucleotide sequences or complements thereof using routine procedures available in the art. In one embodiment, positive wells are subjected to whole well RT-PCR to amplify the heavy and light chain variable regions of the IgG molecule expressed by the clonal daughter plasma cells. These PCR products may be sequenced. [454] The resulting PCR products encoding the heavy and light chain variable regions or portions thereof are then subcloned into human antibody expression vectors and recombinantly expressed according to routine procedures in the art (see, e.g., US Patent No. 7,112,439). The nucleic acid molecules encoding a tumor-specific antibody or fragment thereof, as described herein, may be propagated and expressed according to any of a variety of well-known procedures for nucleic acid excision, ligation, transformation, and transfection. Thus, in certain embodiments expression of an antibody fragment may be preferred in a prokaryotic host cell, such as Escherichia coli (see, e.g., Pluckthun et al., Methods Enzymol. 178:497-515 (1989)). In certain other embodiments, expression of the antibody or an antigen-binding fragment thereof may be preferred in a eukaryotic host cell, including yeast (e.g. , Saccharomyces cerevisiae, Schizosaccharomyces pombe, and Pichia pastoris); animal cells (including mammalian cells); or plant cells. Examples of suitable animal cells include, but are not limited to, myeloma, COS, CHO, or hybridoma cells. Examples of plant cells include tobacco, corn, soybean, and rice cells. By methods known to those having ordinary skill in the art and based on the present disclosure, a nucleic acid vector may be designed for expressing foreign sequences in a particular host system, and then polynucleotide sequences encoding the tumor-specific antibody (or fragment thereof) may be inserted. The regulatory elements will vary according to the particular host. [455] One or more replicable expression vectors containing a polynucleotide encoding a variable and/or constant region may be prepared and used to transform an appropriate cell line, for example, a non-producing myeloma cell line, such as a mouse NSO line or a bacterium, such as E.coli, in which production of the antibody will occur. In order to obtain efficient transcription and translation, the polynucleotide sequence in each vector should include appropriate regulatory sequences, particularly a promoter and leader sequence operatively linked to the variable region sequence. Particular methods for producing antibodies in this way are generally well known and routinely used. For example, molecular biology procedures are described by Sambrook et al. (Molecular Cloning, A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory, New York, 1989; see also Sambrook et al., 3rd ed., Cold Spring Harbor Laboratory, New York, (2001)). While not required, in certain embodiments, regions of polynucleotides encoding the recombinant antibodies may be sequenced. DNA sequencing can be performed as described in Sanger et al. (Proc. Natl. Acad. Sci. USA 74:5463 (1977)) and the Amersham International pic sequencing handbook and including improvements thereto. [456] In particular embodiments, the resulting recombinant antibodies or fragments thereof are then tested to confirm their original specificity and may be further tested for pan- specificity, e.g., with related infectious agents. In particular embodiments, an antibody identified or produced according to methods described herein is tested for cell killing via antibody dependent cellular cytotoxicity (ADCC) or apoptosis, and/or well as its ability to internalize.

[457] The present invention, in other aspects, provides polynucleotide compositions. In preferred embodiments, these polynucleotides encode a polypeptide of the invention, e.g., a region of a variable chain of an antibody that binds to HIVl . Polynucleotides of the invention are single-stranded (coding or antisense) or double-stranded DNA (genomic, cDNA or synthetic) or RNA molecules. RNA molecules include, but are not limited to, HnRNA molecules, which contain introns and correspond to a DNA molecule in a one-to-one manner, and mRNA molecules, which do not contain introns. Alternatively, or in addition, coding or non-coding sequences are present within a polynucleotide of the present invention. Also alternatively, or in addition, a polynucleotide is linked to other molecules and/or support materials of the invention. Polynucleotides of the invention are used, e.g., in hybridization assays to detect the presence of an HIVl antibody in a biological sample, and in the recombinant production of polypeptides of the invention. Further, the invention includes all polynucleotides that encode any polypeptide of the present invention. [458] In other related embodiments, the invention provides polynucleotide variants having substantial identity to the sequences of 1443_C16, 1456_P20, 1460_G14, 1495_C14 or 1496_C09, for example those comprising at least 70% sequence identity, preferably at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% or higher, sequence identity compared to a polynucleotide sequence of this invention, as determined using the methods described herein, (e.g., BLAST analysis using standard parameters). One skilled in this art will recognize that these values can be appropriately adjusted to determine corresponding identity of proteins encoded by two nucleotide sequences by taking into account codon degeneracy, amino acid similarity, reading frame positioning, and the like.

[459] Typically, polynucleotide variants contain one or more substitutions, additions, deletions and/or insertions, preferably such that the immunogenic binding properties of the polypeptide encoded by the variant polynucleotide is not substantially diminished relative to a polypeptide encoded by a polynucleotide sequence specifically set forth herein. [460] In additional embodiments, the present invention provides polynucleotide fragments comprising various lengths of contiguous stretches of sequence identical to or complementary to one or more of the sequences disclosed herein. For example, polynucleotides are provided by this invention that comprise at least about 10, 15, 20, 30, 40, 50, 75, 100, 150, 200, 300, 400, 500 or 1000 or more contiguous nucleotides of one or more of the sequences disclosed herein as well as all intermediate lengths there between. As used herein, the term "intermediate lengths" is meant to describe any length between the quoted values, such as 16, 17, 18, 19, etc.; 21, 22, 23, etc.; 30, 31, 32, etc.; 50, 51, 52, 53, etc.; 100, 101, 102, 103, etc.; 150, 151, 152, 153, etc.; including all integers through 200-500; 500-1,000, and the like. [461] In another embodiment of the invention, polynucleotide compositions are provided that are capable of hybridizing under moderate to high stringency conditions to a polynucleotide sequence provided herein, or a fragment thereof, or a complementary sequence thereof. Hybridization techniques are well known in the art of molecular biology. For purposes of illustration, suitable moderately stringent conditions for testing the hybridization of a polynucleotide of this invention with other polynucleotides include prewashing in a solution of 5 X SSC, 0.5% SDS, 1.0 mM EDTA (pH 8.0); hybridizing at 50°C-60°C, 5 X SSC, overnight; followed by washing twice at 65°C for 20 minutes with each of 2X, 0.5X and 0.2X SSC containing 0.1% SDS. One skilled in the art will understand that the stringency of hybridization can be readily manipulated, such as by altering the salt content of the hybridization solution and/or the temperature at which the hybridization is performed. For example, in another embodiment, suitable highly stringent hybridization conditions include those described above, with the exception that the temperature of hybridization is increased, e.g., to 60-65⁰C or 65-7O⁰C.

[462] In preferred embodiments, the polypeptide encoded by the polynucleotide variant or fragment has the same binding specificity (i.e., specifically or preferentially binds to the same epitope or HIV strain) as the polypeptide encoded by the native polynucleotide. In certain preferred embodiments, the polynucleotides described above, e.g., polynucleotide variants, fragments and hybridizing sequences, encode polypeptides that have a level of binding activity of at least about 50%, preferably at least about 70%, and more preferably at least about 90% of that for a polypeptide sequence specifically set forth herein. [463] The polynucleotides of the present invention, or fragments thereof, regardless of the length of the coding sequence itself, may be combined with other DNA sequences, such as promoters, polyadenylation signals, additional restriction enzyme sites, multiple cloning sites, other coding segments, and the like, such that their overall length may vary considerably. A nucleic acid fragment of almost any length is employed, with the total length preferably being limited by the ease of preparation and use in the intended recombinant DNA protocol. For example, illustrative polynucleotide segments with total lengths of about 10,000, about 5000, about 3000, about 2,000, about 1,000, about 500, about 200, about 100, about 50 base pairs in length, and the like, (including all intermediate lengths) are included in many implementations of this invention.

[464] It will be appreciated by those of ordinary skill in the art that, as a result of the degeneracy of the genetic code, there are multiple nucleotide sequences that encode a polypeptide as described herein. Some of these polynucleotides bear minimal homology to the nucleotide sequence of any native gene. Nonetheless, polynucleotides that encode a polypeptide of the present invention but which vary due to differences in codon usage are specifically contemplated by the invention. Further, alleles of the genes including the polynucleotide sequences provided herein are within the scope of the invention. Alleles are endogenous genes that are altered as a result of one or more mutations, such as deletions, additions and/or substitutions of nucleotides. The resulting mRNA and protein may, but need not, have an altered structure or function. Alleles may be identified using standard techniques (such as hybridization, amplification and/or database sequence comparison). [465] In certain embodiments of the present invention, mutagenesis of the disclosed polynucleotide sequences is performed in order to alter one or more properties of the encoded polypeptide, such as its binding specificity or binding strength. Techniques for mutagenesis are well-known in the art, and are widely used to create variants of both polypeptides and polynucleotides. A mutagenesis approach, such as site-specific mutagenesis, is employed for the preparation of variants and/or derivatives of the polypeptides described herein. By this approach, specific modifications in a polypeptide sequence are made through mutagenesis of the underlying polynucleotides that encode them. These techniques provides a straightforward approach to prepare and test sequence variants, for example, incorporating one or more of the foregoing considerations, by introducing one or more nucleotide sequence changes into the polynucleotide.

[466] Site-specific mutagenesis allows the production of mutants through the use of specific oligonucleotide sequences include the nucleotide sequence of the desired mutation, as well as a sufficient number of adjacent nucleotides, to provide a primer sequence of sufficient size and sequence complexity to form a stable duplex on both sides of the deletion junction being traversed. Mutations are employed in a selected polynucleotide sequence to improve, alter, decrease, modify, or otherwise change the properties of the polynucleotide itself, and/or alter the properties, activity, composition, stability, or primary sequence of the encoded polypeptide.

[467] In other embodiments of the present invention, the polynucleotide sequences provided herein are used as probes or primers for nucleic acid hybridization, e.g., as PCR primers. The ability of such nucleic acid probes to specifically hybridize to a sequence of interest enables them to detect the presence of complementary sequences in a given sample. However, other uses are also encompassed by the invention, such as the use of the sequence information for the preparation of mutant species primers, or primers for use in preparing other genetic constructions. As such, nucleic acid segments of the invention that include a sequence region of at least about a 15-nucleotide long contiguous sequence that has the same sequence as, or is complementary to, a 15 nucleotide long contiguous sequence disclosed herein is particularly useful. Longer contiguous identical or complementary sequences, e.g., those of about 20, 30, 40, 50, 100, 200, 500, 1000 (including all intermediate lengths) including full length sequences, and all lengths in between, are also used in certain embodiments. [468] Polynucleotide molecules having sequence regions consisting of contiguous nucleotide stretches of 10-14, 15-20, 30, 50, or even of 100-200 nucleotides or so (including intermediate lengths as well), identical or complementary to a polynucleotide sequence disclosed herein, are particularly contemplated as hybridization probes for use in, e.g., Southern and Northern blotting, and/or primers for use in, e.g. , polymerase chain reaction (PCR). The total size of fragment, as well as the size of the complementary stretch (es), ultimately depends on the intended use or application of the particular nucleic acid segment. Smaller fragments are generally used in hybridization embodiments, wherein the length of the contiguous complementary region may be varied, such as between about 15 and about 100 nucleotides, but larger contiguous complementarity stretches may be used, according to the length complementary sequences one wishes to detect.

[469] The use of a hybridization probe of about 15-25 nucleotides in length allows the formation of a duplex molecule that is both stable and selective. Molecules having contiguous complementary sequences over stretches greater than 12 bases in length are generally preferred, though, in order to increase stability and selectivity of the hybrid, and thereby improve the quality and degree of specific hybrid molecules obtained. Nucleic acid molecules having gene-complementary stretches of 15 to 25 contiguous nucleotides, or even longer where desired, are generally preferred.

[470] Hybridization probes are selected from any portion of any of the sequences disclosed herein. All that is required is to review the sequences set forth herein, or to any continuous portion of the sequences, from about 15-25 nucleotides in length up to and including the full length sequence, that one wishes to utilize as a probe or primer. The choice of probe and primer sequences is governed by various factors. For example, one may wish to employ primers from towards the termini of the total sequence.

[471] Polynucleotide of the present invention, or fragments or variants thereof, are readily prepared by, for example, directly synthesizing the fragment by chemical means, as is commonly practiced using an automated oligonucleotide synthesizer. Also, fragments are obtained by application of nucleic acid reproduction technology, such as the PCR™ technology of U. S. Patent 4,683,202, by introducing selected sequences into recombinant vectors for recombinant production, and by other recombinant DNA techniques generally known to those of skill in the art of molecular biology.

[472] The invention provides vectors and host cells comprising a nucleic acid of the present invention, as well as recombinant techniques for the production of a polypeptide of the present invention. Vectors of the invention include those capable of replication in any type of cell or organism, including, e.g., plasmids, phage, cosmids, and mini chromosomes. In various embodiments, vectors comprising a polynucleotide of the present invention are vectors suitable for propagation or replication of the polynucleotide, or vectors suitable for expressing a polypeptide of the present invention. Such vectors are known in the art and commercially available.

[473] Polynucleotides of the present invention are synthesized, whole or in parts that are then combined, and inserted into a vector using routine molecular and cell biology techniques, including, e.g., subcloning the polynucleotide into a linearized vector using appropriate restriction sites and restriction enzymes. Polynucleotides of the present invention are amplified by polymerase chain reaction using oligonucleotide primers complementary to each strand of the polynucleotide. These primers also include restriction enzyme cleavage sites to facilitate subcloning into a vector. The replicable vector components generally include, but are not limited to, one or more of the following: a signal sequence, an origin of replication, and one or more marker or selectable genes. [474] In order to express a polypeptide of the present invention, the nucleotide sequences encoding the polypeptide, or functional equivalents, are inserted into an appropriate expression vector, i.e., a vector that contains the necessary elements for the transcription and translation of the inserted coding sequence. Methods well known to those skilled in the art are used to construct expression vectors containing sequences encoding a polypeptide of interest and appropriate transcriptional and translational control elements. These methods include in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. Such techniques are described, for example, in Sambrook, J., et al. (1989) Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, Plainview, N.Y., and Ausubel, F. M. et al. (1989) Current Protocols in Molecular Biology, John Wiley & Sons, New York. N. Y. [475] A variety of expression vector/host systems are utilized to contain and express polynucleotide sequences. These include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with virus expression vectors (e.g., baculovirus); plant cell systems transformed with virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or with bacterial expression vectors (e.g., Ti or pBR322 plasmids); or animal cell systems. [476] Within one embodiment, the variable regions of a gene expressing a monoclonal antibody of interest are amplified from a hybridoma cell using nucleotide primers. These primers are synthesized by one of ordinary skill in the art, or may be purchased from commercially available sources (see, e.g., Stratagene (La Jolla, California), which sells primers for amplifying mouse and human variable regions. The primers are used to amplify heavy or light chain variable regions, which are then inserted into vectors such as ImmunoZAP™ H or ImmunoZAP™ L (Stratagene), respectively. These vectors are then introduced into E. coli, yeast, or mammalian-based systems for expression. Large amounts of a single-chain protein containing a fusion of the V_H and V_L domains are produced using these methods (see Bird et al, Science l^lAli-Alβ (1988)).

[477] The "control elements" or "regulatory sequences" present in an expression vector are those non-translated regions of the vector, e.g., enhancers, promoters, 5' and 3' untranslated regions, that interact with host cellular proteins to carry out transcription and translation. Such elements may vary in their strength and specificity. Depending on the vector system and host utilized, any number of suitable transcription and translation elements, including constitutive and inducible promoters, are used. [478] Examples of promoters suitable for use with prokaryotic hosts include the phoa promoter, β-lactamase and lactose promoter systems, alkaline phosphatase promoter, a tryptophan (trp) promoter system, and hybrid promoters such as the tac promoter. However, other known bacterial promoters are suitable. Promoters for use in bacterial systems also usually contain a Shine-Dalgarno sequence operably linked to the DNA encoding the polypeptide. Inducible promoters such as the hybrid lacZ promoter of the PBLUESCRIPT phagemid (Stratagene, La Jolla, Calif.) or PSPORTl plasmid (Gibco BRL, Gaithersburg, MD) and the like are used.

[479] A variety of promoter sequences are known for eukaryotes and any are used according to the present invention. Virtually all eukaryotic genes have an AT-rich region located approximately 25 to 30 bases upstream from the site where transcription is initiated. Another sequence found 70 to 80 bases upstream from the start of transcription of many genes is a CNCAAT region where N may be any nucleotide. At the 3' end of most eukaryotic genes is an AATAAA sequence that may be the signal for addition of the poly A tail to the 3' end of the coding sequence. All of these sequences are suitably inserted into eukaryotic expression vectors.

[480] In mammalian cell systems, promoters from mammalian genes or from mammalian viruses are generally preferred. Polypeptide expression from vectors in mammalian host cells are controlled, for example, by promoters obtained from the genomes of viruses such as polyoma virus, fowlpox virus, adenovirus (e.g., Adenovirus 2), bovine papilloma virus, avian sarcoma virus, cytomegalovirus (CMV), a retrovirus, hepatitis-B virus and most preferably Simian Virus 40 (SV40), from heterologous mammalian promoters, e.g., the actin promoter or an immunoglobulin promoter, and from heat-shock promoters, provided such promoters are compatible with the host cell systems. If it is necessary to generate a cell line that contains multiple copies of the sequence encoding a polypeptide, vectors based on SV40 or EBV may be advantageously used with an appropriate selectable marker. One example of a suitable expression vector is pcDNA-3.1 (Invitrogen, Carlsbad, CA), which includes a CMV promoter.

[481] A number of viral-based expression systems are available for mammalian expression of polypeptides. For example, in cases where an adenovirus is used as an expression vector, sequences encoding a polypeptide of interest may be ligated into an adenovirus transcription/translation complex consisting of the late promoter and tripartite leader sequence. Insertion in a non-essential El or E3 region of the viral genome may be used to obtain a viable virus that is capable of expressing the polypeptide in infected host cells (Logan, J. and Shenk, T. (1984) Proc. Natl. Acad. Sci. 81 :3655-3659). In addition, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, may be used to increase expression in mammalian host cells.

[482] In bacterial systems, any of a number of expression vectors are selected depending upon the use intended for the expressed polypeptide. For example, when large quantities are desired, vectors that direct high level expression of fusion proteins that are readily purified are used. Such vectors include, but are not limited to, the multifunctional E. coli cloning and expression vectors such as BLUESCRIPT (Stratagene), in which the sequence encoding the polypeptide of interest may be ligated into the vector in frame with sequences for the amino- terminal Met and the subsequent 7 residues of β-galactosidase, so that a hybrid protein is produced; pIN vectors (Van Heeke, G. and S. M. Schuster (1989) J. Biol. Chem. 264:5503- 5509); and the like. pGEX Vectors (Promega, Madison, WI) are also used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption to glutathione- agarose beads followed by elution in the presence of free glutathione. Proteins made in such systems are designed to include heparin, thrombin, or factor XA protease cleavage sites so that the cloned polypeptide of interest can be released from the GST moiety at will. [483] In the yeast, Saccharomyces cerevisiae, a number of vectors containing constitutive or inducible promoters such as alpha factor, alcohol oxidase, and PGH are used. Examples of other suitable promoter sequences for use with yeast hosts include the promoters for 3- phosphoglycerate kinase or other glycolytic enzymes, such as enolase, glyceraldehyde-3- phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose-6-phosphate isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phosphoglucose isomerase, and glucokinase. For reviews, see Ausubel et al. (supra) and Grant et al. (1987) Methods Enzymol. 153:516-544. Other yeast promoters that are inducible promoters having the additional advantage of transcription controlled by growth conditions include the promoter regions for alcohol dehydrogenase 2, isocytochrome C, acid phosphatase, degradative enzymes associated with nitrogen metabolism, metallothionein, glyceraldehyde-3-phosphate dehydrogenase, and enzymes responsible for maltose and galactose utilization. Suitable vectors and promoters for use in yeast expression are further described in EP 73,657. Yeast enhancers also are advantageously used with yeast promoters. [484] In cases where plant expression vectors are used, the expression of sequences encoding polypeptides are driven by any of a number of promoters. For example, viral promoters such as the 35S and 19S promoters of CaMV are used alone or in combination with the omega leader sequence from TMV (Takamatsu, N. (1987) EMBOJ. 6:307-311. Alternatively, plant promoters such as the small subunit of RUBISCO or heat shock promoters are used (Coruzzi, G. et al. (1984) EMBO J. 5:1671-1680; Broglie, R. et al. (1984) Science 224:838-843; and Winter, J., et al. (1991) Results Probl. Cell Differ. 77:85-105). These constructs can be introduced into plant cells by direct DNA transformation or pathogen-mediated transfection. Such techniques are described in a number of generally available reviews {see, e.g., Hobbs, S. or Murry, L. E. in McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill, New York, N.Y.; pp. 191-196). [485] An insect system is also used to express a polypeptide of interest. For example, in one such system, Autographa californica nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes in Spodoptera frugiperda cells or in Trichopliisia larvae. The sequences encoding the polypeptide are cloned into a non-essential region of the virus, such as the polyhedrin gene, and placed under control of the polyhedrin promoter. Successful insertion of the polypeptide-encoding sequence renders the polyhedrin gene inactive and produce recombinant virus lacking coat protein. The recombinant viruses are then used to infect, for example, S. frugiperda cells or Trichoplusia larvae, in which the polypeptide of interest is expressed (Engelhard, E. K. et al. (1994) Proc. Natl. Acad. Sci. 91 :3224-3227). [486] Specific initiation signals are also used to achieve more efficient translation of sequences encoding a polypeptide of interest. Such signals include the ATG initiation codon and adjacent sequences. In cases where sequences encoding the polypeptide, its initiation codon, and upstream sequences are inserted into the appropriate expression vector, no additional transcriptional or translational control signals may be needed. However, in cases where only coding sequence, or a portion thereof, is inserted, exogenous translational control signals including the ATG initiation codon are provided. Furthermore, the initiation codon is in the correct reading frame to ensure correct translation of the inserted polynucleotide. Exogenous translational elements and initiation codons are of various origins, both natural and synthetic.

[487] Transcription of a DNA encoding a polypeptide of the invention is often increased by inserting an enhancer sequence into the vector. Many enhancer sequences are known, including, e.g., those identified in genes encoding globin, elastase, albumin, α-fetoprotein, and insulin. Typically, however, an enhancer from a eukaryotic cell virus is used. Examples include the SV40 enhancer on the late side of the replication origin (bp 100-270), the cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers. See also Yaniv, Nature 297:17-18 (1982) on enhancing elements for activation of eukaryotic promoters. The enhancer is spliced into the vector at a position 5' or 3' to the polypeptide-encoding sequence, but is preferably located at a site 5' from the promoter.

[488] Expression vectors used in eukaryotic host cells (yeast, fungi, insect, plant, animal, human, or nucleated cells from other multicellular organisms) typically also contain sequences necessary for the termination of transcription and for stabilizing the mRNA. Such sequences are commonly available from the 5' and, occasionally 3', untranslated regions of eukaryotic or viral DNAs or cDNAs. These regions contain nucleotide segments transcribed as polyadenylated fragments in the untranslated portion of the mRNA encoding anti-PSCA antibody. One useful transcription termination component is the bovine growth hormone polyadenylation region. See WO94/11026 and the expression vector disclosed therein. [489] Suitable host cells for cloning or expressing the DNA in the vectors herein are the prokaryote, yeast, plant or higher eukaryote cells described above. Examples of suitable prokaryotes for this purpose include eubacteria, such as Gram-negative or Gram-positive organisms, for example, Enterobacteriaceae such as Escherichia, e.g., E. coli, Enterobacter, Erwinia, Klebsiella, Proteus, Salmonella, e.g., Salmonella typhimurium, Serratia, e.g., Serratia marcescans, and Shigella, as well as Bacilli such as B. subtilis and B. licheniformis (e.g., B. licheniformis 41P disclosed in DD 266,710 published 12 Apr. 1989), Pseudomonas such as P. aeruginosa, and Streptomyces. One preferred E. coli cloning host is E. coli 294 (ATCC 31,446), although other strains such as E. coli B, E. coli Xl 776 (ATCC 31,537), and E. coli W3110 (ATCC 27,325) are suitable. These examples are illustrative rather than limiting.

[490] Saccharomyces cerevisiae, or common baker's yeast, is the most commonly used among lower eukaryotic host microorganisms. However, a number of other genera, species, and strains are commonly available and used herein, such as Schizosaccharomyces pombe; Kluyveromyces hosts such as, e.g., K lactis, K.fragilis (ATCC 12,424), K. bulgaricus (ATCC 16,045), Kwickeramii (ATCC 24,178), K. waltii (ATCC 56,500), K. drosophilarum (ATCC 36,906), K. thermotolerans, and K. marxianus; yarrowia (EP 402,226); Pichia pastoris. (EP 183,070); Candida; Trichoderma reesia (EP 244,234); Neurospora crassa; Schwanniomyces such as Schwanniomyces occidentalis; and filamentous fungi such as, e.g., Neurospora, Penicillium, Tolypocladium, and Aspergillus hosts such as A. nidulans and A. niger. [491] In certain embodiments, a host cell strain is chosen for its ability to modulate the expression of the inserted sequences or to process the expressed protein in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation. glycosylation, phosphorylation, lipidation, and acylation. Post-translational processing that cleaves a "prepro" form of the protein is also used to facilitate correct insertion, folding and/or function. Different host cells such as CHO, COS, HeLa, MDCK, HEK293, and WD 8, which have specific cellular machinery and characteristic mechanisms for such post-translational activities, are chosen to ensure the correct modification and processing of the foreign protein.

[492] Methods and reagents specifically adapted for the expression of antibodies or fragments thereof are also known and available in the art, including those described, e.g., in U.S. Patent Nos. 4816567 and 6331415. In various embodiments, antibody heavy and light chains, or fragments thereof, are expressed from the same or separate expression vectors. In one embodiment, both chains are expressed in the same cell, thereby facilitating the formation of a functional antibody or fragment thereof.

[493] Full length antibody, antibody fragments, and antibody fusion proteins are produced in bacteria, in particular when glycosylation and Fc effector function are not needed, such as when the therapeutic antibody is conjugated to a cytotoxic agent (e.g., a toxin) and the immunoconjugate by itself shows effectiveness in infected cell destruction. For expression of antibody fragments and polypeptides in bacteria, see, e.g., U.S. Pat. Nos. 5,648,237, 5,789,199 , and 5,840,523, which describes translation initiation region (TIR) and signal sequences for optimizing expression and secretion. After expression, the antibody is isolated from the E. coli cell paste in a soluble fraction and can be purified through, e.g., a protein A or G column depending on the isotype. Final purification can be carried out using a process similar to that used for purifying antibody expressed e.g., in CHO cells. [494] Suitable host cells for the expression of glycosylated polypeptides and antibodies are derived from multicellular organisms. Examples of invertebrate cells include plant and insect cells. Numerous baculoviral strains and variants and corresponding permissive insect host cells from hosts such as Spodoptera frugiperda (caterpillar), Aedes aegypti (mosquito), Aedes albopicius (mosquito), Drosophila melanogaster (fruitfly), and Bombyx mori have been identified. A variety of viral strains for transfection are publicly available, e.g., the L-I variant of Autographa californica NPV and the Bm-5 strain oϊBombyx mori NPV, and such viruses are used as the virus herein according to the present invention, particularly for transfection of Spodoptera frugiperda cells. Plant cell cultures of cotton, corn, potato, soybean, petunia, tomato, and tobacco are also utilized as hosts.

[495] Methods of propagation of antibody polypeptides and fragments thereof in vertebrate cells in culture (tissue culture) are encompassed by the invention. Examples of mammalian host cell lines used in the methods of the invention are monkey kidney CVl line transformed by SV40 (COS-7, ATCC CRL 1651); human embryonic kidney line (293 or 293 cells subcloned for growth in suspension culture, Graham et al, J. Gen Virol. 36:59 (1977)); baby hamster kidney cells (BHK, ATCC CCL 10); Chinese hamster ovary cells/-DHFR (CHO, Urlaub et al, Proc. Natl. Acad. Sci. USA 77:4216 (1980)); mouse Sertoli cells (TM4, Mather, Biol. Reprod. 23:243-251 (1980)); monkey kidney cells (CVl ATCC CCL 70); African green monkey kidney cells (VERO-76, ATCC CRL-1587); human cervical carcinoma cells (HELA, ATCC CCL 2); canine kidney cells (MDCK, ATCC CCL 34); buffalo rat liver cells (BRL 3A, ATCC CRL 1442); human lung cells (W138, ATCC CCL 75); human liver cells (Hep G2, HB 8065); mouse mammary tumor (MMT 060562, ATCC CCL51); TRl cells (Mather et al, Annals N.Y. Acad. Sci. 383:44-68 (1982)); MRC 5 cells; FS4 cells; and a human hepatoma line (Hep G2).

[496] Host cells are transformed with the above-described expression or cloning vectors for polypeptide production and cultured in conventional nutrient media modified as appropriate for inducing promoters, selecting transformants, or amplifying the genes encoding the desired sequences.

[497] For long-term, high-yield production of recombinant proteins, stable expression is generally preferred. For example, cell lines that stably express a polynucleotide of interest are transformed using expression vectors that contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Following the introduction of the vector, cells are allowed to grow for 1-2 days in an enriched media before they are switched to selective media. The purpose of the selectable marker is to confer resistance to selection, and its presence allows growth and recovery of cells that successfully express the introduced sequences. Resistant clones of stably transformed cells are proliferated using tissue culture techniques appropriate to the cell type. [498] A plurality of selection systems are used to recover transformed cell lines. These include, but are not limited to, the herpes simplex virus thymidine kinase (Wigler, M. et al. (1977) Cell 11:223-32) and adenine phosphoribosyltransferase (Lowy, I. et al. (1990) Cell 22:817-23) genes that are employed in tk^' or aprf cells, respectively. Also, antimetabolite, antibiotic or herbicide resistance is used as the basis for selection; for example, dhfr, which confers resistance to methotrexate (Wigler, M. et al. (1980) Proc. Natl. Acad. Sci. 77:3567- 70); npt, which confers resistance to the aminoglycosides, neomycin and G-418 (Colbere- Garapin, F. et <a/.(1981) J. MoI. Biol. 750:1-14); and als or pat, which confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively (Murry, supra). Additional selectable genes have been described. For example, trpB allows cells to utilize indole in place of tryptophan, and hisD allows cells to utilize histinol in place of histidine (Hartman, S. C. and R. C. Mulligan (1988) Proc. Natl. Acad. Sci. §5:8047-51). The use of visible markers has gained popularity with such markers as anthocyanins, beta-glucuronidase and its substrate GUS, and luciferase and its substrate luciferin, being widely used not only to identify transformants, but also to quantify the amount of transient or stable protein expression attributable to a specific vector system (Rhodes, C. A. et al. (1995) Methods MoI. Biol. 55:121-131).

[499] Although the presence/absence of marker gene expression suggests that the gene of interest is also present, its presence and expression is confirmed. For example, if the sequence encoding a polypeptide is inserted within a marker gene sequence, recombinant cells containing sequences are identified by the absence of marker gene function. Alternatively, a marker gene is placed in tandem with a polypeptide-encoding sequence under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the tandem gene as well.

[500] Alternatively, host cells that contain and express a desired polynucleotide sequence are identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations and protein bioassay or immunoassay techniques which include, for example, membrane, solution, or chip based technologies for the detection and/or quantification of nucleic acid or protein. [501] A variety of protocols for detecting and measuring the expression of polynucleotide- encoded products, using either polyclonal or monoclonal antibodies specific for the product are known in the art. Nonlimiting examples include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), and fluorescence activated cell sorting (FACS). A two- site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non- interfering epitopes on a given polypeptide is preferred for some applications, but a competitive binding assay may also be employed. These and other assays are described, among other places, in Hampton, R. et al. (1990; Serological Methods, a Laboratory Manual, APS Press, St Paul. Minn.) and Maddox, D. E. et al. (1983; J. Exp. Med. /55:1211-1216). [502] Various labels and conjugation techniques are known by those skilled in the art and are used in various nucleic acid and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting sequences related to polynucleotides include oligolabeling, nick translation, end-labeling or PCR amplification using a labeled nucleotide. Alternatively, the sequences, or any portions thereof are cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and are used to synthesize RNA probes in vitro by addition of an appropriate RNA polymerase such as T7, T3, or SP6 and labeled nucleotides. These procedures are conducted using a variety of commercially available kits. Suitable reporter molecules or labels, which are used include, but are not limited to, radionucleotides, enzymes, fluorescent, chemiluminescent, or chromogenic agents as well as substrates, cofactors, inhibitors, magnetic particles, and the like.

[503] The polypeptide produced by a recombinant cell is secreted or contained intracellularly depending on the sequence and/or the vector used. Expression vectors containing polynucleotides of the invention are designed to contain signal sequences that direct secretion of the encoded polypeptide through a prokaryotic or eukaryotic cell membrane.

[504] In certain embodiments, a polypeptide of the invention is produced as a fusion polypeptide further including a polypeptide domain that facilitates purification of soluble proteins. Such purification-facilitating domains include, but are not limited to, metal chelating peptides such as histidine-tryptophan modules that allow purification on immobilized metals, protein A domains that allow purification on immobilized immunoglobulin, and the domain utilized in the FLAGS extension/affinity purification system (Amgen, Seattle, WA). The inclusion of cleavable linker sequences such as those specific for Factor XA or enterokinase (Invitrogen. San Diego, CA) between the purification domain and the encoded polypeptide are used to facilitate purification. An exemplary expression vector provides for expression of a fusion protein containing a polypeptide of interest and a nucleic acid encoding 6 histidine residues preceding a thioredoxin or an enterokinase cleavage site. The histidine residues facilitate purification on IMIAC (immobilized metal ion affinity chromatography) as described in Porath, J. et al. (1992, Prot. Exp. Purif. 3:263-281) while the enterokinase cleavage site provides a means for purifying the desired polypeptide from the fusion protein. A discussion of vectors used for producing fusion proteins is provided in Kroll, D. J. et al. (1993; DNA Cell Biol. 72:441-453). [505] In certain embodiments, a polypeptide of the present invention is fused with a heterologous polypeptide, which may be a signal sequence or other polypeptide having a specific cleavage site at the N-terminus of the mature protein or polypeptide. The heterologous signal sequence selected preferably is one that is recognized and processed (i.e., cleaved by a signal peptidase) by the host cell. For prokaryotic host cells, the signal sequence is selected, for example, from the group of the alkaline phosphatase, penicillinase, lpp, or heat-stable enterotoxin II leaders. For yeast secretion, the signal sequence is selected from, e.g., the yeast invertase leader, α factor leader (including Saccharomyces and Kluyveromyces α factor leaders), or acid phosphatase leader, the C. albicans glucoamylase leader, or the signal described in WO 90/13646. In mammalian cell expression, mammalian signal sequences as well as viral secretory leaders, for example, the herpes simplex gD signal, are available.

[506] When using recombinant techniques, the polypeptide or antibody is produced intracellular^, in the periplasmic space, or directly secreted into the medium. If the polypeptide or antibody is produced intracellularly, as a first step, the particulate debris, either host cells or lysed fragments, are removed, for example, by centrifugation or ultrafiltration. Carter et al, Bio/Technology 10:163-167 (1992) describe a procedure for isolating antibodies that are secreted to the periplasmic space of E. coli. Briefly, cell paste is thawed in the presence of sodium acetate (pH 3.5), EDTA, and phenylmethylsulfonylfluoride (PMSF) over about 30 min. Cell debris is removed by centrifugation. Where the polypeptide or antibody is secreted into the medium, supernatants from such expression systems are generally first concentrated using a commercially available protein concentration filter, for example, an Amicon or Millipore Pellicon ultrafiltration unit. Optionally, a protease inhibitor such as PMSF is included in any of the foregoing steps to inhibit proteolysis and antibiotics are included to prevent the growth of adventitious contaminants.

[507] The polypeptide or antibody composition prepared from the cells are purified using, for example, hydroxylapatite chromatography, gel electrophoresis, dialysis, and affinity chromatography, with affinity chromatography being the preferred purification technique. The suitability of protein A as an affinity ligand depends on the species and isotype of any immunoglobulin Fc domain that is present in the polypeptide or antibody. Protein A is used to purify antibodies or fragments thereof that are based on human γi, γ₂, or γ₄ heavy chains (Lindmark et ai, J. Immunol. Meth. 62:1-13 (1983)). Protein G is recommended for all mouse isotypes and for human 73 (Guss et al, EMBO J. 5:15671575 (1986)). The matrix to which the affinity ligand is attached is most often agarose, but other matrices are available. Mechanically stable matrices such as controlled pore glass or poly(styrenedivinyl)benzene allow for faster flow rates and shorter processing times than can be achieved with agarose. Where the polypeptide or antibody comprises a C_H 3 domain, the Bakerbond ABX™ resin (J. T. Baker, Phillipsburg, NJ.) is useful for purification. Other techniques for protein purification such as fractionation on an ion-exchange column, ethanol precipitation, Reverse Phase HPLC, chromatography on silica, chromatography on heparin SEPHAROSE™ chromatography on an anion or cation exchange resin (such as a polyaspartic acid column), chromatofocusing, SDS-PAGE, and ammonium sulfate precipitation are also available depending on the polypeptide or antibody to be recovered. [508] Following any preliminary purification step(s), the mixture comprising the polypeptide or antibody of interest and contaminants are subjected to low pH hydrophobic interaction chromatography using an elution buffer at a pH between about 2.5-4.5, preferably performed at low salt concentrations (e.g., from about 0-0.25M salt). [509] The invention further includes pharmaceutical formulations including a polypeptide, antibody, or modulator of the present invention, at a desired degree of purity, and a pharmaceutically acceptable carrier, excipient, or stabilizer (Remingion's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980)). In certain embodiments, pharmaceutical formulations are prepared to enhance the stability of the polypeptide or antibody during storage, e.g., in the form of lyophilized formulations or aqueous solutions. [510] Acceptable carriers, excipients, or stabilizers are nontoxic to recipients at the dosages and concentrations employed, and include, e.g., buffers such as acetate, Tris, phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride, benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3- pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; tonicifiers such as trehalose and sodium chloride; sugars such as sucrose, mannitol, trehalose or sorbitol; surfactant such as polysorbate; salt-forming counter-ions such as sodium; metal complexes (e.g. Zn-protein complexes); and/or non-ionic surfactants such as TWEEN™, PLURONICS™ or polyethylene glycol (PEG). In certain embodiments, the therapeutic formulation preferably comprises the polypeptide or antibody at a concentration of between 5-200 mg/ml, preferably between 10-100 mg/ml.

[511] The formulations herein also contain one or more additional therapeutic agents suitable for the treatment of the particular indication, e.g., infection being treated, or to prevent undesired side-effects. Preferably, the additional therapeutic agent has an activity complementary to the polypeptide or antibody of the resent invention, and the two do not adversely affect each other. For example, in addition to the polypeptide or antibody of the invention, an additional or second antibody, anti-viral agent, anti-infective agent and/or cardioprotectant is added to the formulation. Such molecules are suitably present in the pharmaceutical formulation in amounts that are effective for the purpose intended. [512] The active ingredients, e.g., polypeptides and antibodies of the invention and other therapeutic agents, are also entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsules and polymethylmethacylate) microcapsules, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules) or in macroemulsions. Such techniques are disclosed in Remingion's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980).

[513] Sustained-release preparations are prepared. Suitable examples of sustained-release preparations include, but are not limited to, semi-permeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, e.g., films, or microcapsules. Nonlimiting examples of sustained-release matrices include polyesters, hydrogels (for example, poly(2-hydroxyethyl-methacrylate), or poly(vinylalcohol)), polylactides (U.S. Pat. No. 3,773,919), copolymers of L-glutamic acid and γ ethyl-L-glutamate, non-degradable ethylene-vinyl acetate, degradable lactic acid- glycolic acid copolymers such as the LUPRON DEPOT™ (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-D-(-)-3- hydroxyburyric acid. [514] Formulations to be used for in vivo administration are preferably sterile. This is readily accomplished by filtration through sterile filtration membranes. [515] Antibodies of the invention can be coupled to a drug for delivery to a treatment site or coupled to a detectable label to facilitate imaging of a site comprising cells of interest, such as cells infected with HTV. Methods for coupling antibodies to drugs and detectable labels are well known in the art, as are methods for imaging using detectable labels. Labeled antibodies may be employed in a wide variety of assays, employing a wide variety of labels. Detection of the formation of an antibody-antigen complex between an antibody of the invention and an epitope of interest (an HIV epitope) can be facilitated by attaching a detectable substance to the antibody. Suitable detection means include the use of labels such as radionucleotides, enzymes, coenzymes, fluorescers, chemiluminescers, chromogens, enzyme substrates or co- factors, enzyme inhibitors, prosthetic group complexes, free radicals, particles, dyes, and the like. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, β- galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material is luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin; and examples of suitable radioactive material include ¹²⁵1, ¹³¹I, . ³⁵S, or ³H. Such labeled reagents may be used in a variety of well-known assays, such as radioimmunoassays, enzyme immunoassays, e.g., ELISA, fluorescent immunoassays, and the like.

[516] The antibodies are tagged with such labels by known methods. For instance, coupling agents such as aldehydes, carbodiimides, dimaleimide, imidates, succinimides, bid-diazotized benzadine and the like are used to tag the antibodies with the above-described fluorescent, chemiluminescent, and enzyme labels. An enzyme is typically combined with an antibody using bridging molecules such as carbodiimides, periodate, diisocyanates, glutaraldehyde and the like. Various labeling techniques are described in Morrison, Methods in Enzymology 32b, 103 (1974), Syvanen et al, J. Biol. Chem. 284, 3762 (1973) and Bolton and Hunter, Biochem J. 133, 529(1973).

[517] An antibody according to the invention may be conjugated to a therapeutic moiety such as a cytotoxin, a therapeutic agent, or a radioactive metal ion or radioisotope. Examples of radioisotopes include, but are not limited to, 1-131, 1-123, 1-125, Y-90, Re-188, Re-186, At-21 1, Cu-67, Bi-212, Bi-213, Pd- 109, Tc-99, In-111, and the like. Such antibody conjugates can be used for modifying a given biological response; the drug moiety is not to be construed as limited to classical chemical therapeutic agents. For example, the drug moiety may be a protein or polypeptide possessing a desired biological activity. Such proteins may include, for example, a toxin such as abrin, ricin A, pseudomonas exotoxin, or diphtheria toxin.

[518] Techniques for conjugating such therapeutic moiety to antibodies are well known. See, for example, Arnon et al. (1985) "Monoclonal Antibodies for Immunotargeting of Drugs in Cancer Therapy," in Monoclonal Antibodies and Cancer Therapy, ed. Reisfeld et al. (Alan R. Liss, Inc.), pp. 243-256; ed. Hellstrom et al. (1987) "Antibodies for Drug Delivery," in Controlled Drug Delivery, ed. Robinson et al. (2d ed; Marcel Dekker, Inc.), pp. 623-653; Thorpe (1985) "Antibody Carriers of Cytotoxic Agents in Cancer Therapy: A Review," in Monoclonal Antibodies '84: Biological and Clinical Applications, ed. Pinchera et al. pp. 475- 506 (Editrice Kurtis, Milano, Italy, 1985); "Analysis, Results, and Future Prospective of the Therapeutic Use of Radiolabeled Antibody in Cancer Therapy," in Monoclonal Antibodies for Cancer Detection and Therapy, ed. Baldwin et al. (Academic Press, New York, 1985), pp. 303-316; and Thorpe et al. (1982) Immunol. Rev. 62:119-158.

[519] Diagnostic methods generally involve contacting a biological sample obtained from a patient, such as, e.g., blood, serum, saliva, urine, sputum, a cell swab sample, or a tissue biopsy, with an HIVl antibody and determining whether the antibody preferentially binds to the sample as compared to a control sample or predetermined cut-off value, thereby indicating the presence of infected cells. In particular embodiments, at least two-fold, threefold, or five-fold more HIVl antibody binds to an infected cell as compared to an appropriate control normal cell or tissue sample. A pre-determined cut-off value is determined, e.g., by averaging the amount of HIVl antibody that binds to several different appropriate control samples under the same conditions used to perform the diagnostic assay of the biological sample being tested.

[520] Bound antibody is detected using procedures described herein and known in the art. In certain embodiments, diagnostic methods of the invention are practiced using HIVl antibodies that are conjugated to a detectable label, e.g., a fluorophore, to facilitate detection of bound antibody. However, they are also practiced using methods of secondary detection of the HIVl antibody. These include, for example, RIA, ELISA, precipitation, agglutination, complement fixation and immuno-fiuorescence. [521] HIVl antibodies of the present invention are capable of differentiating between patients with and patients without an HTV infection, and determining whether or not a patient has an infection, using the representative assays provided herein. According to one method, a biological sample is obtained from a patient suspected of having or known to have HIVl infection. In preferred embodiments, the biological sample includes cells from the patient. The sample is contacted with an HIVl antibody, e.g., for a time and under conditions sufficient to allow the HIVl antibody to bind to infected cells present in the sample. For instance, the sample is contacted with an HIVl antibody for 10 seconds, 30 seconds, 1 minute, 5 minutes, 10 minutes, 30 minutes, 1 hour, 6 hours, 12 hours, 24 hours, 3 days or any point in between. The amount of bound HIVl antibody is determined and compared to a control value, which may be, e.g., a pre-determined value or a value determined from normal tissue sample. An increased amount of antibody bound to the patient sample as compared to the control sample is indicative of the presence of infected cells in the patient sample. [522] In a related method, a biological sample obtained from a patient is contacted with an HIVl antibody for a time and under conditions sufficient to allow the antibody to bind to infected cells. Bound antibody is then detected, and the presence of bound antibody indicates that the sample contains infected cells. This embodiment is particularly useful when the HIVl antibody does not bind normal cells at a detectable level.

[523] Different HIVl antibodies possess different binding and specificity characteristics. Depending upon these characteristics, particular HTVl antibodies are used to detect the presence of one or more strains of HTVl. For example, certain antibodies bind specifically to only one or several strains of HIVl, whereas others bind to all or a majority of different strains of HIVl. Antibodies specific for only one strain of HIVl are used to identify the strain of an infection.

[524] In certain embodiments, antibodies that bind to an infected cell preferably generate a signal indicating the presence of an infection in at least about 20% of patients with the infection being detected, more preferably at least about 30% of patients. Alternatively, or in addition, the antibody generates a negative signal indicating the absence of the infection in at least about 90% of individuals without the infection being detected. Each antibody satisfies the above criteria; however, antibodies of the present invention are used in combination to improve sensitivity.

[525] The present invention also includes kits useful in performing diagnostic and prognostic assays using the antibodies of the present invention. Kits of the invention include a suitable container comprising an HTVl antibody of the invention in either labeled or unlabeled form. In addition, when the antibody is supplied in a labeled form suitable for an indirect binding assay, the kit further includes reagents for performing the appropriate indirect assay. For example, the kit includes one or more suitable containers including enzyme substrates or derivatizing agents, depending on the nature of the label. Control samples and/or instructions are also included.

[526] Passive immunization has proven to be an effective and safe strategy for the prevention and treatment of viral diseases. {See Keller et al., Clin. Microbiol. Rev. 13:602-14 (2000); Casadevall, Nat. Biotechnol. 20:114 (2002); Shibata et al., Nat. Med. 5:204-10 (1999); and Igarashi et al., Nat. Med. 5:211-16 (1999), each of which are incorporated herein by reference)). Passive immunization using human monoclonal antibodies, provide an immediate treatment strategy for emergency prophylaxis and treatment of HIVl . [527] HTVl antibodies and fragments thereof, and therapeutic compositions, of the invention specifically bind or preferentially bind to infected cells, as compared to normal control uninfected cells and tissue. Thus, these HIVl antibodies are used to selectively target infected cells or tissues in a patient, biological sample, or cell population. In light of the infection-specific binding properties of these antibodies, the present invention provides methods of regulating (e.g., inhibiting) the growth of infected cells, methods of killing infected cells, and methods of inducing apoptosis of infected cells. These methods include contacting an infected cell with an HIVl antibody of the invention. These methods are practiced in vitro, ex vivo, and in vivo.

[528] In various embodiments, antibodies of the invention are intrinsically therapeutically active. Alternatively, or in addition, antibodies of the invention are conjugated to a cytotoxic agent or growth inhibitory agent, e.g., a radioisotope or toxin that is used in treating infected cells bound or contacted by the antibody.

[529] Subjects at risk for HIVl -related diseases or disorders include patients who have come into contact with an infected person or who have been exposed to HIVl in some other way. Administration of a prophylactic agent can occur prior to the manifestation of symptoms characteristic of HIVl -related disease or disorder, such that a disease or disorder is prevented or, alternatively, delayed in its progression.

[530] Methods for preventing an increase in HIVl virus titer, virus replication, virus proliferation or an amount of an HIVl viral protein in a subject are further provided. In one embodiment, a method includes administering to the subject an amount of an HIVl antibody effective to prevent an increase in HIVl titer, virus replication or an amount of an HIVl protein of one or more HIV strains or isolates in the subject.

[531] For in vivo treatment of human and non-human patients, the patient is usually administered or provided a pharmaceutical formulation including an HTVl antibody of the invention. When used for in vivo therapy, the antibodies of the invention are administered to the patient in therapeutically effective amounts (i.e., amounts that eliminate or reduce the patient's viral burden). The antibodies are administered to a human patient, in accord with known methods, such as intravenous administration, e.g., as a bolus or by continuous infusion over a period of time, by intramuscular, intraperitoneal, intracerobrospinal, subcutaneous, intra-articular, intrasynovial, intrathecal, oral, topical, or inhalation routes. The antibodies may be administered parenterally, when possible, at the target cell site, or intravenously. Intravenous or subcutaneous administration of the antibody is preferred in certain embodiments. Therapeutic compositions of the invention are administered to a patient or subject systemically, parenterally, or locally.

[532] For parenteral administration, the antibodies are formulated in a unit dosage injectable form (solution, suspension, emulsion) in association with a pharmaceutically acceptable, parenteral vehicle. Examples of such vehicles are water, saline, Ringer's solution, dextrose solution, and 5% human serum albumin. Nonaqueous vehicles such as fixed oils and ethyl oleate are also used. Liposomes are used as carriers. The vehicle contains minor amounts of additives such as substances that enhance isotonicity and chemical stability, e.g., buffers and preservatives. The antibodies are typically formulated in such vehicles at concentrations of about 1 mg/ml to 10 mg/ml.

[533] The dose and dosage regimen depends upon a variety of factors readily determined by a physician, such as the nature of the infection and the characteristics of the particular cytotoxic agent or growth inhibitory agent conjugated to the antibody (when used), e.g., its therapeutic index, the patient, and the patient's history. Generally, a therapeutically effective amount of an antibody is administered to a patient. In particular embodiments, the amount of antibody administered is in the range of about 0.1 mg/kg to about 50 mg/kg of patient body weight. Depending on the type and severity of the infection, about 0.1 mg/kg to about 50 mg/kg body weight (e.g., about 0.1-15 mg/kg/dose) of antibody is an initial candidate dosage for administration to the patient, whether, for example, by one or more separate administrations, or by continuous infusion. The progress of this therapy is readily monitored by conventional methods and assays and based on criteria known to the physician or other persons of skill in the art.

[534] In one particular embodiment, an immunoconjugate including the antibody conjugated with a cytotoxic agent is administered to the patient. Preferably, the immunoconjugate is internalized by the cell, resulting in increased therapeutic efficacy of the immunoconjugate in killing the cell to which it binds. In one embodiment, the cytotoxic agent targets or interferes with the nucleic acid in the infected cell. Examples of such cytotoxic agents are described above and include, but are not limited to, maytansinoids, calicheamicins, ribonucleases and DNA endonucleases.

[535] Other therapeutic regimens are combined with the administration of the HIVl antibody of the present invention. The combined administration includes co-administration, using separate formulations or a single pharmaceutical formulation, and consecutive administration in either order, wherein preferably there is a time period while both (or all) active agents simultaneously exert their biological activities. Preferably such combined therapy results in a synergistic therapeutic effect.

[536] In certain embodiments, it is desirable to combine administration of an antibody of the invention with another antibody directed against another antigen associated with the infectious agent.

[537] Aside from administration of the antibody protein to the patient, the invention provides methods of administration of the antibody by gene therapy. Such administration of nucleic acid encoding the antibody is encompassed by the expression "administering a therapeutically effective amount of an antibody". See, for example, PCT Patent Application Publication WO96/07321 concerning the use of gene therapy to generate intracellular antibodies.

[538] In another embodiment, anti- HIVl antibodies of the invention are used to determine the structure of bound antigen, e.g., conformational epitopes, the structure of which is then used to develop a vaccine having or mimicking this structure, e.g., through chemical modeling and SAR methods. Such a vaccine could then be used to prevent HIVl infection. [539] The following examples are included to demonstrate preferred embodiments of the invention. It should be appreciated by those of skill in the art that the techniques disclosed in the examples which follow represent techniques discovered by the inventor to function well in the practice of the invention, and thus can be considered to constitute preferred modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention.

EXAMPLES

Example 1 : Selection of patient sample

[540] Serum from approximately 1,800 HIV-I infected donors from Asia, Australia, Europe, North America and sub-Saharan African countries were screened for neutralization activity and donors who exhibit among the broadest and most potent neutralizing serum activity observed to date were identified. (Simek, M.D., J Virol (2009)). Monoclonal antibodies were generated from these donors using different approaches. [541] A patient was selected based upon the patient's eligibility for enrollment, which was defined as: male or female at least 18 years of age with documented HIV infection for at least three years, clinically asymptomatic at the time of enrollment, and not currently receiving antiretroviral therapy. (Simek, M.D., J Virol (2009 JuI) 83(14):7337-48). Selection of individuals for monoclonal antibody generation was based on a rank-order high throughput analytical screening algorithm. The volunteer was identified as an individual with broad neutralizing serum based on broad and potent neutralizing activity against a cross-clade pseudovirus panel.

[542] A novel high-throughput strategy was used to screen IgG-containing culture supernatants from approximately 30,000 activated memory B cells from a clade A infected donor for recombinant, monomeric gpl20jR.cs_F and gp4lHxB2 (Env) binding as well as neutralization activity against HTV- 1J_R.CS_F and HIV- 1 S_FI62 as shown in Table 1. The memory B cells were cultured at near clonal density such that the authentic antibody heavy and light chain pair could be reconstituted from each culture well. Example 2: Generation of Monoclonal Antibodies

[543] The human monoclonal antibody discovery platform utilized a short term B cell culture system to interrogate the memory B cell repertoire. 30,300 CDl 9⁺ and surface IgG- expressing memory B cells were isolated from ten million peripheral blood mononuclear cells (PBMC) of the HIV-I infected donor. CD19⁺/sIgG⁺ B cells were then seeded in 384-well microtiter plates at an average of 1.3 cells/well under conditions that promoted B cell activation, proliferation, terminal differentiation and antibody secretion. Culture supernatants were screened in a high throughput format for binding reactivity to recombinant gpl20 and gp41 indirectly and directly immobilized on ELISA plates, respectively. In parallel, the culture supernatants were also screened for neutralization activity in a high throughput micro- neutralization assay.

[544] Heavy and light variable regions were isolated from lysates of selected neutralizing hits by RT-PCR amplification using family-specific primer sets. From positive family- specific PCR reactions, pools of the VH or VL-region clones were cloned into an expression vector upstream to human IgGl constant domain sequence. Minipreps (QIAGEN, Valencia, CA) of these DNA pools, derived from suspension bacterial cultures, were combined in all possible heavy and light chain family-specific pairs and used to transiently transfect 293 cells. All transfectant supernatants containing secreted recombinant antibodies were screened in ELISA and neutralization assays. For B-cell wells that contained more than one B cell clone per culture well, multiple VH and VL domain sequences were isolated. ELISA (for B- cell wells positive for ELISA) and neutralization screens identified the heavy and light chain combination pools that reconstituted the binding and neutralizing activity as observed for the B-cell well. DNA sequences of the heavy and light chain variable regions for all neutralizing mAbs were confirmed by multiple sequencing reactions using purified DNA from maxipreps (QIAGEN).

Example 3: Screening of Monoclonal Antibodies for Binding to Recombinant gpl20 and gp41 by ELISA assay

[545] Recombinant gpl20 with sequence derived from gpl20 of primary HIV-I isolate JR- CSF and expressed in insect cells was obtained from IAVI NAC repository. Recombinant gp41 generated with sequences derived from HxB2 clone of HIV-I and expressed in Pichia pastoris was manufactured by Vybion, Inc., obtained from IAVI NAC repository Sheep anti- gpl20 antibodies used as capturing agent to indirectly immobilize gpl20 on ELISA plates was purchased from Aalto Bio Reagents (Dublin, Ireland). All ELISA assays were conducted at 25 μL/well on MaxiSorp plates from Nunc.

[546] In anti-gpl20 ELISA, recombinant gpl20 (0.5 μg/ml) was captured on 384 well ELISA plates pre-coated (at 4° C overnight) with goat anti-gpl20 (5 μg/ml) in BSA- containing assay buffer (PBS with 0.05% Tween-20) for 1 hr at room temperature. After excess gpl20 was removed and plates were washed thrice with assay buffer, B cell culture supernatants diluted 5-fold was added to incubate for 1 hr at room temperature. Following three washes in assay buffer, secondary HRP-conjugated goat anti-human Ig Fc in BSA- containing assay buffer was added and incubated for about 1 hr at room temperature. 3,3',5,5'-tetramethylbenzidine (TMB) substrate was used to develop the colorimetric readouts after washing the ELISA plates 3 times.

[547] For anti-gp41 ELISA, recombinant gp41 was directly immobilized on 384 well ELISA plates by adding 1 μg/ml and incubating at 4° C overnight, followed by blocking with BSA-containing assay buffer. The rest of the assay protocol was similar to that for anti- gp 120 ELISA.

[548] Hits from the ELISA assay were identified in a singlet screen based on optical density (OD) values above 3x assay background. A serial titration standard curve of control antibody was included on each plate.

Example 4: Neutralization Assay for Screening Antibodies against Pseudotyped HIV Viruses [549] The neutralization assay approach has been described previously (Binley JM, et al., (2004). Comprehensive Cross-Clade Neutralization Analysis of a Panel of Anti-Human Immunodeficiency Virus Type 1 Monoclonal Antibodies. J. Virol. 78: 13232-13252) and was modified and standardized for implementation in 384-well format. [550] Neutralization by monoclonal antibodies and patient sera was performed using a single round of replication pseudovirus assay. (Richman, D.D., et al. Proc Natl Acad Sci USA 100, 4144-4149 (2003)). Pseudovirus neutralization assays were performed using HIV- I_JR-_CSF alanine mutants as described in Pantophlet, R., et al, J Virol 11, 642-658 (2003). Neutralization activity was measured as a reduction in viral infectivity compared to an antibody-free control using a TZM-BL assay. (Li, M., et al. J Virol 79, 10108-10125 (2005)). Monoclonal antibody neutralization assays using phytohaemgglutinin-activated peripheral blood mononuclear cells (PBMC) isolated from three healthy human donors as target cells were performed as described in Scarlatti, G. et al, (1993) J. Infect. Dis. 168:207- 210; Polonis, V. et al, (2001) AIDS Res. Hum. Retroviruses 17:69-79. Memory B cell supernatants were screened in a micro-neutralization assay against HTV- 1_SFI6₂, HTV- 1J_R.CSF, and SIV_maC239 (negative control). This assay was based on the 96- well pseudotyped HIV-I neutralization assay (Monogram Biosciences) and was modified for screening 15 μl B cell culture supernatants in a 384-well format.

[551] Pseudotyped virus from SF 162 and JR-CSF isolates of HIV-I and SIV mac239 (control virus) were generated by co-transfecting Human Embryonic Kidney 293 cells (293 cells) with 2 plasmids encoding the Envelope cDNA sequence and the rest of the HIV genome separately. In the HIV genome encoding vector, the Env gene was replaced by the firefly luciferase gene. Transfectant supernatants containing pseudotyped virus were co- incubated overnight (18 hours) with B cell supernatants derived from activation of an infected donor's primary peripheral blood mononuclear cells (PBMCs). U87 cells stably transfected with and expressing CD4 plus the CCR5 and CXCR4 coreceptors were added to the mixture and incubated for 3 days at 37° C. Infected cells were quantified by luminometry. SIVmac239 was used as the negative control virus. [552] The neutralization index was expressed as the ratio of normalized relative luminescence units (RLU) of the test viral strain to that of the control virus SIVmac239 derived from the same test B cell culture supernatant. The cut-off values used to distinguish neutralizing hits were determined by the neutralization index of a large number of "negative control wells" containing B cell culture supernatants derived from healthy donors. The false positive rate using the cut-off value of 1.5 was very low (1-3%; Figure 5A), and it was reduced to zero if the cut-off value of 2.0 was used (Figure 5B).

[553] Figure 5 summarizes the screening results from which B cell cultures were selected for antibody rescue and the monoclonal antibodies 1496 C09 (PG9), 1443 C16 (PG 16), 1456_P20 (PG20), 1460_G14 (PGG 14), and 1495_C14 (PGC 14) were derived. The results reveal that the majority of neutralizing B cell culture supernatants did not have binding reactivity to soluble recombinant gpl20 or gp41 proteins.

[554] Table 15 shows the screening results of the monoclonal antibodies 1496_C09 (PG9), 1443_C16 (PG16), 1456_P20 (PG20), 1460_G14 (PGG14), and 1495_C14 (PGC14) during the course of their identification in the method described in this invention. The neutralization activity of each antibody and its corresponding binding reactivity to soluble recombinant gpl20 or gp41, in the context of B cell culture supernatant and recombinant transfectant supernatants are illustrated.

Table 15

Medium grey with black lettering: Denotes clones derived from same recombinant H or L chain pool of the priority well with identical sequences.

Bolded: 1496 C09 λ3 clone 024 is likely a cross-contaminant in the recombinant DNA pool as it is identical to 1443 C16 λ2 019 in sequence. 1496 C09 λ2 017 sequence represents 21/22 clones in the pool.

*Anti-gpl20 and anti-gp41 concentrations were extrapolated from bl2 and 2F5 standard curves in quantitative ELISA, respectively.

N/A = not applicable because these hits were neither gp-120- nor gp-41 positive in B cell culture.

ND = not done.

[555] The purified monoclonal antibodies 1496_C09 (PG9), 1443_C 16 (PG 16), 1456_P20 (PG20), 1460_G14 (PGG14), and 1495_C14 (PGC14) were tested for neutralization of 6 additional HIV strains from clades A (94UG 103), B (92BR020, JR-CSF), C (93IN905, IAVI_C22), and CRFO 1_AE (92TH021) (Table 16). The antibodies 1496_C09 (PG9), 1443_C16 (PG 16) and 1495 C14 (PGC 14) showed neutralization profile similar to that obtained with the donor sera neutralization profile. The pseudoviruses were preincubated with each monoclonal antibody for 1 hour or 18 hours prior to the infection of target cells. IC50 values derived from 1 or 18 hours preincubation were similar. Therefore, in further neutralization assays testing purified monoclonal antibodies, 1 hour of preincubation was used.

[556] Table 17A shows the neutralization profiles for the 5 monoclonal antibodies 1496 C09 (PG9), 1443_C16 (PG 16), 1456_P20 (PG20), 1460_G14 (PGG 14), and 1495_C14 (PGC 14) in IC₅₀ values on an extended panel of 16 pseudoviruses, together with known cross-clade neutralizing antibodies bl2, 2G12, 2F5 and 4E10.

[557] Table 17B shows the IC₉₀ of two monoclonal antibodies, 1443_C 16 (PG 16) and 1496 C09 (PG9) on the same expanded diverse panel of 16 HIV pseudoviruses from different clades, together with known cross-clade neutralizing antibodies bl2, 2G12, 2F5 and 4E10. Figure 4 shows neutralization activity of monoclonal antibodies 1443 C16 (PG 16) and 1496 C09 (PG9) to 3 other pseudoviruses not included in Table 16. [558] Table 16. Neutralizing Antibody Assay: IC50 Summary

" flat inhibition curve - probably <0.0025 with plateau

'"very long, shallow slope

""plateau with very long, shallow slope to curve [559] Table 17A. Neutralization Profile on a Diverse Panel of Viruses: IC₅₀ Values

NA - Not Applicable

IC₅₀: Inhibitory concentration to inhibit 50% of the virus

[560] Table 17B. Neutralization Profile on a Diverse Panel of Viruses: ICg₀ Values for mAbs PG9 and PG16.

I PG9 PGI 6 b12 2G12 2F5 4E10 I

94UG103 33736 1.5915 47-29 >50 46.63 >50 I

Clade A 92RW020 6.5462 >S0 >60 6.23 27.74 , 36.11

93UG077 >50 >50 >50 >50 33.44 >50

92BR020 >50 >50 >50 >50 >50

APV-13 >50 >50 >50 WA N/A WA

Clade B APV-17 >50 >50 >50 N/A N/A N/A

APV-6 1.9591 44.2600 >50 N/A N/A N/A

JRCSF <0.0025 0.0130 1.17 5.38 25,31 44.07

93IN905 1.8945 >50 >50 >50 >50 12.82 I

IAVI-C18 Θ.B6S9 0.2074 >50 >50 N/A >50

Clade C

IAVI-C22 >50 >60 29.6187 >50 >50

LAVf-C3 >50 >50 >50 N/A N/A

92UG024 >50 >50 >50 7.57 34.44 23.71

Clade D

92UG005 >50 >50 >50 >50 >50 >50 I

92TH021 1.9871 23.4110 >50 >50 18.78 23.52

CRF01_AE

CMU02 >50 >50 34.2 >50 1Z25 13.4

Pos C NL43 N/A >50 0.28 15.75 19.32 29.56

Neg C aMLV >50 >60 >60 >50 >50 >50 I

NA - Not Applicable

IC₉₀: Inhibitory concentration to inhibit 90% of the virus

^♦♦♦Plateau effect Example 5: Binding Specificity of Monoclonal Antibodies for HIV gpl20 by ELISA assay [561] The purified anti-gpl20 monoclonal antibodies, 1456_P20 (PG20), 1460_G14 (PGG14), and 1495 C14 (PGC 14), were confirmed for binding reactivity to gρl20 in ELISA assays. When titrated in serial dilutions, all three antibodies exhibited similar binding profiles that suggest significantly higher relative avidity than control anti-gpl20 (bl2). MAb bl2 is directed against an epitope overlapping the CD4 binding site. (Burton DR et al. 1994. Efficient neutralization of primary isolates of HIV-I by a recombinant human monoclonal antibody. Science 266: 1024-1027).

[562] Figure 5 shows dose response curves of 1456_P20 (PG20), 1460 G 14 (PGG 14), and 1495_C14 (PGC 14) binding to recombinant gpl20 in ELISA as compared to control anti-gpl20 (bl2). Data shown represented average OD values of triplicate ELISA wells obtained on the same plate.

[563] The monoclonal antibodies 1443_C16 (PG 16) and 1496_C09 (PG9) were tested for binding to soluble recombinant envelope proteins derived from several HIV strains in ELISA assay. ELISA assays were performed as described in Pantophlet, R., et al. J Virol 11, 642-658 (2003). For antigen binding ELISAs, serial dilutions of PG9 were added to antigen coated wells and binding was probed with alkaline phosphatase-conjugated goat anti-human immunoglobulin G (IgG) F(ab')2 Ab (Pierce). For competition ELISAs, competitor mAbs were added to ELISA wells and incubated for 15 min prior to adding 15 μg/mL biotinylated PG9 to each well. Biotinylated PG9 was detected using alkaline phosphatase conjugated streptavidin (Pierce) and visualized using /7-nitrophenol phosphate substrate (Sigma). HIV-HXB2 gpl20 was used for competition ELISA assays.

[564] Figure 6 shows results from ELISA binding assays of monoclonal antibodies 1443_C16 (PG 16) and 1496_C09 (PG9) to HIV-I YU2 gpl40, JR-CSFgpl20, membrane-proximal external regions (MPER) peptide of gp41 and V3 polypeptide. Specificity of the monoclonal antibodies 1443_C16 (PG 16) and 1496_C09 (PG9) for gp 120 was then confirmed, but it was noted that the binding to soluble envelope glycoprotein was weak.

Example 6: Binding reactivity of monoclonal antibodies 1443 C16 (PG16) and 1496 C09 (PG9^*) to envelope proteins expressed on transfected cell surface and competition by soluble CD4 fsCD4Y [565] MAb cell binding assays were performed as described in Pancera, M. & Wyatt, R. Virology 332, 145-156 (2005). Titrating amounts of PG9 and PG16 were added to HIV-I Env transfected 293T cells, incubated for 1 hr at 4⁰C, washed with FACS buffer, and stained with goat anti-human IgG F(ab') ₂ conjugated to phycoerythin. For competition assays, competitor antibodies were added to the cells 15 min prior to adding 0.1 μg/mL biotinylated PG9 or PG 16. For sCD4 inhibition assays, 40 μg/mL sCD4 was added to the cells and incubated for 1 h at 4°C prior to adding titrating amounts of antibodies. Binding was analyzed using flow cytometry, and binding curves were generated by plotting the mean fluorescence intensity of antigen binding as a function of antibody concentration.

[566] Ninety-six-well ELISA plates were coated overnight at 4⁰C with 50 μL PBS containing 100 ng gpl20 or gpl40 per well. The wells were washed four times with PBS containing 0.025% Tween 20 and blocked with 3% BSA at room temperature for 1 h. Serial dilutions of PG9 were added to antigen coated wells, incubated for 1 h at room temperature, and washed 4x with PBS supplemented with 0.025% Tween 20. Binding was probed with alkaline phosphatase-conjugated goat anti-human immunoglobulin G (IgG) F(ab')2 Ab (Pierce) diluted 1 :1000 in PBS containing 1% BSA and 0.025% Tween 20. The plate was incubated at room temperature for 1 h, washed four times, and the plate was developed by adding 50 μL of alkaline phosphatase substrate (Sigma) to 5 mL alkaline phosphatase staining buffer (pH 9.8), according to the manufacturer's instructions. The optical density at 405 nm was read on a microplate reader (Molecular Devices). For competition ELISAs, competitor mAbs were added to gpl20HxB2 or gpl40γu2 coated ELISA wells and incubated for 15 min prior to adding 15 μg/mL biotinylated PG9 to each well. Biotinylated PG9 was detected using alkaline phosphatase conjugated streptavidin (Pierce) and visualized using p-nitrophenol phosphate substrate (Sigma). For sCD4 inhibition ELISAs, 5 μg/mL sCD4 was added to antigen-coated wells and incubated for 15 min at room temperature prior to adding titrating amounts of PG9. A F ACS Array™ plate reader (BD Biosciences, San Jose, CA) was used for flow cytometric analysis and FlowJo™ software was used for data interpretation.

[567] HIV gpl60 derived from YU2 was transfected in 293 cells. Binding of monoclonal antibodies 1443_C16 (PG 16) and 1496 C09 (PG9) were detected in transfected cells (Figure 7). The preincubation of transfected cells with soluble CD4 (sCD4) partially inhibited binding of monoclonal antibody for 1496_C09 (PG9), and for 1443_C16 (PG 16) suggesting the antibody binding is effected by the presence of sCD4. Binding is inhibited by at least 15%, at least 20%, at least 25%, or at least 30%. Binding of monoclonal antibodies 1443 C16 (PG 16) and 1496_C09 (PG9) to 293 cells transfected with gpl60 derived from JR-CSF and ADA strains was also detected (Figure 8). The binding of both monoclonal antibodies 1443 C16 (PG 16) and 1496_C09 (PG9) to JR-CSF transfected cells was blocked by sCD4. Results further confirm that binding activities of monoclonal antibodies 1443_C16 (PG 16) and 1496 C09 (PG9) are affected by the presence of sCD4.

Example 7: Binding reactivity of monoclonal antibodies 1443 C16 (PG16~) and 1496 C09 (PG9) to pseudoviruses.

[568] In vitro virus capture assay was used to test if monoclonal antibodies 1443_C 16 (PG 16) and 1496_C09 (PG9) bind to intact entry competent pseudoviruses. The monoclonal antibodies 1443 C16 (PG 16) and 1496_C09 (PG9) were coated at the bottom of 96- well plate via anti- human Fc. JR-CSF pseudovirus was added and captured by the monoclonal antibody 1443 C16 (PG 16) or 1496 C09 (PG9) in a dose dependent manner. Target cells were added to initiate infection. Infection measured in RLU then represented the binding and capture activity of monoclonal antibodies 1443_C16 (PG 16) and 1496 C09 (PG9). Figure 9 shows the binding and capture of JR-CSF pseudovirus by both monoclonal antibodies 1443_C16 (PG 16) and 1496_C09 (PG9) in a dose dependent manner, which is similar or better than another known broad and potent neutralizing antibody 2Gl 2.

Example 8: Monoclonal antibodies 1443 C16 (PG16) and 1496 C09 (PG9) cross-compete with each other and with sCD4 in binding to JR-CSF pseudovirus.

[569] In a competition version of virus capture assay where JR-CSF pseudovirus was captured by monoclonal antibodies 1443 C16 (PG 16), competition of the capture by either monoclonal antibodies 1443 C16 (PG 16), 1496_C09 (PG9) and sCD4 was measured. Figure 1OB shows that binding of monoclonal antibody 1443_C16 (PG 16) to JR-CSF pseudovirus was blocked by itself, monoclonal antibody 1496_C09 (PG9) and sCD4 in a dose dependent manner. In a corresponding manner, Figure 1OB shows that binding of monoclonal antibody 1496_C09 (PG9) to JR-CSF pseudovirus was blocked by itself, monoclonal antibody 1443 C16 (PG 16) and sCD4 in a dose dependent manner. Results indicated that the monoclonal antibodies 1443 C16 (PG 16) and 1496 C09 (PG9) bind to closely related epitopes on gpl20 and their binding is affected by the presence of sCD4 presumably due to conformational changes induced on HIV-I envelope by sCD4.

Example 9: Antigen binding properties of PG9 and PG 16.

[570] Antigen binding properties of PG9 and PG 16 were determined by ELISA assays as shown in Figure 1 IA-B. Binding of PG9 and PG 16 to monomeric gpl20 and artificially trimerized gpl40 constructs were determined (Fig 1 IA). Binding of PG9 and PG 16 to Env expressed on the surface of 293T cells as determined by flow cytometry. (Fig. 1 IB). bl2 was used as a control for ELISA assays. The bNAb bl2 and the non-neutralizing antibody b6 were included in the cell surface binding assays to show the expected percentages of cleaved and uncleaved Env expressed on the cell surface.

Example 10: Binding of PG9 and PG16 to cleavage-defective HlV-lvπ? trimers.

[571] Binding of PG9 and PG16 to cleavage-defective HIV-lγu2 trimers was determined by flow cytometry. PG9 and PG 16 bind with high affinity to cleavage-defective HIV- Iγu2 trimers as shown in Figure 12. Binding curves were generated by plotting the mean fluorescence intensity (MFI) of antigen binding as a function of antibody concentration.

Example 11 : Mapping the PG9 and PG 16 epitopes.

[572] Mapping the epitopes of PG9 and PG 16 epitopes was performed by a competitive binding assay as shown in Figure 13. PG9 and PG 16 competed with each other for cell surface

Env binding and neither antibody competed with the CD4bs antibody bl2 for Env binding.

Competitor antibody is indicated at the top of each graph. (Fig. 13A). Ligation of cell surface

Env with sCD4 diminished binding of PG9 and PG 16. 2Gl 2 was included to control for CD4- induced shedding of gpl20. (Fig. 13B). sCD4 inhibited binding of PG9 to artificially trimerized gpl 4Oj_R-CSF as determined by ELISA. (Fig. 13C). PG9 competed with 10/76b (anti-V2),

F425/b4e8 (anti-V3) and X5 (CD4i) for gpl 20 binding in competition ELISA assays. (Fig. 13D).

PG9 and PG 16 failed to bind variable loop deleted HIV-1_JR__CSF variants expressed on the surface of 293T cells. 2G12 was included to control for cell surface Env expression. (Fig. 13E).

Example 12: Competition ELISA assays using PG9.

[573] When competition ELISA assays using PG9 were performed, PG9 competed with cl08g

(anti-V2) and partially competed with 17b (CD4i). No competition was observed with A32

(anti-Cl/C2/C4/CD4i), Cl 1 (Cl), 2G 12 (glycan shield), b6 (CD4bs), b3 (CD4bs) or 23b (C1/C5) for gpl20_HxB2 binding as shown in Figure 14. Example 13: Binding of PG9 and PG 16 to H1V-U.FI E168K.

[574] Antibody binding to HIV-1JR-FLΔCT E168K Env expressed on the surface of 293T cells as determined by flow cytometry is shown in Figure 15. A cytoplasmic tail deleted construct was used to increase cell surface expression. The bNAb bl2 and the non-neutralizing antibody b6 were included in the cell surface binding assays to show the expected percentages of cleaved and uncleaved Env expressed on the cell surface. (Pancera M., et al. Virology 332:145 (2005). HIV-

UR-FL E168K was generated by site-directed mutagenesis. Binding curves were generated by plotting the MFI of antigen binding as a function of antibody concentration.

Example 14: PG9 binding to deglycosylated gpl20.

[575] gpl20ou422 was treated with 40 mU/μg Endoglycosidase H (Endo H, New England

Biolabs) in sodium acetate buffer for 24 hr at 37 ⁰C. Mock treated gpl20 was treated under same conditions, but the enzyme was omitted from the reaction. Binding of PG9 and b6 to EndoH treated and mock treated gpl20 was determined by ELISA as shown in Figure 16.

Example 15: Neutralization activity against HIV-lsFjfi_?_K160N

[576] Neutralization activity of PG9 and PG16 against HIV-1_SFI6₂ and HIV-1 _SFI6₂ K160N was determined using a single-round replication luciferase reporter assay of pseudotyped virus. HIV-

I_SFI62 KI6ON was generated by site-directed mutagenesis as shown in Figure 17.

Example 16: Binding of PG9 and PG16 to mixed trimers

[577] Alanine substitutions at positions 160 and 299 were introduced into HIV- Iγu₂ Env to abolish binding of PG9 and PG 16. An alanine substitution at position 295 was also introduced into the same construct to abrogate binding of 2G12. Co-transfection of 293T cells with WT and mutant plasmids in a 1 :2 ratio resulted in the expression of 29% mutant homotrimers, 44% heterotrimers with two mutant subunits, 23% heterotrimers with one mutant subunit, and 4% wild-type homotrimers. These proportions were calculated using the formula described in Yang,

X., Kurteva, S., Lee, S., and J. Sodroski, J Virol 79(6):3500-3508 (Mar 2005), and assumes that mutant and wild-type gpl20s mix randomly to form trimers. Binding of mAbs to Env trimers was determined by flow cytometry as shown in Figure 18. bl2 was included as control for Env cell surface expression.

Example 17: PG9 or PG 16 neutralization activity on HIV with alanine mutations within gpl20.

[578] Alanine mutations within gpl20 of HIV decrease PG9 or PG 16 neutralization activity as shown in Table 21. In the table, amino acid numbering is based on the sequence of HIV-I _HXB2- Boxes are color coded as follows: white, the amino acid is identical among 0 to 49% of all HIV- 1 isolates; light grey, the amino acid is identical among 50 to 90% of isolates; dark grey, the amino acid is identical among 90 to 100% of isolates. Amino acid identity was determined based on a sequence alignment of HIV-I isolates listed in the HIV sequence database at hiv- web.lanl.gov/content/hiv-db/mainpage.html. C refers to constant domains and V refers to variable loops. Neutralization activity is reported as fold increase in IC50 value relative to WT JR-CSF and was calculated using the equation (IC50 mutant / IC50 WT). Boxes are color coded as follows: white, substitutions which had a negative effect on neutralization activity; light grey, 4 - 9 fold IC50 increase; medium grey, 10 - 100 fold IC50 increase; dark grey, >100 fold IC50 increase. Experiments were performed in triplicate and values represent an average of at least three independent experiments.

[579] Table 18A

[580] Table 18B

[581] Table 18C

[582] Table 18D

[583] Table 18E

[584] Table 18F

^* White squares indicate an IC50 of >50 μg/mL, black squares indicate 50 μg/tnL > IC50 > 10 μg/mL, lightest grey squares indicate 10 μg/mL > IC50 > 1 μg/mL, medium grey squares indicate 1 μg/mL > IC50 > 0.1 μg/mL, darker grey squares indicate IC50 < 0.01 μg/mL. N. D., not done. b White squares indicate an IC50 of < 1 : 100 dilution, darkest grey squares indicate 1 :50 > IC50 > 1 : 150, lightest grey squares indicate 1 : 150 > IC50 > 1 :500, medium grey squares indicate 1 :500 > IC50 > 1 : 1000, darker grey squares indicate IC50 > 1 : 1000 dilution.

[585] Table 19A. Neutralization Potency.

White boxes indicate a medium potency of >50 μg/mL, darkest grey between 20 and 50 μg/mL, lightest grey between 2 and 20 μg/mL, medium grey between 0.2 and 2 μg/mL, and darker grey < 0.2 μg/mL. ^♦CRF 07BC and CRF 08BC viruses not included in the clade analysis because there was only one virus tested from each of these clades.

[586] Table 19B. Neutralization Breadth.

White boxes indicate that no viruses were neutralized, darkest grey indicate 1 to 30% of viruses were neutralized, lightest grey indicate 30 to 60% of viruses were neutralized, medium grey indicate 60 to 90% of viruses were neutralized, and darker grey indicate 90 to 100% of viruses were neutralized. ♦CRF 07BC and CRF 08BC viruses not included in the clade analysis because there was only one virus tested from each of these clades.

JR-CSF pseudovirus

FbU rtialin to wfld-

^a Amino acid number is based on the sequence of HIV-I _HXB2- ^b White boxes indicate that the amino acid is identical among O to 49% of all HIV isolates, light grey boxes indicate that the amino acid is identical among 50-90% of all HIV isolates, and dark grey boxes indicate that the amino acid is identical among 90-100% of all HIV isolates. Amino acid identity was determined based upon a sequence alignment of HIV-I isolates listed in the HIV sequence database at http://hiv-gov/content/hiv-db/rnainpage.html. c C refers to constant domains and V refers to variable loops. d Neutralization activity is reported as fold increase in IC50 value relative to WT JR-CSF and was calculated using the equation (IC50 mutant / IC50 WT). White: substitutions which had a negligible effect on neutralization activity, lightest grey: 4-9 fold IC50 increase, dark grey: 10-100 fold IC50 increase, darkest grey: >100 fold IC50 increase.

Experiments were performed in triplicate and values represent an average of at least three independent experiments.

[588] Table 21. Alanine mutations that decrease PG9 and PG16 neutralization activity. Mutation"'" gp120 domain' Fold IC₅₀ increase relative to wild-type"

a Amino acid numbering is based on the sequence of HIV-I _HXB2- ^b Boxes are color coded as follows: white, the amino acid is identical among 0 to 49% of all HIV-I isolates; light grey, the amino acid is identical among 50 to 90% of isolates; dark grey, the amino acid is identical among 90 to 100% of isolates. Amino acid identity was determined based on a sequence alignment of HIV-I isolates listed in the HTV sequence database at http://hiv-web.lanl.gov/content/hiv- db/mainpage.html. c C refers to constant domains and V refers to variable loops. d Neutralization activity is reported as fold increase in IC₅₀ value relative to WT JR-CSF and was calculated using the equation (IC₅₀ mutant / IC₅₀ WT). Boxes are color coded as follows: white, substitutions which had a negative effect on neutralization activity; light grey, 4 - 9 fold IC₅₀ increase; medium grey, 10 - 100 fold IC₅₀ increase; dark grey, >100 fold IC₅₀ increase. Experiments were performed in triplicate and values represent an average of at least three independent experiments.

Example 18: Identification of 14443 C16 (PG16) sister clones

[589] 1443 C 16 sister clones were identified by screening clonal transfection of rescued variable region genes for JR-CSR neutralization. Thus, antibodies that were identified as sister clones of 1443 C 16 (PG 16) have the similar HIV neutralization profiles as the human monoclonal 1443 C16 (PG 16). Moreover, the nucleic acid or amino acid sequences of the sister clone antibodies are at least 50%, 55%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, 100% or any percentage point in between, identical to those of 1443 C16 (PG 16). [590] Table 22

Note that the constant region of the 1456_A12 heavy chain clones used in transfection contains an error generated during the cloning process that lead to no full-length IgG production.

Example 19: 1443 C16 (PG16) Antibody Sister Clones and the 1443 C16 (PG16) Antibody Exhibit Similar Neutralization Specificity

[591] Antibodies 1456 A12, 1503 H05, 1489 113 and 1469 M23 were tested for neutralization activity against several pseudoviruses containing distinct mutations that map the reactivity epitope of 1443 C16 (PG 16) on gp 120 in a standard TZM-bl assay (Table 23). Like 1443 C16 (PG 16), which does not bind or neutralize wild-type JR-FL, but instead, neutralizes JR-FL with the E168K mutation, all 1443 Cl 6 (PG 16) sister clones neutralize JR-FL(E 168K) with low IC50 values. Similarly, all 1443 Cl 6 (PG 16) sister clones do not neutralize the Y318A mutants and I309A mutants of JR-CSF, where the part of the putative binding epitope is mapped on the V3 tip.

[592] Table 23. Neutralization specificity of 1443 C 16 (PG 16) sister clones as shown with specific mutations on gpl20.

Example 20: 1443 C16 (PG16) Sister Clones Exhibit Similar Neutralization Breadth and Potency as 1443 C 16 (PG 16) for Clade B and Clade C Viruses

[593] The antibodies 1456 A12, 1503 H05, 1489 113 and 1469 M23 exhibit neutralization activity against a panel of clade B and clade C pseudoviruses with similar breadth as does 1443

C16 (PG 16) in a standard TZM-bl assay (Table 24). The neutralization potency of each sister clone for each pseudovirus is comparable to that for 1443 Cl 6 (PG 16). When the IC50 value is determined, the value for the sister clone is within a 0.5 log range from that for 1443 Cl 6

(PG 16).

[594] Table 24. Neutralization breadth and potency of 1443 C 16 (PG 16) sister clones.

OTHER EMBODIMENTS

[595] Although specific embodiments of the invention have been described herein for purposes of illustration, various modifications may be made without deviating from the spirit and scope of the invention. Accordingly, the invention is not limited except as by the appended claims. While the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.

[596] The patent and scientific literature referred to herein establishes the knowledge that is available to those with skill in the art. All United States patents and published or unpublished United States patent applications cited herein are incorporated by reference. All published foreign patents and patent applications cited herein are hereby incorporated by reference. Genbank and NCBI submissions indicated by accession number cited herein are hereby incorporated by reference. All other published references, documents, manuscripts and scientific literature cited herein are hereby incorporated by reference.

[597] While this invention has been particularly shown and described with references to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the invention encompassed by the appended claims.

Claims

CLAIMSWhat is Claimed is:

1. An isolated human monoclonal antibody, wherein said monoclonal antibody neutralizes HIV-I virus in vitro, and further wherein said monoclonal antibody is obtained by a process comprising the steps of:

(a) screening memory B cell cultures from a donor PBMC sample for broad neutralization activity against a plurality of HIV-I species; and then

(b) rescuing the monoclonal antibody from a memory B cell culture that exhibits neutralization activity against a plurality of HIV-I species.

2. The potent, broadly neutralizing monoclonal antibody of claim 1, wherein said antibody effectively neutralizes

(a) an HIV-I species belonging to at least two of clades A, B, C, D and AE; or

(b) at least 60% of HIV-I species selected from the group consisting of MGRM-A- 001, MGRM- A-002, MGRM-A-003, MGRM-A-004, MGRM- A-005, MGRM- A-006, MGRM-A-007, MGRM-A-008, MGRM-A-009, MGRM-A-OlO, MGRM-A-011, MGRM-A- 012, MGRM-A-013, MGRM-A-014, 94UG 103, 92RW020, 93UG077, 94KE 105, 93RW029, 02RW009, 92UG031, 92RW026, 92UG037, 92RW008, 92RW021, VLGCAl, 92RW024, 6535.3, QH0692.42, SC422661.8, PVO.4, TRO.l l, CAAN.A2, TRJ0.58, THR0.18, 92BR010, APV 13, APV 17, APV 6, 93TH305, VLGCB3, JRCSF, NL43, MGRM-Chronic- B-001, MGRM-Chronic-B-002, MGRM-Chronic-B-003, MGRM-Chronic-B-004, MGRM- Chronic-B-008, MGRM-Chronic-B-010, MGRM-Chronic-B-011, MGRM-Chronic-B-012, MGRM-Chronic-B-017, MGRM-Chronic-B-018, MGRM-Chronic-B-020, MGRM-Chronic- B-023, MGRM-Chronic-B-024, JRFL, SF 162, MGRM-C-001, MGRM-C-002, MGRM-C-

003. MGRM-C-004, MGRM-C-005, MGRM-C-006, MGRM-C-007, MGRM-C-008, MGRM-C-009, MGRM-C-010, MGRM-C-011, MGRM-C-012, MGRM-C-013, MGRM-C- 014, MGRM-C-015, MGRM-C-016, MGRM-C-017, MGRM-C-018, MGRM-C-019, MGRM-C-020, MGRM-C-021, MGRM-C-022, MGRM-C-023, MGRM-C-024, MGRM-C- 025, 92IN905, IAVIC 18, IAVI C22, IAVI C3, 98IN022, 93MW959, 97ZA012, 98CN006, 98CN009, MGRM-D-001, MGRM-D-002, MGRM-D-003, MGRM-D-004, MGRM-D-005, MGRM-D-008, MGRM-D-011, MGRM-D-012, MGRM-D-013, MGRM-D-014, MGRM-D- 016, MGRM-D-018, MGRM-D-019, MGRM-D-020, MGRM-D-021, MGRM-D-022, MGRM-D-024, MGRM-D-026, MGRM-D-028, MGRM-D-029, 92UG024, 92UG005, 92UG046, 92UG001, 94UG114, MGRM-AE-OOl, MGRM-AE-002, MGRM-AE-003, MGRM-AE-004, MGRM-AE-005, MGRM-AE-006, MGRM-AE-007, MGRM-AE-008, 92TH021, CMU02, MGRM-AG-OOl, MGRM-AG-002, MGRM- AG-003, MGRM- AG-005, MGRM-AG-006, MGRM-AG-008, MGRM-AG-009, MGRM-AG-011, MGRM-AG-012, MGRM-AG-013, MGRM-G-001, MGRM-G-004, MGRM-G-006, MGRM-G-009, MGRM- G-OI l, MGRM-G-013, MGRM-G-014, MGRM-G-015, MGRM-G-016, MGRM-G-017, MGRM-G-019, MGRM-G-024, MGRM-G-025, MGRM-G-027, MGRM-G-028, MGRM- Fl-004, MGRM-F1-006, MGRM-F1-008, MGRM-Fl-010, MGRM-F1-012, MGRM-F1-013, MGRM-F1-014, MGRM-F1-015, MGRM-F1-016, MGRM-F1-017, MGRM-F1-018, MGRM-F 1-020, MGRM-F 1-021, MGRM-F 1-022, MGRM-F 1-023, and aMLV; and further wherein the potency of neutralization of said HIV-I species is determined by an IC₅₀ value of less than 0.2 μg/mL.

3. The antibody of claim 1 , wherein said antibody is 1496 C09 (PG9), 1443 C 16 (PG16), 1456 P20 (PG20), 1460 G14 (PGG14), or 1495 C14 (PGC14).

4. The antibody of claim 1, wherein said antibody is 1443 C16 (PG 16) or a sister clone thereof.

5. The antibody of claim 4, wherein said antibody is 1443 C 16 (PG 16), 1469 M23 (PG16), 1456 A12 (PG16), 1503 H05 (PG16), 1489 113 (PG16), or 1480 108 (PG 16).

6. An antibody that binds the same epitope as 1496 C09 (PG9), 1443 C16 (PG16), 1456 P20 (PG20), 1460 G14 (PGG14), 1495 C14 (PGC14), 1469 M23 (PG16), 1456 A12 (PG16), 1503 H05 (PG16), 1489 113 (PG16), or 1480 108 (PG16).

7. An isolated anti-HIV antibody, wherein said antibody has a heavy chain with three CDRs comprising an amino acid sequence selected from the group consisting of the amino acid sequences of SGFTFHKYGMH (SEQ ID NO: 88), LISDDGMRKYHSDSMW (SEQ ID NO: 89), and EAGGPIWHDDVKYYDFNDGYYNYHYMDV (SEQ ID NO: 6), and a light chain with three CDRs that include an amino acid sequence selected from the group consisting of the amino acid sequences of NGTSSDVGGFDSVS (SEQ ID NO: 97), DVSHRPSG (SEQ ID NO: 95), and SSLTDRSHRI (SEQ ID NO: 41).

8. An isolated anti-HIV antibody, wherein said antibody has a heavy chain with three CDRs comprising an amino acid sequence selected from the group consisting of the amino acid sequences of SGFTFHKYGMH (SEQ ID NO: 88), LISDDGMRKYHSDSMW (SEQ ID NO: 89), and EAGGPIWHDDVKYYDFNDGYYNYHYMDV (SEQ ID NO: 6), and a light chain with three CDRs that include an amino acid sequence selected from the group consisting of the amino acid sequences of NGTRSDVGGFDSVS (SEQ ID NO: 92), DVSHRPSG (SEQ ID NO: 95), and SSLTDRSHRI (SEQ ID NO: 41).

9. An isolated anti-HIV antibody, wherein said antibody has a heavy chain with three CDRs comprising an amino acid sequence selected from the group consisting of the amino acid sequences of SGFTFHKYGMH (SEQ ID NO: 88), LISDDGMRKYHSDSMW (SEQ ID NO: 89), and EAGGPIWHDDVKYYDFNDGYYNYHYMDV (SEQ ID NO: 6), and a light chain with three CDRs that include an amino acid sequence selected from the group consisting of the amino acid sequences of NGTSRD VGGFDS VS (SEQ ID NO: 93), DVSHRPSG (SEQ ID NO: 95), and SSLTDRSHRI (SEQ ID NO: 41).

10. An isolated anti-HIV antibody, wherein said antibody has a heavy chain with three CDRs comprising an amino acid sequence selected from the group consisting of the amino acid sequences of SGFTFHKYGMH (SEQ ID NO: 88), LISDDGMRKYHSNSMW (SEQ ID NO: 98), and EAGGPIWHDDVKYYDFNDGYYNYHYMDV (SEQ ID NO: 6), and a light chain with three CDRs that include an amino acid sequence selected from the group consisting of the amino acid sequences of NGTSSDVGGFDSVS (SEQ ID NO: 97), DVSHRPSG (SEQ ID NO: 95), and SSLTDRSHRI (SEQ ID NO: 41).

11. An isolated anti-HIV antibody, wherein said antibody has a heavy chain with three CDRs comprising an amino acid sequence selected from the group consisting of the amino acid sequences of SGGTFSSYAFT (SEQ ID NO: 104), MVTPIFGEAKYSQRFE (SEQ ID NO: 105), and RAVPIATDNWLDP (SEQ ID NO: 102), and a light chain with three CDRs that include an amino acid sequence selected from the group consisting of the amino acid sequences of RASQTINNYLN (SEQ ID NO: 107), GASNLQNG (SEQ ID NO: 108), and QQSFSTPRT (SEQ ID NO: 42).

12. An isolated anti-HIV antibody, wherein said antibody has a heavy chain with three CDRs comprising an amino acid sequence selected from the group consisting of the amino acid sequences of SGGTFSSYAFT (SEQ ID NO: 104), MVTPIFGEAKYSQRFE (SEQ ID NO: 105), and RRAVPIATDNWLDP (SEQ ID NO: 103), and a light chain with three CDRs that include an amino acid sequence selected from the group consisting of the amino acid sequences of RASQTINNYLN (SEQ ID NO: 107), GASNLQNG (SEQ ID NO: 108), and QQSFSTPRT (SEQ ID NO: 42).

13. An isolated anti-HIV antibody, wherein said antibody has a heavy chain with three CDRs comprising an amino acid sequence selected from the group consisting of the amino acid sequences of SGGAFSSYAFS (SEQ ID NO: 110), MITPVFGETKYAPRFQ (SEQ ID NO: 111), and RAVPIATDNWLDP (SEQ ID NO: 102), and a light chain with three CDRs that include an amino acid sequence selected from the group consisting of the amino acid sequences of RASQTIHTYL (SEQ ID NO: 113), GASTLQSG (SEQ ID NO: 114), and QQSYSTPRT (SEQ ID NO: 43).

14. An isolated anti-HIV antibody, wherein said antibody has a heavy chain with three CDRs comprising an amino acid sequence selected from the group consisting of the amino acid sequences of SGGAFSSYAFS (SEQ ID NO: 110), MITPVFGETKYAPRFQ (SEQ ID NO: 111), and RRAVPIATDNWLDP (SEQ ID NO: 103), and a light chain with three CDRs that include an amino acid sequence selected from the group consisting of the amino acid sequences of RASQTIHTYL (SEQ ID NO: 113), GASTLQSG (SEQ ID NO: 114), and QQSYSTPRT (SEQ ID NO: 43).

15. An isolated anti-HIV antibody, wherein said antibody has a heavy chain with three CDRs comprising an amino acid sequence selected from the group consisting of the amino acid sequences of SGYSFID YYLH (SEQ ID NO: 116), LIDPENGEARYAEKFQ (SEQ ID NO: 117), AVGADSGSWFDP (SEQ ID NO: 118), and a light chain with three CDRs that include an amino acid sequence selected from the group consisting of the amino acid sequences of SGSKLGDKYVS (SEQ ID NO: 120), ENDRRPSG (SEQ ID NO: 121), QAWETTTTTFVF (SEQ ID NO: 44).

16. An isolated anti-HIV antibody, wherein said antibody has a heavy chain with three CDRs comprising an amino acid sequence selected from the group consisting of the amino acid sequences of SGFDFSRQGMH (SEQ ID NO: 123), FIKYDGSEKYHADSVW (SEQ ID NO: 124), and EAGGPD YRNGYN YYDF YDGYYNYHYMD V (SEQ ID NO: 7), and a light chain with three CDRs that include an amino acid sequence selected from the group consisting of the amino acid sequences of NGTSND VGGYES VS (SEQ ID NO: 126), DVSKRPSG (SEQ ID NO: 127), and KSLTSTRRRV (SEQ ID NO: 45).

17. An isolated anti-HIV antibody, wherein said antibody has a heavy chain with three CDRs comprising an amino acid sequence selected from the group consisting of the amino acid sequences of SGFTFHKYGMH (SEQ ID NO: 88), LISDDGMRKYHSDSMW (SEQ ID NO: 89), EAGGPIWHDDVKYYDFNDGYYNYHYMDV (SEQ ID NO: 6), SGGTFSSYAFT (SEQ ID NO: 104), MVTPIFGEAKYSQRFE (SEQ ID NO: 105), RAVPIATDNWLDP (SEQ ID NO: 102), SGGAFSSYAFS (SEQ ID NO: 110), MITPVFGETKYAPRFQ (SEQ ID NO: 111), SGYSFIDYYLH (SEQ ID NO: 116), LIDPENGEARYAEKFQ (SEQ ID NO: 117), AVGADSGSWFDP (SEQ ID NO: 118), SGFDFSRQGMH (SEQ ID NO: 123), FIKYDGSEKYHADSVW (SEQ ID NO: 124), EAGGPDYRNGYNYYDFYDGYYNYHYMDV (SEQ ID NO: 7),

18. An isolated anti-HIV antibody, wherein said antibody has a light chain with three CDRs that include an amino acid sequence selected from the group consisting of the amino acid sequences of NGTSSDVGGFDSVS (SEQ ID NO: 97), DVSHRPSG (SEQ ID NO: 95), SSLTDRSHRI (SEQ ID NO: 41), RASQTINNYLN (SEQ ID NO: 107), GASNLQNG (SEQ ID NO: 108), QQSFSTPRT (SEQ ID NO: 42), RASQTIHTYL (SEQ ID NO: 113), GASTLQSG (SEQ ID NO: 114), QQSYSTPRT (SEQ ID NO: 43), SGSKLGDKYVS (SEQ ID NO: 120), ENDRRPSG (SEQ ID NO: 121), QAWETTTTTFVF (SEQ ID NO: 44), NGTSNDVGGYESVS (SEQ ID NO: 126), DVSKRPSG (SEQ ID NO: 127), KSLTSTRRRV (SEQ ID NO: 45), NGTRSDVGGFDSVS (SEQ ID NO: 92), NGTSRDVGGFDSVS (SEQ ID NO: 93), wherein said antibody binds to and neutralizes HIV-I.

19. An isolated anti-HIV antibody, wherein said antibody has a heavy chain with three CDRs comprising an amino acid sequence selected from the group consisting of the amino acid sequences of SGFTFHKYGMH (SEQ ID NO: 88), LISDDGMRKYHSDSMW (SEQ ID NO: 89), EAGGPIWHDDVKYYDFNDGYYNYHYMDV (SEQ ID NO: 6), SGGTFSSYAFT (SEQ ID NO: 104), MVTPIFGEAKYSQRFE (SEQ ID NO: 105), RRAVPIATDNWLDP (SEQ ID NO: 103), SGGAFSSYAFS (SEQ ID NO: 110), MITPVFGETKYAPRFQ (SEQ ID NO: 111), SGYSFIDYYLH (SEQ ID NO: 116), LIDPENGEARYAEKFQ (SEQ ID NO: 117), AVGADSGSWFDP (SEQ ID NO: 118), SGFDFSRQGMH (SEQ ID NO: 123), FIKYDGSEKYHADSVW (SEQ ID NO: 124), EAGGPDYRNGYNYYDFYDGYYNYHYMDV (SEQ ID NO: 7),

20. An isolated anti-HIV antibody, wherein said antibody has a light chain with three CDRs that include an amino acid sequence selected from the group consisting of the amino acid sequences of NGTSSDVGGFDSVS (SEQ ID NO: 97), DVSHRPSG (SEQ ID NO: 95), SSLTDRSHRI (SEQ ID NO: 41), RASQTINNYLN (SEQ ID NO: 107), GASNLQNG (SEQ ID NO: 108), QQSFSTPRT (SEQ ID NO: 42), RASQTIHTYL (SEQ ID NO: 113), GASTLQSG (SEQ ID NO: 114), QQSYSTPRT (SEQ ID NO: 43), SGSKLGDKYVS (SEQ ID NO: 120), ENDRRPSG (SEQ ID NO: 121), QAWETTTTTFVF (SEQ ID NO: 44), NGTSNDVGGYESVS (SEQ ID NO: 126), DVSKRPSG (SEQ ID NO: 127), KSLTSTRRRV (SEQ ID NO: 45), NGTRSDVGGFDSVS (SEQ ID NO: 92), NGTSRDVGGFDSVS (SEQ ID NO: 93), wherein said antibody binds to and neutralizes HIV-I.

21. An isolated anti-HIV antibody or fragment thereof, wherein said antibody comprises:

(a) a V_H CDRl region comprising the amino acid sequence of SEQ ID NO: 88, 104, 110, 116, or 123;

(b) a V_H CDR2 region comprising the amino acid sequence of SEQ ID NO: 98, 89, 91, 105, 111, 117, or 124; and

(c) a V_H CDR3 region comprising the amino acid sequence of SEQ ID NO: 6, 102, 103, 118, or 7, wherein said antibody binds to and neutralizes HIV-I .

22. The antibody of claim 21, wherein said antibody further comprises:

(a) a V_L CDRl region comprising the amino acid sequence of SEQ ID NO: 93, 92, 97, 94, 107, 113, 120, or 126;

(b) a V_L CDR2 region comprising the amino acid sequence of SEQ ID NO: 95, 108, 114, 121, or 127; and

(c) a V_L CDR3 region comprising the amino acid sequence of SEQ ID NO: 41, 42, 43, 44, or 45.

23. An isolated fully human monoclonal anti-HIV antibody comprising: a) a heavy chain sequence comprising the amino acid sequence of SEQ ID NO: 31 and a light chain sequence comprising amino acid sequence SEQ ID NO: 32, or b) a heavy chain sequence comprising the amino acid sequence of SEQ ID NO: 33 and a light chain sequence comprising amino acid sequence SEQ ID NO: 34, or c) a heavy chain sequence comprising the amino acid sequence of SEQ ID NO: 35 and a light chain sequence comprising amino acid sequence SEQ ID NO: 36, or d) a heavy chain sequence comprising the amino acid sequence of SEQ ID NO: 37 and a light chain sequence comprising amino acid sequence SEQ ID NO: 38, or e) a heavy chain sequence comprising the amino acid sequence of SEQ ID NO: 39 and a light chain sequence comprising amino acid sequence SEQ ID NO: 40, or f) a heavy chain sequence comprising the amino acid sequence of SEQ ID NO: 140 and a light chain sequence comprising amino acid sequence SEQ ID NO: 96, or g) a heavy chain sequence comprising the amino acid sequence of SEQ ID NO: 48 and a light chain sequence comprising amino acid sequence SEQ ID NO: 51, or h) a heavy chain sequence comprising the amino acid sequence of SEQ ID NO: 54 and a light chain sequence comprising amino acid sequence SEQ ID NO: 57, or i) a heavy chain sequence comprising the amino acid sequence of SEQ ID NO: 60 and a light chain sequence comprising amino acid sequence SEQ ID NO: 32.

24. A composition comprising the an isolated anti-HIV antibody of claim 1, 6, or 23.

25. An antibody as recited in claims 1-23 wherein the antibody is a human monoclonal antibody.

26. A fragment of the antibody of any one of claims 1-23.

27. The fragment of claim 26, which is selected from the group consisting of the Fab, Fab', F(ab')₂, Fv, single chain Fv, diabody and domain antibody (dAb) fragments.

28. A nucleic acid molecule encoding the antibody of any one of claims 1-23, or a fragment thereof.

29. A vector comprising the nucleic acid molecule of claim 28.

30. A cell comprising the vector of claim 29.

31. An immortalized B cell clone expressing the antibody of any one of claims 1 -23.

32. An epitope which binds to the antibody of any one of claims 1 -23.

33. An immunogenic polypeptide or glycopeptides comprising the epitope of claim 32.

34. A pharmaceutical composition comprising at least one antibody or fragment as recited in claims 1-23, and a pharmaceutically acceptable carrier.

35. The pharmaceutical composition of claim 34, further comprising a first antibody or fragment specific for a first epitope, and a second antibody or fragment specific for a second epitope.

36. A pharmaceutical composition comprising the antibody fragment of claim 26, wherein said fragment is selected from the group consisting of the Fab, Fab', F(ab')2 and Fv fragments of said antibody.

37. A method of immunizing or reducing the effect of an HIV infection or an HIV-related disease comprising the steps of identifying a patient in need of such treatment and administering to said patient a therapeutically effective amount of at least one antibody as recited in any one of claims 1-23.

38. The method of claim 37, additionally comprising the administration of a second therapeutic agent.

39. The method as recited in claim 38, wherein said second therapeutic agent is an antiviral agent.

40. A method of immunizing or reducing the effect of an HIV infection or an HIV-related disease comprising the steps of identifying a patient in need of such treatment and administering to said patient a therapeutically effective amount of: a first antibody as recited in claims 1-23, or fragment thereof, specific for a first epitope which binds to said first antibody and a second antibody as recited in claims 1-23, or fragment thereof, specific for a second epitope which binds to said second antibody.

41. A method for preparing a recombinant mammalian cell, comprising the steps of:(i) sequencing nucleic acid from an immortalized B cell clone expressing an antibody as recited in claims 1-23; and (ii) using the sequence information from step (i) to prepare nucleic acid for inserting into an expression host in order to permit expression of the antibody of interest in that host.

42. The method as recited in claim 41, wherein the mammalian cell is a human cell.

43. A method for producing antibodies as recited in claim 1 comprising :(i) culturing an immortalized B cell clone expressing an antibody as recited in claim 1 and (ii) isolating antibodies.

44. A method of screening for polypeptides that can induce an immune response against HIV, comprising screening polypeptide libraries using the antibody of claim 1.

45. A method of monitoring the quality of anti-HIV vaccines, comprising the use of an antibody, or a fragment thereof, as recited in claim 1 to check that the antigen in said vaccine contains the correct epitope in the correct conformation.

46. A vaccine comprising an epitope which specifically binds to an antibody as recited in claim 1.

47. A purified, neutralizing human monoclonal antibody, or a fragment thereof, having at least one complementarity-determining region (CDR) which binds to an HIVl epitope.

48. A method for producing recombinant neutralizing antibody having high potency in neutralizing human immunodeficiency virus (HIV), or a fragment thereof, comprising the use of a nucleic acid molecule comprising a sequence selected from the variable region encoding sequences of the heavy chains selected from the group consisting of SEQ ID NO: 99, 101, 109, 115, 122, 128, 130, 132, and 134, and the light chains selected from the group consisting of SEQ ID NO: 100, 106, 112, 119, 125, 129, 131, 133, 135, 136, and 137.

49. An isolated human monoclonal antibody, wherein said monoclonal antibody binds HIV-I antigens and broadly and potently neutralizes HIV-I virus in vitro, and further wherein further wherein said monoclonal antibody is obtained by a process comprising the steps of:

(a) screening memory B cell cultures from a donor PBMC sample for neutralization activity against either HIV-I strains belonging to at least two different clades, or at least 60% of HIV-I species selected from the group consisting of MGRM-A-OOl, MGRM- A-002, MGRM- A-003, MGRM-A-004, MGRM- A-005, MGRM- A-006, MGRM-A-007, MGRM-A-008, MGRM-A-009, MGRM-A-010, MGRM-A-011, MGRM-A-012, MGRM-A-013, MGRM-A-014, 94UG 103, 92RW020, 93UG077, 94KE105, 93RW029, 02RW009, 92UG031, 92RW026, 92UG037, 92RW008, 92RW021, VLGCAl, 92RW024, 6535.3, QH0692.42, SC422661.8, PVO.4, TRO.11, CAAN.A2, TRJ0.58, THR0.18, 92BR010, APV 13, APV 17, APV 6, 93TH305, VLGCB3, JRCSF, NL43, MGRM-Chronic-B-001, MGRM-Chronic-B-002, MGRM- Chronic-B-003, MGRM-Chronic-B-004, MGRM-Chronic-B-008, MGRM-Chronic- B-010, MGRM-Chronic-B-011, MGRM-Chronic-B-012, MGRM-Chronic-B-017, MGRM-Chronic-B-018, MGRM-Chronic-B-020, MGRM-Chronic-B-023, MGRM- Chronic-B-024, JRFL, SF 162, MGRM-C-001, MGRM-C-002, MGRM-C-003, MGRM-C-004, MGRM-C-005, MGRM-C-006, MGRM-C-007, MGRM-C-008, MGRM-C-009, MGRM-C-010, MGRM-C-011, MGRM-C-012, MGRM-C-013, MGRM-C-014, MGRM-C-015, MGRM-C-016, MGRM-C-017, MGRM-C-018, MGRM-C-019, MGRM-C-020, MGRM-C-021, MGRM-C-022, MGRM-C-023, MGRM-C-024, MGRM-C-025, 92IN905, IAVIC 18, IAVI C22, IAVI C3, 98IN022, 93MW959, 97ZA012, 98CN006, 98CN009, MGRM-D-001, MGRM-D-002, MGRM-D-003, MGRM-D-004, MGRM-D-005, MGRM-D-008, MGRM-D-011, MGRM-D-012, MGRM-D-013, MGRM-D-014, MGRM-D-016, MGRM-D-018, MGRM-D-019, MGRM-D-020, MGRM-D-021, MGRM-D-022, MGRM-D-024, MGRM-D-026, MGRM-D-028, MGRM-D-029, 92UG024, 92UG005, 92UG046, 92UG001, 94UG114, MGRM-AE-001, MGRM-AE-002, MGRM-AE-003, MGRM- AE-004, MGRM-AE-005, MGRM-AE-006, MGRM-AE-007, MGRM-AE-008, 92TH021, CMU02, MGRM-AG-OOl, MGRM-AG-002, MGRM- AG-003, MGRM- AG-005, MGRM-AG-006, MGRM-AG-008, MGRM-AG-009, MGRM-AG-011, MGRM-AG-012, MGRM-AG-013, MGRM-G-001, MGRM-G-004, MGRM-G-006, MGRM-G-009, MGRM-G-011, MGRM-G-013, MGRM-G-014, MGRM-G-015, MGRM-G-016, MGRM-G-017, MGRM-G-019, MGRM-G-024, MGRM-G-025, MGRM-G-027, MGRM-G-028, MGRM-F 1-004, MGRM-F 1-006, MGRM-F 1-008, MGRM-Fl-010, MGRM-F 1-012, MGRM-F 1-013, MGRM-F 1-014, MGRM-F 1-015, MGRM-F 1-016, MGRM-F 1-017, MGRM-F 1-018, MGRM-F 1-020, MGRM-F 1-021, MGRM-F 1-022, MGRM-F 1-023, and aMLV;

(b) screening the memory B cell cultures for binding activity against HIV-I antigens; and then

(c) rescuing the monoclonal antibody from a clonal memory B cell culture that exhibits neutralization activity against one or more HIV-I species with an IC50 value of less than 0.2 μg/mL.

50. The neutralizing antibody of claim 40 which is effective in neutralizing a SF 162 strain of HIV-I.

51. The neutralizing antibody of claim 49, comprising a heavy chain selected from the group consisting of SEQ ID NO: 12, 16, 20, 24, 28, 42, 47, 53, 59, and 65.

52. The neutralizing antibody of claim 49, comprising a heavy chain comprising a CDR selected from the group consisting of SEQ ID NO: SGFTFHKYGMH (SEQ ID NO: 88), LISDDGMRKYHSDSMW (SEQ ID NO: 89),

EAGGPIWHDDVKYYDFNDGYYNYHYMDV (SEQ ID NO: 6), SGGTFSSYAFT (SEQ ID NO: 104), MVTPIFGEAKYSQRFE (SEQ ID NO: 105), RAVPIATDNWLDP (SEQ ID NO: 102), SGGAFSSYAFS (SEQ ID NO: 110), MITPVFGETKYAPRFQ (SEQ ID NO: 111), SGYSFIDYYLH (SEQ ID NO: 116), LIDPENGEARYAEKFQ (SEQ ID NO: 117), AVGADSGSWFDP (SEQ ID NO: 118), SGFDFSRQGMH (SEQ ID NO: 123), FIKYDGSEKYHADSVW (SEQ ID NO: 124), EAGGPDYRNGYNYYDFYDGYYNYHYMDV (SEQ ID NO: 7), LISDDGMRKYHSNSMW (SEQ ID NO: 98).

53. The neutralizing antibody of claim 49, comprising a heavy chain comprising a CDR selected from the group consisting of SEQ ID NOs: SGFTFHKYGMH (SEQ ID NO: 88), LISDDGMRKYHSDSMW (SEQ ID NO: 89), EAGGPIWHDDVKYYDFNDGYYNYHYMDV (SEQ ID NO: 6), SGGTFSSYAFT (SEQ ID NO: 104), MVTPIFGEAKYSQRFE (SEQ ID NO: 105), RRAVPIATDNWLDP (SEQ ID NO: 103), SGGAFSSYAFS (SEQ ID NO: 110), MITPVFGETKYAPRFQ (SEQ ID NO: 111), SGYSFIDYYLH (SEQ ID NO: 116), LIDPENGEARYAEKFQ (SEQ ID NO: 117), AVGADSGSWFDP (SEQ ID NO: 118), SGFDFSRQGMH (SEQ ID NO: 123), FIKYDGSEKYHADSVW (SEQ ID NO: 124), EAGGPDYRNGYNYYDFYDGYYNYHYMDV (SEQ ID NO: 7), LISDDGMRKYHSNSMW (SEQ ID NO: 98).

54. The neutralizing antibody of claim 49, comprising a light chain selected from the group consisting of SEQ ID NOs: 14, 18, 22, 26, 30, 45, 50, and 56.

55. The neutralizing antibody of claim 49, comprising a light chain comprising a CDR selected from the group consisting of SEQ ID NOs: NGTSSDVGGFDSVS (SEQ ID NO: 97), DVSHRPSG (SEQ ID NO: 95), SSLTDRSHRI (SEQ ID NO: 41), RASQTINNYLN (SEQ ID NO: 107), GASNLQNG (SEQ ID NO: 108), QQSFSTPRT (SEQ ID NO: 42), RASQTIHTYL (SEQ ID NO: 113), GASTLQSG (SEQ ID NO: 114), QQSYSTPRT (SEQ ID NO: 43), SGSKLGDKYVS (SEQ ID NO: 120), ENDRRPSG (SEQ ID NO: 121), QAWETTTTTFVF (SEQ ID NO: 44), NGTSND VGGYES VS (SEQ ID NO: 126), DVSKRPSG (SEQ ID NO: 127), KSLTSTRRRV (SEQ ID NO: 45), NGTRSD VGGFD SVS (SEQ ID NO: 92), NGTSRDVGGFDSVS (SEQ ID NO: 93).

56. The neutralizing antibody of claim 49, wherein said antibody is a monoclonal antibody selected from the group consisting of 1496 C09 (PG9), 1443 C16 (PG 16), 1456 P20 (PG20), 1460 G14 (PGG14), 1495 C14 (PGC14), 1469 M23 (PG16), 1456 A12 (PG16), 1503 H05 (PG16), 1489 113 (PG16), and 1480 108 (PG16).

57. A fragment of the antibody of claim 56.

58. A nucleic acid molecule encoding the antibody of claim 49.

59. A vector comprising a nucleic acid molecule as recited in claim 58.

60. A cell comprising a vector as recited in claim 59.

61. An immortalized B cell clone expressing the antibody of claim 49.

62. An epitope which binds to the antibody of claim 32.

63. An immunogenic polypeptide comprising the epitope as recited in claim 26.

64. A pharmaceutical composition comprising at least one antibody or fragment as recited in claim 49, and a pharmaceutically acceptable carrier.

65. The antibody according to any of claims 1-23 wherein the antibody either (a) neutralizes HIV-I belonging to two or more clades selected from Clade A, Clade B, Clade C, Clade D and Clade AE or (b) neutralizes at least 60% of HIV-I species listed in selected from the group consisting of MGRM-A-OOl, MGRM- A-002, MGRM- A-003, MGRM-A-004, MGRM-A-005, MGRM-A-006, MGRM-A-007, MGRM-A-008, MGRM-A-009, MGRM-A- 010, MGRM-A-011, MGRM-A-012, MGRM-A-013, MGRM-A-014, 94UG 103, 92RW020, 93UG077, 94KE105, 93RW029, 02RW009, 92UG031, 92RW026, 92UG037, 92RW008, 92RW021, VLGCAl, 92RW024, 6535.3, QH0692.42, SC422661.8, PVO.4, TRO.11, CAAN.A2, TRJ0.58, THR0.18, 92BR010, APV 13, APV 17, APV 6, 93TH305, VLGCB3, JRCSF, NL43, MGRM-Chronic-B-001, MGRM-Chronic-B-002, MGRM-Chronic-B-003, MGRM-Chronic-B-004, MGRM-Chronic-B-008, MGRM-Chronic-B-010, MGRM-Chronic- B-011, MGRM-Chronic-B-012, MGRM-Chronic-B-017, MGRM-Chronic-B-018, MGRM- Chronic-B-020, MGRM-Chronic-B-023, MGRM-Chronic-B-024, JRFL, SF 162, MGRM-C-

001, MGRM-C-002, MGRM-C-003, MGRM-C-004, MGRM-C-005, MGRM-C-006, MGRM-C-007, MGRM-C-008, MGRM-C-009, MGRM-C-010, MGRM-C-011, MGRM-C-

012, MGRM-C-013, MGRM-C-014, MGRM-C-015, MGRM-C-016, MGRM-C-017, MGRM-C-018, MGRM-C-019, MGRM-C-020, MGRM-C-021, MGRM-C-022, MGRM-C- 023, MGRM-C-024, MGRM-C-025, 92IN905, IAVIC 18, IAVI C22, IAVI C3, 98IN022, 93MW959, 97ZA012, 98CN006, 98CN009, MGRM-D-001, MGRM-D-002, MGRM-D-003, MGRM-D-004, MGRM-D-005, MGRM-D-008, MGRM-D-011, MGRM-D-012, MGRM-D-

013, MGRM-D-014, MGRM-D-016, MGRM-D-018, MGRM-D-019, MGRM-D-020, MGRM-D-021, MGRM-D-022, MGRM-D-024, MGRM-D-026, MGRM-D-028, MGRM-D- 029, 92UG024, 92UG005, 92UG046, 92UG001, 94UG114, MGRM-AE-001, MGRM-AE-

002, MGRM- AE-003, MGRM-AE-004, MGRM-AE-005, MGRM-AE-006, MGRM-AE-007, MGRM-AE-008, 92TH021, CMU02, MGRM-AG-001, MGRM-AG-002, MGRM-AG-003, MGRM-AG-005, MGRM-AG-006, MGRM-AG-008, MGRM-AG-009, MGRM-AG-011, MGRM-AG-012, MGRM-AG-013, MGRM-G-001, MGRM-G-004, MGRM-G-006, MGRM-G-009, MGRM-G-011, MGRM-G-013, MGRM-G-014, MGRM-G-015, MGRM-G- 016, MGRM-G-017, MGRM-G-019, MGRM-G-024, MGRM-G-025, MGRM-G-027, MGRM-G-028, MGRM-F1-004, MGRM-F1-006, MGRM-F1-008, MGRM-Fl-010, MGRM- F 1-012, MGRM-F 1-013, MGRM-F 1-014, MGRM-F 1-015, MGRM-F 1-016, MGRM-F 1-017, MGRM-F1-018, MGRM-F1-020, MGRM-F1-021, MGRM-F1-022, MGRM-F1-023, and aMLV, and further wherein the potency of neutralization of at least a plurality of HIV-I species is determined by an IC50 value of less than 0.2 μg/mL.

66. The antibody according to any of claims 1-23 wherein the antibody binds gpl20.

67. The antibody according to any of claims 1-23 wherein the antibody does not bind gp41, MPER peptide of gp41 or V3 peptide.

68. The antibody according to any of claims 1-23 wherein the antibody exhibit relatively stronger binding to trimeric forms of the HIV-I Env (gpl60 and gpl40) than to the monomeric gpl20.

69. The antibody according to any of claims 1-23 wherein the antibody binds HIV-I envelope transfected cells.

70. The antibody according to any of claims 1-23 wherein the antibody binds HIV-I gpl20 at a site different from those bound by bl2 and 2Gl 2.

71. The antibody according to any of claims 65-70 wherein the antibody is selected from the group consisting of PG 16 and PG9.

72. A method for obtaining a broadly neutralizing human monoclonal antibody, the method comprising:

(a) screening memory B cell cultures from a donor PBMC sample for a broad neutralization activity against a plurality of HIV-I species;

(b) cloning a memory B cell that exhibits broad neutralization activity; and then

(c) rescuing the monoclonal antibody from the clonal memory B cell culture that exhibits broad neutralization activity.

73. The method of claim 72, wherein cloning the memory B cell culture comprises a method selected from the group consisting of B cell culture, hybridoma formation, EBV immortalization and electrofusion.

74. The method of claim 72, wherein the memory B cells are isolated from the PBMC of an HIVl -positive donor whose plasma exhibits potent or broad neutralization activity.

75. The method of claim 72, further comprising screening the memory B cell cultures for binding activity against HIV-I antigens prior to cloning.

76. A method for treating an individual infected with HIV-I comprising administering to the individual an effective amount of the antibody composition of claim 24.

77. The method of claim 76, wherein the antibody is administered in combination with other therapies.

78. The use of the antibody fragment of claim 26 or 57, or the nucleic acid molecule of claim 28 or 58 in the manufacture of an adjuvant formulation.

79. A method for treating an individual infected with HIV-I comprising administering to the patient an effective amount of an antibody according to claims 1-23 or a fragment thereof wherein the antibody is administered as an adjuvant therapy.

80. The method of claim 79, wherein the antibody is administered as an adjuvant therapy in multiple doses.

81. The method of claim 79, wherein the antibody or the antibody fragment thereof is selected from the group consisting of monoclonal antibodies 1496 C09 (PG9), 1443 C16 (PG16), 1456 P20 (PG20), 1460 G14 (PGG14), 1495 C14 (PGC14), 1469 M23 (PG16), 1456 A12 (PG16), 1503 H05 (PG16), 1489 113 (PG16), and 1480 108 (PG16), antigen binding fragments thereof such as Fab, Fab', F(ab')2, Fv, single chain Fv, diabody, domain antibody (dAb), sFv, dsFv and chimerized, humanized and fully human variants thereof.

82. A method for treatment of HIV-I infection in an individual, or post-exposure prophylaxis of an individual, comprising administering to the mammal an immunotherapeutically effective amount of an antibody according to claims 1-23 or a fragment thereof.

83. The method of claim 82, wherein the antibody or the antibody fragment thereof is selected from the group consisting of monoclonal antibodies 1496 C09 (PG9), 1443 C16 (PG16), 1456 P20 (PG20), 1460 G14 (PGG14), 1495 C14 (PGC14), 1469 M23 (PG16), 1456 A12 (PG16), 1503 H05 (PG16), 1489 113 (PG16), and 1480 108 (PG16), antigen binding fragments thereof such as Fab, Fab', F(ab')2, Fv, single chain Fv, diabody, domain antibody (dAb), sFv, dsFv and chimerized, humanized and fully human variants thereof.

84. A potent, broadly neutralizing antibody (bNAb) wherein the antibody neutralizes at least 60% of HIV-I species listed in selected from the group consisting of MGRM-A-001, MGRM- A-002, MGRM- A-003, MGRM-A-004, MGRM-A-005, MGRM- A-006, MGRM-A- 007, MGRM-A-008, MGRM-A-009, MGRM-A-010, MGRM-A-011, MGRM-A-012, MGRM-A-013, MGRM-A-014, 94UG 103, 92RW020, 93UG077, 94KE 105, 93RW029, 02RW009, 92UG031, 92RW026, 92UG037, 92RW008, 92RW021, VLGCAl, 92RW024, 6535.3, QH0692.42, SC422661.8, PVO.4, TRO.l l, CAAN.A2, TRJ0.58, THR0.18, 92BR010, APV 13, APV 17, APV 6, 93TH305, VLGCB3, JRCSF, NL43, MGRM-Chronic- B-001, MGRM-Chronic-B-002, MGRM-Chronic-B-003, MGRM-Chronic-B-004, MGRM- Chronic-B-008, MGRM-Chronic-B-010, MGRM-Chronic-B-011, MGRM-Chronic-B-012, MGRM-Chronic-B-017, MGRM-Chronic-B-018, MGRM-Chronic-B-020, MGRM-Chronic- B-023, MGRM-Chronic-B-024, JRFL, SF 162, MGRM-C-OOl, MGRM-C-002, MGRM-C- 003, MGRM-C-004, MGRM-C-005, MGRM-C-006, MGRM-C-007, MGRM-C-008, MGRM-C-009, MGRM-C-010, MGRM-C-011, MGRM-C-012, MGRM-C-013, MGRM-C- 014, MGRM-C-015, MGRM-C-016, MGRM-C-017, MGRM-C-018, MGRM-C-019, MGRM-C-020, MGRM-C-021, MGRM-C-022, MGRM-C-023, MGRM-C-024, MGRM-C- 025, 92IN905, IAVIC 18, IAVI C22, IAVI C3, 98IN022, 93MW959, 97ZA012, 98CN006, 98CN009, MGRM-D-001, MGRM-D-002, MGRM-D-003, MGRM-D-004, MGRM-D-005, MGRM-D-008, MGRM-D-011, MGRM-D-012, MGRM-D-013, MGRM-D-014, MGRM-D- 016, MGRM-D-018, MGRM-D-019, MGRM-D-020, MGRM-D-021, MGRM-D-022, MGRM-D-024, MGRM-D-026, MGRM-D-028, MGRM-D-029, 92UG024, 92UG005, 92UG046, 92UG001, 94UG114, MGRM-AE-001, MGRM-AE-002, MGRM-AE-003, MGRM-AE-004, MGRM-AE-005, MGRM-AE-006, MGRM-AE-007, MGRM-AE-008, 92TH021, CMU02, MGRM-AG-001, MGRM-AG-002, MGRM- AG-003, MGRM- AG-005, MGRM-AG-006, MGRM-AG-008, MGRM-AG-009, MGRM-AG-011, MGRM-AG-012, MGRM-AG-013, MGRM-G-001, MGRM-G-004, MGRM-G-006, MGRM-G-009, MGRM- G-OI l, MGRM-G-013, MGRM-G-014, MGRM-G-015, MGRM-G-016, MGRM-G-017, MGRM-G-019, MGRM-G-024, MGRM-G-025, MGRM-G-027, MGRM-G-028, MGRM- Fl-004, MGRM-F1-006, MGRM-F1-008, MGRM-Fl-010, MGRM-F1-012, MGRM-F1-013, MGRM-F1-014, MGRM-F1-015, MGRM-F1-016, MGRM-F1-017, MGRM-F1-018, MGRM-F 1-020, MGRM-F 1-021, MGRM-F 1-022, MGRM-F 1-023, and aMLV, and further wherein the potency of neutralization of at least a plurality of the HIV-I species is determined by an IC50 value of less than 0.2 μg/mL.

85. A potent, broadly neutralizing antibody (bNAb) wherein the antibody neutralizes HIV-I species belonging to two or more clades, and further wherein the potency of neutralization of at least one member of each clade is determined by an IC50 value of less than 0.2 μg/mL.

86. The antibody of claim 84 or 85 wherein the clades are selected from Clade A, Clade B, Clade C, Clade D and Clade AE.

87. The antibody of claim 86 wherein the HIV-I belonging two or more clades are non- Clade B viruses.

88. The antibody of claim 84 or 85 wherein the antibody neutralizes at least one member of each clade with a potency greater than that of the bNAbs bl2, 2Gl 2, 2F5 and 4E10 respectively.

89. The antibody of claim 84 or 85 wherein the antibody does not bind monomeric gpl20 or gp41 proteins of the HIV-I env gene.

90. The antibody of claim 84 or 85 wherein the antibody binds with higher affinity to trimeric forms of the HIV-I Env expressed on a cell surface than to the monomeric gpl20 or artificially trimerized gpl40.

91. The antibody of claim 90 wherein the antibody binds with high affinity to uncleaved HIV-I gpl60 trimers on a cell surface.

92. The antibody of any of claims 84, 85, 98, 90, or 91 wherein the antibody binds an epitope within the variable loop of gpl20.

93. The antibody of claim 92, wherein the epitope comprises the conserved regions of V2 and V3 loops of gpl20.

94. The antibody of claim 93, wherein the epitope comprises N-glycosylation site at residue Asn-160 within the V2 loop of gpl20.

95. The antibody of claim 94, wherein the antibody does not neutralize the HIV-I in the absence of N-glycosylation site at residue Asn-160 within the V2 loop of gpl20.

96. The antibody of any of claims 84, 85, 98, 90, or 91 wherein the antibody binds an epitope presented by a trimeric spike of gpl20 on a cell surface, wherein the epitope is not presented when gpl20 is artificially trimerized.

97. The antibody according to any of claims 84-96 wherein the antibody is selected from the group consisting of PG 16 and PG9.

98. The antibody according to any of claims 84-96 wherein the antibody is a human or humanized monoclonal antibody.

99. An antigen for producing a potent, broadly neutralizing antibody (bNAb) by an immune response, the antigen comprising an epitope within the variable loop of gpl20, wherein the bNAb either (a) neutralizes HIV-I species belonging to two or more clades, or (b) neutralizes at least 60% of HIV-I species listed in selected from the group consisting of MGRM-A-001, MGRM- A-002, MGRM-A-003, MGRM-A-004, MGRM- A-005, MGRM-A- 006, MGRM-A-007, MGRM-A-008, MGRM-A-009, MGRM-A-OlO, MGRM-A-011, MGRM-A-012, MGRM-A-013, MGRM-A-014, 94UG 103, 92RW020, 93UG077, 94KE 105, 93RW029, 02RW009, 92UG031, 92RW026, 92UG037, 92RW008, 92RW021, VLGCAl, 92RW024, 6535.3, QH0692.42, SC422661.8, PVO.4, TRO.l l, CAAN.A2, TRJ0.58, THR0.18, 92BR010, APV 13, APV 17, APV 6, 93TH305, VLGCB3, JRCSF, NL43, MGRM-Chronic-B-001, MGRM-Chronic-B-002, MGRM-Chronic-B-003, MGRM-Chronic- B-004, MGRM-Chronic-B-008, MGRM-Chronic-B-010, MGRM-Chronic-B-011, MGRM- Chronic-B-012, MGRM-Chronic-B-017, MGRM-Chronic-B-018, MGRM-Chronic-B-020, MGRM-Chronic-B-023, MGRM-Chronic-B-024, JRFL, SF162, MGRM-C-001, MGRM-C- 002, MGRM-C-003, MGRM-C-004, MGRM-C-005, MGRM-C-006, MGRM-C-007, MGRM-C-008, MGRM-C-009, MGRM-C-010, MGRM-C-011, MGRM-C-012, MGRM-C- 013, MGRM-C-014, MGRM-C-015, MGRM-C-016, MGRM-C-017, MGRM-C-018, MGRM-C-019, MGRM-C-020, MGRM-C-021, MGRM-C-022, MGRM-C-023, MGRM-C- 024, MGRM-C-025, 92IN905, IAVIC 18, IAVI C22, IAVI C3, 98IN022, 93MW959, 97ZA012, 98CN006, 98CN009, MGRM-D-001, MGRM-D-002, MGRM-D-003, MGRM-D- 004, MGRM-D-005, MGRM-D-008, MGRM-D-011, MGRM-D-012, MGRM-D-013, MGRM-D-014, MGRM-D-016, MGRM-D-018, MGRM-D-019, MGRM-D-020, MGRM-D- 021, MGRM-D-022, MGRM-D-024, MGRM-D-026, MGRM-D-028, MGRM-D-029, 92UG024, 92UG005, 92UG046, 92UG001, 94UG114, MGRM-AE-001, MGRM-AE-002, MGRM- AE-003, MGRM-AE-004, MGRM- AE-005, MGRM- AE-006, MGRM-AE-007, MGRM-AE-008, 92TH021, CMU02, MGRM-AG-001, MGRM-AG-002, MGRM-AG-003, MGRM-AG-005, MGRM-AG-006, MGRM-AG-008, MGRM-AG-009, MGRM-AG-011, MGRM-AG-012, MGRM-AG-013, MGRM-G-001, MGRM-G-004, MGRM-G-006, MGRM-G-009, MGRM-G-011, MGRM-G-013, MGRM-G-014, MGRM-G-015, MGRM-G- 016, MGRM-G-017, MGRM-G-019, MGRM-G-024, MGRM-G-025, MGRM-G-027, MGRM-G-028, MGRM-F1-004, MGRM-F1-006, MGRM-F1-008, MGRM-Fl-010, MGRM- F 1-012, MGRM-F 1-013, MGRM-F 1-014, MGRM-F 1-015, MGRM-F 1-016, MGRM-F 1-017, MGRM-F1-018, MGRM-F1-020, MGRM-F1-021, MGRM-F1-022, MGRM-F1-023, and aMLV, and further wherein the potency of neutralization of at least a plurality of HIV-I species is determined by an IC50 value of less than 0.2 μg/mL.

100. The antigen of claim 99, wherein the epitope comprises the conserved regions of V2 and V3 loops of gpl20.

101. The antigen of claim 100, wherein the epitope comprises N-glycosylation site at residue Asn-160 within the V2 loop of gpl20.

102. The antigen of claim 101, wherein the epitope comprises an N-glycosylated residue at Asn-160 within the V2 loop of gpl20.

103. The antigen according to any of claims 99-102, wherein the epitope is presented by a trimeric spike of gpl20 on a cell surface, and the epitope is not presented when gpl20 is monomeric or artificially trimerized.

104. An immunogenic polypeptide comprising an epitope according to any of claims 99- 102.

105. A vaccine comprising the immunogenic polypeptide of claim 104.

106. The vaccine of claim 105, further comprising an adjuvant.

107. A method for immunizing an individual against a plurality of HIV-I species, the method comprising: providing a potent, broadly neutralizing antibody (bNAb) wherein the bNAb either (a) neutralizes HIV-I species belonging to two or more clades, or (b) neutralizes at least 60% of HIV-I species listed in selected from the group consisting of MGRM-A-001, MGRM- A-002, MGRM- A-003, MGRM-A-004, MGRM-A-005, MGRM- A-006, MGRM-A- 007, MGRM-A-008, MGRM-A-009, MGRM-A-010, MGRM-A-011, MGRM-A-012, MGRM-A-013, MGRM-A-014, 94UG 103, 92RW020, 93UG077, 94KE 105, 93RW029, 02RW009, 92UG031, 92RW026, 92UG037, 92RW008, 92RW021, VLGCAl, 92RW024, 6535.3, QH0692.42, SC422661.8, PVO.4, TRO.l l, CAAN.A2, TRJ0.58, THR0.18, 92BR010, APV 13, APV 17, APV 6, 93TH305, VLGCB3, JRCSF, NL43, MGRM-Chronic- B-001, MGRM-Chronic-B-002, MGRM-Chronic-B-003, MGRM-Chronic-B-004, MGRM- Chronic-B-008, MGRM-Chronic-B-010, MGRM-Chronic-B-011, MGRM-Chronic-B-012, MGRM-Chronic-B-017, MGRM-Chronic-B-018, MGRM-Chronic-B-020, MGRM-Chronic- B-023, MGRM-Chronic-B-024, JRFL, SF 162, MGRM-C-001, MGRM-C-002, MGRM-C- 003, MGRM-C-004, MGRM-C-005, MGRM-C-006, MGRM-C-007, MGRM-C-008, MGRM-C-009, MGRM-C-010, MGRM-C-011, MGRM-C-012, MGRM-C-013, MGRM-C- 014, MGRM-C-015, MGRM-C-016, MGRM-C-017, MGRM-C-018, MGRM-C-019, MGRM-C-020, MGRM-C-021, MGRM-C-022, MGRM-C-023, MGRM-C-024, MGRM-C- 025, 92IN905, IAVIC 18, IAVI C22, IAVI C3, 98IN022, 93MW959, 97ZA012, 98CN006, 98CN009, MGRM-D-001, MGRM-D-002, MGRM-D-003, MGRM-D-004, MGRM-D-005, MGRM-D-008, MGRM-D-011, MGRM-D-012, MGRM-D-013, MGRM-D-014, MGRM-D- 016, MGRM-D-018, MGRM-D-019, MGRM-D-020, MGRM-D-021, MGRM-D-022, MGRM-D-024, MGRM-D-026, MGRM-D-028, MGRM-D-029, 92UG024, 92UG005, 92UG046, 92UG001, 94UG114, MGRM-AE-OOl, MGRM-AE-002, MGRM-AE-003, MGRM-AE-004, MGRM-AE-005, MGRM-AE-006, MGRM-AE-007, MGRM-AE-008, 92TH021, CMU02, MGRM-AG-OOl, MGRM-AG-002, MGRM- AG-003, MGRM- AG-005, MGRM-AG-006, MGRM-AG-008, MGRM-AG-009, MGRM-AG-011, MGRM-AG-012, MGRM-AG-013, MGRM-G-001, MGRM-G-004, MGRM-G-006, MGRM-G-009, MGRM- G-OI l, MGRM-G-013, MGRM-G-014, MGRM-G-015, MGRM-G-016, MGRM-G-017, MGRM-G-019, MGRM-G-024, MGRM-G-025, MGRM-G-027, MGRM-G-028, MGRM- Fl-004, MGRM-F1-006, MGRM-F1-008, MGRM-Fl-010, MGRM-F1-012, MGRM-F1-013, MGRM-F1-014, MGRM-F1-015, MGRM-F1-016, MGRM-F1-017, MGRM-F1-018, MGRM-F 1-020, MGRM-F 1-021, MGRM-F 1-022, MGRM-F 1-023, and aMLV, and further wherein the potency of neutralization of at least a plurality of HIV-I species is determined by an IC50 value of less than 0.2 μg/mL.

108. The method of claim 107, wherein the antibody is provided by passive immunization.

109. The method of claim 107, comprising a heavy chain comprising a CDR selected from the group consisting of SEQ ID NO: 88, 89, 6, 123, 124, 7, and 98.

110. The method of claim 107, comprising a light chain comprising a CDR selected from the group consisting of SEQ ID NOs: 97, 95, 41 , 126, 127, 45, 92, and 93.

111. The method of claim 107, wherein the antibody is selected from the group consisting ofPG9 and PG16.

112. The method of claim 107, wherein the antibody is provided by active immunization with an antigen comprising an epitope within the variable loop of gpl20.

113. The method of claim 112, wherein the epitope comprises the conserved regions of V2 and V3 loops of gpl20.

114. The method of claim 113, wherein the epitope comprises an N-glycosylation site at residue Asn-160 within the V2 loop of gpl20.

115. The method of claim 107, wherein the epitope is presented by a trimeric spike of gpl20 on a cell surface, and the epitope is not presented when gpl20 is monomeric or artificially trimerized.

116. The potent, broadly neutralizing antibody (bNAb) of any one of claims 1-23 wherein the bNAb neutralizes at least 70% of HIV-I species selected from the group consisting of MGRM-A-OOl, MGRM- A-002, MGRM-A-003, MGRM-A-004, MGRM- A-005, MGRM-A- 006, MGRM-A-007, MGRM-A-008, MGRM-A-009, MGRM-A-010, MGRM-A-011, MGRM-A-012, MGRM-A-013, MGRM-A-014, 94UG 103, 92RW020, 93UG077, 94KE 105, 93RW029, 02RW009, 92UG031, 92RW026, 92UG037, 92RW008, 92RW021, VLGCAl, 92RW024, 6535.3, QH0692.42, SC422661.8, PVO.4, TRO.l l, CAAN.A2, TRJ0.58, THR0.18, 92BR010, APV 13, APV 17, APV 6, 93TH305, VLGCB3, JRCSF, NL43, MGRM-Chronic-B-001, MGRM-Chronic-B-002, MGRM-Chronic-B-003, MGRM-Chronic- B-004, MGRM-Chronic-B-008, MGRM-Chronic-B-010, MGRM-Chronic-B-011, MGRM- Chronic-B-012, MGRM-Chronic-B-017, MGRM-Chronic-B-018, MGRM-Chronic-B-020, MGRM-Chronic-B-023, MGRM-Chronic-B-024, JRFL, SF162, MGRM-C-001, MGRM-C- 002, MGRM-C-003, MGRM-C-004, MGRM-C-005, MGRM-C-006, MGRM-C-007, MGRM-C-008, MGRM-C-009, MGRM-C-010, MGRM-C-011, MGRM-C-012, MGRM-C- 013, MGRM-C-014, MGRM-C-015, MGRM-C-016, MGRM-C-017, MGRM-C-018, MGRM-C-019, MGRM-C-020, MGRM-C-021, MGRM-C-022, MGRM-C-023, MGRM-C- 024, MGRM-C-025, 92IN905, IAVIC 18, IAVI C22, IAVI C3, 98IN022, 93MW959, 97ZA012, 98CN006, 98CN009, MGRM-D-001, MGRM-D-002, MGRM-D-003, MGRM-D- 004, MGRM-D-005, MGRM-D-008, MGRM-D-011, MGRM-D-012, MGRM-D-013, MGRM-D-014, MGRM-D-016, MGRM-D-018, MGRM-D-019, MGRM-D-020, MGRM-D- 021, MGRM-D-022, MGRM-D-024, MGRM-D-026, MGRM-D-028, MGRM-D-029, 92UG024, 92UG005, 92UG046, 92UG001, 94UG114, MGRM-AE-001, MGRM-AE-002, MGRM- AE-003, MGRM-AE-004, MGRM- AE-005, MGRM- AE-006, MGRM-AE-007, MGRM-AE-008, 92TH021, CMU02, MGRM-AG-001, MGRM-AG-002, MGRM-AG-003, MGRM-AG-005, MGRM-AG-006, MGRM-AG-008, MGRM-AG-009, MGRM-AG-011, MGRM-AG-012, MGRM-AG-013, MGRM-G-001, MGRM-G-004, MGRM-G-006, MGRM-G-009, MGRM-G-011, MGRM-G-013, MGRM-G-014, MGRM-G-015, MGRM-G- 016, MGRM-G-017, MGRM-G-019, MGRM-G-024, MGRM-G-025, MGRM-G-027, MGRM-G-028, MGRM-F1-004, MGRM-F1-006, MGRM-F1-008, MGRM-Fl-010, MGRM- F 1-012, MGRM-F 1-013, MGRM-F 1-014, MGRM-F 1-015, MGRM-F 1-016, MGRM-F 1-017, MGRM-F1-018, MGRM-F1-020, MGRM-F1-021, MGRM-F1-022, MGRM-F1-023, and aMLV.

117. The potent, broadly neutralizing antibody (bNAb) of any one of claims 1 -23 wherein the bNAb neutralizes at least 80% of HIV-I species selected from the group consisting of MGRM-A-OOl, MGRM- A-002, MGRM-A-003, MGRM-A-004, MGRM- A-005, MGRM-A- 006, MGRM-A-007, MGRM-A-008, MGRM-A-009, MGRM-A-010, MGRM-A-011, MGRM-A-012, MGRM-A-013, MGRM-A-014, 94UG 103, 92RW020, 93UG077, 94KE 105, 93RW029, 02RW009, 92UG031, 92RW026, 92UG037, 92RW008, 92RW021, VLGCAl, 92RW024, 6535.3, QH0692.42, SC422661.8, PVO.4, TRO.l l, CAAN.A2, TRJ0.58, THR0.18, 92BR010, APV 13, APV 17, APV 6, 93TH305, VLGCB3, JRCSF, NL43, MGRM-Chronic-B-001, MGRM-Chronic-B-002, MGRM-Chronic-B-003, MGRM-Chronic- B-004, MGRM-Chronic-B-008, MGRM-Chronic-B-010, MGRM-Chronic-B-011, MGRM- Chronic-B-012, MGRM-Chronic-B-017, MGRM-Chronic-B-018, MGRM-Chronic-B-020, MGRM-Chronic-B-023, MGRM-Chronic-B-024, JRFL, SF162, MGRM-C-001, MGRM-C- 002, MGRM-C-003, MGRM-C-004, MGRM-C-005, MGRM-C-006, MGRM-C-007, MGRM-C-008, MGRM-C-009, MGRM-C-010, MGRM-C-011, MGRM-C-012, MGRM-C- 013, MGRM-C-014, MGRM-C-015, MGRM-C-016, MGRM-C-017, MGRM-C-018, MGRM-C-019, MGRM-C-020, MGRM-C-021, MGRM-C-022, MGRM-C-023, MGRM-C- 024, MGRM-C-025, 92IN905, IAVIC 18, IAVI C22, IAVI C3, 98IN022, 93MW959, 97ZA012, 98CN006, 98CN009, MGRM-D-001, MGRM-D-002, MGRM-D-003, MGRM-D- 004, MGRM-D-005, MGRM-D-008, MGRM-D-011, MGRM-D-012, MGRM-D-013, MGRM-D-014, MGRM-D-016, MGRM-D-018, MGRM-D-019, MGRM-D-020, MGRM-D- 021, MGRM-D-022, MGRM-D-024, MGRM-D-026, MGRM-D-028, MGRM-D-029, 92UG024, 92UG005, 92UG046, 92UG001, 94UG114, MGRM-AE-001, MGRM-AE-002, MGRM- AE-003, MGRM-AE-004, MGRM- AE-005, MGRM- AE-006, MGRM-AE-007, MGRM-AE-008, 92TH021, CMU02, MGRM-AG-001, MGRM-AG-002, MGRM-AG-003, MGRM-AG-005, MGRM-AG-006, MGRM-AG-008, MGRM-AG-009, MGRM-AG-011, MGRM-AG-012, MGRM-AG-013, MGRM-G-001, MGRM-G-004, MGRM-G-006, MGRM-G-009, MGRM-G-011, MGRM-G-013, MGRM-G-014, MGRM-G-015, MGRM-G- 016, MGRM-G-017, MGRM-G-019, MGRM-G-024, MGRM-G-025, MGRM-G-027, MGRM-G-028, MGRM-F1-004, MGRM-F1-006, MGRM-F1-008, MGRM-Fl-010, MGRM- F 1-012, MGRM-F 1-013, MGRM-F 1-014, MGRM-F 1-015, MGRM-F 1-016, MGRM-F 1-017, MGRM-F1-018, MGRM-F1-020, MGRM-F1-021, MGRM-F1-022, MGRM-F1-023, and aMLV.

118. The potent, broadly neutralizing antibody (bNAb) of any one of claims 1-23 wherein the bNAb neutralizes at least 90% of HIV-I species selected from the group consisting of MGRM-A-OOl, MGRM- A-002, MGRM-A-003, MGRM-A-004, MGRM- A-005, MGRM-A- 006, MGRM-A-007, MGRM-A-008, MGRM-A-009, MGRM-A-010, MGRM-A-011, MGRM-A-012, MGRM-A-013, MGRM-A-014, 94UG 103, 92RW020, 93UG077, 94KE 105, 93RW029, 02RW009, 92UG031, 92RW026, 92UG037, 92RW008, 92RW021, VLGCAl, 92RW024, 6535.3, QH0692.42, SC422661.8, PVO.4, TRO.l l, CAAN.A2, TRJ0.58, THR0.18, 92BR010, APV 13, APV 17, APV 6, 93TH305, VLGCB3, JRCSF, NL43, MGRM-Chronic-B-001, MGRM-Chronic-B-002, MGRM-Chronic-B-003, MGRM-Chronic- B-004, MGRM-Chronic-B-008, MGRM-Chronic-B-010, MGRM-Chronic-B-011, MGRM- Chronic-B-012, MGRM-Chronic-B-017, MGRM-Chronic-B-018, MGRM-Chronic-B-020, MGRM-Chronic-B-023, MGRM-Chronic-B-024, JRFL, SF162, MGRM-C-001, MGRM-C- 002, MGRM-C-003, MGRM-C-004, MGRM-C-005, MGRM-C-006, MGRM-C-007, MGRM-C-008, MGRM-C-009, MGRM-C-010, MGRM-C-011, MGRM-C-012, MGRM-C- 013, MGRM-C-014, MGRM-C-015, MGRM-C-016, MGRM-C-017, MGRM-C-018, MGRM-C-019, MGRM-C-020, MGRM-C-021, MGRM-C-022, MGRM-C-023, MGRM-C- 024, MGRM-C-025, 92IN905, IAVIC 18, IAVI C22, IAVI C3, 98IN022, 93MW959, 97ZA012, 98CN006, 98CN009, MGRM-D-001, MGRM-D-002, MGRM-D-003, MGRM-D- 004, MGRM-D-005, MGRM-D-008, MGRM-D-011, MGRM-D-012, MGRM-D-013, MGRM-D-014, MGRM-D-016, MGRM-D-018, MGRM-D-019, MGRM-D-020, MGRM-D- 021, MGRM-D-022, MGRM-D-024, MGRM-D-026, MGRM-D-028, MGRM-D-029, 92UG024, 92UG005, 92UG046, 92UG001, 94UG114, MGRM-AE-001, MGRM-AE-002, MGRM- AE-003, MGRM-AE-004, MGRM- AE-005, MGRM- AE-006, MGRM-AE-007, MGRM-AE-008, 92TH021, CMU02, MGRM-AG-001, MGRM-AG-002, MGRM-AG-003, MGRM-AG-005, MGRM-AG-006, MGRM-AG-008, MGRM-AG-009, MGRM-AG-011, MGRM-AG-012, MGRM-AG-013, MGRM-G-001, MGRM-G-004, MGRM-G-006, MGRM-G-009, MGRM-G-011, MGRM-G-013, MGRM-G-014, MGRM-G-015, MGRM-G- 016, MGRM-G-017, MGRM-G-019, MGRM-G-024, MGRM-G-025, MGRM-G-027, MGRM-G-028, MGRM-F1-004, MGRM-F1-006, MGRM-F1-008, MGRM-Fl-010, MGRM- F 1-012, MGRM-F 1-013, MGRM-F 1-014, MGRM-F 1-015, MGRM-F 1-016, MGRM-F 1-017, MGRM-F1-018, MGRM-F1-020, MGRM-F1-021, MGRM-F1-022, MGRM-F1-023, and aMLV.

119. The potent, broadly neutralizing antibody (bNAb) any one of claims 1-23 wherein the bNAb neutralizes a HIV-I strain with an IC50 value of less than 0.15 μg/mL.

120. The potent, broadly neutralizing antibody (bNAb) any one of claims 1-23 wherein the bNAb neutralizes a HIV-I strain with an IC₅₀ value of less than 0.1 μg/mL.

121. The potent, broadly neutralizing antibody (bNAb) any one of claims 1-23 wherein the bNAb neutralizes a HIV-I strain with an IC50 value of less than 0.05 μg/mL.

122. The potent, broadly neutralizing antibody (bNAb) any one of claims 1-23 wherein the bNAb neutralizes a HIV-I strain with an IC₉₀ value of less than 2.0 μg/mL.

123. The potent, broadly neutralizing antibody (bNAb) any one of claims 1-23 wherein the bNAb neutralizes a HIV-I strain with an IC90 value of less than 1.0 μg/mL.

124. The potent, broadly neutralizing antibody (bNAb) any one of claims 1-23 wherein the bNAb neutralizes a HIV-I strain with an IC₉₀ value of less than 0.5 μg/mL.